

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment
ISSN (print): 0250-7005; ISSN (online): 1791-7530

VOLUME 29
2009

This volume is dedicated to the memory of

I. B. WEINSTEIN

Editorial Board

B. B. Aggarwal	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
J. P. Armand	Institut Gustav-Roussy, Villejuif, France
D. Assimakopoulos	Department of Otorhinolaryngology, Medical School, University of Ioannina, Greece
V. I. Avramis	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
R. C. Bast	Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
G. Bauer	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
E. E. Baulieu	INSERM U488 and College de France, Le Kremlin-Bicetre, France
Y. Becker	Department of Molecular Virology, Hebrew University of Jerusalem, Israel
E. J. Benz, Jr.	Dana-Farber Cancer Institute, Boston, MA, USA
J. Bergh	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
J. L. Biedler	Department of Biological Sciences, Fordham University, Bronx, NY, USA
D. D. Bigner	Department of Pathology, Duke University Medical Center, Durham, NC, USA
A. Böcking	Institute for Cytopathology, University of Düsseldorf, Germany
G. Bonadonna	Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
G. Broich	Istituto Ortopedico Galeazzi, Milan, Italy
J. M. Brown	Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA
Ø. S. Bruland	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cancer Research Center of Hawaii, Honolulu, HI, USA
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
L. Cheng	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
J.-G. Chung	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. De Loecker	Department of Biochemistry, Katholieke Universiteit Leuven, Belgium
W. Den Otter	VUMC, Department of Urology, Amsterdam, The Netherlands
E. P. Diamandis	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
W. Ebert	Thoraxclinic HD-Rohrbach, Heidelberg, Germany
U. Eppenberger	Laboratory of Biochemistry/Endocrinology, University Clinic, Basel, Switzerland
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
W. Fiers	Department of Molecular Biomedical Research, Ghent University and VIB, Belgium
N. E. Fusenig	Division of Differentiation, DKFZ, Heidelberg, Germany
G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
A. F. Gazdar	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
A. Giordano	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
R. H. Goldfarb	Sopherion Therapeutics, Inc., Princeton, NJ, USA
J. W. Gorrod	Toxicology Unit, John Tabor Laboratories, University of Essex, Colchester, Essex, UK
S. Hammarström	Department of Immunology, University of Umeå, Sweden
I. Hart	Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK

- I. Hellström** Harborview Medical Center, Seattle, WA, USA
- L. Helson** Department of Experimental Therapeutics, New York Medical College, Valhalla, NY, USA
- R. B. Herberman** Pittsburgh Cancer Institute, Pittsburgh, PA, USA
- R. M. Hoffman** Department of Surgery, University of California, San Diego, CA, USA
- C. G. Ioannides** Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
- S. C. Jhanwar** Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- J. V. Johannessen** Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
- B. Kaina** Institute of Toxicology, University of Mainz, Germany
- B. K. Keppler** School of Medicine, University of Vienna, Austria
- D. G. Kieback** DIAKO, Ev. Diakonie-Hospital, Bremen, Germany
- J. Kieler** Danish Cancer Society, Copenhagen, Denmark
- R. Klapdor** Medical Clinic, University of Hamburg, Germany
- U. R. Kleeborg** Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany
- P. Kleihues** Department of Pathology, University Hospital Zürich, Switzerland
- E. Klein** Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
- S. von Kleist** Institut für Immunologie der Universität der Freiburg, Germany
- S. D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
- G. R. F. Krueger** Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
- D. W. Kufe** Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
- Pat Kumar** Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
- Shant Kumar** Department Pathology, University of Manchester Medical School, Manchester, UK
- M. Kuroki** Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan
- O. D. Laerum** Department of Pathology, The Gade Institute, University of Bergen, Norway
- F. J. Lejeune** Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
- C. J. Link** Iowa Cancer Research Foundation, Clive, IA, USA
- L. A. Liotta** Center of Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
- L. F. Liu** Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
- D. M. Lopez** Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
- E. Lundgren** Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
- H. T. Lynch** Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA
- J. Marescaux** IRCAD, University of Strasbourg, France
- J. Mark** Department of Pathology, Kärnshjukhuset, Skövde, Sweden
- J. F. Marshall** Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK
- D. Medina** Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA
- S. Mitra** Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX, USA
- F. M. Muggia** New York University Cancer Institute, School of Medicine, NY, USA
- M. J. Murphy, Jr.** Hipple Cancer Research Center, Dayton, OH, USA
- R. Narayanan** Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- K. Nilsson** Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
- J. F. Novak** Department of Biology, Bucknell University, Lewisburg, PA, USA
- S. Pathak** Department of Cell Biology, University of Texas, Houston, TX, USA
- S. Pestka** Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
- G. J. Pilkington** Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
- C. D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA
- F. Podo** Laboratory of Cell Biology, Istituto Superiore di Sanità, Rome, Italy

A. Polliack	Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
M. F. Rajewsky	Institute of Cell Biology, University of Essen Medical School, Essen, Germany
G. Rebel	IRCAD, Hopitaux Universitaires, Strasbourg, France
M. Rigaud	Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France
U. Ringborg	Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
M. Roselli	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
A. Schauer	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
M. Schneider	Department of Organic Chemistry, Bergische University, Wuppertal, Germany
A. Seth	Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
G. V. Sherbet	Cancer Research Unit, University of Newcastle-upon-Tyne, UK
G.-I. Soma	Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan
G. S. Stein	Department of Cell Biology, University of Massachusetts Medical Center, Worcester, MA, USA
T. Stigbrand	Department of Immunology, Umeå University, Umeå, Sweden
K. Takagi	Kennan Takagi Clinic, Kumamoto, Japan
D. Tarin	University of California at San Diego, Cancer Center, La Jolla, CA, USA
G. B. de Thé	Institut Pasteur, Paris, France
T. M. Theophanides	Department of Chemistry, Technical University of Athens, Greece
B. Toth	The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA
E. Trell	Department of General Practice and Primary Care, Faculty of Health Sciences, University of Linköping, Sweden
P. M. Ueland	Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
P. T. Vihko	Department of Clinical Chemistry, University of Oulu, Finland
M. Volm	German Cancer Research Center, Heidelberg, Germany
G. Weber	Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USA
I. B. Weinstein	Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
B. Westermark	Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
B. Zumoff	Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

Acknowledgements

The following Organisations supported many of the works published in Anticancer Research, Volume 29, 2009.

- Aage and Johannes Louis-Hansen Foundation, Germany
 Aakre Cancer Foundation, Norway
 Academy of Finland
 Academy of Science, Prague, Czech Republic
 Acción Transversal del Cáncer-Instituto Carlos III, Spain
 ACUMED, Tytherington, U.K.
 Agenzia Italiana del Farmaco (AIFA), Roma, Italia
 Aichi Cancer Center Hospital, Aichi, Japan
 Ajinomoto Co., Inc., Tokyo, Japan
 Albert Pahlsson Foundation, Sweden
 Alfred und Ursula Kulemann Stiftung, Philipps University Marburg, Germany
 American Brain Tumor Association (ABTA), Des Plaines, IL, U.S.A.
 American Cancer Society, U.S.A.
 American Heart Association Midwest Affiliate, Dallas, TX, U.S.A.
 American Institute of Cancer Research, Washington, DC, U.S.A.
 American Research Foundation, U.S.A.
 American Thyroid Association, Falls Church, Virginia, U.S.A.
 Amgen Inc., Thousand Oaks, CA, U.S.A.
 Anna-Lisa and Bror Björnssons Foundation, Sweden
 Antigen Express, Inc., Worcester, MA, U.S.A.
 Arizona Cancer Center, Tucson, AZ, U.S.A.
 Association Coeur et Cancer de Cherbourg, France
 Association de Transfusion Sanguine et de Biogénétique Gaetan Saleun, Brest, France
 Association Grenobloise d'Aide à la Recherche en Oncologie (AGARO), Grenoble, France
 Association pour la Recherche sur le Cancer, Villejuif, France
 Austrian Cancer Aid/Styria, Graz, Austria
 Austrian Cancer Society-Tyrol, Austria
 Austrian National Bank, Vienna, Austria
- Ba Men Anti-epidemic Station, Lin He, Inner Mongolia, China
 Barncancerfonden, Stockholm, Sweden
 Beckett Foundation, Reading, UK
 Bernese Cancer League, Bern, Switzerland
 BMBF Translational Sarcoma Research Network (TransSarNet), Berlin, Germany
- BMBF/DLR Kompetenznetz Pädiatrische Onkologie, Berlin, Germany
 Breastopia Namba Hospital, Miyazaki, Japan
 Bristol-Myers Squibb AB, Bromma, Sweden
 British Columbia Cancer Foundation, Canada
- Caisse d'Epargne Régionale de Basse-Normandie, France
 Caisse d'Epargne Régionale de Basse-Normandie, Paris, France
 Canadian Breast Cancer Foundation
 Canadian Breast Cancer Research Alliance
 Canadian Institutes of Health Research (CIHR), Ottawa, ON, Canada
 Cancer and Polio Research Fund, Hoylake, Wirral, U.K.
 Cancer Center of the Medical College of Wisconsin, Milwaukee, WI, U.S.A.
 Cancer Institute Hospital, Tokyo, Japan
 Cancer Research Campaign of Great Britain
 Cancer Research Institute, Seoul, Republic of Korea
 Cancer Society (Cancerföreningen) in Stockholm, Sweden
 Cancer Treatment and Research Foundation, U.S.A.
 Cancerfonden, Stockholm, Sweden
 Cell Culture and Gene Transfer Facility Core, Detroit, MI, U.S.A.
 Centocor, Inc., Horsham, PA, U.S.A.
 Central Research Institute, Fukuoka University, Japan
 Centre National de la Recherche Scientifique (CNRS), France
 Centre of Laboratory Animal Research, Zhejiang College of Traditional Chinese Medicine, China
 Chang Gung Memorial Hospital, Kaohsiung. College of Medicine, Chang Gung University, Taiwan, R.O.C.
 Charitable Leadership Foundation, Clifton Park, NY, U.S.A.
 Children's Cancer Foundation of Sweden
 China Medical University Hospital, Taichung, Taiwan, R.O.C.
 China Medical University, Taichung, Taiwan, R.O.C.
 Chiyoda Kaihatsu Co., Ltd., Tokyo, Japan
 Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
 Chung Shan Medical University, Taichung City, Taiwan, R.O.C.
 City of Hope Cancer Center, Duarte, CA, U.S.A.
 CLF Medical Technology Acceleration Program, Inc., Clifton Park, NY, U.S.A.

- Comité du Finistère, La Ligue Nationale Contre le Cancer, Paris, France
- Concerted Research Initiative of Ghent University, Belgium
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil
- Cotton Inc., Cary, NC, U.S.A.
- Crafoordska Stiftelsen, Lund, Sweden
- Crusade Laboratories, Glasgow, U.K.
- Curie Institut, Paris, France
- Czech Ministry of Industry and Trade, Prague, Czech Republic
- Czech Science Foundation
- Dairy Farmers of Canada, Ottawa, ON, Canada
- Danish Cancer Society
- Danish Medical Research Council
- Dental Research Foundation, Medical College of Georgia, Augusta, GA, U.S.A.
- Department of Anatomical Pathology, Mount Sinai Hospital in Toronto, Canada
- Department of Education, Universities and Research, Spain
- Department of Health of the Basque Government, Bilbao, Spain
- Department of Health, Taiwan, R.O.C.
- Department of Internal Medicine, Wayne State University, Detroit, MI, U.S.A.
- Department of Pharmacology, College of Medicine, Howard University, Washington, DC, U.S.A.
- Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA, U.S.A.
- Department of Radiology, Clinical Center, NIH, U.S.A.
- Department of Surgery at the University of California, San Francisco, CA, U.S.A.
- Department of Surgery II, Oita University Faculty of Medicine, Oita, Japan
- Deutsche Forschungsgemeinschaft, Bonn, Germany
- Deutsche José Carreras Stiftung für Leukämieforschung, Germany
- Deutsche Krebshilfe e.V.: Dr. Mildred Scheel Stiftung, Bonn, Germany
- Direct Insurance Ltd., Essex, U.K.
- EC Marie Curie Research Training Network, European Union
- EGIDE, France
- Else-Kröner-Fresenius Stiftung, Bad Homburg, Germany
- EuroBoNet, Germany
- European Commission, The European Union
- European Social Fund (ESF), England
- European Social Fund and National Resources (EPEAEK II “Pythagoras”), The European Union
- European Sunlight Association, Loupoigne, Belgium
- EuroTransBio, European Union
- Eustathios and Euphrosina Maroulis Memorial Fund, The European Union
- Faculty of Mechanical Engineering BUT, Brno University of Technology, Brno, Czech Republic
- Faculty of Science and Engineering, Kinki University, Osaka, Japan
- Far Eastern Memorial Hospital, Taiwan, R.O.C.
- Federal Ministry of Education and Research, Germany
- Finnish Cancer Society, Helsinki, Finland
- Flemish Government, Belgium
- Florida’s Breast Cancer Coalition Research Foundation, Hallandale Beach, FL, U.S.A.
- Fondation Vésale, Brussels, Belgium
- Fondazione of the Cassa di Risparmio della Provincia di Chieti, Italy
- Fonds voor Wetenschappelijk Onderzoek, Brussels, Belgium
- Foundation for Polish Science
- Foundation for Promotion of Cancer Research, Japan
- Foundation of Tianjin Nature Science, China
- Franz Lanyar Foundation, Graz, Austria
- Fresenius Biotech, Bad Homburg, Germany
- Fukuoka Cancer Society, Fukuoka, Japan
- Fukuoka University Hospital, Fukuoka, Japan
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), São Paulo, Brazil
- Fundação para a Ciência e a Tecnologia (FCT), Portugal
- Fundación Mutua Madrileña Automovilística, Madrid, Espana
- General Secretary of Research and Technology (GSRT), Ministry of Development, Greece
- Genzyme Corporation, Konstanz, Germany
- German Federal Ministry for Education and Science, Bonn, Germany
- German Jose Carreras Leukämie-Stiftung, München, Germany
- Government of the Republic of Korea
- Gunma University Hospital, Gunma, Japan
- Gunnar Nilsson Cancer Foundation, Sweden
- Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO, U.S.A.

- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
- Helsinki University Central Hospital, Finland
- Henan University, China
- Hiroshima City Asa Hospital, Hiroshima, Japan
- Holley Pharmaceuticals, Brea, CA, U.S.A.
- Hôpitaux Universitaires de Strasbourg, France
- Howard Hughes Medical Institute (HHMI), Chevy Chase, MD, U.S.A.
- Howard University, Washington, DC, U.S.A.
- HRH Crown Princess Lovisa's Association for Child Medical Care, Sweden
- Human Tumour Biology Group, The Oncology Research Unit Laboratories, The University of Liverpool School of Clinical Sciences, Liverpool, U.K.
- Hungarian National Science and Research Foundation
- Hungarian Science Foundation
- IASIS, Greece
- Indian Council of Medical Research (ICMR), New Delhi, India
- Indiana University Cancer Center Translational Research Acceleration Collaboration (ITRAC), Indianapolis, IN, U.S.A.
- Inner Mongolia Center for Endemic Disease Control and Research, Lin He, Inner Mongolia, China
- Innovative Research Institute for Cell Therapy, Seoul, Republic of Korea
- Institut de Chimie des Substances Naturelles, CNRS, France
- Institut National de la Sante et de la Recherche Medicale (INSERM), France
- Institut National du Cancer, Boulogne Billancourt, France
- Institute for Biomedical Research and Innovation, Hyogo, Japan
- Institute of Human Genetics, University of Bonn, Germany
- INTAS, Brussels, Belgium
- IOCB and Centre of New Antivirals and Antineoplastics, Ministry of Education, Youth and Sports, Prague, Czech Republic
- IPSEN/Biomeasure Inc., Milford, MA, U.S.A.
- ISPO, Florence, Italy
- Israel Cancer Association
- Israeli Ministry of Science and Technology (MOST)
- Istanbul University, Turkey
- Italian Association for Cancer Research (I' AIRC), Italy
- Italian Ministry of Health
- Japan Health Sciences Foundation
- Japanese Society for the Promotion of Science (JSPS), Tokyo, Japan
- Japanese Society of Geriatric Gastroenterology, Tokyo, Japan
- Jarislowsky Foundation, Montreal, Quebec, Canada
- Jiangsu Simcere Pharmaceutical Research Co., Ltd., China
- Johannes und Frieda Marohn-Stiftung, Erlangen, Germany
- Johns Hopkins Cancer Center, Baltimore, MD, U.S.A.
- Kanazawa University Hospital, Ishikawa, Japan
- Kangbuk Samsung Hospital, Seoul, South Korea
- Kansai Rosai Hospital, Hyogo, Japan
- Karolinska Institutet, Stockholm, Sweden
- Kawasaki Medical School Hospital, Okayama, Japan
- Kazan, McClain, Edises, Abrams, Fernandez, Lyons and Farrise Foundation, U.S.A.
- Key Project Foundation of Guangdong Province, China
- King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia
- Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
- Kitasato University Hospital, Kanagawa, Japan
- Köln Fortune Stiftung, Cologne, Germany
- Korea Science and Engineering Foundation (KOSEF), Daejeon, Republic of Korea
- KU Leuven Research Council, Belgium
- Kumamoto City Hospital, Kumamoto, Japan
- Kunlig Fysiografisk Sällskapet, Lund, Sweden
- Kuopio University, Finland
- Kurokawa Cancer Research Foundation, Japan
- Kyowa Hakko Pharmaceutical Co., Ltd., Tokyo, Japan
- La Ligue Nationale Contre le Cancer, Paris, France
- Laboratory of Pathology, Toyama University Hospital, Toyama, Japan
- Larry Hall Memorial Trust, U.S.A.
- Latvian Cancer Hospitals
- Latvian Medical Academy
- Lemelbaum Family, Israel
- Libyan Board of Medical Specialties
- Libyan Ministry of Health
- Lions Cancer Research Fund, Umea, Sweden
- Lions Foundation in Umea, Sweden
- Lloyd Carr-Harris Foundation, Canada
- LUA Foundations from the University of Gothenburg and Uppsala, Sweden
- Lund University Medical Faculty, Sweden
- Luso-Hungarian Cooperation, Hungary
- Lymphoma Foundation, NY, U.S.A.

- M.D. Anderson Cancer Center, Graduate School of Biomedical Sciences, Houston, TX, U.S.A.
- Madrid Mutual Foundation [Fundación Mutua Madrileña], Spain
- MAGIC core of the National Research Program for Genomic Medicine, National Science Council, Taipei, Taiwan, R.O.C.
- Mainz University Research Foundation (MAIFOR), Mainz, Germany
- Malmö Hospital Foundation, Sweden
- MAS Cancer Foundation, Sweden
- Medical College of Wisconsin, Milwaukee, WI, U.S.A.
- Medical Research Center, Seoul, Republic of Korea
- Medical University of Lodz, Poland
- Mercedes Castresana Foundation, Vitoria, Spain
- Michael Smith Foundation for Health Research (MSFHR), British Columbia, Canada
- Ministère de l'Éducation Nationale, France
- Ministerio de Ciencia e Innovación, España
- Ministerio de Sanidad y Consumo, España
- Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan
- Ministry of Education, Prague, Czech Republic
- Ministry of Education, Youth and Sports, Prague, Czech Republic
- Ministry of Health and Welfare, Hungary
- Ministry of Health of the Czech Republic
- Ministry of Health, Labor and Welfare, Tokyo, Japan
- Ministry of Land, Transport and Maritime, Republic of S. Korea
- Ministry of Science and Higher Education, Poland
- Ministry of Scientific Research and Information Technology, Warsaw, Poland
- MIR Preclinical Services, Ann Arbor, MI, U.S.A.
- Miyagi Cancer Center, Miyagi, Japan
- Miyata Foundation, Meikai University School of Dentistry, Saitama, Japan
- Molecular and Genetic Imaging Core, National Research Program for Genomic Medicine, Taipei, Taiwan, R.O.C.
- Monika Kutzner Stiftung, Berlin, Germany
- Münster University Hospital, Germany
- Nagoya City University Hospital, Aichi, Japan
- National Cancer Center Hospital, Tokyo, Japan
- National Cancer Center, Gyeonggi-do, Republic of Korea
- National Cancer Institute (NCI), NIH, Bethesda, MD, U.S.A.
- National Health and Environmental Effects Research Laboratory, Research Triangle Park, NC, U.S.A.
- National Health Research Institute, Taipei, Taiwan, R.O.C.
- National Institute of Biomedical Innovation (NiBio), Osaka, Japan
- National Institute of Dental and Craniofacial Research, Bethesda, MD, U.S.A.
- National Institute of Environmental Health and Sciences (NIEHS), Research Triangle Park, NC, U.S.A.
- National Institutes of Health (NIH), Bethesda, MD, U.S.A.
- National Kyushu Cancer Center, Fukuoka, Japan
- National Natural Sciences Foundation, Guangdong Province, China
- National Science Council, Taipei, Taiwan, R.O.C.
- New York College of Podiatric Medicine, NY, U.S.A.
- Nihon University College of Pharmacy, Tokyo, Japan
- Nikolaus Fiebiger Centre, University of Erlangen, Germany
- Ningbo Puai Biotech, Co., Ltd., China
- North Carolina Children's Hospital, Chapel Hill, NC, U.S.A.
- Norwegian Cancer Association
- Norwegian Cancer Society
- Norwegian Research Council
- Novartis Pharma AG, Basel, Switzerland
- Nuclear Medicine Department, Clinical Center, NIH, U.S.A.
- Obel Foundation, Aalborg, Denmark
- Okayama University Hospital, Okayama, Japan
- Ordway Research Institute, Inc., Albany, NY, U.S.A.
- Örebro County Research Committee, Sweden
- Osaka City University Hospital, Osaka, Japan
- Osaka City University Medical Research Foundation, Osaka, Japan
- Osaka Medical College Hospital, Osaka, Japan
- Osaka Medical Research Foundation for Incurable Diseases, Osaka, Japan
- Ovar'coming Together and Riley Children's Foundation, U.S.A.
- Paavo Koistinen Foundation, Finland
- Pathology Section, Kanazawa University Hospital, Kanazawa, Japan
- Pennsylvania Department of Health, Harrisburg, PA, U.S.A.
- Peripro, Tyrol, Austria
- Pfizer, Inc., New York, NY, U.S.A.
- Pharmaceutical Research Institute, Albany, NY, U.S.A.
- Polish Ministry of Science (Polish State Committee for Scientific Research)
- Polish State Committee for Scientific Research

- Portuguese Association of Urology
 Possehl-Stiftung, Lübeck, Germany
- Radiology Department, "G. Dossetti" Hospital, Bassano,
 Bologna, Italy
 Research Foundation of the Norwegian Radium Hospital,
 Oslo, Norway
 Research Foundation, Istanbul University, Turkey
 Research Laboratory, Department of Pathology, The
 Norwegian Radium Hospital, Oslo, Norway
 RiscRad, European Union
 Roche, Nutley, NJ, U.S.A.
 Rose Hills Foundation, Los Angeles, CA, U.S.A.
 Royal Manchester Children's Hospital Children's Cancer
 and Leukaemia, Manchester, U.K.
 Rudolf Bartling Stiftung, Hannover, Germany
 Russian Foundation for Basic Research
- Saarland University, Homburg/Saar, Germany
 Sagara Hospital, Kagoshima, Japan
 Saitama Cancer Center, Saitama, Japan
 Salford University, Greater Manchester, U.K.
 Sanofi-Aventis, Paris, France
 Schering-Plough, France
 Science and Technology Foundation, Portugal (FCT)
 Scottish Executive, Department of Enterprise and Lifelong
 Learning
 Sealy Center for Cancer Cell Biology Fellowship,
 Galveston, TX, U.S.A.
 Seidel Family Trust, Israel
 Seoul National University College of Medicine, Seoul,
 Republic of Korea
 Shinshu University Hospital, Nagano, Japan
 Showa University, Tokyo, Japan
 Sign Path Pharma, Inc., Quakertown, PA, U.S.A.
 Sigrid Jusélius Foundation, Finland
 Sigval Bergesen D.Y. og hustru Nenkis Foundation,
 Norway
 Smoking Research Foundation, Japan
 Society for Experimental Biology and Medicine,
 Maywood, NJ, U.S.A.
 Soluscience S.A., Clermont-Ferrand, France
 Sonnenfeld-Stiftung, Berlin, Germany
 Spanish National Network of Cancer Centers
 St. Baldrick's Foundation, Pasadena, CA, U.S.A.
 State Committee for Scientific Research, Warsaw, Poland
 Sterix Ltd, member of the Ipsen Group, Slough, U.K.
 Stichting Bevordering Diagnostische Morfometrie,
 Middelburg, The Netherlands
- Stichting tegen Kanker, Belgium
 Stockholm Cancer Society, Sweden
 Susan G. Komen Breast Cancer Foundation, TX,
 U.S.A.
 Swedish Cancer Foundations
 Swedish Cancer Research Council
 Swedish Cancer Society
 Swedish Cancer Research Foundation, Northern
 Sweden
 Swedish Cancerfonden
 Swedish Children Cancer Foundation
 Swedish City Council
 Swedish Medical Research Council
 Swedish National Research Council
 Swedish Research Council for Environment,
 Agricultural Sciences and Spatial Planning (FORMAS),
 Stockholm, Sweden
 Swedish Research Council, Stockholm, Sweden
 Swedish Society of Medicine
 Szeged Foundation for Cancer Research, Hungary
- Taiho Pharmaceutical Co., Ltd., Nagoya, Japan
 Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
 Taiwan Liposome Company, Taipei, Taiwan, R.O.C.
 Tang Foundations, Las Vegas, NV, U.S.A.
 Terry Fox Cancer Research Foundation, Chilliwack, BC,
 Canada
 The Executive Yuan, Taiwan, R.O.C.
 Tim Kelly for Insight Medical Communications Inc.
 (a division of Grey Healthcare Group, on behalf of
 Roche), Nutley, NJ, U.S.A.
 Tissue Bank in China Medical University Hospital,
 Taichung, Taiwan, R.O.C.
 Tohoku University, Sendai, Japan
 Turku University Hospital, Finland
 Tyrolean Regional Government, Innsbruck, U.S.A.
- U.S. Army Medical Research, Frederick, MD, U.S.A.
 U.S. Department of Veterans Affairs, Washington, DC,
 U.S.A.
 U.S. Environmental Protection Agency (EPA),
 U.S.A.
 U.S. Public Health Service, Rockville, MD, U.S.A.
 Uehara Memorial Foundation, Japan
 United States Department of Defense, Washington, DC,
 U.S.A.
 University Hospital of Lund, Sweden
 University of British Columbia Department of Surgery,
 Canada

University of California, San Francisco Academic Senate,
San Francisco, CA, U.S.A.
University of Mississippi Medical Center, Jackson, MS,
U.S.A.
University of Missouri-Columbia School of Medicine
Department of Radiology, Columbia, MO, U.S.A.
University of New South Wales, Australia
University of Palermo, Italy
University of Strasbourg, France
University of Surrey, U.K.
University of Umea, Sweden
University of Virginia Cancer Center, Charlottesville,
VA, U.S.A.
US Military Cancer Institute, Washington, DC, U.S.A.
UV Foundation, McLean, VA, U.S.A.
Veterans General Hospital, Taipei, Taiwan, R.O.C.
Vitamin D Society, Canada
Vlaamse Liga tegen Kanker, Belgium
W.M. Keck Foundation, Los Angeles, CA, U.S.A.
Weleda AG, Arlesheim, Switzerland
Werner and Klara Kreitz Stiftung, Kiel, Germany
Wilhelm-Sander Stiftung, München, Germany
Wisconsin Breast Cancer Showhouse for a Cure,
Thiensville, WI, U.S.A.
Women's Cancer Association, University of Miami, Miami,
FL, U.S.A.
Wuhan University of Science and Technology, Hubei, P.R.
China

Contents, Volume 29, 2009

Number 1

Experimental Studies

Bortezomib Therapeutic Effect is Associated with Expression of FGFR3 in Multiple Myeloma Cells. M. GUAN, L. ZHU, G. SOMLO, A. HUGHES, B. ZHOU, Y. YEN (*Duarte, CA, USA; Zhejiang, China*)..... 1

Utilization of a Right-handed Coiled-coil Protein from Archaeobacterium *Staphylothermus marinus* as a Carrier for Cisplatin. M. ERIKSSON, S. HASSAN, R. LARSSON, S. LINDER, T. RAMQVIST, H. LÖVBORG, T. VIKINGE, E. FIGGEMEIER, J. MÜLLER, J. STETEFELD, T. DALIANIS, S. ÖZBEK (*Stockholm; Uppsala; Linköping, Sweden; Basel, Switzerland; Winnipeg, Manitoba, Canada; Heidelberg, Germany*) 11

Gene Amplification of *Myc* and its Coamplification with *ERBB2* and *EGFR* in Gallbladder Adenocarcinoma. A. OOI, S. SUZUKI, K. NAKAZAWA, J. ITAKURA, I. IMOTO, H. NAKAMURA, Y. DOBASHI (*Ishikawa; Yamanishi; Tokyo; Saitama, Japan*) 19

Effect of Verapamil on the Expression of EGFR and NM23 in A549 Human Lung Cancer Cells. C. ZHANG, F. LV, L. ZHOU, X. LI, X.-X. WU, R.M. HOFFMAN (*Harbin; Qiqihaer, China; Kagawa, Japan; San Diego, CA, USA*) 27

Antioxidant Effects of Quercetin and Coenzyme Q10 in Mini Organ Cultures of Human Nasal Mucosa Cells. M. REITER, K. RUPP, P. BAUMEISTER, S. ZIEGER, U. HARRÉUS (*Munich, Germany*) 33

Distinct Patient Responses to Activation of T-cells by Free HER-2, G89 (777-789) and Protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} Peptides Could Lead to Development of Personalized Cancer Vaccines. Y. LI, S. MATSUEDA, C.L. EFFERSON, N. TSUDA, K. KAWANO, H. GAO, G.E. PEOPLES, C.G. IOANNIDES (*Houston; San Antonio, TX, USA*) 41

Adhesion/Growth-regulatory Tissue Lectin Galectin-1 in Relation to Angiogenesis/Lymphocyte Infiltration and Prognostic Relevance of Stromal Up-regulation in Laryngeal Carcinomas. S. SAUSSEZ, C. DECAESTECKER, S. CLUDTS, P. ERNOUX, D. CHEVALIER, K. SMETANA Jr., S. ANDRÉ, X. LEROY, H.-J. GABIUS (*Mons; Brussels, Belgium; Lille, France; Prague, Czech Republic; Munich, Germany*) 59

Differences in the Gene Expression Profile of Matrix Metalloproteinases (MMPs) and their Inhibitors (TIMPs) in Primary Colorectal Tumors and their Synchronous Liver Metastases. B. GENTNER, A. WEIN, R.S. CRONER, I. ZEITRAEGER, R.M. WIRTZ, F. ROEDEL, A. DIMMLER, L. DORLAQUE, W. HOHENBERGER, E.G. HAHN, W.M. BRUECKL (*Erlangen; Leverkusen; Frankfurt; Karlsruhe, Germany*) 67

Changes in Plasma TIMP-1 Levels after Resection for Primary Colorectal Cancer. C. FREDERIKSEN, A.F. LOMHOLT, G.J. DAVIS, B.L. DOWELL, M.A. BLANKENSTEIN, I.J. CHRISTENSEN, N. BRÜNNER, H.J. NIELSE (*Hvidovre; Frederiksberg; Copenhagen, Denmark; Abbott Park, IL, USA; Amsterdam, The Netherlands*) 75

Arsenic Trioxide Affects the Trace Element Balance in Tissues in Infected and Healthy Mice Differently. Y. MOLIN, P. FRISK, N.-G. ILBÄCK (*Uppsala, Sweden*) 83

Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts. K. KOLINSKY, Y.-E ZHANG, U. DUGAN, D. HEIMBROOK, K. PACKMAN, B. HIGGINS (*Nutley, NJ, USA*) 91

DNA Image Cytometry Predicts Disease Outcome in Stage II Colorectal Carcinoma. A. BUHMEIDA, M. HILSKA, A. ELZAGHEID, M. LAATO, Y. COLLAN, K. SYRJÄNEN, S. PYRHÖNEN (<i>Turku, Finland; Benghazi, Libya</i>)	99
Effect of a Metalloporphyrin Antioxidant (MnTE-2-PyP) on the Response of a Mouse Prostate Cancer Model to Radiation. A.Y. MAKINDE, X. LUO-OWEN, A. RIZVI, J.D. CRAPO, R.D. PEARLSTEIN, J.M. SLATER, D.S. GRIDLEY (<i>Loma Linda, CA; Denver, CO; Durham, NC, USA</i>)	107
Rho/ROCK and MAPK Signaling Pathways Are Involved in Glioblastoma Cell Migration and Proliferation. V.M. ZHRABIAN, B. FORZANI, Z. CHAU, R. MURALI, M. JHANWAR-UNIYAL (<i>Valhalla, NY, USA</i>)	119
The Role of the Integrin $\alpha\text{v}\beta\text{6}$ in Regulating the Epithelial to Mesenchymal Transition in Oral Cancer. D.M. RAMOS, D. DANG, S. SADLER (<i>San Francisco, CA, USA</i>)	125
Inhibition of <i>In Vivo</i> Tumour Growth by the Blocking of Host $\alpha\text{v}\beta\text{3}$ and $\alpha\text{IIb}\beta\text{3}$ Integrins. O. ENGEBRAATEN, M. TRIKHA, S. JUELL, S. GARMAN-VIK, Ø. FODSTAD (<i>Oslo, Norway; Malvern, PA, USA</i>)	131
Epigenetic Modifications of the <i>Estrogen Receptor β</i> Gene in Epithelial Ovarian Cancer Cells. O.W.S. YAP, G. BHAT, L. LIU, T.O. TOLLEFSBOL (<i>Atlanta, GA; Birmingham, AL, USA</i>)	139
Preclinical Evaluation of Adoptive Cell Therapy for Patients with Metastatic Renal Cell Carcinoma. G MARKEL, T. COHEN-SINAI, M.J. BESSER, K. OVED, O. ITZHAKI, R. SEIDMAN, A.J. TREVES, E. FRIDMAN, Y. KEISARI, Z. DOTAN, J. RAMON, J. SCHACHTER (<i>Tel Hashomer; Tel Aviv; Haifa, Israel</i>)	145
Expression of 25-Hydroxyvitamin D-1- α -Hydroxylase, and Vitamin D Receptor mRNA in Normal and Malignant Breast Tissue. K. McCARTHY, C. LABAN, S.A. BUSTIN, W. OGUNKOLADE, S. KHALAF, R. CARPENTER, P.J. JENKINS (<i>London, United Kingdom</i>)	155
Critical Role of Bad Phosphorylation by Akt in Cytostatic Resistance of Human Bladder Cancer Cells. A. SZANTO, Z. BOGNAR, A. SZIGETI, A. SZABO, L. FARKAS, F. GALLYAS Jr. (<i>Pecs, Hungary</i>)	159
Capsaicin-induced Apoptosis in Human Hepatoma HepG2 Cells. S.-P. HUANG, J.-C. CHEN, C.-C. WU, C.-T. CHEN, N.-Y. TANG, Y.-T. HO, C. LO, J.-P. LIN, J.-G. CHUNG, J.-G. LIN (<i>Taichung; Tainan, Taiwan, ROC</i>)	165
Type of Cell Death Induced by α -Trifluoromethyl Acylolins in Oral Squamous Cell Carcinoma. A. IDEO, K. HASHIMOTO, J. SHIMADA, M. KAWASE, H. SAKAGAMI (<i>Saitama; Ehime, Japan</i>)	175
Expression and Prognostic Value of Activating Transcription Factor 2 (ATF2) and its Phosphorylated Form in Mammary Carcinomas. S. KNIPPEN, T. LÖNING, V. MÜLLER, C. SCHRÖDER, F. JÄNICKE, K. MILDE-LANGOSCH (<i>Hamburg, Germany</i>)	183
Biological Evaluation of 2,3-Dichloro-5,8-Dimethoxy-1,4-Naphthoquinone as an Anti-breast Cancer Agent. Y.M. KANAAN, J.R. DAS, O. BAKARE, N.M. ENWEREM, S. BERHE, D. BEYENE, V. WILLIAMS, Y. ZHOU, R.L. COPELAND Jr. (<i>Washington, DC, USA</i>)	191
Tissue Microarrays are Reliable Tools for the Clinicopathological Characterization of Lung Cancer Tissue. L.H. SCHMIDT, S. BIESTERFELD, A. KÜMMEL, A. FALDUM, M. SEBASTIAN, C. TAUBE, R. BUHL, R. WIEWRODT (<i>Mainz, Germany</i>)	201
Specific Activation of Sodium Iodide Symporter Gene in Hepatoma Using Alpha-fetoprotein Promoter Combined with Hepatitis B Virus Enhancer (EIIAPA). R.-S. LIU, Y.-J. HSIEH, C.-C. KE, F.-D. CHEN, L. HWU, F.-H. WANG, J.-J. HWANG, C.-W. CHI, C.-H. LEE, S.-H. YEH (<i>Taipei; Taichung, Taiwan, ROC</i>)	211

Survivin May Enhance DNA Double-strand Break Repair Capability by Up-regulating Ku70 in Human KB Cells. G. JIANG, B. REN, L. XU, S. SONG, C. ZHU, F. YE (<i>Wuhan; Guangzhou, China</i>)	223
Expression of ErbB Receptors and their Cognate Ligands in Gastric and Colon Cancer Cell Lines. W.K.K. WU, T.T.M. TSE, J.J.Y. SUNG, Z.J. LI, L. YU, C.H. CHO (<i>Shatin, NT, Hong Kong, China</i>)	229
Application of Therapeutic Insonation to Malignant Glioma Cells and Facilitation by Echo-contrast Microbubbles of Levovist. Y. MANOME, H. FURUHATA, A. HASHIMOTO, N. FUNAMIZU, R. SUZUKI, S. ISHIZAWA, N. AKIYAMA, T. KOBAYASHI, M. WATANABE (<i>Tokyo, Japan</i>)	235
Sonodynamic Effects of Lomefloxacin Derivatives Conjugated with Methoxy Polyethylene Glycol on Sarcoma 180 Cells. C. KOMORI, K. OKADA, K. KAWAMURA, N. SUZUKI, S. CHIDA, T. SUZUKI (<i>Akita, Japan</i>)	243
Expression of CEACAM-1 in Pulmonary Adenocarcinomas and their Metastases. I. THÖM, O. SCHULT-KRONEFELD, I. BURKHOLDER, G. SCHUCH, B. ANDRITZKY, H. KASTENDIECK, L. EDLER, C. WAGENER, C. BOKEMEYER, U. SCHUMACHER, E. LAACK (<i>Hamburg; Heidelberg, Germany</i>)	249
Neoadjuvant Chemotherapy Followed by Limited Surgery in a Mouse Model of Head and Neck Cancer. J.J. LEE, J.-H. HAH, S.-A. IM, S.-Y. KIM, M.-W. SUNG, K.H. KIM, D.S. HEO (<i>Seoul, South Korea</i>)	255
Enhancement of Paclitaxel-induced Apoptosis by Inhibition of Mitogen-activated Protein Kinase Pathway in Colon Cancer Cells. R. XU, N. SATO, K. YANAI, T. AKIYOSHI, S. NAGAI, J. WADA, K. KOGA, R. MIBU, M. NAKAMURA, M. KATANO (<i>Fukuoka, Japan</i>)	261
Aberrant Methylation of the <i>UNC5C</i> Gene is Frequently Detected in Advanced Colorectal Cancer. K. HIBI, H. MIZUKAMI, A. SHIRAHATA, T. GOTO, M. SAKATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	271
Aberrant Methylation of the <i>p16</i> Gene Is Frequently Detected in Advanced Colorectal Cancer. T. GOTO, H. MIZUKAMI, A. SHIRAHATA, M. SAKATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Yokohama, Japan</i>)	275
<i>Vimentin</i> Methylation as a Marker for Advanced Colorectal Carcinoma. A. SHIRAHATA, M. SAKATA, K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Yokohama, Japan</i>)	279
Mechanisms of Grape Seed Procyanidin-induced Apoptosis in Colorectal Carcinoma Cells. C.-P. HSU, Y.-H. LIN, C.-C. CHOU, S.-P. ZHOU, Y.-C. HSU, C.-L. LIU, F.-M. KU, Y.-C. CHUNG (<i>Hsinchu; Tao Yuan, Taiwan, ROC</i>)	283
Hematogenous Cytokeratin 20 mRNA Detection Has Prognostic Impact in Oral Squamous Cell Carcinoma: Preliminary Results. T. TOYOSHIMA, E. VAIRAKTARIS, E. NKENKE, K.A. SCHLEGEL, F.W. NEUKAM, J. RIES (<i>Erlangen; Mainz, Germany; Athens, Greece</i>)	291
Immunogenicity of Native or Pegylated <i>E. coli</i> and <i>Erwinia</i> Asparaginases Assessed by ELISA and Surface Plasmon Resonance (SPR-Biacore) Assays of IgG Antibodies (Ab) in Sera from Patients with Acute Lymphoblastic Leukemia (ALL). V.I. AVRAMIS, E.V. AVRAMIS, W. HUNTER, M.C. LONG (<i>Los Angeles; Davis, CA; Piscataway, NJ, USA</i>)	299
MAP Kinase Modulation in Squamous Cell Carcinoma of the Oral Cavity. A. AGUZZI, D. MAGGIONI, G. NICOLINI, G. TREDICI, R.M. GAINI, W. GARAVELLO (<i>Monza, Italy</i>)	303
The Roles of Endoplasmic Reticulum Stress and Ca ²⁺ on Rhein-induced apoptosis in A-549 Human Lung Cancer cells. T.-C. HSIA, J.-S. YANG, G.-W. CHEN, T.-H. CHIU, H.-F. LU, M.-D. YANG, F.-S. YU, K.-C. LIU, K.-C. LAI, C.-C. LIN, J.-G. CHUNG (<i>Taichung; Kaohsiung; Taipei; Fong Yuan; Yunlin, Taiwan, ROC</i>)	309

Telomerase Reverse Transcriptase (TERT) Expression in Canine Mammary Tissues: A Specific Marker for Malignancy? M. ZAVLARIS, K. ANGELOPOULOU, I. VLEMMAS, N. PAPAIOANNOU (<i>Thessaloniki, Greece</i>).....	319
Emodin Induces Apoptosis of Human Tongue Squamous Cancer SCC-4 Cells through Reactive Oxygen Species and Mitochondria-dependent Pathways. S.-Y. LIN, W.-W. LAI, C.-C. HO, F.-S. YU, G.-W. CHEN, J.-S. YANG, K.-C. LIU, M.-L. LIN, P.-P. WU, M.-J. FAN, J.-G. CHUNG (<i>Taichung; Taiwan, ROC</i>)	327
Effect of Promoter Methylation of Multidrug Resistance 1 (<i>MDR1</i>) Gene in Gastric Carcinogenesis. T. TAHARA, T. ARISAWA, T. SHIBATA, H. YAMASHITA, D. YOSHIOKA, I. HIRATA (<i>Ishikawa, Japan</i>)	337
Cell Death Induced by Nutritional Starvation in Mouse Macrophage-like RAW264.7 Cells. H. SAKAGAMI, K. KISHINO, O. AMANO, Y. KANDA, S. KUNII, Y. YOKOTE, H. OIZUMI, T. OIZUMI (<i>Saitama; Kawasaki, Kanagawa, Japan</i>)	343
Serum Stimulates <i>Pleiotrophin</i> Gene Expression in an AP-1-dependent Manner in Human Endothelial and Glioblastoma Cells. E. POIMENIDI, M. HATZIAPOSTOLOU, E. PAPADIMITRIOU (<i>Patras, Greece</i>)	349
Resveratrol Inhibits Tumor Cell Adhesion to Endothelial Cells by Blocking ICAM-1 Expression. J.S. PARK, K.M. KIM, M.H. KIM, H.J. CHANG, M.K. BAEK, S.M. KIM, Y.D. JUNG (<i>Kwangju, South Korea</i>).....	355
Promoter Methylation Primarily Occurs in Tumor Cells of Patients with Non-small Cell Lung Cancer. W.K. DE JONG, G.F. VERPOOTEN, H. KRAMER, J. LOUWAGIE, H.J.M. GROEN (<i>Groningen, The Netherlands; Liège, Belgium</i>)	363
The Glutamatergic System Expression in Human PC-3 and LNCaP Prostate Cancer Cells. N. PISSIMISSIS, E. PAPAGEORGIOU, P. LEMBESSIS, A. ARMAKOLAS, M. KOUTSILIERIS (<i>Athens, Greece</i>).....	371
Effect of Tropolone, Azulene and Azulenequinone Derivatives on Prostaglandin E ₂ Production by Activated Macrophage-like Cells. M. NISHISHIRO, T. KURIHARA, H. WAKABAYASHI, H. SAKAGAMI (<i>Saitama, Japan</i>)	379
Effect of Splenectomy on Antitumor Immune System in Mice. J. HIGASHIJIMA, M. SHIMADA, M. CHIKAKIYO, T. MIYATANI, K. YOSHIKAWA, M. NISHIOKA, T. IWATA, N. KURITA (<i>Tokushima, Japan</i>) ..	385
Curcumin Synergizes the Growth Inhibitory Properties of Indian Toad (<i>Bufo melanostictus Schneider</i>) Skin-derived Factor (BM-ANF1) in HCT-116 Colon Cancer Cells. B. GIRI, A. GOMES, R. SENGUPTA, S. BANERJEE, J. NAUTIYAL, F.H. SARKAR, A.P.N. MAJUMDAR (<i>Kolkata, India; Detroit, MI, USA</i>)	395
Synthetic Inhibitors of Galectin-1 and -3 Selectively Modulate Homotypic Cell Aggregation and Tumor Cell Apoptosis. I. IURISCI, A. CUMASHI, A.A. SHERMAN, Y.E. TSVETKOV, N. TINARI, E. PICCOLO, M. D'EGIDIO, V. ADAMO, C. NATOLI, G.A. RABINOVICH, S. IACOBELLI, N.E. NIFANTIEV; ON BEHALF OF THE CONSORZIO INTERUNIVERSITARIO NAZIONALE PER LA BIO-ONCOLOGIA (CINBO), ITALY (<i>Chieti-Pescara; Messina, Italy; Moscow, Russia; Buenos Aires, Argentina</i>)	403
Endostar Induces Apoptotic Effects in HUVECs through Activation of Caspase-3 and Decrease of Bcl-2. Y. LING, N. LU, Y. GAO, Y. CHEN, S. WANG, Y. YANG, Q. GUO (<i>Nanjing, China</i>)	411
Release of Volatile Organic Compounds from the Lung Cancer Cell Line NCI-H2087 <i>In Vitro</i> . A. SPONRING, W. FILIPIAK, T. MIKOVINY, C. AGER, J. SCHUBERT, W. MIEKISCH, A. AMANN, J. TROPFMAIR (<i>Innsbruck, Austria; Rostock, Germany</i>)	419
* Review: Parasporin, a New Anticancer Protein Group from <i>Bacillus thuringiensis</i> . M. OHBA, E. MIZUKI, A. UEMORI (<i>Fukuoka; Kurume; Tokyo, Japan</i>).....	427

Inhibitory Effects of 5-Fluorouracil and Oxaliplatin on Human Colorectal Cancer Cell Survival Are Synergistically Enhanced by Sulindac Sulfide. S. FLIS, J. SPŁAWIŃSKI (<i>Warsaw, Poland</i>)	435
The Stem Cell Mobilizer StemEnhance® Does Not Promote Tumor Growth in an Orthotopic Model of Human Breast Cancer. C. DRAPEAU, H. MA, Z. YANG, L. TANG, R.M. HOFFMAN, D.J. SCHAEFFER (<i>San Clemente; San Diego, CA, Urbana, IL, USA</i>)	443
Ultrastructural Descriptions of Pericyte/Endothelium Peg-socket Interdigitations in the Microvasculature of Human Gastric Carcinomas. R.A. CARUSO, F. FEDELE, G. FINOCCHIARO, G. PIZZI, M. NUNNARI, G. GITTO, V. FABIANO, A. PARISI, A. VENUTI (<i>Messina, Italy</i>)	449
Tumor-specific Cytotoxicity and Type of Cell Death Induced by Naphtho[2,3- <i>b</i>]furan-4,9-diones and Related Compounds in Human Tumor Cell Lines: Relationship to Electronic Structure. A. TAKANO, K. HASHIMOTO, M. OGAWA, J. KOYANAGI, T. KURIHARA, H. WAKABAYASHI, H. KIKUCHI, Y. NAKAMURA, N. MOTOHASHI, H. SAKAGAMI, K. YAMAMOTO, A. TANAKA (<i>Saitama; Tokyo, Japan</i>)	455
* Review (page 427)	

Number 2

Clinical Studies

Spontaneous Regression of Colorectal Cancer Metastatic to Retroperitoneal Lymph Nodes. A.S. BIR, A.A. FORA, C. LEVEA, M.G. FAKIH (<i>Buffalo, NY, USA</i>)	465
The Diagnostic Hurdle of an Elderly Male with Bone Pain: How ¹⁸ F-FDG-PET Led to Diagnosis of a Leiomyosarcoma of the Adrenal Gland. H.W.M. VAN LAARHOVEN, M. VINKEN, R. MUS, U. FLUCKE, W.J.G. OYEN, W.T. VAN DER GRAAF (<i>Nijmegen, The Netherlands</i>)	469
Management of Thyroid Nodules as Secondary Involvement of Renal Cell Carcinoma: Case Report and Literature Review. R. DE STEFANO, R. CARLUCCIO, E. ZANNI, D. MARCHIORI, G. CICCHETTI, A. BERTACCINI, L. SENSI, L. PEDRINI, G. MARTORANA, E. MARLIA (<i>Bazzano; Bologna, Italy</i>)...	473
Small Cell Neuroendocrine Cervical Carcinoma with 1-Year Follow-up: Case Report and Review. G. BIFULCO, V.D. MANDATO, P. GIAMPAOLINO, R. PICCOLI, L. INSABATO, N. DE ROSA, C. NAPPI (<i>Naples, Italy</i>)..	477
Effect of Polymorphisms in the 3'-Untranslated Region (3'-UTR) of VEGF Gene on Gastric Pre-malignant Condition. T. TAHARA, T. ARISAWA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H. FUJITA, M. NAGASAKA, M. IWATA, K. TAKAHAMA, M. WATANABE, H. NAKANO, I. HIRATA (<i>Toyoake; Ishikawa, Japan</i>)	485
Usefulness of Combined Sestamibi Scintimammography, Axillary Ultrasonography and FNA Cytology in Reducing the Number of Sentinel Node Procedures in Patients with Early-stage Breast Cancer. F. LUMACHI, S. BORSATO, A. TREGNAGHI, G. FERRETTI, M. POVOLATO, D. CECCHIN, M.C. MARZOLA, P. ZUCCHETTA, F. BUI, A. FASSINA (<i>Padova; Udine, Italy</i>)	491
Intravenous Leiomyomatosis of the Uterus with Pulmonary Metastases or a Case with Benign Metastasizing Leiomyoma? B. BODNER-ADLER, M. BARTL, G. WAGNER (<i>Vienna, Austria</i>)	495
Malignant Myoepithelioma in the Maxillary Sinus: Case Report and Review of the Literature. M. HATA, K. TOKUUYE, Y. SHIOYAMA, S. NOMOTO, Y. INADOME, N. FUKUMITSU, H. NAKAYAMA, S. SUGAHARA, K. OHARA, M. NOGUCHI, Y. AKINE (<i>Yokohama, Kanagawa; Tsukuba, Ibaraki; Fukuoka, Fukuoka, Japan</i>)	497

Concomitant Right Subscapular and Left Olecranon Elastofibroma Followed by Inversion of the Lesions: Case Report. M. MAZZOCCHI, A. MARTANO, S. DI RONZA, E. DODBIBA, L. DIVONA, N. SCUDERI (<i>Perugia; Rome, Italy</i>).....	503
Overexpression of Cytochrome P450 1B1 in Advanced Non-small Cell Lung Cancer: A Potential Therapeutic Target. J.-M. SU, P. LIN, C.-K. WANG, H. CHANG (<i>Taichung; Miaoli, Taiwan, ROC</i>).....	509
Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer. J. Horiguchi, T. OYAMA, Y. KOIBUCHI, T. YOKOE, D. TAKATA, F. IKEDA, H. NAGAOKA, N. ROKUTANDA, R. NAGAOKA, Y. ISHIKAWA, H. ODAWARA, M. KIKUCHI, A. SATO, Y. IINO, I. TAKEYOSHI (<i>Gunma; Tochigi; Takasaki; Ogawa, Japan</i>)	517
Development of Gastro-lymphatic Fistula During Chemoradiotherapy for Advanced Esophageal Cancer: A Case Report. G. KASUYA, K. OGAWA, H. SHIMOJI, W. TAMAKI, H. KARIMATA, T. TOITA, Y. KAKINOHANA, T. ARIGA, T. NISHIMAKI, S. MURAYAMA (<i>Okinawa, Japan</i>)	525
Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck. G. FOUNTZILAS, A. BAMIAS, A. KALOGERA-FOUNTZILA, G. KARAYANNOPOULOU, M. BOBOS, E. ATHANASSIOU, K.T. KALOGERAS, C. TOLIS, P. TSEKERIS, P. PAKAKOSTAS, C. VAMVOUKA, T. ZARAMBOUKAS, P. KOSMIDIS, N. ZAMBOGLOU, D. MISAILIDOU (<i>Thessaloniki; Athens, Greece; Offenbach, Germany</i>)	529
Concomitant Overexpression of Heat-shock Protein 70 and HLA Class-I in Hepatitis C Virus-related Hepatocellular Carcinoma. S. YOSHIDA, S. HAZAMA, K. TOKUNO, K. SAKAMOTO, M. TAKASHIMA, T. TAMESA, T. TORIGOE, N. SATO, M. OKA (<i>Ube, Yamaguchi; Sapporo, Japan</i>)	539
Clinicopathological Prognostic Factors and Patterns of Recurrence in Vulvar Cancer. L. WOELBER, S. MAHNER, K. VOELKER, C.Z. EULENBURG, F. GIESEKING, M. CHOSCHZICK, F. JAENICKE, J. SCHWARZ (<i>Hamburg, Germany</i>)	545
Combination Chemotherapy of Vinorelbine and Cisplatin: A Phase I Pharmacokinetic Study in Patients with Metastatic Solid Tumors. J.-P. DELORD, C. PUOZZO, F. LEFRESNE, R. BUGAT (<i>Toulouse; Boulogne Billancourt, France</i>).....	553
Favourable Prognosis with Modified Dosing of Docetaxel and Cisplatin in Japanese Patients with Ovarian Cancer. D. AOKI, Y. WATANABE, T. JOBO, K. USHIJIMA, K. HASEGAWA, N. SUSUMU, N. SUZUKI, R. AOKI, S. ISONISHI, S. SAGAE, B. ISHIZUKA, T. KAMURA, Y. UDAGAWA, H. HOSHIAI, Y. OHASHI, K. OCHIAI, K. NODA (<i>Tokyo; Osaka; Kanagawa; Fukuoka; Aichi; Hokkaido, Japan</i>)	561
Immunotherapy in Patients with Less than Complete Response to Chemotherapy. F. RECCHIA, G. CANDELORO, S. NECOZIONE, R. BISEGNA, M. BRATTA, S. REA (<i>Avezzano; Rome; L'Aquila, Italy</i>)	567
Test of Ovarian Cancer Multiplex xMAP Technology Panel. J. VRZALOVA, M. PRAZAKOVA, Z. NOVOTNY, O. TOPOLCAN, M. CASOVA, L. HOLUBEC JR. (<i>Prague; Pilsen, Czech Republic</i>)	573
Outpatient Chemotherapy with S-1 for Recurrent Head and Neck Cancer. T. YAMASHITA, S. SHINDEN, T. WATABE, A. SHIOTANI (<i>Saitama; Tochigi, Japan</i>)	577
Validity of Hepatic Resection of Colorectal Liver Metastases in the Elderly (75 Years and Older). K. NOJIRI, Y. NAGANO, K. TANAKA, K. MATSUO, S. YAMAGISHI, M. OTA, S. FUJII, C. KUNISAKI, S. TOGO, H. SHIMADA (<i>Yokohama, Japan</i>)	583
Correlation of Metallothionein Expression with Clinical Progression of Cancer in the Oral Cavity. J. SZELACHOWSKA, P. DZIEGIEL, J. JELEN-KRZESZEWSKA, M. JELEN, R. TARKOWSKI, B. SPYTKOWSKA, R. MATKOWSKI, J. KORNAFEL (<i>Wroclaw; Poznan, Poland</i>)	589

The Combination of Low Cytoplasmic and High Nuclear Expression of p27 Predicts a Better Prognosis in High-grade Astrocytoma. T. HIDAHA, S. HAMA, P. SHRESTHA, T. SAITO, Y. KAJIWARA, F. YAMASAKI, K. SUGIYAMA, K. KURISU (<i>Hiroshima, Japan</i>)	597
* Review: Chronic Lymphocytic Leukaemia. J. BOELEN, S. LUST, B. VANHOECKE, F. OFFNER (<i>Ghent, Belgium</i>).....	605
Association of Metastin/a G-protein-coupled Receptor Signaling and Down Syndrome Critical Region 1 in Epithelial Ovarian Cancer. K. HATA, Y. WATANABE, H. NAKAI, T. MINAMI, H. OHSAKI, E. HIRAKAWA, H. HOSHIAI (<i>Takamatsu; Osaka-Sayama; Tokyo, Japan</i>).....	617
Phase II Study of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer in Japan. J. Horiguchi, Y. RAI, K. TAMURA, T. TAKI, K. HISAMATSU, Y. ITO, T. SERIU, T. TAJIMA (<i>Gunma; Kagoshima; Fukuoka; Osaka; Hiroshima; Ariake, Japan; Princeton, NJ, USA</i>).....	625
* Review: Therapy-induced Toxicity of the Lungs: An Overview. A.G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K.D. DILANA, E.M. KARAPANAGIOTOU, K.N. SYRIGOS (<i>Athens, Greece</i>).....	631
Circulating Vascular Endothelial Growth Factors and their Soluble Receptors in Pre-invasive, Invasive and Recurrent Cervical Cancer. S. KUEMMEL, A. THOMAS, S. LANDT, A. FUGER, P. SCHMID, M. KRINER, J.-U. BLOHMER, J. SEHOULI, G. SCHALLER, W. LICHTENEGGER, A. KÖNINGER, I. FUCHS (<i>Essen; Berlin; Munich, Germany; London, UK</i>)	641
Characterization of a MAGE-1-derived HLA-A24 Epitope-specific CTL Line from a Japanese Metastatic Melanoma Patient. Y. AKIYAMA, K. MARUYAMA, S. TAI, M. KOMIYAMA, A. IIZUKA, M. TAKIKAWA, C. OHSHITA, A. YAMAMOTO, N. YAMAZAKI, Y. KIYOHARA, K. YAMAGUCHI (<i>Shizuoka; Saitama; Tokyo, Japan</i>)	647
Further Studies Support the Participation of Stem Cells in the Cell Turnover of Duodenal Adenomas. C.A. RUBIO (<i>Stockholm, Sweden</i>)	657
Efficacy of Concurrent Chemoradiotherapy for T1 and T2 Laryngeal Squamous Cell Carcinoma Regarding Organ Preservation. G. NISHIMURA, M. TSUKUDA, Y. MIKAMI, H. MATSUDA, C. HORIUCHI, T. TAGUCHI, M. TAKAHASHI, M. KAWAKAMI, M. WATANABE, T. NIHO, H. ABO, S. YAMOMOTO (<i>Yokohama, Japan</i>)	661
A Phase II Trial of Oral Vinorelbine and Capecitabine in Anthracycline Pretreated Patients with Metastatic Breast Cancer. J. FINEK, L. HOLUBEC JR., T. SVOBODA, L. SEFRHANSOVA, I. PAVLIKOVA, M. VOTAVOVA, M. SEDIVA, S. FILIP, R. KOZEVNIKOVA, S. KORMUNDA (<i>Pilsen; Prague; Hradec Kralove, Czech Republic</i>).....	667
Procollagen Type 1 Amino-terminal Propeptide: A Marker for Bone Metastases in Prostate Carcinoma. M. KLEPZIG, D. JONAS, G.M. OREMEK (<i>Frankfurt/Main, Germany</i>)	671
Successful Treatment with Three-weekly Paclitaxel of an Anthracycline-refractory Classical Kaposi's Sarcoma. N. SILVESTRIS, D. GALETTA, G. COLUCCI (<i>Bari, Italy</i>)	675
First Report of Liposarcoma of the Spermatic Cord after Radical Prostatectomy for Prostate Cancer. T. YOSHINO, K. YONEDA, T. SHIRANE (<i>Hiroshima, Japan</i>)	677
GnRH Receptor and Androgen Receptor Status and Outcome of Advanced Prostate Carcinomas. J. SZABÓ, K. BARTÓK, T. KRENÁCS, Z. SZEPESVÁRY, B. SZENDE (<i>Budapest, Hungary</i>)	681
Wall-invasion Pattern Correlates with Survival of Patients with Gallbladder Adenocarcinoma. K.-I. OKADA, H. KIJIMA, T. IMAIZUMI, K. HIRABAYASHI, M. MATSUYAMA, N. YAZAWA, Y. OIDA, S. DOWAKI, K. TOBITA, Y. OHTANI, M. TANAKA, S. INOKUCHI, H. MAKUUCHI (<i>Kanagawa; Aomori, Japan</i>) ...	685

Effects of Epoetin- α on Quality of Life of Cancer Patients with Solid Tumors Receiving Chemotherapy. C. CHRISTODOULOU, U. DAFNI, G. ARAVANTINOS, A. KOUTRAS, E. SAMANTAS, M. KARINA, J. JANINIS, P. PAKOSTAS, D. SKARLOS, H.P. KALOFONOS, G. FOUNTZILAS (<i>Athens; Patras; Thessaloniki, Greece</i>)	693
The Potential Role of Bcl-2 Expression, Apoptosis and Cell Proliferation (Ki-67 Expression) in Cases of Gastric Carcinoma and Correlation with Classic Prognostic Factors and Patient Outcome. A.C. TSAMANDAS, D. KARDAMAKIS, P. TSIAMALOS, A. LIAVA, V. TZELEPI, V. VASSILIOU, T. PETSAS, K. VAGENAS, V. ZOLOTA, C.D. SCOPA (<i>Patras, Greece</i>)	703
Initial Results of Colorectal Polyposis Research in Latvia. V. BOROŠENKO, A. IRMEJS, I. MELBĀRDEGORKUŠA, A. GARDOVSKIS, M. PAVĀRS, A. VANAGS, G. TROFIMOVIČS, E. MIKLAŠEVIČS, J. GARDOVSKIS (<i>Riga, Latvia</i>)	711
Preliminary Study of TIP47 as a Possible New Biomarker of Cervical Dysplasia and Invasive Carcinoma. A. SZIGETI, O. MINIK, E. HOCSAK, E. POZSGAI, A. BORONKAI, R. FARKAS, A. BALINT, J. BODIS, B. SUMEGI, S. BELLYEI (<i>Pécs, Hungary</i>)	717
Lung Cancer Susceptibility and Genetic Polymorphisms of <i>Exo1</i> Gene in Taiwan. N.-Y. HSU, H.-C. WANG, C.-H. WANG, C.-F. CHIU, H.-C. TSENG, S.-Y. LIANG, C.-W. TSAI, C.-C. LIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	725
Angiogenic Factors in Plasma of Brain Tumour Patients. A. ILHAN, W. GARTNER, D. NEZIRI, T. CZECH, W. BASE, W.H. HÖRL, L. WAGNER (<i>Vienna, Austria</i>)	731
Analysis of 7 Immunohistochemical Markers in Male Germ Cell Tumors Demonstrates the Prognostic Significance of p53 and MIB-1. D. PECTASIDES, G. PAPAXOINIS, M. NIKOLAOU, C. VALAVANIS, G. ARAVANTINOS, G. FOUNTZILAS, N. TAMVAKIS, E. PECTASIDES, I. LEKKA, P. ARAPANTONIDADIOTI, A. ZIZI, I. GHICONTI, T. ECONOMOPOULOS (<i>Athens; Piraeus; Thessaloniki, Greece</i>)	737
Epithelial Ovarian Cancer in Greece: A Retrospective Study of 1,791 Patients by the Hellenic Cooperative Oncology Group (HeCOG). D. PECTASIDES, G. PAPAXOINIS, G. FOUNTZILAS, G. ARAVANTINOS, A. BAMIAS, N. PAVLIDIS, H.P. KALOFONOS, E. TIMOTHEADOU, E. SAMANTAS, E. BRIASOULIS, D.V. SKARLOS, T. ECONOMOPOULOS, M.A. DIMOPOULOS (<i>Athens; Thessaloniki; Ioannina; Patras; Piraeus, Greece</i>)	745
* Review: Genetic Polymorphisms of Smoking-related Carcinogen Detoxifying Enzymes and Head and Neck Cancer Susceptibility. M. LACKO, M.B. OUDE OPHUIS, W.H.M. PETERS, J.J. MANNI (<i>Maastricht; Nijmegen, The Netherlands</i>)	753
Recently Intensified Chemotherapy for High-grade Osteosarcoma May Affect Fertility in Long-term Male Survivors. T. YONEMOTO, T. ISHII, Y. TAKEUCHI, Y. HAGIWARA, S. IWATA, S.-I. TATEZAKI (<i>Chiba, Japan</i>)	763
Combination Chemotherapy with Docetaxel, Vinorelbine and Estramustine Phosphate in Metastatic Androgen-resistant Prostate Cancer: A Single Institution Experience. D. PECTASIDES, E. PECTASIDES, G. PAPAXOINIS, A. KOUMARIANOU, A. PSYRRI, N. XIROS, N. TOUNTAS, K. KAMPOSIORAS, G. PAPATSIBAS, T. FLOROS, P. GOVERIS, S. KARAGEORGOPOULOU, T. ECONOMOPOULOS (<i>Athens, Greece</i>)	769
Cardiopulmonary Response to Exercise in Patients with Different Degrees of Lung Toxicity after Radiochemotherapy for Hodgkin's Disease. F. VILLANI, A. BUSIA, M. VILLANI, A. LAFFRANCHI, S. VIVIANI, V. BONFANTE (<i>Milan, Italy</i>)	777
p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up. G.E. THEODOROPOULOS, E. KARAFOKA, J.G. PAPAILIOU, P. STAMOPOULOS, C.P. ZAMBIRINIS, K. BRAMIS, S.-G. PANOUSSOPOULOS, E. LEANDROS, J. BRAMIS (<i>Athens, Greece</i>)	785
Errata	793
* Review (pages 605, 631, 753)	

Number 3

Proceedings of the 11th Annual Meeting of the Society for Biotherapeutic Approaches, December 1, 2007, Tokyo, Japan Special Issue Edited by G.I. Soma, M. Kato, H. Terada

Preface.....	795
* Review: Inhibition of Cancer Invasion and Metastasis by Targeting the Molecular Chaperone Heat-shock Protein 90. F. KOGA, K. KIHARA, L. NECKERS (<i>Tokyo, Japan; Bethesda, MD, USA</i>)	797
* Review: High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer. S. OHNO, Y. OHNO, N. SUZUKI, G.-I. SOMA, M. INOUE (<i>Ishikawa; Tokushima; Chiba; Kagawa, Japan</i>)	809
* Review: ROS and Innate Immunity. C. KOHCHI, H. INAGAWA, T. NISHIZAWA, G.-I. SOMA (<i>Kagawa-ken; Tokushima-ken; Chiba-ken; Yamaguchi-ken, Japan</i>)	817
* Review: Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands. S. MIYAMOTO, T. FUKAMI, H. YAGI, M. KUROKI, F. YOTSUMOTO (<i>Fukuoka, Japan</i>)	823
Long-term Outcome of Immunotherapy for Patients with Refractory Pancreatic Cancer. M. NAKAMURA, J. WADA, H. SUZUKI, M. TANAKA, M. KATANO, T. MORISAKI (<i>Fukuoka, Japan</i>)	831
Innate Host-defensive Function of a Hepatic Lipid Fraction Produced in Low-dose Carbon Tetrachloride-pretreated Mice. Z. TAIRA, H. MONMASU, Y. UEDA (<i>Tokushima, Japan</i>)	837
A Protein-bound Polysaccharide, PSK, Enhances Tumor Suppression Induced by Docetaxel in a Gastric Cancer Xenograft Model. A. YAMASAKI, M. SHODA, H. IJIMA, S. NAGAI, J. WADA, H. SUZUKI, N. CHIKAZAWA, T. TASAKA, C. KAMEDA, H. TANAKA, M. IKEBE, E. JO, N. SATO, M. NAKAMURA, F. SEKINE, T. MORISAKI, M. KATANO (<i>Fukuoka, Japan</i>)	843
Claudin-1 Protein is a Major Factor Involved in the Tumorigenesis of Colorectal Cancer. Q. HUO, T. KINUGASA, L. WANG, J. HUANG, J. ZHAO, H. SHIBAGUCHI, M. KUROKI, T. TANAKA, Y. YAMASHITA, K. NABESHIMA, H. IWASAKI, M. KUROKI (<i>Fukuoka, Japan</i>).....	851
* Review: Utility and Safety of LPS-based Fermented Flour Extract as a Macrophage Activator. Y. TANIGUCHI, N. YOSHIOKA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (<i>Tokushima; Kagawa; Yamaguchi; Chiba, Japan</i>)	859
Intracellular Localization of CD14 Protein in Intestinal Macrophages. N. YOSHIOKA, Y. TANIGUCHI, A. YOSHIDA, K. NAKATA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (<i>Tokushima; Kagawa; Osaka; Yamaguchi; Chiba, Japan</i>)	865
The Hedgehog Pathway is a Possible Therapeutic Target for Patients with Estrogen Receptor-negative Breast Cancer. C. KAMEDA, H. TANAKA, A. YAMASAKI, M. NAKAMURA, K. KOGA, N. SATO, M. KUBO, S. KUROKI, M. TANAKA, M. KATANO (<i>Fukuoka, Japan</i>)	871
The Contribution of Vascular Endothelial Growth Factor to the Induction of Regulatory T-Cells in Malignant Effusions. J. WADA, H. SUZUKI, R. FUCHINO, A. YAMASAKI, S. NAGAI, K. YANAI, K. KOGA, M. NAKAMURA, M. TANAKA, T. MORISAKI, M. KATANO (<i>Fukuoka, Japan</i>)	881
Effects of Focused Ultrasound Sonodynamic Treatment on the Rat Blood–Brain Barrier. S.-I. YOSHINO, T. FUKUSHIMA, S. HAYASHI, M. NONAKA, K. OGAWA, K. SASAKI, S.-I. UMEMURA (<i>Fukuoka; Saitama, Japan</i>)	889

Mechanism of Photofrin-enhanced Ultrasound-induced Human Glioma Cell Death. S. HAYASHI, M. YAMAMOTO, K. TACHIBANA, Y. UENO, G. BU, T. FUKUSHIMA (<i>Fukuoka, Japan; St. Louis, MO, USA</i>) .	897
* Review: The Role of Toll-like Receptor 2 in Survival Strategies of <i>Mycobacterium tuberculosis</i> in Macrophage Phagosomes. A. YOSHIDA, H. INAGAWA, C. KOHCHI, T. NISHIZAWA, G.-I. SOMA (<i>Tokushima; Chiba; Yamaguchi; Kagawa, Japan</i>)	907
Efficacy of Temozolomide Treatment in Patients with High-grade Glioma. S. OSHIRO, H. TSUGU, F. KOMATSU, T. OHMURA, M. OHTA, S. SAKAMOTO, T. FUKUSHIMA, T. INOUE (<i>Fukuoka, Japan</i>).....	911
Management of Pilomyxoid Astrocytomas: Our Experience. H. TSUGU, S. OSHIRO, F. YANAI, F. KOMATSU, H. ABE, T. FUKUSHIMA, Y. NOMURA, S. MATSUMOTO, K. NABESHIMA, K. TAKANO, H. UTSUNOMIYA (<i>Fukuoka, Japan</i>)	919
Infliximab Treatment for Anal Fistula in Patients with Crohn's Disease. D. HIGASHI, K. FUTAMI, Y. EGAWA, K. HIRANO, T. TOMIYASU, Y. ISHIBASHI, T. SIMOMURA, K. NII, H. KUROKI, T. MAEKAWA, Y. ONO, T. MATSUI (<i>Chikushino-shi, Japan</i>)	927
Flexible Structure of Cytochrome P450: Promiscuity of Ligand Binding in the CYP3A4 Heme Pocket. K. OHKURA, Y. KAWAGUCHI, Y. WATANABE, Y. MASUBUCHI, Y. SHINOHARA, H. HORI (<i>Chiba; Tokushima, Japan</i>)	935
Sonodynamic Therapy Consisting of Focused Ultrasound and a Photosensitizer Causes a Selective Antitumor Effect in a Rat Intracranial Glioma Model. M. NONAKA, M. YAMAMOTO, S. YOSHINO, S.-I. UMEMURA, K. SASAKI, T. FUKUSHIMA (<i>Fukuoka; Saitama, Japan</i>)	943
* Reviews (pages 797, 809, 817, 823, 859, 907)	

Number 4

Experimental Studies

Cell Growth Stimulation by CRASH, an Asparaginase-like Protein Overexpressed in Human Tumors and Metastatic Breast Cancers. U.H. WEIDLE, V. EVTIMOVA, S. ALBERTI, E. GUERRA, N. FERSIS, S. KAUL (<i>Penzberg; Heidelberg, Germany; Chieti, Italy</i>).....	951
Overexpression of <i>Cap43</i> is Associated with Malignant Status of Esophageal Cancer. M. SOHDA, Y. MOCHIDA, H. KATO, T. MIYAZAKI, M. NAKAJIMA, M. FUKUCHI, R. MANDA, Y. FUKAI, N. MASUDA, M. ONO, M. KUWANO, H. KUWANO (<i>Maebashi; Fukuoka; Kurume, Japan</i>)	965
Vessel Dilator and Kaliuretic Peptide Inhibit Ras in Human Prostate Cancer Cells. Y. SUN, E.J. EICHELBAUM, W.P. SKELTON IV, A. LENZ, H. WANG, D.L. VESELY (<i>Tampa, FL, USA</i>)	971
TP-110, a New Proteasome Inhibitor, Down-regulates IAPs in Human Multiple Myeloma Cells. M. IJIMA, I. MOMOSE, D. IKEDA (<i>Shizuoka, Japan</i>)	977
Noninvasive Bioluminescent and MicroPET Imaging for the Regulation of NF- κ B in Human Hepatoma-bearing Mice. T.-J. CHANG, Y.-J. CHANG, T.-Y. HO, C.-Y. HSIANG, C.-Y. YU, T.-W. LEE, W.-J. LIN, C.-H. CHANG (<i>Taoyuan; Taichung, Taiwan, ROC</i>)	987
23-Hydroxyursolic Acid Causes Cell Growth-Inhibition by Inducing Caspase-Dependent Apoptosis in Human Cervical Squamous Carcinoma HeLa Cells. M. TAKAYA, M. NOMURA, T. TAKAHASHI, Y. KONDO, K.-T. LEE, S. KOBAYASHI (<i>Ishikawa, Japan; Seoul, South Korea</i>)	995

Significance of 5-Fluorouracil-related Enzyme Activities in Predicting Sensitivity to 5-Fluorouracil in Bladder Carcinoma. H. FURUSE, Y. HIRANO, M. HARADA, L.H. MING, T. AOKI, Y. KURITA, S. MUGIYA, T. USHIYAMA, S. OZONO (<i>Hamamatsu, Japan</i>)	1001
Development of Targeted Therapy with Paclitaxel Incorporated into EGF-conjugated Nanoparticles. T. SHIMADA, M. UEDA, H. JINNO, N. CHIBA, M. WADA, J. WATANABE, K. ISHIHARA, Y. KITAGAWA (<i>Tokyo; Osaka, Japan</i>)	1009
A Novel Strategy of Cancer Gene Therapy by Transcriptional Targeting of an Allogeneic Histocompatibility Transgene. E. KUWADA, K. NOGUCHI, N. SEO, H. YAMASHIRO, K. EGAWA (<i>Tokyo; Shizuoka, Japan</i>) ...	1015
Up-regulation of Nuclear Receptor Corepressor (NCoR) in Progesterin-induced Growth Suppression of Endometrial Hyperplasia and Carcinoma. H. KASHIMA, A. HORIUCHI, J. UCHIKAWA, T. MIYAMOTO, A. SUZUKI, T. ASHIDA, I. KONISHI, T. SHIOZAWA (<i>Matsumoto; Kyoto, Japan</i>).....	1023
* Review: <i>RUNXI</i> Translocations in Malignant Hemopathies. E. DE BRAEKELEER, C. FÉREC, M. DE BRAEKELEER (<i>Brest, France</i>)	1031
The Use of Laser Microdissection and SELDI-TOF MS in Ovarian Cancer Tissue to Identify Protein Profiles. I. CADRON, T. VAN GORP, F. AMANT, I. VERGOTE, P. MOERMAN, E. WAELKENS, A. DAEMEN, R. VAN DE PLAS, B. DE MOOR, R. ZEILLINGER (<i>Leuven, Belgium; Vienna, Austria</i>)	1039
Levonorgestrel, Medroxyprogesterone and Progesterone Cause a Concentration-dependent Reduction in Endometrial Cancer (Ishikawa) Cell Density, and High Concentrations of Progesterone and Mifepristone Act in Synergy. B.T. MOE, A.B. VEREIDE, A. ØRBO, R. JÆGER, G. SAGER (<i>Tromsø, Norway</i>)	1047
High Concentrations of Progesterone and Mifepristone Mutually Reinforce Cell Cycle Retardation and Induction of Apoptosis. B.G. MOE, A.B. VEREIDE, A. ØRBO, G. SAGER (<i>Tromsø, Norway</i>).....	1053
Pharmacological Interplay between Breast Cancer Resistance Protein and Gefitinib in Epidermal Growth Factor Receptor Signaling. K. KATAYAMA, K. SHIBATA, J. MITSUHASHI, K. NOGUCHI, Y. SUGIMOTO (<i>Tokyo, Japan</i>).....	1059
Effect of Onconase on Double-stranded RNA <i>In Vitro</i> . A. SAXENA, S.K. SAXENA, K. SHOGEN (<i>Somerset, NJ, USA</i>)	1067
The Process Behind the Expression of <i>mdr-1/P-gp</i> and <i>mrp/MRP</i> in Human Leukemia/Lymphoma. M. HIROSE (<i>Tokushima, Japan</i>)	1073
Heparin Induces Apoptosis through Suppression of AKt in Oral Squamous Cell Carcinoma Cells. K. UEDA, S. INOUE, Y. ZHANG, T. KUTSUNA, S. INOUE, K. NOTO, N. ARAI, M. NOGUCHI (<i>Toyama, Japan; Beijing, China</i>)	1079
Indirect Antitumor Effects of Bisphosphonates on Prostatic LNCaP Cells Co-cultured with Bone Cells. T. TANAKA, H. KAWASHIMA, K. OHNISHI, K. MATSUMURA, R. YOSHIMURA, M. MATSUYAMA, K. KURATSUKURI, T. NAKATANI (<i>Osaka, Japan</i>).....	1089
* Review: Oestrogen-synthesising Enzymes and Breast Cancer. M. KULENDRAN, M. SALHAB, K. MOKBEL (<i>London; Uxbridge, Middlesex, UK</i>)	1095
EGFR Mutation Up-regulates EGR1 Expression through the ERK Pathway. M. MAEGAWA, T. ARAO, H. YOKOTE, K. MATSUMOTO, K. KUDO, K. TANAKA, H. KANEDA, Y. FUJITA, F. ITO, K. NISHIO (<i>Osaka, Japan</i>)	1111
Characterization of Phosphodiesterase 1 in Human Malignant Melanoma Cell Lines. K. SHIMIZU, T. MURATA, Y. WATANABE, C. SATO, H. MORITA, T. TAGAWA (<i>Tsu, Mie, Japan</i>)	1119

Tumor-specific Cytotoxicity and Type of Cell Death Induced by Benzo[b]cyclohept[e][1,4]oxazine and 2-Aminotropone Derivatives. T. NARITA, A. SUGA, M. KOBAYASHI, K. HASHIMOTO, H. SAKAGAMI, N. MOTOHASHI, T. KURIHARA, H. WAKABAYASHI (<i>Saitama; Tokyo, Japan</i>)	1123
Insulin-like Growth Factor-binding Protein-3 in Breast Cancer: Analysis with Tissue Microarray. S.-M. SHEEN-CHEN, H. ZHANG, C.-C. HUANG, R.-P. TANG (<i>Kaohsiung; Taoyuan, Taiwan, ROC; Xiamen, China</i>)	1131
Apoptosis-related Factors (TRAIL, DR4, DR5, DcR1, DcR2, Apoptotic Cells) and Proliferative Activity in Ameloblastomas. C. RIZZARDI, P. LEOCATA, L. VENTURA, M. ZWEYER, A. BROLLO, M. SCHNEIDER, M. MELATO (<i>Trieste; L'Aquila; Gorizia, Italy</i>)	1137
Rapamycin Effects on mTOR Signaling in Benign, Premalignant and Malignant Human Breast Epithelial Cells. S.H. KIM, K. ZUKOWSKI, R.F. NOVAK (<i>Detroit, MI, USA; Kangnung, South Korea</i>)	1143
* Review: Genetic and Molecular Abnormalities in Cholangiocarcinogenesis. V.J. HASSID, F.A. ORLANDO, Z.T. AWAD, D. TAN, T. KHOURY, B.H. AHMED, S.J. ALRAWI (<i>Jacksonville; Gainesville, FL; Houston, TX; Buffalo, NY, USA</i>)	1151
Increased Human Telomerase Reverse Transcriptase (hTERT) mRNA Expression but not Telomerase Activity is Related to Survival in Curatively Resected Non-small Cell Lung Cancer. R. METZGER, D. VALLBOHMER, C. MÜLLER-TIDOW, H. HIGASHI, E. BOLLSCHWEILER, U. WARNECKE-EBERZ, J. BRABENDER, S.E. BALDUS, H. XI, W.E. BERDEL, H. SERVE, A.H. HOELSCHER, P.M. SCHNEIDER (<i>Cologne; Münster, Germany; Kagoshima, Japan; Beijing, China; Zurich, Switzerland</i>)	1157
Gene Expression Changes in a Chemoresistant Model with Human Esophageal Cancer Xenografts Using cDNA Microarray. T. YOSHIDA, T. MIYOSHI, J.-I. SEIKE, H. YAMAI, H. TAKECHI, Y. YUASA, A. TANGOKU (<i>Tokushima, Japan</i>)	1163
ZD1839 (IRESSA®) Stabilizes p27 ^{Kip1} and Enhances Radiosensitivity in Cholangiocarcinoma Cell Lines. S. YABUUCHI, Y. KATAYOSE, A. ODA, M. MIZUMA, S. SHIRASOU, T. SASAKI, K. YAMAMOTO, M. OIKAWA, T. RIKIYAMA, T. ONOGAWA, H. YOSHIDA, H. OHTUSKA, F. MOTOI, S. EGAWA, M. UNNO (<i>Sendai, Japan</i>)	1169
Cisplatin Resistance of the HNSCC Cell Line UT-SCC-26A Can be Overcome by Stimulation of the EGF-Receptor. R. MANDIC, C.J. RODGARKIA-DARA, V. KROHN, S. WIEGAND, R. GRÉNMAN, J.A. WERNER (<i>Marburg, Germany; Vienna, Austria; Turku, Finland</i>)	1181
Expression of Metallothionein and p53 Antigens are Correlated in Oral Squamous Cell Carcinoma. S.V. CARDOSO, J.B. SILVEIRA-JÚNIOR, V. DE CARVALHO MACHADO, A.M. BATISTA DE PAULA, A.M. LOYOLA, M.C. FERREIRA DE AGUIAR (<i>Uberlândia; Belo Horizonte; Montes Claros, Brazil</i>)	1189
Subset of Esophageal Adenocarcinoma Expresses Adhesion Molecule L1 in Contrast to Squamous Cell Carcinoma. T. RAWNAQ, H. KLEINHANS, M. UTO, P.G. SCHURR, U. REICHEL, G. CATALDEGIRMEN, K.A. GAWAD, E.F. YEKEBAS, M. SCHACHNER, J.R. IZBICKI, J.T. KAIFI (<i>Hamburg, Germany</i>)	1195
Clock Gene Mouse Period2 Overexpression Inhibits Growth of Human Pancreatic Cancer Cells and Has Synergistic Effect with Cisplatin. A. ODA, Y. KATAYOSE, S. YABUUCHI, K. YAMAMOTO, M. MIZUMA, S. SHIRASOU, T. ONOGAWA, H. OHTSUKA, H. YOSHIDA, H. HAYASHI, T. RIKIYAMA, H. KIM, Y. CHOE, K. KIM, H. SON, F. MOTOI, S. EGAWA, M. UNNO (<i>Miyagi, Japan; Seoul, South Korea</i>)	1201
Effect of Fucoidan on the Biotinidase Kinetics in Human Hepatocellular Carcinoma. K. HAYAKAWA, T. NAGAMINE (<i>Tokyo; Gunma, Japan</i>)	1211

Effects of Bortezomib on Human Neuroblastoma Cells <i>In Vitro</i> and in a Metastatic Xenograft Model. U. VALENTINER, C. HAANE, N. NEHMANN, U. SCHUMACHER (<i>Hamburg, Germany</i>)	1219
Down-regulation of C/EBP α in Breast Cancer Cells by Hypoxia-Estrogen Combination is Mainly Due to Hypoxia. R. SEIFEDDINE, M.-C. FULCHIGNONI-LATAUD, L. MASSAAD-MASSADE (<i>Paris; Orsay; Villejuif, France</i>)	1227
Oct3/4 and Sox2 Are Significantly Associated with an Unfavorable Clinical Outcome in Human Esophageal Squamous Cell Carcinoma. Q. WANG, W. HE, C. LU, Z. WANG, J. WANG, K.E. GIERCKSKY, J.M. NESLAND, Z. SUO (<i>Oslo, Norway; Dalian; Zhengzhou; Anyang, China</i>)	1233
Gene Mutations in Esophageal Mucosa of Chagas Disease Patients. F. DA S. MANOEL-CAETANO, A.F.P. SILVEIRA, A.E. SILVA (<i>São José do Rio Preto, SP, Brazil</i>)	1243
Effect of Citrate on Malignant Pleural Mesothelioma Cells: A Synergistic Effect with Cisplatin. X. ZHANG, E. VARIN, S. ALLOUCHE, Y. LU, L. POULAIN, P. ICARD (<i>Caen, France; Guangxi, China</i>)	1249
Molecular Characterization of Permanent Cell Lines from Primary, Metastatic and Recurrent Malignant Peripheral Nerve Sheath Tumors (MPNST) with Underlying Neurofibromatosis-1. Y. FANG, A. ELAHI, R.C. DENLEY, P.H. RAO, M.F. BRENNAN, S.C. JHANWAR (<i>New York, NY; Tampa, FL; Houston, TX, USA</i>)	1255
Effects of Cepharanthine Alone and in Combination with Fluoropyrimidine Anticancer Agent, S-1, on Tumor Growth of Human Oral Squamous Cell Carcinoma Xenografts in Nude Mice. K. HARADA, T. FERDOUS, Y. ITASHIKI, M. TAKII, T. MANO, Y. MORI, Y. UEYAMA (<i>Yamaguchi; Tokushima, Japan</i>)	1263
Association of <i>GNB4</i> Intron-1 Haplotypes with Survival in Patients with UICC Stage III and IV Colorectal Carcinoma. K. RIEMANN, H. STRUWE, H. ALAKUS, B. OBERMAIER, K.J. SCHMITZ, K.W. SCHMID, W. SIFFERT (<i>Essen; Cologne; Martinsried, Germany</i>)	1271
Significant Association of Ku80 Single Nucleotide Polymorphisms with Bladder Cancer Susceptibility in Taiwan. C.-H. CHANG, C.-F. CHIU, S.-Y. LIANG, H.-C. WU, C.-L. CHANG, C.-W. TSAI, H.-C. WANG, H.-Z. LEE, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	1275
The Role of the Homeobox Genes BFT and CDX2 in the Pathogenesis of Non-small Cell Lung Cancer. P. GRIMMINGER, F.C. LING, S. NEISS, D. VALLBÖHMER, G. LURJE, P.M. SCHNEIDER, A. H. HÖLSCHER, R. METZGER, J. BRABENDER (<i>Cologne, Germany; Zurich, Switzerland</i>)	1281
Relevance of Apoptosis and Tolerance to Hypoxic Stress in Cells Transfected with Receptor for Advanced Glycation End Products (RAGE). K. HIWATASHI, S. UENO, F. KUBO, M. SAKODA, T. TATENO, T. HAYASHI, K. ABEYAMA, S. NATSUGOE (<i>Kagoshima, Japan</i>)	1287
<i>In Vivo</i> Modulation of Angiogenic Gene Expression by Acyclic Nucleoside Phosphonates PMEDAP and PMEG. B. OTOVÁ, J. HRDÝ, I. VOTRUBA, A. HOLÝ (<i>Prague, Czech Republic</i>)	1295
Declined Asparagine Synthetase mRNA Expression and Enhanced Sensitivity to Asparaginase in HL-60 Cells Committed to Monocytic Differentiation. K. HASHIMOTO, F. SUZUKI, H. SAKAGAMI (<i>Saitama, Japan</i>)	1303
<i>Ex Vivo</i> Evaluation of a Bipolar Application Concept for Radiofrequency Ablation. U. ZURBUCHEN, B. FRERICKS, A. ROGGAN, K. LEHMANN, D. BÖSSENROTH, H.-J. BUHR, J.-P. RITZ (<i>Berlin, Germany</i>) ..	1309
Both AP-1 and NF- κ B Seem to be Involved in Tumour Growth in an Experimental Rat Hepatoma. R. MOORE-CARRASCO, S. BUSQUETS, M. FIGUERAS, M. PALANKI, F.J. LÓPEZ-SORIANO, J.M. ARGILÉS (<i>Barcelona, Spain; Talca, Chile; San Diego, CA, USA</i>)	1315
Role of Ape1 and Base Excision Repair in the Radioresponse and Heat-radiosensitization of HeLa Cells. C.N. BATUELLO, M.R. KELLEY, J.R. DYNLACHT (<i>Indianapolis, IN, USA</i>)	1319

EGFR Inhibition Using Gefitinib Is Not Active in Neuroblastoma Cell Lines. J. RÖSSLER, E. ODENTHAL, B. GEOERGER, A. GERSTENMEYER, J. LAGODNY, C.M. NIEMEYER, G. VASSAL (<i>Freiburg, Germany; Villejuif, France</i>).....	1327
Matrix Metalloproteinases Are Involved in Both Type I (Apoptosis) and Type II (Autophagy) Cell Death Induced by Sodium Phenylacetate in MDA-MB-231 Breast Tumour Cells. S. AUGUSTIN, M. BERARD, S. KELLAF, N. PEYRI, F. FAUVEL-LAFÈVE, C. LEGRAND, L. HE, M. CRÉPIN (<i>Paris; Bobigny, France</i>).....	1335
Variations in Blood Ghrelin Levels in Prostate Cancer Patients Submitted to Hormone Suppressive Treatment. A. BERTACCINI, R. PERNETTI, D. MARCHIORI, U. PAGOTTO, F. PALLADORO, F. PALMIERI, G. VITULLO, M. GUIDI, G. MARTORANA (<i>Bologna, Italy</i>).....	1345
G ₂ -Phase Arrest Through <i>p21(WAF1/Cip1)</i> Induction and <i>cdc2</i> Repression by Gnidimacrin in Human Hepatoma HLE Cells. M. YOSHIDA, Y. MATSUI, A. IIZUKA, Y. IKARASHI (<i>Tokyo, Japan</i>)	1349
Comparison of the Cytotoxicity of 4 Preparations of Anti-T-cell Globulins in Various Hematological Malignancies. F. AYUK, N. MAYWALD, S. HANNEMANN, U. LARSEN, A. ZANDER, N. KRÖGER (<i>Hamburg, Germany</i>).....	1355
Colon Cancer and Protein Arginine Methyltransferase 1 Gene Expression. A. PAPADOKOSTOPOULOU, K. MATHIOUDAKI, A. SCORILAS, D. XYNOPOULOS, A. ARDAVANIS, E. KOUROUMALIS, M. TALIERI (<i>Athens; Heraklion, Greece</i>).....	1361
siRNA Targeting HIF-1 α Induces Apoptosis of Pancreatic Cancer Cells through NF- κ B-independent and -dependent Pathways under Hypoxic Conditions. C. CHEN, Z. YU (<i>TianJin, China; Stockholm, Sweden</i>)	1367
Overexpression of hnRNPA2/B1 in Bronchoscopic Specimens: a Potential early Detection Marker in Lung Cancer. S. KATSIMPOULA, M. PATRINOUGEOURGA, N. MAKRILIA, K. DIMAKOU, A. GUIALIS, D. ORFANIDOU, K.N. SYRIGOS (<i>Athens, Greece</i>).....	1373
Mannose-6-Phosphate/Insulin-like Growth Factor-II Receptor in Human Melanoma Cells: Effect of Ligands and Antibodies on the Receptor Expression. F. LAUBE (<i>Halle, Germany</i>).....	1383
Bladder Cancer and Polymorphisms of DNA Repair Genes (<i>XRCC1, XRCC3, XPD, XPG, APE1, hOGG1</i>). K.F. NARTER, A. ERGEN, B. AĞAÇHAN, U. GÖRMÜŞ, Ö. TİMİRCİ, T. İSBİR (<i>Istanbul, Turkey</i>).....	1389
ARE-I Polymorphism on PSA Gene in Prostate Cancer Patients of a Turkish Population. E. KALAY, A. ERGEN, F. NARTER, B. AĞAÇHAN, U. GÖRMÜŞ, N. YİĞİT, T. İSBİR (<i>Istanbul, Turkey</i>).....	1395
Design, Synthesis, Radiolabeling and <i>In Vitro</i> and <i>In Vivo</i> Characterization of Tumor-antigen- and Antibody-derived Peptides for the Detection of Breast Cancer. S.M. OKARVI, I.A. JAMMAZ (<i>Riyadh, Saudi Arabia</i>)	1399
Effects of Quercetin on the Pharmacokinetics of Etoposide after Oral or Intravenous Administration of Etoposide in Rats. X. LI, J.-S. CHOI (<i>Jilin, China; Gwangju, South Korea</i>).....	1411
Anti-proliferative and Apoptosis Induction Activity of Green Tea Polyphenols on Human Promyelocytic Leukemia HL-60 Cells. D.H. HAN, J.H. JEONG, J.H. KIM (<i>Seoul, South Korea</i>)	1417
Pro-apoptosis and Anti-proliferation Effects of a Recombinant Dominant-negative Survivin-T34A in Human Cancer Cells. C. SHEN, W. LIU, A.K. BUCK, S.N. RESKE (<i>Ulm, Germany; Huaihua, China</i>).....	1423
Cytotoxicity and Cellular Uptake of Doxorubicin and its Formamidine Derivatives in HL60 Sensitive and HL60/MX2 Resistant Cells. K. KIK, M. WASOWSKA-LUKAWSKA, I. OSZCZAPOWICZ, L. SZMIGIERO (<i>Lodz; Warsaw, Poland</i>).....	1429
(-)-Epigallocatechin Gallate Induced Apoptosis in Human Adrenal Cancer NCI-H295 Cells through Caspase-dependent and Caspase-independent Pathway. P.-P. WU, S.-C. KUO, W.-W. HUANG, J.-S. YANG, K.-C. LAI, H.-J. CHEN, K.-L. LIN, Y.-J. CHIU, L.-J. HUANG, J.-G. CHUNG (<i>Taichung; Yunlin; Tainan, Taiwan, ROC</i>)	1435

Novel Therapy for Malignant Pleural Mesothelioma Based on Anti-energetic Effect: An Experimental Study Using 3-Bromopyruvate on Nude Mice. X. ZHANG, E. VARIN, M. BRIAND, S. ALLOUCHE, N. HEUTTE, L. SCHWARTZ, L. POULAIN, P. ICARD (<i>Caen; Saclay, France; Guangxi, China</i>).....	1443
Intracellular Glutathione Regulates Sesquiterpene Lactone-induced Conversion of Autophagy to Apoptosis in Human Leukemia HL60 Cells. T. ITOH, K. OHGUCHI, Y. NOZAWA, Y. AKAO (<i>Gifu, Japan</i>)	1449
Immunohistochemical Staining of Ki-67 Using the Monoclonal Antibody Ki-S11 Is a Prognostic Indicator for Laryngeal Squamous Cell Carcinoma. C. CORDES, A-K. MÜNZEL, P. RUDOLPH, M. HOFFMANN, I. LEUSCHNER, S. GOTTSCHLICH (<i>Kiel, Germany</i>)	1459
* Reviews (pages 1031, 1095, 1151)	

Number 5

Clinical Studies

Human Papillomavirus Infection as a Prognostic Factor in Oropharyngeal Squamous Cell Carcinomas Treated in a Prospective Phase II Clinical Trial. S. JO, A. JUHASZ, K. ZHANG, C. RUEL, S. LOERA, S.P. WILCZYNSKI, Y. YEN, X. LIU, J. ELLENHORN, D. LIM, B. PAZ, G. SOMLO, N. VORA, S. SHIBATA (<i>Duarte, CA, USA</i>)	1467
Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients. P. DE CREMOUX, L. GRANDIN, V. DIÉRAS, A. SAVIGNONI, A. DEGEORGES, R. SALMON, M.A. BOLLET, F. REYAL, B. SIGAL-ZAFRANI, A. VINCENT-SALOMON, X. SASTRE-GARAU, H. MAGDELÉNAT, L. MIGNOT, A. FOURQUET; ON BEHALF OF THE BREAST CANCER STUDY GROUP OF THE INSTITUT CURIE (<i>Paris, France</i>)	1475
A Randomized Controlled Trial Investigating the Effects of Celecoxib in Patients with Localized Prostate Cancer. P. SOORIAKUMARAN, H.M. COLEY, S.B. FOX, P. MACANAS-PIRARD, D.P. LOVELL, A. HENDERSON, C.G. EDEN, P.D. MILLER, S.E.M. LANGLEY, R.W. LAING (<i>Guildford; Redhill, Surrey; Headington, Oxford, UK</i>)	1483
ErbB 1-4 Expression Alterations in Primary Colorectal Cancers and their Corresponding Metastases. I. LJUSLINDER, B. MALMER, M. ISAKSSON-METTÄVAINIO, Å. ÖBERG, R. HENRIKSSON, R. STENLING, R. PALMQVIST (<i>Umeå; Mölndal, Sweden</i>)	1489
Collision Tumor versus Multiphenotypic Differentiation: A Case of Carcinoma with Features of Colonic and Lung Primary Tumors. P. MURTHAIAH, A.M. TRUSKINOVSKY, S. SHAH, A.Z. DUDEK (<i>Minneapolis, MN, USA</i>).....	1495
Pathological Classification of DCIS and Planning of Therapeutic Management. O. BUONOMO, P. ORSARIA, G. CONTINO, D. VARVARAS, A. GIOIA, E. BONANNO, C. PISTOLESE, E. COSSU, T. PERRETTA, O. SCHILLACI, G. DEL MONTE, M. ROSELLI, T.C. MINEO, G. PETRELLA (<i>Rome, Italy</i>).....	1499
Carbon-11-Methionine PET Imaging of Choroidal Melanoma and the Time Course after Carbon Ion Beam Radiotherapy. K. TAMURA, K. YOSHIKAWA, H. ISHIKAWA, M. HASEBE, H. TSUJI, T. YANAGI, K. SUZUKI, A. KUBO, H. TSUJII (<i>Chiba; Tokyo, Japan</i>)	1507
Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan. T. ISHIKAWA, S. SHIMIZU, K. KATAYAMA, T. CHISHIMA, Y. HAMAGUCHI, T. DOI, M. TANABE, A. KASAHARA, N. YAMAGUCHI, K. NARUI, I. OHTA, C. MATSUMOTO, D. SHIMIZU, A. KITO, T. SUDA, M. INABA, T. ASAGA, N. MOMIYAMA, Y. ICHIKAWA, M. YOSHIMOTO, S. MORITA, H. SHIMADA (<i>Tokyo; Kanagawa; Yokohama, Japan</i>).....	1515

A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer. Y. ITANI, K. HOSOKAWA, K. ITO, S. TAKEUCHI, T. TABATA, H. TSUBAMOTO, H. FUJITA, M. AKIYAMA, S. ADACHI (<i>Nara; Kyoto; Hyogo; Mie; Shiga, Japan; Indianapolis, IN, USA</i>)	1521
Increased Prevalence of Regulatory T-Cells in the Peripheral Blood of Patients with Gastrointestinal Cancer. K. TOKUNO, S. HAZAMA, S. YOSHINO, S. YOSHIDA, M. OKA (<i>Ube, Yamaguchi, Japan</i>)	1527
A Pilot Study of Quality of Life of Patients with Hormone-refractory Prostate Cancer after Gene Therapy. S. TERAOKA, T. SHIRAKAWA, B. ACHARYA, M. MIYATA, N. HINATA, K. TANAKA, A. TAKENAKA, I. HARA, M. NAOE, K. FUJI, T. OKEGAWA, E. HIGASHIHARA, S. KAMIDONO, M. FUJISAWA, A. GOTOH (<i>Nishinomiya; Kobe; Wakayama; Tokyo, Japan</i>)	1533
Assessing the Size of Polyp Phantoms in Tandem Colonoscopies. C.A. RUBIO, C.M. HÖÖG, O. BROSTRÖM, J. GUSTAVSSON, M. KARLSSON, P. MORITZ, R. STIG, O. WIKMAN, L. MATTSSON, D. PALLI (<i>Stockholm, Sweden; Florence, Italy</i>).....	1539
Gemcitabine-Capecitabine plus Intra-arterial Epirubicin-Cisplatin in Pretreated Pancreatic Cancer Patients: A Phase I Study. A. MAMBRINI, P. PACETTI, A. DEL FREO, R. DELLA SETA, D. PEZZUOLO, T. TORRI, M. ORLANDI, R. TARTARINI, M. CANTORE (<i>Carrara, Italy</i>).....	1547
* Review: Cancer-induced Hypercalcemia. F. LUMACHI, A. BRUNELLO, A. ROMA, U. BASSO (<i>Padova, Italy</i>)	1551
Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer. R.J. BROOM, P.A. TANG, C. SIMMONS, L. BORDELEAU, A.M. MULLIGAN, F.P. O'MALLEY, N. MILLER, I.L. ANDRULIS, D.M. BRENNER, M.J. CLEMONS (<i>Toronto, ON, Canada</i>)	1557
Poster Abstracts of the 1st Capital Congress of the Gynecologic Oncology of the North-Eastern German Society of Gynecological Oncology (<i>Berlin, Germany</i>)	1563
Prognostic Value of Serum and Ascites Levels of Estradiol, FSH, LH and Prolactin in Ovarian Cancer. F. C.-K. CHEN, G. OSKAY-ÖZCELIK, K.J. BÜHLING, U. KÖPSTEIN, M. MENTZE, W. LICHTENEGGER, J. SEHOULI (<i>Berlin, Germany</i>)	1575
DNA Image Cytometry in the Differential Diagnosis of Benign and Malignant Lesions of the Bile Duct, the Pancreatic Duct and the Papilla of Vater. S. BIESTERFELD, L. DEACU (<i>Mainz, Germany</i>)	1579
Usefulness of Current Risk Groups in the Treatment of Surgically Staged Endometrial Carcinomas; A Population-based Study from Western Sweden. G. PAULSSON, A. GENELL, A.-M. JAKOBSEN, G. HORVATH (<i>Skövde; Göteborg, Sweden</i>)	1585
Primary Abdominal Wall Clear Cell Carcinoma: Case Report and Review of Literature. C. WILLIAMS, P. PETIGNAT, A. BELISLE, P. DROUIN (<i>Montreal, QC, Canada; Geneva, Switzerland</i>).....	1591
Tumor Immune Systems in Esophageal Cancer with Special Reference to Heat-shock Protein 70 and Humoral Immunity. M. NAKAJIMA, H. KATO, T. MIYAZAKI, M. FUKUCHI, N. MASUDA, Y. FUKAI, M. SOHDA, F. AHMAD, H. KUWANO (<i>Gunma, Japan</i>)	1595
High Incidence of Synchronous or Metachronous Breast Cancer in Patients with Malignant and Benign Thyroid Tumor or Tumor-like Disorders. Y. NIO, C. IGUCHI, M. ITAKURA, T. TOGA, K. HASHIMOTO, M. KOIKE, H. OMORI, Y. SATO, S.-I. ENDO (<i>Kyoto; Shimane; Hyogo, Japan</i>)	1607
Mifepristone May Halt Progression of Extensively Metastatic Human Adenocarcinoma of the Colon – Case Report. J.H. CHECK, E. DIX, L. SANSOUCIE, D. CHECK (<i>Camden, NJ, USA</i>).....	1611

Microsatellite Instability Does Not Predict the Efficacy of Chemotherapy in Metastatic Colorectal Cancer. A Systematic Review and Meta-Analysis. G. DES GUETZ, B. UZZAN, P. NICOLAS, O. SCHISCHMANOFF, G.-Y. PERRET, J.-F. MORERE (<i>Bobigny, France</i>).....	1615
Clinical and Pathological Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Hormonal Receptors, Her2 Status, Grading and Ki-67 Proliferation Index. L. MIGLIETTA, P. VANELLA, L. CANOBBIO, M.A. PARODI, P. GUGLIELMINI, F. BOCCARDO (<i>Genoa, Italy</i>).....	1621
Management of Cardiac Adverse Events Occurring with Sunitinib Treatment. M. SCHMIDINGER, A. BOJIC, U.M. VOGL, W. LAMM, C.C. ZIELINSKI (<i>Vienna, Austria</i>).....	1627
Genetic Polymorphisms in <i>CYP1A1</i> , <i>CYP1B1</i> , <i>COMT</i> , <i>GSTP1</i> and <i>NAT2</i> Genes and Association with Bladder Cancer Risk in a French Cohort. L. FONTANA, L. DELORT, L. JOUMARD, N. RABIAU, R. BOSVIEL, S. SATHI, L. GUY, J.-P. BOITEUX, Y.-J. BIGNON, A. CHAMOUX, D.J. BERNARD-GALLON (<i>Clermont-Ferrand, France</i>).....	1631
Comparison of Robotic-assisted <i>versus</i> Retropubic Radical Prostatectomy Performed by a Single Surgeon. Y.-C. OU, C.-R. YANG, J. WANG, C.-L. CHENG, V.R. PATEL (<i>Taichung, Taiwan, ROC; Orlando, FL, USA</i>).....	1637
Comparison of Clofarabine Activity in Childhood and Adult Acute Leukemia: Individual Tumor Response Study. J. STYCZYNSKI, L. GIL, K. DERWICH, J. WACHOWIAK, W. BALWIERZ, W. BADOWSKA, M. KRAWCZUK-RYBAK, M. MATYSIAK, M. WIECZOREK, A. BALCERSKA, D. SONTAJAKIMCZYK, J. STEFANIAK, J. KOWALCZYK, T. URASINSKI, G. SOBOL, M. KOMARNICKI, M. WYSOCKI (<i>Bydgoszcz; Poznan; Cracow; Olsztyn; Bialystok; Warsaw; Chorzow; Gdansk, Zabrze; Lublin; Szczecin; Katowice, Poland</i>).....	1643
The Clinical Significance of Serum Markers of Bone Turnover in NSCLC Patients: Surveillance, Management and Prognostic Implications. E. TERPOS, M. KIAGIA, E.M. KARAPANAGIOTOU, A. CHARPIDOU, K.D. DILANA, E. NASOTHIMIOU, K.J. HARRINGTON, A. POLYZOS, K.N. SYRIGOS (<i>Athens, Greece; London, UK</i>).....	1651
CYP17 Gene Polymorphism and its Association in North Indian Prostate Cancer Patients. R.C. SOBTI, L. GUPTA, H. THAKUR, A. SETH, S.K. SINGH, P. KAUR (<i>Chandigarh; New Delhi, India</i>).....	1659
Gastric Perforation Presenting as Empyema in a Patient with Pancreatic Cancer on Bevacizumab Treatment. Y.-Y. SHAO, Z.-Z. LIN, P.-C. LIANG, Y.-W. TIEN, A.-L. CHENG (<i>Taipei, Taiwan, ROC</i>).....	1665
Reconstruction of Periacetabular Bone Tumor by Vascularized Fibula Graft and Irradiated Autograft. K. MURAMATSU, K. IHARA, Y. TANI, R. IWANAGA, T. TAGUCHI (<i>Yamaguchi, Japan</i>).....	1669
Lymphatic Vessel Density in Correlation to Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. S. FRECH, K. HÖRMANN, F. RIEDEL, K. GÖTTE (<i>Mannheim, Germany</i>).....	1675
Clinicopathological Features of Perforated Colorectal Cancer. M. OGAWA, M. WATANABE, K. ETO, T. OMACHI, M. KOSUGE, K. HANYU, L. NOAKI, T. FUJITA, K. YANAGA (<i>Tokyo, Japan</i>).....	1681
Expression of Matriptase and Clinical Outcome of Human Endometrial Cancer. K. NAKAMURA, A. HONGO, J. KODAMA, F. ABARZUA, Y. NASU, H. KUMON, Y. HIRAMATSU (<i>Okayama, Japan</i>) ..	1685
Immunohistochemical Detection of WT1 Protein in Endometrial Cancer. S. OHNO, S. DOHI, Y. OHNO, S. KYO, H. SUGIYAMA, N. SUZUKI, M. INOUE (<i>Ishikawa; Tokyo; Osaka, Japan</i>).....	1691
Prognosis for Isolated Skin Recurrence after Breast Cancer Treated by Mastectomy. F. JAFFRE, V. LAVOUE, H. MESBAH, S. ROUQUETTE, O. AUDRAIN, J.F. LAURENT, J. LEVEQUE (<i>Rennes, France</i>).....	1697

Kinetics of HER2/neu ECD in 45 Patients Treated with Trastuzumab (Herceptin®) between January 2001 and June 2005 at the Grenoble University Hospital. A.-S. GAUCHEZ, M. COLONNA, F.-X. BRAND, N. RAVANEL, D. PASQUIER, R. PAYAN, M. MOUSSEAU (<i>Meylan; Saint Martin d'Hères; Grenoble, France</i>)	1703
GSTM1 and NAT2 Polymorphisms and Colon, Lung and Bladder Cancer Risk: A Case-control Study. A. ZUPA, A. SGAMBATO, G. BIANCHINO, G. IMPROTA, V. GRIECO, G. LA TORRE, B. CAMPISI, A. TRAFICANTE, M. AIETA, A. CITTADINI (<i>Potenza; Rome, Italy</i>)	1709
Lymph-vascular Space Involvement and Outer One-third Myometrial Invasion Are Strong Predictors of Distant Haematogeneous Failures in Patients with Stage I-II Endometrioid-type Endometrial Cancer. A. GADDUCCI, A. CAVAZZANA, S. COSIO, C. DI CRISTOFANO, R. TANA, A. FANUCCHI, G. TETI, R. CRISTOFANI, A.R. GENAZZANI (<i>Pisa; Massa-Carrara; Latina, Italy</i>)	1715
Comparison of Antiemetic Efficacy between Single and Repeated Treatments with a 5-HT ₃ Receptor Antagonist in Breast Cancer Patients with High-risk Emetogenic Chemotherapy. K. TAGUCHI, H. IHARA, M. ISHIHARA, Y. KOMORI, K. TANIZAWA, K. MATSUURA, Y. ITOH (<i>Gifu, Japan</i>)	1721
Phase I Study of the Sequential Administration of S-1 and Cisplatin for Metastatic Gastric Cancer. E. BABA, H. FUJISHIMA, H. KUSABA, T. ESAKI, H. ARIYAMA, K. KATO, R. TANAKA, K. MITSUGI, Y. SHIBATA, M. HARADA, S. NAKANO (<i>Fukuoka; Kagoshima, Japan</i>)	1727
Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer. T. HIROSE, T. SUGIYAMA, S. KUSUMOTO, T. SHIRAI, M. NAKASHIMA, T. YAMAOKA, K. OKUDA, K. OGURA, T. OHNISHI, T. OHMORI, M. ADACHI (<i>Tokyo, Japan</i>)	1733
Genetic Alterations in the PI3K Pathway in Prostate Cancer. X. SUN, J. HUANG, T. HOMMA, D. KITA, H. KLOCKER, G. SCHAFER, P. BOYLE, H. OHGAKI (<i>Lyon, France; Innsbruck, Austria</i>)	1739
Different Biological Materials are Found in Neoplastic Glands with Pores at the Invading Edge of Sporadic Colonic Carcinomas. C.A. RUBIO, C. LENANDER (<i>Stockholm, Sweden</i>).....	1745
Efficacy and Feasibility of IDEA Therapy for Refractory or Relapsed Non-Hodgkin's Lymphoma. H. NISHIMORI, N. FUJII, Y. MAEDA, K.-I. MATSUOKA, K. TAKENAKA, K. SHINAGAWA, K. IKEDA, K. MATSUO, M. HARADA, M. TANIMOTO (<i>Okayama; Fukuoka; Nagoya, Japan</i>)	1749
Carboplatin and Vinorelbine Combined with Subcutaneous Interleukin-2 in Metastatic Melanoma with Poor Prognosis. M.-S. VUORISTO, P. VIHINEN, T. SKYTTÄ, K. TYYNELÄ, P. KELLOKUMPU-LEHTINEN (<i>Tampere; Turku; Kuopio, Finland</i>)	1755
Topotecan-induced Long-term Remission of an Advanced Endometrial Cancer After Treatment with Cisplatinum, an Anthracycline and Paclitaxel. T. IDRIS, R. WINTER, U. LANG, E. PETRU (<i>Graz, Austria</i>)	1761
Clinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation for 30 Adults with Hematological Malignancies. K. KOBAYASHI, Y. MAEDA, Y. HARA, M. NISHIE-KATAOKA, H. NISHIMORI, H. SUGIYAMA, N. NAMBA, S. KUBONISHI, M. NIIYA, K. SHINAGAWA, K. IKEDA, M. TANIMOTO (<i>Okayama, Japan</i>)	1763
Correlation of Nuclear Morphometry of Breast Cancer in Histological Sections with Clinicopathological Features and Prognosis. F. ABDALLA, J. BODER, R. MARKUS, H. HASHMI, A. BUHMEIDA, Y. COLLAN (<i>Turku, Finland; Tripoli; Sabratha, Libya</i>)	1771
Significant Association of an XRCC4 Single Nucleotide Polymorphism with Bladder Cancer Susceptibility in Taiwan. C.-H. CHANG, C.-L. CHANG, C.-W. TSAI, H.-C. WU, C.-F. CHIU, R.-F. WANG, C.-S. LIU, C.-C. LIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	1777

Treatment of Patients with Unresectable Advanced Carcinoma of Biliary Tract – Chemotherapy and Surgical Resection. Z. MORISE, A. SUGIOKA, Y. TANAHASHI, Y. OKABE, M. IKEDA, T. KAGAWA, C. TAKEURA (<i>Aichi, Japan</i>).....	1783
Influence of Catumaxomab on Tumor Cells in Bone Marrow and Blood in Ovarian Cancer. P. WIMBERGER, M. HEUBNER, H. LINDHOFER, M. JÄGER, R. KIMMIG, S. KASIMIR-BAUER (<i>Essen; Munich; Martinsried, Germany</i>)	1787
Differences in Cytokine Levels in Melanoma Patients with and without Redness (Brenner Sign). J. MASHIAH, S. BRENNER, Y. PESSACH, V. BARAK, J. SCHACHTER (<i>Tel Aviv; Jerusalem, Israel</i>)	1793
Continuous Finasteride Therapy for Benign Prostate Hypertrophy Upgrades Both Neuroendocrine Differentiation and Aggressive Prostate Cancer. M. TARLE, B. SPAJIC, I. KRALJIC, Z. KUSIC (<i>Zagreb, Croatia</i>)	1797
Mutation Status of K-ras, p53 and Allelic Losses at 9p and 18q Are Not Prognostic Markers in Patients with Pancreatic Cancer. C. SALEK, P. MINARIKOVA, L. BENESOVA, V. NOSEK, R. STRNAD, M. ZAVORAL, M. MINARIK (<i>Prague, Czech Republic</i>)	1803
Mutation Analysis of IgVH Genes in Splenic Marginal Zone Lymphomas: Correlation with Clinical Characteristics and Outcome. C. KALPADAKIS, G.A. PANGALIS, E. DIMITRIADOU, M.K. ANGELOPOULOU, M.P. SIAKANTARIS, M.-C. KYRTSONIS, M. XIMERIS, T. TZENOU, S. SAHANAS, X. YIAKOUMIS, E.A. PAPAOKI, P. PANAYIOTIDIS, T. VASSILAKOPOULOS (<i>Athens; Heraklion, Greece</i>)	1811
Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung. Y. KIM, H.S. KIM, Z.Y. CUI, H.-S. LEE, J.S. AHN, C.K. PARK, K. PARK, M.-J. AHN (<i>Seoul, South Korea</i>)	1817
* Review: Molecular Imaging of Tumor Blood Vessels in Prostate Cancer. D. TILKI, M. SEITZ, B.B. SINGER, S. IRMAK, C.G. STIEF, O. REICH, S. ERGÜN (<i>Munich; Essen, Germany; New York, NY, USA</i>).....	1823
Clinical Correlations between Treatment with Anticoagulants/Antiaggregants and Late Rectal Toxicity after Radiotherapy for Prostate Cancer. K. TAKEDA, Y. OGAWA, H. ARIGA, M. KOTO, T. SAKAYAUCHI, K. FUJIMOTO, K. NARAZAKI, M. MITSUYA, Y. TAKAI, S. YAMADA (<i>Sendai, Japan</i>)	1831
Single Nucleotide Polymorphisms and Clinical Outcome in Patients with Biliary Tract Carcinoma Treated with Epirubicin, Cisplatin and Capecitabine. P. PACETTI, E. GIOVANNETTI, A. MAMBRINI, S. NANNIZZI, M. ORLANDI, R. TARTARINI, A. DEL FREO, M. DEL TACCA, R. DANESI, M. CANTORE (<i>Carrara; Pisa, Italy</i>)	1835
Multicenter Phase II Trial of First-line Docetaxel/Gemcitabine in Advanced Breast Cancer Pretreated with Adjuvant Anthracyclines. P. VICI, F. GIOTTA, L. DI LAURO, M. BRANDI, V. GEBBIA, P. FOGGI, V. LORUSSO, C. VITUCCI, D. SERGI, S.I. FATTORUSO, D. GIANNARELLI, G. VIOLA, S. CORSETTI, G. COLUCCI, M. LOPEZ (<i>Rome; Bari; Palermo; Lecce, Italy</i>).....	1841
Effects of the Conventional Antitumor Therapies Surgery, Chemotherapy, Radiotherapy and Immunotherapy on Regulatory T Lymphocytes in Cancer Patients. P. LISSONI, F. BRIVIO, L. FUMAGALLI, G. MESSINA, S. MEREGALLI, G. PORRO, F. ROVELLI, L. VIGORÈ, E. TISI, G. D'AMICO (<i>Monza, Milan, Italy</i>)	1847
Local Recurrence following Adjuvant Chemotherapy without Radiotherapy in Completely Resected Stomach and Gastroesophageal Junction Adenocarcinoma. G. BAR-SELA, M. TSALIC, M. STEINER, M. WOLLNER, N. HAIM (<i>Haifa, Israel</i>).....	1853
Erratum	1857
* Reviews (pages 1551, 1823)	

Number 6

Experimental Studies

- Differentially Regulated Genes in *MEN1*-transfected BON Cells Using RT-differential Display and Oligonucleotide Microarrays. J.R. LOPEZ-EGIDO, Y. WANG, M. GRÖNBERG, P. GRIMFJÄRD, S. WANG, P. STÅLBERG, B. SKOGSEID (*Uppsala, Sweden*) 1859
- Combination of PI3K/mTOR Inhibition Demonstrates Efficacy in Human Chordoma. J. SCHWAB, C. ANTONESCU, P. BOLAND, J. HEALEY, A. ROSENBERG, P. NIELSEN, J. IAFRATE, T. DELANEY, S. YOON, E. CHOY, D. HARMON, K. RASKIN, C. YANG, H. MANKIN, D. SPRINGFIELD, F. HORNICEK, Z. DUAN (*Boston, MA; New York, NY, USA*)..... 1867
- Efficacy of a Genetically-modified *Salmonella typhimurium* in an Orthotopic Human Pancreatic Cancer in Nude Mice. C. NAGAKURA, K. HAYASHI, M. ZHAO, K. YAMAUCHI, N. YAMAMOTO, H. TSUCHIYA, K. TOMITA, M. BOUVET, R.M. HOFFMAN (*San Diego, CA, USA; Kanazawa, Ishikawa, Japan*) 1873
- Alendronate Inhibits Growth of High-grade Chondrosarcoma Cells. M. SUSA, T. MORII, H. YABE, K. HORIUCHI, Y. TOYAMA, L. WEISSBACH, F.J. HORNICEK, H. MORIOKA (*Tokyo, Japan; Boston, MA, USA*) 1879
- Atrial Natriuretic Peptide and Long-acting Natriuretic Peptide Inhibit Ras in Human Prostate Cancer Cells. Y. SUN, E.J. EICHELBAUM, A. LENZ, W.P. SKELTON IV, H. WANG, D.L. VESELY (*Tampa, FL, USA*) 1889
- Determination of Minimum Effective Dose and Optimal Dosing Schedule for Liposomal Curcumin in a Xenograft Human Pancreatic Cancer Model. C.M. MACH, L. MATHEW, S.A. MOSLEY, R. KURZROCK, J.A. SMITH (*Houston, TX, USA*)..... 1895
- Cleavage of the Ewing Tumour-specific *EWSRI-FLII* mRNA by Hammerhead Ribozymes. R. HÜHN, M.S. STAEGE, M. HESSE, B. LIEBIG, S.E.G. BURDACH (*Halle; München, Germany*) 1901
- * Review: Tissue Transglutaminase Promotes or Suppresses Tumors Depending on Cell Context. A. CHHABRA, A. VERMA, K. MEHTA (*Houston, TX, USA*) 1909
- 5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increase Adenoma and Flat ACF Number in the Intestine of *Min/+* Mice. C. SVENDSEN, T. HUSØY, H. GLATT, J.E. PAULSEN, J. ALEXANDER (*Oslo, Norway; Nuthetal, Germany*) 1921
- Conversion from Calcineurin Inhibitors to Sirolimus Reduces Vascularization and Thickness of Post-transplant Cutaneous Squamous Cell Carcinomas. A.-L. RIVAL-TRINGALI, S. EUVRARD, E. DECULLIER, A. CLAUDY, M. FAURE, J. KANITAKIS (*Lyon, France*)..... 1927
- Spontaneous Regression of Human Cancer Cells *In Vitro*: Potential Role of Disruption of Cdk1/Cdk4 Co-expression. H. WARENIUS, L. KYRITSI, I. GRIERSON, A. HOWARTH, L. SEABRA, M. JONES, C. THOMAS, P. BROWNING, R. WHITE (*Southampton; Wirral; Liverpool; Surrey; Manchester; Sheffield, UK; Ermoupolis, Greece*) 1933
- Inhibition of IGF-I Receptor Signaling in Combination with Rapamycin or Temsirolimus Increases MYC-N Phosphorylation. D.W. COULTER, M.B. WILKIE, B.M. MOATS-STAATS (*Omaha, NE; Chapel Hill, NC, USA*)..... 1943
- Establishment and Characterization of Three Novel Cell Lines – P-STS, L-STS, H-STS – Derived from a Human Metastatic Midgut Carcinoid. R. PFRAGNER, A. BEHMEL, H. HÖGER, A. BEHAM, E. INGOLIC, I. STELZER, B. SVEJDA, V. AGUIRIANO MOSER, A.C. OBENAUF, V. SIEGL, O. HAAS, B. NIEDERLE (*Graz; Himberg; Vienna, Austria*) 1951

A Novel Iodomethylene-dimethyl-dihydropyranone Induces G ₂ /M Arrest and Apoptosis in Human Cancer Cells. J. BIGNON, M. BÉNÉCHIE, D. HERLEM, J.-M. LIU, A. PINAULT, F. KHUONG-HUU, J. WDZIECZAK-BAKALA (<i>Gif-sur-Yvette, France</i>)	1963
Ribavirin Acts <i>via</i> Multiple Pathways in Inhibition of Leukemic Cell Proliferation. S. KÖKÉNY, J. PAPP, G. WEBER, T. VASZKÓ, P. CARMONA-SAEZ, E. OLÁH (<i>Budapest, Hungary; Indianapolis, IN, USA; Madrid, Spain</i>)	1971
Promoted Cell Proliferation by Connexin 30 Gene Transfection to Head-and-Neck Cancer Cell Line. H. OZAWA, H. MUTAI, T. MATSUNAGA, Y. TOKUMARU, M. FUJII, K. SAKAMOTO, T. TOMITA, K. OGAWA (<i>Tokyo, Japan</i>)	1981
Impact of Tumor Cell VEGF Expression on the <i>In Vivo</i> Efficacy of Vandetanib (ZACTIMA™; ZD6474). D.W. SIEMANN, C.M. NORRIS, A. RYAN, W. SHI (<i>Gainesville, FL, USA; Cheshire, UK</i>)	1987
Assessment of Erlotinib in Chemoresponse Assay. S.D. RICE, J.E. BUSH, S.L. BROWER (<i>Pittsburgh, PA, USA</i>)	1993
Prioritization of EGFR/IGF-IR/VEGFR2 Combination Targeted Therapies Utilizing Cancer Models. J.R. TONRA, E. CORCORAN, D.S. DEEVI, P. STEINER, J. KEARNEY, H. LI, D.L. LUDWIG, Z. ZHU, L. WITTE, D. SURGULADZE, D.J. HICKLIN (<i>New York, NY, USA</i>)	1999
14-3-3 σ -Dependent Resistance to Cisplatin. Z. HAN, K. DIMAS, X. TIAN, Y. WANG, H. HEMMI, K. YAMADA, N. KATO, P. PANTAZIS, R.J. RAMANUJAM, S. ANANT, J.H. WYCHE, C.W. HOUCHEM (<i>New York, NY; Oklahoma City, OK; Minneapolis, MN, USA; Athens, Greece; Tokyo, Japan</i>)	2009
Overexpression of Adenovirus-mediated p27 ^{kip1} Lacking the Jab1-binding Region Enhances Cytotoxicity and Inhibits Xenografted Human Cholangiocarcinoma Growth. S. SHIRASO, Y. KATAYOSE, K. YAMAMOTO, M. MIZUMA, S. YABUUCHI, A. ODA, T. RIKIYAMA, T. ONOGAWA, H. YOSHIDA, H. HAYASHI, H. OHTSUKA, F. MOTOI, S. EGAWA, J. KATO, M. UNNO (<i>Sendai; Nara, Japan</i>)	2015
Promoter Demethylation of <i>WIF-1</i> by Epigallocatechin-3-gallate in Lung Cancer Cells. Z. GAO, Z. XU, M.-S. HUNG, Y.-C. LIN, T. WANG, M. GONG, X. ZHI, D.M. JABLON, L. YOU (<i>Beijing, China; San Francisco, CA, USA; Chiayi, Taiwan, ROC</i>)	2025
* Review: Heat-shock Protein 90 (Hsp90) as a Molecular Target for Therapy of Gastrointestinal Cancer. C. MOSER, S.A. LANG, O. STOELTZING (<i>Regensburg; Mainz, Germany</i>)	2031
Identification of $\alpha\beta$ 6-Positive Stem Cells in Oral Squamous Cell Carcinoma. D. DANG, D.M. RAMOS (<i>San Francisco, CA, USA</i>)	2043
Decreased Levels of Both Stat1 and Stat3 in T Lymphocytes from Mice Bearing Mammary Tumors. M.E. HANDEL-FERNANDEZ, D. ILKOVITCH, V. IRAGAVARAPU-CHARYULU, L.M. HERBERT, D.M. LOPEZ (<i>Miami; Boca Raton, FL, USA</i>)	2051
Chemopreventive Effect of 4-[3,5-Bis(trimethylsilyl) benzamido] Benzoic Acid (TAC-101) on MNU-induced Colon Carcinogenesis in a Rat Model. Y. NAKAYAMA, Y. INOUE, N. MINAGAWA, K. ONITSUKA, J. NAGATA, K. SHIBAO, K. HIRATA, T. SAKO, N. NAGATA, K. YAMAGUCHI (<i>Kita-Kyushu; Joetsu, Japan</i>) .	2059
<i>In Vitro</i> and <i>In Vivo</i> Effects of CpG-Oligodeoxynucleotides (CpG-ODN) on Murine Transitional Cell Carcinoma and on the Native Murine Urinary Bladder Wall. P.J. OLBERT, A.J. SCHRADER, C. SIMON, A. DALPKE, P. BARTH, R. HOFMANN, A. HEGELE (<i>Marburg; Heidelberg, Germany</i>)	2067
Cytoplasmic Accumulation of Glycogen Synthase Kinase-3 β Is Associated with Aggressive Clinicopathological Features in Human Prostate Cancer. R. LI, S. ERDAMAR, H. DAI, M. SAYEEDUDDIN, A. FROLOV, T.M. WHEELER, G.E. AYALA (<i>Houston, TX, USA; Istanbul, Turkey</i>)	2077

Molecular Mechanisms of Sequence-dependent Antitumor Effects of SN-38 and 5-Fluorouracil Combination Therapy against Colon Cancer Cells. S. TORIGOE, Y. OGATA, K. MATONO, K. SHIROUZU (<i>Kurume, Japan</i>).....	2083
Latrunculin A Has a Strong Anticancer Effect in a Peritoneal Dissemination Model of Human Gastric Cancer in Mice. H. KONISHI, S. KIKUCHI, T. OCHIAI, H. IKOMA, T. KUBOTA, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, C. SAKAKURA, T. SONOYAMA, Y. KOKUBA, H. SASAKI, T. MATSUI, E. OTSUJI (<i>Kyoto; Tokyo, Japan</i>)	2091
An Orally Active Small Molecule TGF- β Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer. M.P. RAUSCH, T. HAHN, L. RAMANATHAPURAM, D. BRADLEY-DUNLOP, D. MAHADEVAN, M.E. MERCADO-PIMENTEL, R.B. RUNYAN, D.G. BESSELSSEN, X. ZHANG, H.-K. CHEUNG, W.-C. LEE, L.E. LING, E.T. AKPORIAYE (<i>Tucson, AZ; Portland, OR; Cambridge, MA, USA</i>)	2099
Improvement of Biodistribution and Therapeutic Index <i>via</i> Increase of Polyethylene Glycol on Drug-carrying Liposomes in an HT-29/ <i>luc</i> Xenografted Mouse Model. T.-H. CHOW, Y.-Y. LIN, J.-J. HWANG, H.-E. WANG, Y.-L. TSENG, S.-J. WANG, R.-S. LIU, W.-J. LIN, C.-S. YANG, G. TING (<i>Taipei; Taoyuan, Taiwan, ROC</i>)	2111
Renal Capsule-Parathyroid Lymph Node Complex: A New <i>In Vivo</i> Metastatic Model in Rats. G. TRENCSENYI, P. KERTAI, F. BAKO, J. HUNYADI, T. MARIAN, Z. HARGITAI, I. POCSI, E. MURANYI, L. HORNYAK, G. BANFALVI (<i>Debrecen; Pecs, Hungary</i>)	2121
* Review: Proton Transport Inhibitors as Potentially Selective Anticancer Drugs. S. HARGUINDEY, J.L. ARRANZ, M.L. WAHL, G. ORIVE, S.J. RESHKIN (<i>Vitoria, Spain; Durham, NC, USA; Bari, Italy</i>)	2127
Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme. Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, H. FUJII (<i>Yamanashi, Japan</i>)	2137
The Hedgehog Signaling Pathway Plays an Essential Role in Maintaining the CD44 ⁺ CD24 ^{-/low} Subpopulation and the Side Population of Breast Cancer Cells. H. TANAKA, M. NAKAMURA, C. KAMEDA, M. KUBO, N. SATO, S. KUROKI, M. TANAKA, M. KATANO (<i>Fukuoka, Japan</i>)	2147
Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy. L. BRAIDWOOD, P.D. DUNN, S. HARDY, T.R. EVANS, S.M. BROWN (<i>Glasgow, UK</i>)	2159
Differential Effects of Aromatase Inhibitors and Antiestrogens on Estrogen Receptor Expression in Breast Cancer Cells. M. SMOLLICH, M. GÖTTE, J. FISCHGRÄBE, I. RADKE, L. KIESEL, P. WÜLFING (<i>Münster, Germany</i>)	2167
Demonstration of the Activity of P-glycoprotein by a Semi-automated Fluorometric Method. G. SPENGLER, M. VIVEIROS, M. MARTINS, L. RODRIGUES, A. MARTINS, J. MOLNAR, I. COUTO, L. AMARAL (<i>Lisboa; Caparica, Portugal; Szeged, Hungary</i>)	2173
(-)-Gossypol Reduces Invasiveness in Metastatic Prostate Cancer Cells. Y.-W. HUANG, L.-S. WANG, M.K. DOWD, P.J. WAN, Y.C. LIN (<i>Columbus, OH; New Orleans, LA, USA</i>)	2179
Expression of <i>ERas</i> Oncogene in Gastric Carcinoma. R. KAIZAKI, M. YASHIRO, O. SHINTO, K. YASUDA, T. MATSUZAKI, T. SAWADA, K. HIRAKAWA (<i>Osaka, Japan</i>).....	2189
Riluzole Induces Apoptotic Cell Death in Human Prostate Cancer Cells <i>via</i> Endoplasmic Reticulum Stress. K. AKAMATSU, M.-A. SHIBATA, Y. ITO, Y. SOHMA, H. AZUMA, Y. OTSUKI (<i>Osaka; Tokyo, Japan</i>)	2195
Osteopontin Modulates Malignant Pleural Mesothelioma Cell Functions <i>In Vitro</i> . R. OHASHI, K. TAJIMA, F. TAKAHASHI, R. CUI, T. GU, K. SHIMIZU, K. NISHIO, K. FUKUOKA, T. NAKANO, K. TAKAHASHI (<i>Tokyo; Osaka; Hyogo, Japan</i>).....	2205

Demethylation of the <i>CDH3</i> Gene Is Frequently Detected in Advanced Colorectal Cancer. K. HIBI, T. GOTO, H. MIZUKAMI, Y.-H. KITAMURA, K. SAKURABA, M. SAKATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>).....	2215
Expression of Bone Morphogenetic Proteins in Giant Cell Tumor of Bone. N. KUDO, A. OGOSE, T. ARIIZUMI, H. KAWASHIMA, T. HOTTA, H. HATANO, T. MORITA, M. NAGATA, Y. SIKI, A. KAWAI, Y. HOTTA, M. HOSHINO, N. ENDO (<i>Niigata; Tokyo, Japan</i>)	2219
Frequent Methylation of <i>Vimentin</i> in Well-differentiated Gastric Carcinoma. Y.-H. KITAMURA, A. SHIRAHATA, M. SAKATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Yokohama, Japan</i>)	2227
Methylation of <i>HACE1</i> in Gastric Carcinoma. M. SAKATA, Y.-H. KITAMURA, K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Yokohama, Japan</i>)	2231
Demethylation of the <i>CD133</i> Gene Is Frequently Detected in Advanced Colorectal Cancer. K. HIBI, M. SAKATA, Y.-H. KITAMURA, K. SAKURABA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	2235
Significant Association of Ku80 Single Nucleotide Polymorphisms with Colorectal Cancer Susceptibility in Central Taiwan. M.-D. YANG, Y.-M. HSU, Y.-S. KUO, H.-S. CHEN, C.-L. CHANG, C.-N. WU, C.-H. CHANG, Y.-M. LIAO, H.-C. WANG, M.-F. WANG, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	2239
Selective Activity Against Proliferating Tumor Endothelial Cells by CVX-22, A Thrombospondin-1 Mimetic CovX-Body™. J. CORONELLA, L. LI, K. JOHNSON, S. PIRIE-SHEPHERD, G. ROXAS, N. LEVIN (<i>San Diego, CA, USA</i>)	2243
The RING Finger Protein11 Binds to Smad4 and Enhances Smad4-dependant TGF-β Signalling. P.B. AZMI, A.K. SETH (<i>Toronto, ON, Canada</i>).....	2253
Estimation of Relationship Between the Structure of 1,2,3,4-Tetrahydroisoquinoline Derivatives Determined by a Semiempirical Molecular-Orbital Method and their Cytotoxicity. M. ISHIHARA, H. HATANO, M. KAWASE, H. SAKAGAMI (<i>Saitama; Ehime, Matsuyama, Japan</i>)	2265
The Characterisation of Flavone-DNA Isoform Interactions as a Basis for Anticancer Drug Development. P.A. RAGAZZON, T. BRADSHAW, C. MATTHEWS, J. ILEY, S. MISSAILIDIS (<i>Milton Keynes; Nottingham, UK</i>)	2273
Structure-activity Studies of the Binding of the Flavonoid Scaffold to DNA. P.A. RAGAZZON, J. ILEY, S. MISSAILIDIS (<i>Milton Keynes, UK</i>)	2285
Epigenetic Modifiers Exacerbate Oxidative Stress in Renal Proximal Tubule Cells. E. NADASI, J.S. CLARK, I. SZANYI, T. VARJAS, I. EMBER, R. BALIGA, I. ARANY (<i>Budapest; Pecs, Hungary; Jackson, MS, USA</i>)...	2295
Black Tea Polyphenols Target Matrix Metalloproteinases, RECK, Proangiogenic Molecules and Histone Deacetylase in a Rat Hepatocarcinogenesis Model. R.S. MURUGAN, G. VINOTHINI, Y. HARA, S. NAGINI (<i>Tamil Nadu, India; Tokyo, Japan</i>)	2301
The Pathogenetic Mechanism of Anthracycline-induced Palmar-plantar Erythrodysesthesia. A. MARTSCHICK, J. SEHOULI, A. PATZELT, H. RICHTER, U. JACOBI, G. OSKAY-ÖZCELIK, W. STERRY, J. LADEMANN (<i>Berlin, Germany</i>)	2307
Combination Effect between Bortezomib and Tumor Necrosis Factor α on Gefitinib-resistant Non-small Cell Lung Cancer Cell Lines. S. KUSUMOTO, T. SUGIYAMA, K. ANDO, T. HOSAKA, H. ISHIDA, T. SHIRAI, T. YAMAOKA, K. OKUDA, T. HIROSE, T. OHNISHI, F. INOUE, T. KANOME, T. KADOFUKU, N. SAIJO, M. ADACHII, T. OHMORI (<i>Tokyo; Chiba, Japan</i>)	2315

A Role for the Substance P/NK-1 Receptor Complex in Cell Proliferation in Oral Squamous Cell Carcinoma. S. BRENER, M.A. GONZÁLEZ-MOLES, D. TOSTES, F. ESTEBAN, J.A. GIL-MONTOYA, I. RUIZ-ÁVILA, M. BRAVO, M. MUÑOZ (<i>Sao Paulo, Brazil; Granada; Sevilla; Jaen, Spain</i>)	2323
IL-6 and PPAR γ Signalling in Human PC-3 Prostate Cancer Cells. N. PITULIS, E. PAPAGEORGIOU, R. TENTA, P. LEMBESSIS, M. KOUTSILIERIS (<i>Athens, Greece</i>).....	2331
Proving Tumour Cells by Acute Nutritional/Energy Deprivation as a Survival Threat: A Task for Microscopy. HA. JANECKOVA, P. VESELY, R. CHMELIK (<i>Brno; Prague, Czech Republic</i>)	2339
Breast Tumor Cells Transendothelial Migration Induces Endothelial Cell Anoikis Through Extracellular Matrix Degradation. N. PEYRI, M. BERARD, F. FAUVEL-LAFEVE, V. TROCHON, B. ARBEILLE, H. LU, C. LEGRAND, M. CREPIN (<i>Paris; Tours; Bobigny, France</i>)	2347
Expression of <i>HMGA2-LPP</i> and <i>LPP-HMGA2</i> Fusion Genes in Lipoma: Identification of a Novel Type of <i>LPP-HMGA2</i> Transcript in Four Cases. T. KUBO, Y. MATSUI, N. NAKA, N. ARAKI, T. GOTO, K. YUKATA, K. ENDO, N. YASUI, A. MYOUI, H. KAWABATA, H. YOSHIKAWA, T. UEDA (<i>Tokushima; Osaka, Japan</i>)	2357
Antitumor Effect of Combined Treatment of Mice with Cytostatic Agents and Bacteriophage T4. K. SZCZAURSKA-NOWAK, K. DĄBROWSKA, M. CELKA, A. KURZĘPA, D. NEVOZHAY, J. WIETRZYK, K. ŚWITAŁA-JELEŃ, D. SYPER, G. POŹNIAK, A. OPÓLSKI, A. GÓRSKI, C. RADZIKOWSKI (<i>Wrocław; Warsaw; Częstochowa, Poland</i>)	2361
Interleukin-6 Augments Activation of Liver Regeneration in Porcine Model of Partial Portal Vein Ligation. V. LISKA, V. TRESKA, H. MIRKA, J. KOBR, R. SYKORA, T. SKALICKY, A. SUTNAR, J. BRUHA, O. FIALA, O. VYCITAL, A. CHLUMSKA, L. HOLUBEC, M. MATEJOVIC (<i>Plzen, Czech Republic</i>).....	2371
Association of Polymorphisms in <i>Tumor Necrosis Factor Alpha</i> and <i>Beta</i> Genes with Increased Risk for Oral Cancer. C. YAPIJAKIS, Z. SEREFOGLOU, A. VYLLIOTIS, E. NKENKE, S. DERKA, S. VASSILIOU, D. AVGOUSTIDIS, F.W. NEUKAM, E. PATSOURIS, E. VAIRAKTARIS (<i>Athens, Greece; Nürnberg, Germany</i>)	2379
A Novel Method to Display [gal α 1, 3 gal] Antigens on Human Leukemic Cells for Preparation of Anti-leukemia Vaccines. K.J. POSEKANY, J.E. WILEY, G.A. GAGNON (<i>Greenville, NC, USA</i>)	2387
Potent Neutralization of Vacuolating Cytotoxin (VacA) of <i>Helicobacter pylori</i> by Immunoglobulins Against the Soluble Recombinant VacA. M.-R. KI, I.-H. HONG, J.-K. PARK, K.-S. HONG, O.-K. HWANG, J.-Y. HAN, A.-R. JI, S.-I. PARK, S.-K. LEE, S.-E. YOO, K.-S. JEONG (<i>Daegu; Daejeon, South Korea</i>).....	2393
Antioxidant and Cyclooxygenase-2-Inhibiting Activity of 4,4'-Biphenol, 2,2'-Biphenol and Phenol. Y. MURAKAMI, H. ISHII, S. HOSHINA, N. TAKADA, A. UEKI, S. TANAKA, Y. KADOMA, S. ITO, M. MACHINO, S. FUJISAWA (<i>Saitama; Tokyo, Japan</i>)	2403
The Sonodynamic Antitumor Effect of Methylene Blue on Sarcoma180 Cells <i>In Vitro</i> . C. KOMORI, K. OKADA, K. KAWAMURA, S. CHIDA, T. SUZUKI (<i>Akita, Japan</i>)	2411
Apurinic/Apyrimidinic Endonuclease (<i>APE1</i>) Gene Polymorphisms and Lung Cancer Risk in Relation To Tobacco Smoking. B. AĞAÇHAN, Ö. KÜÇÜKHÜSEYİN, P. AKSOY, A. TURNA, İ. YAYLIM, U. GÖRMÜŞ, A. ERGEN, Ü. ZEYBEK, B. DALAN, T. İSBİR (<i>Istanbul, Turkey</i>).....	2417

* Reviews (pages 1909, 2031, 2127)

Number 7

Experimental Studies

- Efficacy of Dietary Antioxidants Combined with a Chemotherapeutic Agent on Human Colon Cancer Progression in a Fluorescent Orthotopic Mouse Model. H. MA, T. DAS, S. PEREIRA, Z. YANG, M. ZHAO, P. MUKERJI, R.M. HOFFMAN (*San Diego, CA; Columbus, OH, USA*) 2421
- N*-Terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], Aid Differentiation of E75-TCR⁺CD8⁺ Cells to Perforin-positive Cells. S. MATSUEDA, H. GAO, C.L. EFFERSON, N. TSUDA, S. ISHIYAMA, Y. LI, M.G. IOANNIDES, B. FISK, G.E. PEOPLES, C.G. IOANNIDES (*Houston; San Antonio, TX; Washington DC, USA; Athens, Greece*) 2427
- Anaplastic Thyroid Carcinoma Exhibits Intratumoral Molecular Homogeneity for a Therapeutic Target Panel. S. DEEN, O.L. GRIFFITH, H. MASOUDI, A. GOWN, S.J.M. JONES, S.M. WISEMAN (*Vancouver, BC, Canada; Seattle, WA, USA*) 2437
- The Prognostic Role of Tumor-infiltrating CD4 and CD8 T Lymphocytes in Breast Cancer. R. MATKOWSKI, I. GISTEREK, A. HALON, A. LACKO, K. SZEWCZYK, U. STASZEK, M. PUDELKO, B. SZYNGLAREWICZ, J. SZELACHOWSKA, A. ZOLNIEREK, J. KORNAFEL (*Wroclaw, Poland*) 2445
- FEN1 is Overexpressed in Testis, Lung and Brain Tumors. T. NIKOLOVA, M. CHRISTMANN, B. KAINA (*Mainz, Germany*) 2453
- * Review: Immunobiological and Experimental Aspects of Malignant Astrocytoma. R. NANO, E. CAPELLI, A. FACOETTI, E. BENERICETTI (*Pavia; Parma, Italy*) 2461
- Expression of JNK-interacting Protein JIP-1 and Insulin-like Growth Factor II in Wilms Tumour Cell Lines and Primary Wilms Tumours. W. ENGSTRÖM, M. GRANERUS (*Uppsala, Sweden*) 2467
- Toll-like Receptor 4 Activation Increases Akt Phosphorylation in Colon Cancer Cells. H.Q. DOAN, K.A. BOWEN, L.A. JACKSON, B.M. EVERS (*Galveston, TX, USA*) 2473
- MYC* Insertions in Diffuse-type Gastric Adenocarcinoma. D.Q. CALCAGNO, A.C. GUIMARÃES, M.F. LEAL, A.D. SEABRA, A.S. KHAYAT, T.B. PONTES, P.P. ASSUMÇÃO, M. DE ARRUDA CARDOSO SMITH, R.R. BURBANO (*Belém, PA; São Paulo, SP, Brazil*) 2479
- Panaxanthone Isolated from Pericarp of *Garcinia mangostana* L. Suppresses Tumor Growth and Metastasis of a Mouse Model of Mammary Cancer. H. DOI, M.-A. SHIBATA, E. SHIBATA, J. MORIMOTO, Y. AKAO, M. IINUMA, N. TANIGAWA, Y. OTSUKI (*Osaka; Gifu, Japan*) 2485
- Conversion of Prostate Cancer from Hormone Independency to Dependency Due to AMACR Inhibition: Involvement of Increased AR Expression and Decreased IGF1 Expression. K. TAKAHARA, H. AZUMA, T. SAKAMOTO, S. KIYAMA, T. INAMOTO, N. IBUKI, T. NISHIDA, H. NOMI, TA. UBAI, N. SEGAWA, Y. KATSUOKA (*Osaka, Japan*) 2497
- Doxorubicin and Congo Red Effectiveness on Prion Infectivity in Golden Syrian Hamster. M. CORATO, P. OGLIARI, F. CECILIANI, E. COVA, V. BELLOTTI, C. CEREDA, G. MERLINI, M. CERONI (*Pavia; Milan, Italy*) 2507
- Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in Lung Tissue of Patients with Non-small Cell Lung Cancer (NSCLC) and Benign Pulmonary Disease. J. SAFRANEK, M. PESTA, L. HOLUBEC, V. KULDA, J. DRESLEROVA, J. VRZALOVA, O. TOPOLCAN, M. PESEK, J. FINEK, V. TRESKA (*Pilsen, Czech Republic*) 2513

Role of <i>L-MYC</i> Polymorphism in Oral Squamous Cell Carcinoma in Turkey. K. BEKTAŞ-KAYHAN, M. ÜNÜR, İ. YAYLIM-ERALTAN, A. ERGEN, G. HAFİZ, A. KARADENİZ, T. İSBİR (<i>İstanbul, Turkey</i>)	2519
Expression of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Human Breast Carcinoma Cells and Tissues. W.T.Y. LOO, L.W.C. CHOW, T. SUZUKI, K. ONO, T. ISHIDA, H. HIRAKAWA, N. OHUCHI, H. SASANO (<i>Sendai, Japan; Hong Kong, PRC</i>)	2525
Abnormal Expression of Fibrinogen Gamma (FGG) and Plasma Level of Fibrinogen in Patients with Hepatocellular Carcinoma. W.-L. ZHU, B.-L. FAN, D.-L. LIU, W.-X. ZHU (<i>Xinxiang; Zhengzhou, P.R. of China</i>)	2531
O ⁶ -Methylguanine-DNA Methyltransferase Hypermethylation Modulated by 17β-Estradiol in Lung Cancer Cells. J.-C. LAI, J.-Y. WU, Y.-W. CHENG, K.-T. YEH, T.-C. WU, C.-Y. CHEN, H. LEE (<i>Taichung; Changhua, Taiwan, ROC</i>)	2535
Development of a Novel Cell-based Assay to Evaluate the Malignant Potential of Cancer <i>In Vitro</i> . C. HIRAKAWA, K. TANAKA, Y. TAKAYA, S. NAKAGAWA, Y. KATAOKA, Y. TAGAWA, M. NIWA (<i>Nagasaki; Fukuoka, Japan</i>)	2541
<i>Clinical Studies</i>	
Significance of S100A4 as a Prognostic Marker of Lung Squamous Cell Carcinoma. M. TSUNA, S.-I. KAGEYAMA, J. FUKUOKA, H. KITANO, Y. DOKI, H. TEZUKA, H. YASUDA (<i>Kanagawa; Toyama; Yamanashi, Japan</i>)	2547
Preoperative Chemoradiotherapy for Esophageal Cancer: Factors Associated with Clinical Response and Postoperative Complications. M. MORITA, T. MASUDA, S. OKADA, K. YOSHINAGA, H. SAEKI, E. TOKUNAGA, K. ENDO, Y. EMI, Y. KAKEJI, Y. MAEHARA (<i>Fukuoka, Japan</i>)	2555
Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans. J. MONTEIL, N. MAHMOUDI, S. LEOBON, P.Y. ROUDAUT, A. EL BADAoui, S. VERBEKE, L. VENAT-BOUVET, J. MARTIN, V. LE BRUN-LY, S. LAVAU-DENES, A. MAUBON, P. BOUILLET, M. POUQUET, J.C. VANDROUX, N. TUBIANA-MATHIEU (<i>Limoges, France</i>)	2563
Anaemia and Other Predictors of Fatigue Among Patients on Palliative Therapy for Advanced Cancer. A. LATVALA, K. SYRJÄNEN, H. SALMENOJA, E. SALMINEN (<i>Turku, Finland</i>)	2569
Discrepancies in Expression and Prognostic Value of Tumor Markers in Adenocarcinoma and Squamous Cell Carcinoma in Cervical Cancer. A.K. LINDSTRÖM, T. TOT, U. STENDAHL, S. SYRJÄNEN, K. SYRJÄNEN, D. HELLBERG (<i>Falun; Umeå; Uppsala, Sweden; Turku, Finland</i>)	2577
Insulin-like Growth Factor-binding Protein-3 in Osteosarcomas and Normal Bone Tissues. S. RESSLER, J. RADHI, T. AIGNER, C. LOO, W. ZWERSCHKE, C. SERGI (<i>Innsbruck, Austria; Hamilton, ON; Edmonton, AB, Canada; Leipzig, Germany; Herston, QLD, Australia</i>)	2579
* Review: New Markers and Multivariate Models for Prostate Cancer Detection. C. STEPHAN, H. RITTENHOUSE, H. CAMMANN, M. LEIN, M. SCHRADER, S. DEGER, K. MILLER, K. JUNG (<i>Berlin, Germany; Diego, CA, USA</i>)	2589
Amitriptyline in the Prevention of Chemotherapy-induced Neuropathic Symptoms. A.-L. KAUTIO, M. HAANPÄÄ, A. LEMINEN, E. KALSO, H. KAUTIAINEN, T. SAARTO (<i>Helsinki; Tampere; Jyväskylä, Finland</i>)	2601
Pseudoprogression and <i>MGMT</i> Status in Glioblastoma Patients: Implications in Clinical Practice. A. FABI, M. RUSSILLO, G. METRO, A. VIDIRI, S. DI GIOVANNI, F. COGNETTI (<i>Rome, Italy</i>)	2607

Efficacy of Orally Administered Superfine Dispersed Lentinan (β -1,3-Glucan) for the Treatment of Advanced Colorectal Cancer. S. HAZAMA, S. WATANABE, M. OHASHI, M. YAGI, M. SUZUKI, K. MATSUDA, T. YAMAMOTO, Y. SUGA, T. SUGA, S. NAKAZAWA, M. OKA (<i>Yamaguchi; Sapporo; Hokkaido; Niigata; Ishikawa; Wakayama; Kanagawa; Tokyo; Aichi, Japan</i>)	2611
Quantitative Analysis of Tumor-derived Methylated <i>RUNX3</i> Sequences in the Serum of Gastric Cancer Patients. C. SAKAKURA, T. HAMADA, K. MIYAGAWA, M. NISHIO, A. MIYASHITA, H. NAGATA, H. IDA, S. YAZUMI, E. OTSUJI, T. CHIBA, K. ITO, Y. ITO (<i>Kyoto; Nagasaki, Japan; Singapore, Singapore</i>).....	2619
Definitive Conformal Radiotherapy for Localized Prostate Cancer: A Long-term Follow-up Study. C.M.C. DEICHMUELLER, G. WEGENER, J.H. KARSTENS, F. BRUNS (<i>Hannover, Germany</i>)	2627
VEGF in Patients with Non-small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel. M. SHINGYOJI, S. ANDO, H. NISHIMURA, T. NAKAJIMA, A. ISHIKAWA, M. ITAKURA, T. IIZASA, H. KIMURA (<i>Chiba, Japan</i>)	2635
Does Distance to Treatment Centre Influence the Rate of Palliative Radiotherapy in Adult Cancer Patients? C. NIEDER, J. NORUM, O. SPANNE, I. BILBERG, G. VAGSTAD, A. DALHAUG (<i>Bodø; Tromsø, Norway</i>)	2641
Prospective Study on Neck Dissection after Primary Chemoradiation Therapy in Stage IV Pharyngeal Cancer. M. BREMKE, P.J. BARTH, A.M. SESTERHENN, V. BUDACH, R. ENGENHART-CABILLIC, J.A. WERNER (<i>Marburg; Berlin, Germany</i>)	2645
Giant Basal Cell Carcinoma: Clinicopathological Analysis of 51 Cases and Review of the Literature. M. ARCHONTAKI, S.D. STAVRIANOS, D.P. KORKOLIS, N. ARNOGIANNAKI, V. VASSILIADIS, I.E. LIAPAKIS, H. CHRIST, A.D. RAPIDIS, G. KOKKALIS (<i>Athens, Greece; Köln, Germany</i>)	2655
* Review: Novel Strategy of Anti-angiogenic Therapy for Uterine Cervical Carcinomas. J. FUJIMOTO (<i>Gifu, Japan</i>)	2665
Impact of Interstitial Lung Disease on Survival for Patients with Non-small Cell Lung Cancer. K. MIYAZAKI, H. SATOH, K. KURISHIMA, R. NAKAMURA, H. ISHIKAWA, K. KAGOHASHI, G. OHARA, N. HIZAWA (<i>Ibaraki, Japan</i>)	2671
Side-effects of Pre-operative Epirubicin-Paclitaxel Therapy in Primary Breast Cancer Associated with Tumor Biology. M. WARM, R. KATES, A. THOMAS, T. FISCHER, N. HARBECK (<i>Cologne; Otterfing; Berlin, Germany</i>).....	2675
Cisplatin–Ifosfamide–Gemcitabine as Salvage Chemotherapy in Ovarian Cancer Patients Pretreated with Platinum Compounds and Paclitaxel. A. POLYZOS, N. TSAVARIS, H. GOGAS, A. LAGADAS, K. POLYZOS, K. GIANNAKOPOULOS, E. FELEKOURAS, C. TSIGRIS, T. KARATZAS, O. PAPAPOPOULOS, A. GIANNOPOULOS (<i>Athens, Greece</i>).....	2681
Preoperative Leukocytosis, Anemia and Thrombocytosis Are Associated with Poor Survival in Non-small Cell Lung Cancer. M. TOMITA, T. SHIMIZU, M. HARA, T. AYABE, T. ONITSUKA (<i>Miyazaki, Japan</i>)	2687
Biological and Clinical Features in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-analysis. M.C. GARASSINO, K. BORGONOVO, A. ROSSI, A. MANCUSO, O. MARTELLI, A. TINAZZI, S. DI COSIMO, N. LA VERDE, P. SBURLATI, C. BIANCHI, G. FARINA, V. TORRI (<i>Avellino; Milan, Italy</i>)	2691
Clinical Characteristics of Laryngeal Cancer in <i>BRCA-1</i> Mutation Carriers. E. JAWOROWSKA, C. TARNOWSKA, J. LUBIŃSKI, P. SERRANO-FERNANDEZ, T. HUZARSKI, B. GÓRSKI, B. MASOJĆ, J. JAKUBISZYN, A. KORYTOWSKA, A. KRAM, J. RABCZYNSKI, J. LUBIŃSKI (<i>Szczecin; Opole; Poznan; Wrocław, Poland</i>)	2703

Altered Calcium Metabolism in Patients on Long-term Bisphosphonate Therapy for Metastatic Breast Cancer. C. SIMMONS, E. AMIR, G. DRANITSARIS, M. CLEMONS, B. WONG, R. VEITH, D.E.C. COLE (Toronto, ON, Canada).....	2707
Decrease of E-Cadherin Expression in Canine Cutaneous Histiocytoma Appears to be Related to its Spontaneous Regression. I. PIRES, F.L. QUEIROGA, A. ALVES, F. SILVA, C. LOPES (Vila Real; Porto, Portugal)	2713
Fifty-five Minimally Invasive Esophagectomies: A Single Centre Experience. S.F. SCHOPPMANN, G. PRAGER, F. LANGER, M. RIEGLER, E. FLEISCHMAN, J. ZACHERL (Vienna, Austria).....	2719
Review: Colorectal Cancer and Inflammatory Bowel Disease: Epidemiology, Risk Factors, Mechanisms of Carcinogenesis and Prevention Strategies. J.K. TRIANTAFILLIDIS, G. NASIOULAS, P.A. KOSMIDIS (Athens, Greece)	2727
Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer. K. OBA, M. KOBAYASHI, T. MATSUI, Y. KODERA, J. SAKAMOTO (Kyoto; Kochi; Okazaki; Nagoya, Japan)...	2739
Gefitinib Plus Paclitaxel after Failure of Gefitinib in Non-small Cell Lung Cancer Initially Responding to Gefitinib. T. SHUKUYA, T. TAKAHASHI, A. TAMIYA, A. ONO, S. IGAWA, Y. NAKAMURA, A. TSUYA, H. MURAKAMI, T. NAITO, K. KAIRA, M. ENDO, N. YAMAMOTO (Shizuoka, Japan)	2747
DYRK2 Expression May be a Predictive Marker for Chemotherapy in Non-small Cell Lung Cancer. S.-I. YAMASHITA, M. CHUJO, T. MOROGA, K. ANAMI, K. TOKUISHI, M. MIYAWAKI, Y. KAWANO, S. TAKENO, S. YAMAMOTO, K. KAWAHARA (Yufu, Oita, Japan).....	2753
Efficacy of a Lumbo-peritoneal Shunt for Meningeal Carcinomatosis Refractory to Gefitinib Treatment. T. KUBO, N. TAKIGAWA, K. KIURA, A. NISHIDA, N. OCHI, H. KASHIHARA, S. UMEMURA, A. HISAMOTO, M. TANIMOTO (Okayama, Japan)	2759
Gastrointestinal Stromal Tumor with Chondroid Differentiation. G. PULCINI, V. VILLANACCI, E. ROSSI, F. GHEZA, E. CERVI, A.B. FERRARI, G. CERVI, G. BASSOTTI (Brescia; Perugia, Italy)	2761
Dominance of EGFR and Insignificant KRAS Mutations in Prediction of Tyrosine-kinase Therapy for NSCLC Patients Stratified by Tumor Subtype and Smoking Status. M. PESEK, L. BENESOVA, B. BELSANOVA, P. MUKENSNABL, F. BRUHA, M. MINARIK (Pilsen; Prague, Czech Republic)	2767
Docetaxel and S-1 as a First-line Treatment in Patients with Advanced or Recurrent Gastric Cancer. Y. TSUTANI, M. OHARA, T. SUZUKI, K. MINAMI, E. MIYAHARA, A. KAMEDA, Y. NOSO (Hiroshima, Japan).....	2775
Complete Pelvic Lymphadenectomy in Patients with Clinical Early, Grade I and II Endometrioid Corpus Cancer. S. FOTIOU, E.L. TRIMBLE, K. PAPAKONSTANTINOY, A. KONDI-PAFITI, T. PANOSKALTSIS, G. DELICONSTANTINOS, G. CREATSAS (Athens, Greece; Bethesda, MD, USA)	2781
Prospective Pilot-study of Combined Bipolar Radiofrequency Ablation and Application of Bone Cement in Bone Metastases. D. PROSCHEK, A. KURTH, P. PROSCHEK, T.J. VOGL, M.G. MACK (Mainz; Frankfurt, Germany)	2787
* Review: Brain Metastases from Epithelial Ovarian Cancer: Overview and Optimal Management. K. PIETZNER, G. OSKAY-OEZCELIK, K. EL KHALFAOUI, D. BOEHMER, W. LICHTENEGGER, J. SEHOULI (Berlin, Germany)	2793
* Review: Evidence-based Perioperative Management: Strategic Shifts in Times of Fast Track Surgery. S.S. CHOPRA, S.C. SCHMIDT, C. FOTOPOULOU, J. SEHOULI, G. SCHUMACHER (Berlin, Germany) ...	2799

* Review: Pros and Cons of Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer. A.G. ZEIMET, D. REIMER, A.C. RADL, A. REINTHALLER, C. SCHAUER, E. PETRU, N. CONCIN, S. BRAUN, C. MARTH (<i>Innsbruck; Vienna; Graz, Austria</i>).....	2803
Surgical Outcome and Survival Analysis of Young Patients with Primary Epithelial Ovarian Cancer. C. FOTOPOULOU, K. SAVVATIS, G. SCHUMACHER, W. LICHTENEGGER, J. SEHOULI (<i>Berlin, Germany</i>).....	2809
Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction. S. MAHNER, L. WOELBER, S. JUNG, C.Z. EULENBURG, M. IHNEN, J. SCHWARZ, J. SEHOULI, F. JAENICKE (<i>Hamburg; Berlin, Germany</i>)	2817
Surgical Management of Multiple Bilateral Fibroadenoma of the Breast: The Ribeiro Technique Modified by Rezai. O. CAMARA, A. EGBE, I. KOCH, J. HERRMANN, M. GAJDA, P. BALTZER, I.B. RUNNEBAUM (<i>Jena, Germany</i>).....	2823
Venous Coupler for Free-flap Anastomosis. O. CAMARA, J. HERRMANN, A. EGBE, I. KOCH, M. GAJDA, I.B. RUNNEBAUM (<i>Jena, Germany</i>)	2827
Pros and Cons for Systemic Therapy in Recurrent Ovarian Cancer. G. OSKAY-ÖZCELİK, J. SEHOULI (<i>Berlin, Germany</i>)	2831
* Review: Controversies in the Management of Ovarian Cancer – Pros and Cons for Lymph Node Dissection in Ovarian Cancer. O. CAMARA, J. SEHOULI (<i>Berlin, Germany</i>)	2837
Circulating <i>hTERT</i> DNA in Early Breast Cancer. R. DIVELLA, S. TOMMASI, R. LACALAMITA, A. DANIELE, I. ABBATE, V.M. GARRISI, E. SAVINO, M. COVIELLO, V. RUBINI, G. SIMONE, A. PARADISO, M. QUARANTA (<i>Bari, Italy</i>)	2845
Salvage Chemotherapy with Oxaliplatin and Capecitabine for Breast Cancer Patients Pretreated with Anthracyclines and Taxanes. A. POLYZOS, H. GOGAS, C. MARKOPOULOS, N. TSAVARIS, O. PAPAPOULOS, K. POLYZOS, A. GIANNOPOULOS (<i>Athens, Greece</i>).....	2851
Impact of Catechol- <i>O</i> -methyltransferase (<i>COMT</i>) Gene Polymorphism on Promoter Methylation Status in Gastric Mucosa. T. TAHARA, T. SHIBATA, T. ARISAWA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H. FUJITA, M. NAGASAKA, M. IWATA, K. TAKAHAMA, M. WATANABE, I. HIRATA (<i>Toyoake, Aichi, Japan</i>)	2857
Phase II Study of Weekly Paclitaxel as a Second-line Treatment for S-1-refractory Advanced Gastric Cancer. G. MATSUDA, C. KUNISAKI, H. MAKINO, M. FUKAHORI, J. KIMURA, T. SATO, T. OSHIMA, Y. NAGANO, S. FUII, R. TAKAGAWA, T. KOSAKA, H.A. ONO, H. AKIYAMA, Y. ICHIKAWA (<i>Yokohama, Japan</i>)	2863
Phase I Study of Capecitabine, Carboplatin and Intensity-modulated Radiation Therapy for Head and Neck Cancer. C.Y. THOMAS, P. READ, G. PETRONI, J. REIBEL, P.A. LEVINE (<i>Charlottesville, VA, USA</i>)	2869
* Reviews (pages 2461, 2589, 2665, 2793, 2799, 2803, 2837)	

Number 8

Experimental Studies

- Ovarian Cancer-associated Ascites Demonstrates Altered Immune Environment: Implications for Antitumor Immunity. R.L. GIUNTOLI, II, T.J. WEBB, A. ZOSO, O. ROGERS, T.P. DIAZ-MONTES, R.E. BRISTOW, M. OELKE (*Baltimore, MD, USA*) 2875
- Cytogenetic Effects of 18.0 and 16.5 GHz Microwave Radiation on Human Lymphocytes *In Vitro*. I.-L. HANSTEEN, L. LÅGEIDE, K.O. CLAUSEN, V. HAUGAN, M. SVENDSEN, J.G. ERIKSEN, R. SKIAKER, E. HAUGER, A.I. VISTNES, E.H. KURE (*Skien; Bø in Telemark; Kjeller; Oslo, Norway*) 2885
- Induction of Apoptosis by Staurosporine Involves the Inhibition of Expression of the Major Cell Cycle Proteins at the G₂/M Checkpoint Accompanied by Alterations in Erk and Akt Kinase Activities. A. ANTONSSON, J.L. PERSSON (*Malmö, Sweden*) 2893
- Loss of Anti-proliferative Effect of All-*trans* Retinoic Acid in Advanced Stage of Breast Carcinogenesis. E.H. AHN, C.-C. CHANG, D.A. TALMAGE (*New York, NY; East Lansing, MI, USA*) 2899
- Cytotoxic Effects of Camptothecin and Cisplatin Combined with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2L/TRAIL) in a Model of Primary Culture of Non-small Cell Lung Cancer. S. FRESE, A. SCHÜLLER, M. FRESE-SCHAPER, M. GUGGER, R.A. SCHMID (*Bern, Switzerland*) 2905
- Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma. M.E. HERCEG, A.C. TSIATIS, J.L. HALPERN, G.E. HOLT, H.S. SCHWARTZ, V.L. KEEDY, J.M.M. CATES (*Nashville, TN; Baltimore, MD, USA*) 2913
- Expression of E-Cadherin, β -Catenin and APC protein in Canine Colorectal Tumours. B. RESTUCCI, M. MARTANO, G. DE VICO, L. LO MUZIO, P. MAIOLINO (*Naples; Foggia, Italy*) 2919
- Methylnaltrexone, a Peripherally Acting Opioid Receptor Antagonist, Enhances Tumoricidal Effects of 5-FU on Human Carcinoma Cells. C.-Z. WANG, X.-L. LI, SHI SUN, J.-T. XIE, H.H. AUNG, R. TONG, E. MCENTEE, C.-S. YUAN (*Chicago, IL, USA*) 2927
- Biotinylated Poly(amido)amine (PAMAM) Dendrimers as Carriers for Drug Delivery to Ovarian Cancer Cells *In Vitro*. V.K. YELLEPEDDI, A. KUMAR, S. PALAKURTHI (*Kingsville, TX, USA*) 2933
- Antiangiogenic Properties of *Viscum Album* Extracts Are Associated with Endothelial Cytotoxicity. S.R. ELLURU, J.-P.D. VAN HUYEN, S. DELIGNAT, F. PROST, D. HEUDES, M.D. KAZATCHKINE, A. FRIBOULET, S.V. KAVERI (*Compiègne; Paris, France*) 2945
- Comparison of Cell Death-inducing Effect of Novel Taxane SB-T-1216 and Paclitaxel in Breast Cancer Cells. J. KOVÁŘ, M. EHRLICHOVÁ, B. ŠMEJKALOVÁ, I. ZANARDI, I. OJIMA, I. GUT (*Prague, Czech Republic; Stony Brook, NY, USA*) 2951
- Inhibition of Proteasome Activity by Bortezomib in Renal Cancer Cells Is p53 Dependent and VHL Independent. S.A.J. VAZIRI, D.R. GRABOWSKI, J. HILL, L.R. RYBICKI, R. BURK, R.M. BUKOWSKI, M.K. GANAPATHI, R. GANAPATHI (*Cleveland, OH; Bronx, NY, USA*) 2961
- Biochemical Changes and Cytotoxicity Associated with Methionine Depletion in Paediatric Central Nervous System Tumour Cell Lines. N. NAJIM, I.D. PODMORE, A. MCGOWN, E.J. ESTLIN (*Salford; Pendlebury, UK*) 2971
- Mifepristone Treatment Improves Length and Quality of Survival of Mice with Spontaneous Leukemia. J.H. CHECK, L. SANSOUCIE, J. CHERN, N. AMADI, Y. KATZ (*Camden, NJ, USA*) 2977

Differential Inhibition of Single and Cluster Type Tumor Cell Migration. R. HARISI, I. KENESSEY, J.N. OLAH, F. TIMAR, I. BABO, G. POGANY, S. PAKU, A. JENEY (<i>Budapest, Hungary</i>)	2981
LY294002 Enhances Boswellic Acid-induced Apoptosis in Colon Cancer Cells. J.-J. LIU, R.-D. DUAN (<i>Republic of Singapore; Lund, Sweden</i>).....	2987
Selective Cytotoxic Activities of Two Novel Synthetic Drugs on Human Breast Carcinoma MCF-7 Cells. R.B. BADISA, S.F. DARLING-REED, P. JOSEPH, J.S. COOPERWOOD, L.M. LATINWO, C.B. GOODMAN (<i>Tallahassee, FL, USA</i>)	2993
Improved Gene Transfer into Renal Carcinoma Cells Using Adenovirus Vector Containing RGD Motif. S. TERAOKA, B. ACHARYA, T. SUZUKI, T. AOI, M. NAOE, K. HAMADA, H. MIZUGUCHI, A. GOTOH (<i>Hyogo; Kyoto; Ehime; Osaka, Japan</i>)	2997
Vinorelbine Induces β 3-Tubulin Gene Expression through an AP-1 Site. J. SAUSSEDE-AIM, E.-L. MATERA, S. HERVEAU, J.-P. ROUAULT, C. FERLINI, C. DUMONTET (<i>Lyon, France; Rome, Italy</i>)	3003
Antiproliferative Effects of Resveratrol and the Mediating Role of Resveratrol Targeting Protein NQO2 in Androgen Receptor-positive, Hormone-non-responsive CWR22Rv1 Cells. T.-C. HSIEH (<i>Valhalla, NY, USA</i>)	3011
Effect of Head and Neck Cancer Supernatant and CpG-Oligonucleotides on Migration and IFN- α Production of Plasmacytoid Dendritic Cells. A. THIEL, R. PRIES, S. JESKE, T. TRENKLE, B. WOLLENBERG (<i>Lübeck, Germany</i>)	3019
<i>In Vitro</i> Evaluation of Histone Deacetylase Inhibitors as Combination Agents for Colorectal Cancer. J.C. KIM, E.S. SHIN, C.W. KIM, S.A. ROH, D.H. CHO, Y.S. NA, T.W. KIM, M.B. KIM, Y.L. HYUN, S. RO, S.Y. KIM, Y.S. KIM (<i>Seoul; Daejeon, South Korea</i>)	3027
Spontaneous Tumor Formation in <i>Trp53</i> -deficient Epidermis Mediated by Chromosomal Instability and Inflammation. A.B. MARTÍNEZ-CRUZ, M. SANTOS, R. GARCÍA-ESCUADERO, M. MORAL, C. SEGRELLES, C. LORZ, C. SAIZ, A. BUITRAGO-PÉREZ, C. COSTA, J.M. PARAMIO (<i>Madrid, Spain</i>) ...	3035
Scutellarin Sensitizes Drug-evoked Colon Cancer Cell Apoptosis through Enhanced Caspase-6 Activation. J.Y. CHAN, B.K.-H. TAN, S.C. LEE (<i>Republic of Singapore</i>).....	3043
Correlation between Proliferation Markers: PCNA, Ki-67, MCM-2 and Antiapoptotic Protein Bcl-2 in Colorectal Cancer. K. GUZIŃSKA-USTYMOWICZ, A. PRYCYNICZ, A. KEMONA, J. CZYŻEWSKA (<i>Białystok, Poland</i>)	3049
Decreased Levels of Circulating Regulatory NK Cells in Patients with Head and Neck Cancer throughout all Tumor Stages. S. WULFF, R. PRIES, K. BÖRNGEN, T. TRENKLE, B. WOLLENBERG (<i>Lübeck, Germany</i>)	3053
SPARC is Expressed in Human Uveal Melanoma and its Abrogation Reduces Tumor Cell Proliferation. S.C. MALONEY, J.-C. MARSHALL, E. ANTECKA, M.E. ORELLANA, B.F. FERNANDES, C. MARTINS, E. CASTIGLIONE, S. DI CESARE, P. LOGAN, M.N. BURNIER, JR. (<i>Montreal, QC, Canada</i>).....	3059
Mutation of Ameloblastin Gene in Calcifying Epithelial Odontogenic Tumor. P.F. PERDIGÃO, V.M. CARVALHO, L. DE MARCO, R.S. GOMEZ (<i>Belo Horizonte, MG, Brazil</i>)	3065
Preclinical and Clinical Aspects of Carboplatin and Gemcitabine Combined with Whole-body Hyperthermia for Pancreatic Adenocarcinoma. A. BAKSHANDEH-BATH, A.S. STOLTZ, N. HOMANN, T. WAGNER, S. STÖLTING, S.O. PETERS (<i>Luebeck, Germany</i>)	3069
Tumor-specific Cytotoxic Activity of 1,2,3,4-Tetrahydroisoquinoline Derivatives against Human Oral Squamous Cell Carcinoma Cell Lines. H. HATANO, F. TAKEKAWA, K. HASHIMOTO, M. ISHIHARA, M. KAWASE, C. QING, W. QIN-TAO, H. SAKAGAMI (<i>Saitama; Ehime, Japan; Xi'an, Shaanxi, P.R. China</i>)	3079

mTOR, S6 and AKT Expression in Relation to Proliferation and Apoptosis/Autophagy in Glioma. L. ANNOVAZZI, M. MELLAI, V. CALDERA, G. VALENTE, L. TESSITORE, D. SCHIFFER (<i>Vercelli; Novara, Italy</i>)	3087
Co-inhibition of Cyclooxygenase-2 and Dihydropyrimidine Dehydrogenase by Non-steroidal Anti-inflammatory Drugs in Tumor Cells and Xenografts. A. RÉTI, É. PAP, A. ZALATNAI, A. JENEY, J. KRALOVÁNSZKY, B. BUDAI (<i>Budapest, Hungary</i>)	3095
Methionine Restriction Reduces the Chemosensitivity of Central Nervous System Tumour Cell Lines. N. NAJIM, I.D. PODMORE, A. MCGOWN, E.J. ESTLIN (<i>Salford; Pendlebury, UK</i>)	3103
Possible Mechanism of CCL2-induced Akt Activation in Prostate Cancer Cells. K. MIZUTANI, H. ROCA, Z. VARSOS, K.J. PIENTA (<i>Ann Arbor, MI, USA</i>)	3109
Chemosensitiveness Associated with Canonical Molecular Changes in Colorectal Adenocarcinomas. J.C. KIM, S.A. ROH, D.H. CHO, T.W. KIM, S.N. YOON, C.W. KIM, C.S. YU, S.Y. KIM, Y.S. KIM (<i>Seoul; Daejeon, South Korea</i>)	3115
Extent of Cell Electrofusion <i>In Vitro</i> and <i>In Vivo</i> Is Cell Line Dependent. S. ŠALOMSKAITĖ-DAVALGIENĖ, K. ČEPURNIENĖ, S. ŠATKAUSKAS, M.S. VENSCLAUSKAS, L.M. MIR (<i>Kaunas, Lithuania; Villejuif, France</i>)	3125
Cobalt Chloride-induced Hypoxia Modulates the Invasive Potential and Matrix Metalloproteinases of Primary and Metastatic Breast Cancer Cells. O-Y. FU, M.-F. HOU, S.-F. YANG, S.-C. HUANG, W.-Y. LEE (<i>Kaohsiung; Tainan; Taipei, Taiwan, ROC</i>)	3131
Induction of Mitotic Arrest and Apoptosis by a Novel Synthetic Quinolone Analogue, CWC-8, <i>via</i> Intrinsic and Extrinsic Apoptotic Pathways in Human Osteogenic Sarcoma U-2 OS Cells. Y.-H. CHANG, J.-S. YANG, S.-C. KUO, J.-G. CHUNG (<i>Taichung, Taiwan, ROC</i>)	3139
Diagnostic and Prognostic Value of CD10 in Peripheral Nerve Sheath Tumors. D. CABIBI, M. ZERILLI, G. CARADONNA, L. SCHILLACI, B. BELMONTE, V. RODOLICO (<i>Palermo, Italy</i>)	3149
Phagocytosis of Cancer Cells by Mast Cells in Breast Cancer. F. DELLA ROVERE, A. GRANATA, M. MONACO, G. BASILE (<i>Messina, Italy</i>)	3157
Effects of Tetrandrine plus Radiation on Neuroblastoma Cells. Y. CHEN, J.-C. CHEN, S.-H. TSENG (<i>Taipei; Taoyuan; Chia-Yi, Taiwan, ROC</i>)	3163
Combination Chemotherapy of Nafamostat Mesilate with Gemcitabine for Pancreatic Cancer Targeting NF- κ B Activation. T. UWAGAWA, P.J. CHIAO, T. GOCHO, S. HIROHARA, T. MISAWA, K. YANAGA (<i>Tokyo, Japan; Houston, TX, USA</i>)	3173
Effect of Free Radicals on the Biological Action of Genistein <i>In Vitro</i> and Synergism with Mitomycin C.J. HARTMANN, N. GETOFF (<i>Vienna, Austria</i>)	3179
Curcumin Inhibits Proliferation of Colorectal Carcinoma by Modulating Akt/mTOR Signaling. S.M. JOHNSON, P. GULHATI, I. ARRIETA, X. WANG, T. GAO, B.M. EVERS (<i>Galveston, TX, USA</i>)	3185
A Common 9 bp Deletion in the Ataxia-telangiectasia-mutated Gene Is Not Associated with Oral Cancer. S. SPYRIDONIDOU, C. YAPIJAKIS, E. NKENKE, T. TOYOSHIMA, A. VYLLIOTIS, Z. SEREFOGLOU, F.W. NEUKAM, E. PATSOURIS, E. VAIRAKTARIS (<i>Athens, Greece; Nurnberg, Germany</i>)	3191
Keratinocyte Growth Factor (KGF) Regulates Estrogen Receptor- α (ER- α) Expression and Cell Apoptosis <i>via</i> Phosphatidylinositol 3-kinase (PI3K)/Akt Pathway in Human Breast Cancer Cells. H.-L. CHANG, Y. SUGIMOTO, S. LIU, L.-S. WANG, Y.-W. HUANG, W. YE, Y.C. LIN (<i>Columbus, OH, USA</i>)	3191

Methylation Mediated Silencing of TMS1 in Breast Cancer and its Potential Contribution to Docetaxel Cytotoxicity. E. GORDIAN, K. RAMACHANDRAN, R. SINGAL (<i>Miami, FL, USA</i>)	3207
Antitumor Potential of Three Herbal Extracts against Human Oral Squamous Cell Lines. Q. CHU, K. SATOH, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, Q. WANG, H. SAKAGAMI (<i>Xi'an, P.R. of China; Saitama; Tokyo; Kanagawa, Japan</i>)	3211
The Effects of Sirolimus on Urothelial Lesions Chemically Induced in ICR Mice by BBN. P.A. OLIVEIRA, R. ARANTES-RODRIGUES, C. SOUSA-DINIZ, A. COLAÇO, L. LOURENÇO, L. FELIPE DE LA CRUZ P., V. MOREIRA DA SILVA, J. AFONSO, C. LOPES, L. SANTOS (<i>Vila Real; Porto; Póvoa do Lanhoso, Portugal; Lugo, Spain</i>).....	3221
Enhanced Antitumour Activity of Cyclopentadienyl-substituted Metallocene Dihalides in Human Breast and Colon Cancer Cells. X. STACHTEA, N. KARAMANOS, N. KLOURAS (<i>Patras, Greece</i>).....	3227
Cancer Cell Growth and Extracellular Matrix Remodeling Mechanism of Ascorbate; Beneficial Modulation by <i>P. leucotomos</i> . N. PHILIPS, L. DULAJ, T. UPADHYA (<i>Teaneck, NJ, USA</i>)	3233
<i>Clinical Studies</i>	
Intrahepatic Cholangiocarcinoma and Hepatitis: Case Study and Literature Review. F. LUH, A. KUEI, P. FANN, P. CHU, Y. YEN (<i>Duarte, CA, USA</i>)	3239
CEA in Activated Macrophages. New Diagnostic Possibilities for Tumor Markers in Early Colorectal Cancer. D. JAPINK, M.P.G. LEERS, M.N. SOSEF, M. NAP (<i>Heerlen, The Netherlands</i>)	3245
Elevated <i>ERCC1</i> Gene Expression in Blood Cells Associated with Exposure to Arsenic from Drinking Water in Inner Mongolia. J. MO, Y. XIA, Z. NING, T.J. WADE, J.L. MUMFORD (<i>Chapel Hill; Triangle Park, NC, USA; Huhhot; Lin He, Inner Mongolia, China</i>)	3253
First Experiences with Low-dose Anti-angiogenic Treatment in Gliomatosis Cerebri with Signs of Angiogenic Activity. M. SEIZ, P. KOHLHOF, M.A. BROCKMANN, E. NEUMAIER-PROBST, P. HERMES, A. VON DEIMLING, P. VAJKOCZY, K. SCHMIEDER, J. TUETTENBERG (<i>Heidelberg; Berlin, Germany</i>).....	3261
Prognostic Impact of CD68 and Kallikrein 6 in Human Glioma. T. STROJNIK, R. KAVALAR, I. ZAJC, E.P. DIAMANDIS, K. OIKONOMOPOULOU, T.T. LAH (<i>Maribor; Ljubljana, Slovenia; Toronto, ON, Canada</i>).....	3269
Tandem High-dose Chemotherapy Followed by Autologous Transplantation in Patients with Locally Advanced or Metastatic Sarcoma. A. LASHKARI, W.A. CHOW, F. VALDES, L. LEONG, V. PHAN, P. TWARDOWSKI, N. KAPOOR, A. MOLINA, Z. AL-KADHIMI, P. FRANKEL, G. SOMLO (<i>Duarte, CA, USA</i>)	3281
* Review: New Molecular Biomarkers for the Prognosis and Management of Prostate Cancer – The Post PSA Era. B. BICKERS, C. AUKIM-HASTIE (<i>Portsmouth, Hampshire, UK</i>)	3289
Analysis of Factors Influencing Dysphagia Severity Following Treatment of Head and Neck Cancer. N.P. NGUYEN, C. FRANK, C.C. MOLTZ, U. KARLSSON, P.D. NGUYEN, H.W.C. WARD, P. VOS, H.J. SMITH, S. HUANG, L.M. NGUYEN, C. LEMANSKI, A. LUDIN, S. SALLAH (<i>Tucson, AZ; Dallas, TX; Greenville, NC; Ann Arbor, MI; Cleveland, OH, USA; Montpellier, France; Athens, Greece</i>)	3299
Induction of Severe Cataract and Late Renal Dysfunction Following Total Body Irradiation: Dose–Effect Relationships. H.B. KAL, M.L. VAN KEMPEN-HARTEVELD (<i>Utrecht, The Netherlands</i>)	3305
The Angiogenic Growth Factors HGF and VEGF in Serum and Plasma from Neuroblastoma Patients. E.G. SKÖLDENBERG, A. LARSSON, Å. JAKOBSON, F. HEDBORG, P. KOGNER, R.H. CHRISTOFFERSON, F. AZARBAYJANI (<i>Uppsala; Stockholm, Sweden</i>)	3311

Prognostic Significance of Serum Adipokine Levels in Colorectal Cancer Patients. F. GUADAGNI, M. ROSELLI, F. MARTINI, A. SPILA, S. RIONDINO, R. D'ALESSANDRO, G. DEL MONTE, V. FORMICA, A. LAUDISI, I. PORTARENA, R. PALMIROTTA, P. FERRONI (<i>Rome, Italy</i>)	3321
Placement of an Expandable Metallic Stent Improves the Efficacy of Chemoradiotherapy for Pancreatic Cancer with Malignant Portal Vein Stenosis or Obstruction. Y. NIO, C. IGUCHI, M. ITAKURA, T. NISHI, K. HASHIMOTO, H. TAKEDA, M. TAKAMURA, H. OMORI, Y. SATO, M. KOIKE, S.-I. ENDO (<i>Kyoto; Shimane; Hyogo, Japan</i>)	3329
Effect of Aromatase Inhibitors on Lipid Metabolism, Inflammatory Response and Antioxidant Balance in Patients with Breast Carcinoma. B. MELICHAR, H. KALÁBOVÁ, L. KRČMOVÁ, L. URBÁNEK, R. HYŠPLER, D. SOLICHOVÁ, K. MELICHAROVÁ, M. PECKA, Z. ZADÁK (<i>Hradec Králové; Olomouc, Czech Republic</i>)	3337
Frequency of Lymph Node Metastasis to the Splenic Hilus and Effect of Splenectomy in Proximal Gastric Cancer. S. SASADA, M. NINOMIYA, M. NISHIZAKI, M. HARANO, Y. OJIMA, H. MATSUKAWA, H. AOKI, S. SHIOZAKI, S. OHNO, N. TAKAKURA (<i>Hiroshima, Japan</i>)	3347
* Review: Current and Future Options in the Treatment of Malignant Ascites in Ovarian Cancer. H. WOOPEN, J. SEHOULI (<i>Berlin, Germany</i>)	3353
MRSA-pyomyositis in a Patient with Acute Myelogenous Leukemia after Intensive Chemotherapy. T. FUKUSHIMA, H. IWAO, A. NAKAZIMA, M. MIKI, T. SAKAI, T. SAWAKI, M. TANAKA, Y. MASAKI, Y. HIROSE, H. UMEHARA (<i>Ishikawa, Japan</i>)	3361
Texture Image Analysis in Differentiating Malignant from Benign Adrenal Cortical Tumors in Children and Adults. N.K. SHIRATA, S.T. SREDNI, A. CASTELO, A. SANTINELLI, B. MENDONÇA, R. MONTIRONI, A. LONGATTO FILHO, M.C.N. ZERBINI (<i>São Paulo, Brazil; Chicago, IL, USA; Ancona, Italy; Braga, Portugal</i>)	3365
A Novel <i>K-ras</i> Mutation in Colorectal Cancer. A Case Report and Literature Review. R. PALMIROTTA, A. SAVONAROLA, V. FORMICA, G. LUDOVICI, G. DEL MONTE, M. ROSELLI, F. GUADAGNI (<i>Rome, Italy</i>)	3369
Clinicopathological and Immunohistochemical Characteristics of Esophageal Carcinosarcoma. A. SANO, S. SAKURAI, H. KATO, M. SAKAI, N. TANAKA, T. INOSE, K. SAITO, M. SOHDA, M. NAKAJIMA, K. SAKAMOTO, T. SANO, Y. HOSOYA, T. ENOMOTO, T. KANDA, Y. AJIOKA, T. OYAMA, H. KUWANO (<i>Gunma; Tochigi; Niigata, Japan</i>)	3375
Image-guided Robotic Stereotactic Radiosurgery for Unresectable Liver Metastases: Preliminary Results. G. AMBROSINO, F. POLISTINA, G. COSTANTIN, P. FRANCESCON, R. GUGLIELMI, P. ZANCO, F. CASAMASSIMA, A. FEBBRARO, G. GERUNDA, F. LUMACHI (<i>Padova; Vicenza; Firenze; Benevento; Modena, Italy</i>)	3381
Feasibility Study of S-1 plus Weekly Docetaxel Combined with Concurrent Radiotherapy in Advanced Gastric Cancer Refractory to First-line Chemotherapy. K. FUJITANI, T. TSUJINAKA, H. YAMASAKI, M. HIRAO, K. YOSHIDA, Y. KUROKAWA (<i>Osaka, Japan</i>)	3385
Background, Reasons and Benefits Using the Vienna Protocol for the Treatment of Painful Bone Recurrences with ¹⁵³ Samarium-EDTMP. H. SINZINGER, K. WEISS, J. HILTUNEN (<i>Vienna; Neustadt, Austria</i>)	3393
Kidney-autotransplantation before Radiotherapy: A Case Report. T. BÖLLING, K. JANKE, H.H. WOLTERS, M. GLASHÖRSTER, I. ERNST, N. WILLICH, J. BROCKMANN, S. KÖNEMANN (<i>Münster, Germany</i>) ...	3397
Comparison of Cytology, Colposcopy, HPV Typing and Biomarker Analysis in Cervical Neoplasia. M. ADAMOPOULOU, E. KALKANI, E. CHARVALOS, D. AVGOUSTIDIS, D. HAIDOPOULOS, C. YAPIJAKIS (<i>Athens, Greece</i>)	3401

Extrapulmonary Small Cell Carcinoma (EPSCC): 10 Years' Multi-disciplinary Experience at Charite. S. OCHSENREITHER, S. MARNITZ-SCHULTZE, A. SCHNEIDER, C. KOEHLER, S. DAUM, C. LODDENKEMPER, V. BUDACH, E. THIEL, U. KEILHOLZ, A. SCHMITTEL (<i>Berlin, Germany</i>).....	3411
Influence of KGF on the Progression of Pancreatic Cancer. X.-P. ZANG, M. LERNER, D. BRACKETT, J.T. PENTO (<i>Oklahoma City, OK, USA</i>)	3417
Cyfra 21-1 as a Serum Tumor Marker for Follow-up of Patients with Laryngeal and Hypopharyngeal Squamous Cell Carcinoma. H. AL-SHAGAHIN, K. ALKOTYFAN, H.-H. MÜLLER, A.M. SESTERHENN, J.A. WERNER (<i>Marburg, Germany</i>)	3421
A Comparison of Stage of Presentation for Pancreatic and Colorectal Cancer in Pennsylvania 2000-2005. M. CHIRUMBOLE, N. GUSANI, A. HOWARD, T. LEONARD, P. LEWIS, J. MUSCAT (<i>Hershey, PA, USA</i>) ...	3427
Efficiency of Iloprost Treatment for Chemotherapy-associated Osteonecrosis after Childhood Cancer. M. JÄGER, C. ZILKENS, B. WESTHOFF, E.M. JELINEK, G. KOZINA, R. KRAUSPE (<i>Düsseldorf, Germany</i>)	3433
Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study. M. RALLI, I. TOURKANTONIS, N. MAKRILIA, E. GKINI, E. KOTTEAS, I. GKIOZOS, N. KATIRTZOGLU, K. SYRIGOS (<i>Athens, Greece</i>)	3441
Clinicopathological Characteristics of Recurrence More than 10 Years after Surgery in Patients with Breast Carcinoma. H. TAKEUCHI, Y. MUTO, H. TASHIRO (<i>Beppu; Oita, Japan</i>)	3445
The AA Genotype of a <i>L1C</i> G842A Polymorphism Is Associated with an Increased Risk for Ovarian Cancer. M. HEUBNER, P. WIMBERGER, S. KASIMIR-BAUER, F. OTTERBACH, R. KIMMIG, W. SIFFERT (<i>Duisburg-Essen, Germany</i>)	3449
The BB Genotype of <i>Heat-shock Protein (HSP) 70-2</i> Gene Is Associated with Gastric Pre-malignant Condition in <i>H. pylori</i> -infected Older Patients. T. TAHARA, T. SHIBATA, T. ARISAWA, M. NAKAMURA, D. YOSHIOKA, M. OKUBO, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H. FUJITA, M. NAGASAKA, M. IWATA, H. YAMASHITA, H. NAKANO, I. HIRATA (<i>Aichi; Ishikawa, Japan</i>)	3453
Preliminary Study of Detecting Urothelial Malignancy with FDG PET in Taiwanese ESRD Patients. S.-S. SUN, C.-H. CHANG, H.-J. DING, C.-H. KAO, H.-C. WU, T.-C. HSIEH (<i>Taichung; Kaohsiung, Taiwan, ROC</i>)	3459
Serum and Tissue Selenium Levels in Gastric Cancer Patients and Correlation with CEA. K. CHARALABOPOULOS, A. KOTSALOS, A. BATISTATOU, A. CHARALABOPOULOS, D. PESCHOS, P. VEZYRAKI, V. KALFAKAKOU, A. METSIOS, A. CHARALAMPOPOULOS, A. MACHERAS, N. AGNANTIS, A. EVANGELOU (<i>Ioannina; Athens, Greece</i>)	3465

* Reviews (pages 3289, 3353)

Number 9

Part A: Proceedings of the Symposium “Vitamin D Analogs in Cancer Prevention and Therapy”, May 2008, Krefeld, Germany. Edited by J. Reichrath and M. Friedrich

Part B: Proceedings of the Symposium “Vitamin D, Calcium and Cancer”, 8th International Conference of Anticancer Research, October 2008, Kos, Greece. Edited by H.S. Cross and M. Peterlik

Part A

- Vitamin D Analogs in Cancer Prevention and Therapy: An Ancient Friend Revisited. J. REICHRATH, W. TILGEN, K. DIEDRICH, M. FRIEDRICH (*Homburg/Saar; Lübeck; Krefeld, Germany*) 3469
- * Review: The Impact of 1,25(OH)₂D₃ and its Structural Analogs on Gene Expression in Cancer Cells – A Microarray Approach. C. KRIEBITZSCH, L. VERLINDEN, G. EELEN, B.K. TAN, M. VAN CAMP, R. BOUILLON, A. VERSTUYF (*Leuven, Belgium*) 3471
- * Review: A Genomic Perspective on Vitamin D Signaling. C. CARLBERG, S. SEUTER (*Luxembourg; Kuopio, Finland*) 3485
- * Review: Sun and Sun Beds: Inducers of Vitamin D and Skin Cancer. E. CICARMA, A.C. POROJNICU, Z. LAGUNOVA, A. DAHLBACK, A. JUZENIENE, J. MOAN (*Oslo, Norway*) 3495
- * Review: Solar Radiation, Vitamin D and Cancer Incidence and Mortality in Norway. J. MOAN, A. DAHLBACK, Z. LAGUNOVA, E. CICARMA, A.C. POROJNICU (*Oslo, Norway*) 3501
- * Review: The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of the Literature. K. KÖSTNER, N. DENZER, C.S.L. MÜLLER, R. KLEIN, W. TILGEN, J. REICHRATH (*Homburg; Kaiserslautern, Germany*) 3511
- Air Pollution in Relation to U.S. Cancer Mortality Rates: An Ecological Study; Likely Role of Carbonaceous Aerosols and Polycyclic Aromatic Hydrocarbons. W.B. GRANT (*San Francisco, CA, USA*) 3537
- Evaluation of 19-Nor-2 α -(3-hydroxypropyl)-1 α ,25-dihydroxyvitamin D₃ as a Therapeutic Agent for Androgen-dependent Prostate Cancer. J.N. FLANAGAN, S. ZHENG, K.-C. CHIANG, A. KITTAKA, T. SAKAKI, S. NAKABAYASHI, X. ZHAO, R.A. SPANJAARD, K.S. PERSONS, J.S. MATHIEU, M.F. HOLICK, T.C. CHEN (*Boston, MA, USA; Kaohsiung, Taiwan, ROC; Kanagawa; Toyama, Japan; Stockholm, Sweden*) 3547
- Regulation of Steroid Receptor Expression by 1 α -Hydroxyvitamin D₅ in Hormone-responsive Breast Cancer Cells. E.A. HUSSAIN-HAKIMJEE, R.G. MEHTA (*Chicago, IL, USA*) 3555
- Synthesis and Biological Activities of 14-*epi*-MART-10 and 14-*epi*-MART-11: Implications for Cancer and Osteoporosis Treatment. A. KITTAKA, H. HARA, M. TAKANO, D. SAWADA, M.A. ARAI, K. TAKAGI, T. CHIDA, Y. HARADA, H. SAITO, K. TAKENOUCHE, S. ISHIZUKA, K. HAYASHI, S. IKUSHIRO, T. SAKAKI, T. SUGIURA, T.C. CHEN (*Kanagawa; Tokyo; Toyama, Japan; Boston, MA, USA*) 3563
- Synthesis of All Possible A-ring Diastereomers at the 1- and 3-Positions of 1 α ,25-Dihydroxy-2 β -(3-hydroxypropoxy)vitamin D₃ (ED-71) Using C₂-Symmetrical Epoxide as a Common Starting Material. N. KUBODERA, S. HATAKEYAMA (*Tokyo; Nagasaki, Japan*) 3571
- Antiproliferative and Calcemic Actions of *Trans*-Decalin CD-Ring Analogs of 1,25-Dihydroxyvitamin D₃. G. EELEN, L. VERLINDEN, J. LAUREYS, S. MARCELIS, P. DE CLERCQ, C. MATHIEU, R. BOUILLON, A. VERSTUYF (*Leuven; Ghent, Belgium*) 3579

Microarray Analysis of MCF-7 Breast Cancer Cells Treated with 1,25 Dihydroxyvitamin D ₃ or a 17-Methyl-D-ring Analog. E. VANOIRBEEK, G. EELEN, L. VERLINDEN, K. MARCHAL, K. ENGELEN, B. DE MOOR, I. BEULLENS, S. MARCELIS, P. DE CLERCQ, R. BOUILLON, A. VERSTUYF (<i>Leuven; Heverlee; Ghent, Belgium</i>)	3585
Fish Oil Enhances the Antiproliferative Effect of 1 α ,25-Dihydroxyvitamin D ₃ on Liver Cancer Cells. K.-C. CHIANG, K.S. PERSONS, N.W. ISTFAN, M.F. HOLICK, T.C. CHEN (<i>Kaohsiung, Taiwan, ROC; Boston, MA, USA</i>)	3591
* Review: Current Impediments to Acceptance of the Ultraviolet-B-Vitamin D-Cancer Hypothesis. W.B. GRANT, B.J. BOUCHER (<i>San Francisco, CA, USA; London, UK</i>)	3597
A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer. S. SRINIVAS, D. FELDMAN (<i>Stanford, CA, USA</i>)	3605
Expression of Prostaglandin Metabolizing Enzymes COX-2 and 15-PGDH and VDR in Human Granulosa Cells. M. THILL, S. BECKER, D. FISCHER, T. CORDES, A. HORNEMANN, K. DIEDRICH, D. SALEHIN, M. FRIEDRICH (<i>Lübeck; Krefeld, Germany</i>)	3611
Prostaglandin Metabolizing Enzymes in Correlation with Vitamin D Receptor in Benign and Malignant Breast Cell Lines. M. THILL, D. FISCHER, S. BECKER, T. CORDES, C. DITTMER, K. DIEDRICH, D. SALEHIN, M. FRIEDRICH (<i>Lübeck; Krefeld, Germany</i>)	3619
25-Hydroxyvitamin D ₃ 1 α -Hydroxylase Splice Variants in Benign and Malignant Ovarian Cell Lines and Tissue. D. FISCHER, M. THOMÉ, S. BECKER, T. CORDES, K. DIEDRICH, M. FRIEDRICH, M. THILL (<i>Lübeck; Krefeld, Germany</i>)	3627
Expression of 25-Hydroxyvitamin D ₃ -24-Hydroxylase in Benign and Malignant Ovarian Cell Lines and Tissue. D. FISCHER, M. THOMÉ, S. BECKER, T. CORDES, K. DIEDRICH, M. FRIEDRICH, M. THILL (<i>Lübeck; Krefeld, Germany</i>)	3635
Vitamin D-24-Hydroxylase in Benign and Malignant Breast Tissue and Cell Lines. D. FISCHER, S. BECKER, T. CORDES, B. BÜCKER, K. DIEDRICH, M. FRIEDRICH, D. SALEHIN, M. THILL (<i>Lübeck; Krefeld, Germany</i>)	3641
Cross-talk between Vitamin D Receptor (VDR)- and Peroxisome Proliferator-activated Receptor (PPAR)-signaling in Melanoma Cells. P. SERTZNIG, T. DUNLOP, M. SEIFERT, W. TILGEN, J. REICHRATH (<i>Homburg/Saar, Germany; Kuopio, Finland</i>)	3647
Expression of 25-Hydroxyvitamin D-1 α -Hydroxylase (1 α OHase, <i>CYP27B1</i>) Splice Variants in HaCaT Keratinocytes and Other Skin Cells: Modulation by Culture Conditions and UV-B Treatment <i>In Vitro</i> . M. SEIFERT, W. TILGEN, J. REICHRATH (<i>Homburg, Germany</i>)	3659
Reduced Serum 25-Hydroxyvitamin D Levels in Stage IV Melanoma Patients. B. NÜRNBERG, S. GRÄBER, B. GÄRTNER, J. GEISEL, C. PFÖHLER, D. SCHADENDORF, W. TILGEN, J. REICHRATH (<i>Homburg; Essen, Germany</i>)	3669
* Review: How to Optimize Vitamin D Supplementation to Prevent Cancer, Based on Cellular Adaptation and Hydroxylase Enzymology. R. VIETH (<i>Toronto, ON, Canada</i>)	3675
Part B	
Preface: Vitamin D, Calcium, and Cancer. H.S. CROSS, M. PETERLIK (<i>Vienna, Austria</i>)	3685
* Review: Calcium, Vitamin D and Cancer. M. PETERLIK, W.B. GRANT, H.S. CROSS (<i>Vienna, Austria; San Francisco, CA, USA</i>)	3687

* Review: Epidemiology of Vitamin D Insufficiency and Cancer Mortality. S. PILZ, A. TOMASCHITZ, B. OBERMAYER-PIETSCH, H. DOBNIG, T.R. PIEBER (<i>Graz, Austria</i>)	3699
* Review: Modulation of Vitamin D Synthesis and Catabolism in Colorectal Mucosa: A New Target for Cancer Prevention. H.S. CROSS, T. NITTKKE, M. PETERLIK (<i>Vienna, Austria</i>)	3705
The Dependency of Vitamin D Status on Body Mass Index, Gender, Age and Season. Z. LAGUNOVA, A.C. POROJNICU, F. LINDBERG, S. HEXEBERG, J. MOAN (<i>Oslo, Norway</i>)	3713
Mutual Associations between Malignancy, Age, Gender, and Subsite Incidence of Colorectal Cancer. W. BROZEK, S. KRIWANEK, E. BONNER, M. PETERLIK, H.S. CROSS (<i>Vienna, Austria</i>)	3721
Parallel Elevation of Colonic 1,25-Dihydroxyvitamin D ₃ Levels and Apoptosis in Female Mice on a Calcium-deficient Diet. T. NITTKKE, E. KALLAY, T. MANHARDT, H.S. CROSS (<i>Vienna, Austria</i>)	3727
* Reviews (pages 3471, 3485, 3495, 3501, 3511, 3597, 3675, 3687, 3699, 3705)	

Number 10

Experimental Studies

Apoptosis Induced by Capsaicin and Resveratrol in Colon Carcinoma Cells Requires Nitric Oxide Production and Caspase Activation. M.Y. KIM, L.J. TRUDEL, G.N. WOGAN (<i>Cambridge, MA, USA</i>)	3733
p53-Mediated Down-regulation of the Human DNA Repair Gene O ⁶ -Methylguanine-DNA Methyltransferase (<i>MGMT</i>) via Interaction with Sp1 Transcription Factor. D. BOCANGEL, S. SENGUPTA, S. MITRA, K.K. BHAKAT (<i>Galveston, TX, USA</i>)	3741
STX140 and STX641 Cause Apoptosis via the Intrinsic Mitochondrial Pathway and Down-regulate Survivin and XIAP Expression in Ovarian and Prostate Cancer Cells. P.A. FOSTER, Y.T. HO, S.P. NEWMAN, M.P. LEESE, B.V.L. POTTER, M.J. REED, A. PUROHIT (<i>London; Bath, UK</i>)	3751
* Review: Role of MGMT in Tumor Development, Progression, Diagnosis, Treatment and Prognosis. S. SHARMA, F. SALEHI, B.W. SCHEITHAUER, F. ROTONDO, L.V. SYRO, K. KOVACS (<i>Toronto, ON, Canada; Rochester, NY, USA; Medellin, Colombia</i>)	3759
Cyclin-mediated G1 Arrest by Celecoxib Differs in Low- versus High-grade Bladder Cancer. J.R. GEE, C.B. BURMEISTER, T.C. HAVIGHURST, K. KIM (<i>Madison, WI, USA</i>)	3769
<i>In Vivo</i> Imaging of Human Colorectal Cancer Using Radiolabeled Analogs of the Uroguanylin Peptide Hormone. D. LIU, D. OVERBEY, L.D. WATKINSON, S. DAIBES-FIGUEROA, T.J. HOFFMAN, L.R. FORTE, W.A. VOLKERT, M.F. GIBLIN (<i>Columbia, MO, USA</i>)	3777
The Expression and Function of IGFBP-3 in Normal and Malignant Breast Tissue. K. MCCARTHY, C. LABAN, C.J. MCVITTIE, W. OGUNKOLADE, S. KHALAF, S. BUSTIN, R. CARPENTER, P.J. JENKINS (<i>London, UK</i>)	3785
Potent Inhibition of Tubulin Polymerisation and Proliferation of Paclitaxel-resistant 1A9PTX22 Human Ovarian Cancer Cells by Albendazole. S.W.L. CHU, S. BADAR, D.L. MORRIS, M.H. POURGHOLAMI (<i>Sydney, NSW, Australia</i>)	3791
Xanthohumol Activates the Proapoptotic Arm of the Unfolded Protein Response in Chronic Lymphocytic Leukemia. S. LUST, B. VANHOECKE, M. VAN GELE, J. BOELENS, H. VAN MELCKEBEKE, M. KAILEH, W.V. BERGHE, G. HAEGEMAN, J. PHILIPPÉ, M. BRACKE, F. OFFNER (<i>Ghent, Belgium</i>) ...	3797

Artemisinin-Transferrin Conjugate Retards Growth of Breast Tumors in the Rat. H. LAI, I. NAKASE, E. LACOSTE, N.P. SINGH, T. SASAKI (<i>Seattle, WA, USA</i>).....	3807
Exogenous Expression of Caspase-14 Induces Tumor Suppression in Human Salivary Cancer Cells by Inhibiting Tumor Vascularization. M. WU, I. KODANI, D. DICKINSON, F. HUFF, K.U.E. OGBUREKE, H. QIN, S. ARUN, R. DULEBOHN, M. AL-SHABRAWAY, A. TAWFIK, S. PRATER, J. LEWIS, J. WATAHA, R. MESSER, S. HSU (<i>Hangzhou, China; Yonago, Japan; Augusta, GA; Seattle, WA, USA</i>)....	3811
Down-regulation of 20-HETE Synthesis and Signaling Inhibits Renal Adenocarcinoma Cell Proliferation and Tumor Growth. A. ALEXANIAN, V.A. RUFANOVA, B. MILLER, A. FLASCH, R.J. ROMAN, A. SOROKIN (<i>Milwaukee, WI, USA</i>).....	3819
Tetraidothyoacetic Acid (Tetrac) and Tetrac Nanoparticles Inhibit Growth of Human Renal Cell Carcinoma Xenografts. M. YALCIN, D.J. BHARALI, L. LANSING, E. DYSKIN, S.S. MOUSA, A. HERCBERGS, F.B. DAVIS, P.J. DAVIS, S.A. MOUSA (<i>Rensselaer; Albany, NY; Cleveland, OH, USA; Bursa, Turkey</i>) ..	3825
* Short Review: Telomeres and Telomerase in Sarcomas. T. MATSUO, S. SHIMOSE, T. KUBO, J. FUJIMORI, Y. YASUNAGA, M. OCHI (<i>Hiroshima, Japan</i>)	3833
The Effect of MAPK Inhibitors on Arsenic Trioxide-treated Calu-6 Lung Cells in Relation to Cell Death, ROS and GSH Levels. Y.H. HAN, H.J. MOON, B.R. YOU, S.Z. KIM, S.H. KIM, W.H. PARK (<i>JeonJu, Republic of Korea</i>)	3837
Antitumor Efficacy and Molecular Mechanism of TLK58747, a Novel DNA-Alkylating Prodrug. H. XU, Z. WANG, J.C. DONALDSON, H. YAO, S. ZHOU, A.B. KELSON, W. MA, K.T. WEBER, E. LABORDE, M. CHENG, L. SAMBUCETTI, J.G. KECK (<i>Palo Alto, CA, USA</i>).....	3845
Inhibitory Effect of Cordycepin on Hematogenic Metastasis of B16-F1 Mouse Melanoma Cells Accelerated by Adenosine-5'-diphosphate. N. YOSHIKAWA, M. KUNITOMO, S. KAGOTA, K. SHINOZUKA, K. NAKAMURA (<i>Hyogo, Japan</i>).....	3857
Expression of M-CSF and CSF-1R Is Correlated with Histological Grade in Soft Tissue Tumors. E. RICHARDSEN, S.W. SØRBYE, J.P. CROWE, J.-L. YANG, L.-T. BUSUND (<i>Tromsø, Norway; Randwick; Sydney, NSW, Australia</i>).....	3861
Formulation, Characterization and Evaluation of Curcumin-loaded PLGA Nanospheres for Cancer Therapy. A. MUKERJEE, J.K. VISHWANATHA (<i>Fort Worth, TX, USA</i>)	3867
Infiltration by Macrophages and Lymphocytes in Transplantable Mouse Sarcoma after Irradiation with High-intensity Focused Ultrasound. S. CHIDA, K. OKADA, N. SUZUKI, C. KOMORI, Y. SHIMADA (<i>Akita, Japan</i>)	3877
<i>c-FLIP</i> Gene Silencing Eliminates Tumor Cells in Breast Cancer Xenografts Without Affecting Stromal Cells. T.W. DAY, A.L. SINN, S. HUANG, K.E. POLLOK, G.E. SANDUSKY, A.R. SAFA (<i>Indianapolis, IN, USA</i>)..	3883
The Expression of MT1 Melatonin Receptor and Ki-67 Antigen in Melanoma Malignum. K. DANIELCZYK, P. DZIEGIEL (<i>Wrocław; Poznań, Poland</i>)	3887
Association of Genetic Polymorphisms of <i>EXO1</i> Gene with Risk of Breast Cancer in Taiwan. H.-C. WANG, C.-F. CHIU, R.-Y. TSAI, Y.-S. KUO, H.-S. CHEN, R.-F. WANG, C.-W. TSAI, C.-H. CHANG, C.-C. LIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	3897
Significant Association of XPD Codon 312 Single Nucleotide Polymorphism with Bladder Cancer Susceptibility in Taiwan. C.-H. CHANG, R.-F. WANG, R.-Y. TSAI, H.-C. WU, C.-H. WANG, C.-W. TSAI, C.-L. CHANG, Y.-A. TSOU, C.-S. LIU, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>).....	3903

Clusterin Overexpression and Relapse-free Survival in Breast Cancer. C.K. YOM, H.-Y. WOO, S.Y. MIN, S.Y. KANG, H.S. KIM (<i>Seoul, South Korea</i>)	3909
PTP4A3 Expression Increases Strongly in Lymph Node Metastases from Colorectal Carcinoma. K. GUZIŃSKA-USTYMOWICZ, A. PRYCZYNICZ, A. KEMONA (<i>Białystok, Poland</i>)	3913
The Effect of a Novel Botanical Agent TBS-101 on Invasive Prostate Cancer in Animal Models. S. EVANS, N. DIZEYI, P.-A. ABRAHAMSSON, J. PERSSON (<i>Malmö, Sweden</i>)	3917
Effects of 5-FU on DNA Synthesis and Cytotoxicity of Human Lymphocytes Induced by IL-2, TGF- β 3 and PGE ₂ . A. EISENTHAL, K. EYTAN, E. BRAZOWSKI, G. GITSTEIN, R. GREENBERG, Y. SKORNICK (<i>Tel Aviv, Israel</i>)	3925
Cisplatin and Oxaliplatin Cytotoxic Effects in Sensitive and Cisplatin-resistant Human Cervical Tumor Cells: Time and Mode of Application Dependency. L. MARTELLI, E. RAGAZZI, F. DI MARIO, M. BASATO, M. MARTELLI (<i>Padova; Parma, Italy</i>)	3931
<i>CDK10</i> Is Not a Target for Aberrant DNA Methylation in Breast Cancer. G. HELLER, B. ZIEGLER, A. BRANDSTETTER, S. NOVAK, M. RUDAS, G. HENNIG, M. GEHRMANN, T. ACHT, S. ZÖCHBAUER-MÜLLER, M. FILIPITS (<i>Vienna, Austria; Cologne, Germany</i>)	3939
Frequent <i>CDH3</i> Demethylation in Advanced Gastric Carcinoma. K. HIBI, Y.-H. KITAMURA, H. MIZUKAMI, T. GOTO, K. SAKURABA, M. SAKATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	3945
Decreased Plasma Ghrelin Levels in Patients with Advanced Cancer and Weight Loss in Comparison to Healthy Individuals. I. LEGAKIS, J. STATHOPOULOS, T. MATZOURIDIS, G.P. STATHOPOULOS (<i>Athens, Greece</i>)	3949
Down-regulation of <i>Tip60</i> Gene as a Potential Marker for the Malignancy of Colorectal Cancer. K. SAKURABA, T. YASUDA, M. SAKATA, Y.-H. KITAMURA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Yokohama, Japan</i>)	3953
Glutathione Modulation Reverses the Growth-promoting Effect of Growth Factors, Improving the 5-Fluorouracil Antitumour Response in WiDr Colon Cancer Cells. T. PALOMARES, M. CARAMÉS, I. GARCÍA-ALONSO, A. ALONSO-VARONA (<i>Leioa, Vizcaya, Spain</i>)	3957
Transition of Cleaved Notch1 and Gene Expression Changes in Myeloblastic Leukemia Cells Stimulated with Notch Ligands. L. FU, K.-I. KATSUBE, S. TOHDA (<i>Tokyo, Japan</i>)	3967
3-Dimensional Microarray Analysis of Estrogen Signal-related Genes in Breast Cancer Tissues. M. MATSUMOTO, H. SAKAMOTO, Y. YAMAGUCHI, Y. SEINO, H. TAKEI, M. KUROSUMI, H. SASANO, N. YAEGASHI, S.-I. HAYASHI (<i>Sendai; Tokyo; Saitama, Japan</i>)	3971
BCL-2, BAX and P53 Expression Profiles in Endometrial Carcinoma as Studied by Real-time PCR and Immunohistochemistry. O. PORICHI, M.-E. NIKOLAIDOU, A. APOSTOLAKI, A. TSERKEZOGLOU, N. ARNOGIANNAKI, D. KASSANOS, L. MARGARITIS, E. PANOTOPOULOU (<i>Athens, Greece</i>)	3977
Evaluation of the Cytotoxic and Genotoxic Effects of Orthodontic Bonding Adhesives upon Human Gingival Papillae through Immunohistochemical Expression of p53, p63 and p16. F. ANGIERO, G. FARRONATO, E. DESSY, S. MAGISTRO, R. SERAMONDI, D. FARRONATO, S. BENEDICENTI, S. TETÈ (<i>Milan; Brescia; Genoa; Chieti, Italy</i>)	3983
Evaluation of Cucurbitane-type Triterpenoids from <i>Momordica balsamina</i> on P-Glycoprotein (ABCB1) by Flow Cytometry and Real-time Fluorometry. G. SPENGLER, C. RAMALHETE, M. MARTINS, A. MARTINS, J. SERLY, M. VIVEIROS, J. MOLNÁR, N. DUARTE, S. MULHOVO, M.-J.U. FERREIRA, L. AMARAL (<i>Lisboa, Portugal; Szeged, Hungary; Chokwe, Mozambique</i>)	3989

Doxycycline Induces Apoptosis in PANC-1 Pancreatic Cancer Cells. K. SON, S. FUJIOKA, T. IIDA, K. FURUKAWA, T. FUJITA, H. YAMADA, P.J. CHIAO, K. YANAGA (<i>Tokyo, Japan; Houston, TX, USA</i>)	3995
Molecular Imaging Application of Radioiodinated Anti-EGFR Human Fab to EGFR-overexpressing Tumor Xenografts. N. XU, G. CAI, W. YE, X. WANG, Y. LI, P. ZHAO, A. ZHANG, R. ZHANG, B. CAO (<i>Jiangsu, P.R. China; Grand Rapids, MI, USA</i>)	4005
MG-63 Osteoblast-like Cells Enhance the Osteoprotegerin Expression of PC-3 Prostate Cancer Cells. H. KATOPODIS, A. PHILIPPOU, R. TENTA, C. DOILLON, K.K. PAPACHRONI, A.G. PAPAVALASSILOU, M. KOUTSILIERIS (<i>Athens, Greece; Quebec, QC, Canada</i>)	4013
HER2 Status on Persistent Disseminated Tumor Cells after Adjuvant Therapy May Differ from Initial HER2 Status on Primary Tumor. N. KRAWCZYK, M. BANYS, H. NEUBAUER, E.-F. SOLOMAYER, C. GALL, M. HAHN, S. BECKER, R. BACHMANN, D. WALLWIENER, T. FEHM (<i>Tuebingen, Germany</i>)	4019
Targeting CWR22Rv1 Prostate Cancer Cell Proliferation and Gene Expression by Combinations of the Phytochemicals EGCG, Genistein and Quercetin. T.-C. HSIEH, J.M. WU (<i>Valhalla, NY, USA</i>)	4025
Expression of L1 Cell Adhesion Molecule Is a Significant Prognostic Factor in pT3-stage Gastric Cancer. Y. KODERA, H. NAKANISHI, S. ITO, K. MISAWA, Y. ITO, G. NAKAYAMA, M. KOIKE, M. FUJIWARA, Y. YAMAMURA, A. NAKAO (<i>Aichi, Japan</i>)	4033
192R Allele of Paraoxanase 1 (<i>PON1</i>) Gene as a New Marker for Susceptibility to Bladder Cancer. O. ÖZTÜRK, Ö.F. KAĞNICI, T. ÖZTÜRK, H. DURAK, B.M. TÜZÜNER, H.I. KISAKESEN, C. ÇAKALIR, T. İSBİR (<i>Istanbul, Turkey</i>)	4041
Mutations of <i>LKB1</i> Gene in Pancreatic Ductal Adenocarcinomas Induced by N-Nitrosobis(2-oxopropyl)amine in Hamsters. M. FURUKAWA, A. YAMASAKI, J. YOSHIDA, M. TSUJINO, N. WAKABAYASHI, K. HONOKI, T. TSUJIUCHI (<i>Osaka; Nara, Japan</i>)	4047
<i>In Vivo</i> Model of Pseudomyxoma Peritonei for Novel Candidate Drug Discovery. T.C. CHUA, J. AKTHER, P. YAO, D.L. MORRIS (<i>Sydney, NSW, Australia</i>)	4051
Expression and Mutational Status of PDGFR in Thymic Tumours. M. MEISTER, P. KAHL, T. MULEY, A. MORRESI-HAUF, C. SEBENING, M.A. KERN, M. BREINIG, P. SCHNABEL, H. DIENEMANN, P. SCHIRMACHER, R.J. RIEKER (<i>Heidelberg; Bonn; Gauting, Germany; Innsbruck, Austria</i>)	4057
Berberine Induced Apoptosis <i>via</i> Promoting the Expression of Caspase-8, -9 and -3, Apoptosis-inducing Factor and Endonuclease G in SCC-4 Human Tongue Squamous Carcinoma Cancer Cells. Y.-T. HO, C.-C. LU, J.-S. YANG, J.-H. CHIANG, T.-C. LI, S.-W. IP, T.-C. HSIA, C.-L. LIAO, J.-G. LIN, W.G. WOOD, J.-G. CHUNG (<i>Taichung, Taiwan, ROC; Minneapolis, MN, USA</i>)	4063
Rapid Induction of P-Glycoprotein mRNA and Protein Expression by Cytarabine in HL-60 Cells. M. PRENKERT, B. UGGLA, E. TINA, U. TIDEFELT, H. STRID (<i>Örebro; Stockholm, Sweden</i>)	4071
Estimation of Relationship Between Descriptors and Cytotoxicity of Newly Synthesized 1,2,3,4-Tetrahydroisoquinoline Derivatives. M. ISHIHARA, H. HATANO, F. TAKEKAWA, M. KAWASE, H. SAKAGAMI (<i>Saitama; Ehime, Japan</i>)	4077
<i>Clinical Studies</i>	
Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma. Y. YEN, S. SO, M. ROSE, M.W. SAIF, E. CHU, S.-H. LIU, A. FOO, Z. JIANG, T. SU, Y.-C. CHENG (<i>Duarte; Stanford, CA; West Haven; New Haven, CT, USA</i>)	4083

Reconstruction Using a Frozen Bone Method for Osteosarcoma of the Talus. A Case Report and Review of the Literature. K. SAKAYAMA, T. KIDANI, Y. SUGAWARA, H. TAUCHI, T. FUJIBUCHI, N. TANJI, H. YAMAMOTO, H. TSUCHIYA (<i>Ehime; Kanazawa, Japan</i>)	4093
Clinicopathological Significance of Sip1-associated Epithelial Mesenchymal Transition in Non-small Cell Lung Cancer Progression. N. MIURA, T. YANO, F. SHOJI, D. KAWANO, T. TAKENAKA, K. ITO, Y. MORODOMI, I. YOSHINO, Y. MAEHARA (<i>Fukuoka; Chiba, Japan</i>)	4099
* Review: Cancer Nanotargeted Radiopharmaceuticals for Tumor Imaging and Therapy. G. TING, C.-H. CHANG, H.-E. WANG (<i>Miaoli; Taoyuan; Taipei, Taiwan, ROC</i>)	4107
Methylene Blue Dye, an Accurate Dye for Sentinel Lymph Node Identification in Early Breast Cancer. C. MATHÉLIN, S. CROCE, D. BRASSE, B. GAIRARD, M. GHARBI, N. ANDRIAMISANDRATSOA, V. BEKAERT, Z. FRANCIS, J.-L. GUYONNET, D. HUSS, S. SALVADOR, R. SCHAEFFER, D. GRUCKER, C. MARIN, J.-P. BELLOCQ (<i>Strasbourg Cedex, France</i>)	4119
High-dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors. M.K. CHADHA, J. LOMBARDO, T. MASHTARE, G.E. WILDING, A. LITWIN, C. RACZYK, J.F. GIBBS, B. KUVSHINOFF, M.M. JAVLE, R.V. IYER (<i>Buffalo, NY; Houston, TX, USA</i>)	4127
Determinants of Homocysteine Levels in Colorectal and Breast Cancer Patients. P. FERRONI, R. PALMIROTTA, F. MARTINI, S. RIONDINO, A. SAVONAROLA, A. SPILA, F. CIATTI, V. SINI, S. MARIOTTI, G. DEL MONTE, M. ROSELLI, F. GUADAGNI (<i>Rome, Italy</i>)	4131
Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined or Not with Systemic Chemotherapy. P. PILATI, E. MAMMANO, S. MOCELLIN, E. TESSARI, M. LISE, D. NITTI (<i>Padova, Italy</i>)	4139
“Glassy” Cells in Barrett’s Mucosa. C.A. RUBIO (<i>Stockholm, Sweden</i>)	4145
Conservative Management of Low-grade Endometrial Stromal Sarcoma Followed by Pregnancy and Severe Recurrence. M. KOSKAS, P. MORICE, C. YAZBECK, P. DUVILLARD, F. WALKER, P. MADELENAT (<i>Paris; Villejuif, France</i>)	4147
Relationships of P53 and Bak with EPO and EPOR in Human Colorectal Cancer. M. BALTAZIAK, M. KODA, A. WINCEWICZ, M. SULKOWSKA, L. KANCZUGA-KODA, S. SULKOWSKI (<i>Bialystok, Poland</i>)	4151
S100A8 and S100A9 Expression Is a Crucial Factor for Dedifferentiation in Thyroid Carcinoma. Y. ITO, K. ARAI, R. NOZAWA, H. YOSHIDA, M. HIROKAWA, M. FUKUSHIMA, H. INOUE, C. TOMODA, M. KIHARA, T. HIGASHIYAMA, Y. TAKAMURA, A. MIYA, K. KOBAYASHI, F. MATSUZUKA, A. MIYAUCHI (<i>Kobe; Shizuoka, Japan</i>)	4157
Survivin Expression as a Strong Indicator of Recurrence in Urothelial Bladder Cancer. Predictive Value of Nuclear versus Cytoplasmic Staining. L. SKAGIAS, E. POLITI, A. KARAMERIS, D. SAMBAZIOTIS, A. ARCHONDAKIS, A. NTINIS, I. MOREAS, O. VASOU, H. KOUTSELINI, E. PATSOURIS (<i>Athens, Greece</i>) ...	4163
Association between <i>XRCC1</i> Polymorphisms and Head and Neck Cancer in a Hungarian Population. A. CSEJTEI, A. TIBOLD, K. KOLTAI, Z. VARGA, I. SZANYI, G. GOBEL, I. PRANTNER, D. STEFFLER, G. FEHER, A. DE BLASIO, I. EMBER, I. KISS (<i>Pécs, Hungary</i>)	4169
Diverse Prognostic Roles of Akt Isoforms, PTEN and PI3K in Tumor Epithelial Cells and Stromal Compartment in Non-small Cell Lung Cancer. S. AL-SAAD, T. DONNEM, K. AL-SHIBLI, M. PERSSON, R.M. BREMNES, L.-T. BUSUND (<i>Tromsø; Bodø, Norway</i>)	4175

Circulating Tumor Cells in Metastatic Breast Cancer: Timing of Blood Extraction for Analysis. M. MARTÍN, J.Á. GARCÍA-SÁENZ, M.L. MAESTRO DE LAS CASAS, M. VIDAURRETA, J. PUENTE, S. VEGANZONES, L. RODRÍGUEZ-LAJUSTICIA, V. DE LA ORDEN, B. OLIVA, J.-C. DE LA TORRE, S. LÓPEZ-TARRUELLA, A. CASADO, J. SASTRE, E. DÍAZ-RUBIO (<i>Madrid, Spain</i>)	4185
Single-institution Outcome of High-dose Interleukin-2 (HD IL-2) Therapy for Metastatic Melanoma and Analysis of Favorable Response in Brain Metastases. S. POWELL, A.Z. DUDEK (<i>Minneapolis, MN, USA</i>)...	4189
Pegylated Liposomal Doxorubicin and Carboplatin in Late-relapsing Ovarian Cancer: A GINECO Group Phase II Trial. B. WEBER, A. LORTHOLARY, F. MAYER, H. BOURGEOIS, H. ORFEUVRE, M. COMBE, C. PLATINI, J. CRETIN, D. FRIC, D. PARAISO, E. PUJADE-LAURAINÉ (<i>Vandoeuvre-les-Nancy; Dijon; Le Mans; Nîmes; Montargis; Paris, France</i>)	4195
Altered p53 and pRb Expression Is Predictive of Response to BCG Treatment in T1G3 Bladder Cancer. L. CORMIO, I. TOLVE, P. ANNESE, A. SARACINO, R. ZAMPARESE, F. SANGUEDOLCE, P. BUFO, M. BATTAGLIA, F.P. SELVAGGI, G. CARRIERI (<i>Foggia; Bari, Italy</i>)	4201
Clinical Outcome of Tailored Adjuvant Postoperative Chemoradiotherapy in IB FIGO Stage Cervical Cancer. M.G. FABRINI, A. GADDUCCI, F. PERRONE, S. COSIO, C. LALISCIA, F. PASQUALETTI, S. GRESPI, L. CIONINI (<i>Pisa, Italy</i>)	4205
Induction Chemotherapy with Docetaxel, 5-FU and CDDP (DFP) for Advanced Gastric Cancer. K. YAMAMOTO, Y. FUJIWARA, T. NISHIDA, S. TAKIGUCHI, K. NAKAJIMA, H. MIYATA, M. YAMASAKI, M. MORI, Y. DOKI (<i>Osaka, Japan</i>).....	4211
Treatment after the Failure of Gefitinib in Patients with Advanced or Recurrent Non-small Cell Lung Cancer. R. MARUYAMA, H. WATAYA, T. SETO, Y. ICHINOSE (<i>Fukuoka, Japan</i>)	4217
A Throbbing Pain in the Head: Trastuzumab-induced Migraine. F.G. VAN ROOIJ, L.D.A. DORRESTEIJN, M.M.J.A. VAN BOKHOVEN, C.C.P. VERSTAPPEN (<i>Nijmegen; Enschede; Gorinchem, The Netherlands</i>)....	4223
Elevated Malondialdehyde Correlates with the Extent of Primary Tumor and Predicts Poor Prognosis of Oropharyngeal Cancer. R. SALZMAN, L. PÁCAL, J. TOMANDL, K. KAŇKOVA, E. TÓTHOVÁ, B. GÁL, R. KOSTŘICA, P. SALZMAN (<i>Brno, Czech Republic; Rochester, NY, USA</i>)	4227
An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma. M. KROPFF, J. KIENAST, G. BISPING, W.E. BERDEL, B. GASCHLER-MARKEFSKI, P. STOPFER, M. STEFANIC, G. MUNZERT (<i>Muenster; Biberach, Germany</i>)	4233
Serum Levels of CA15-3, KL-6 and BCA225 Are Positively Correlated with Each Other in the General Population. G. RI, S. OHNO, T. YAMAMOTO, E. ITO, M. FURUTANI, Y. FURUTANI, Y. UMEDA, T. TSUKAHARA, N. HAGITA, R. MATSUOKA (<i>Tokyo, Japan</i>)	4239
Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided <i>versus</i> Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer. Y.W. MOON, J.H. SOHN, Y.T. KIM, H. CHANG, J.H. JEONG, Y.J. LEE, J. CHANG, S.K. KIM, M. JUNG, S. HONG, S.H. CHOI, J.-H. KIM (<i>Seoul; Gyeonggi-do, South Korea</i>)	4243
Comparison between ^{99m} Tc-Sestamibi Scintimammography and X-ray Mammography in the Characterization of Clusters of Microcalcifications: A Prospective Long-term Study. M. GROSSO, S. CHIACCHIO, F. BIANCHI, C. TRAINO, C. MARINI, A. CILOTTI, G. MANCA, D. VOLTERRANI, M. RONCELLA, L. RAMPIN, M.C. MARZOLA, D. RUBELLO, G. MARIANI (<i>Pisa; Rovigo, Italy</i>)	4251
Hypofractionated Stereotactic Radiotherapy and Radiosurgery for the Treatment of Patients with Radioresistant Brain Metastases. M. SCORSETTI, A. FACOETTI, P. NAVARRIA, M. BIGNARDI, M. DE SANTIS, S.A. NINONE, P. LATTUADA, G. URSO, S. VIGORITO, P. MANCOSU, M. DEL VECCHIO (<i>Rozzano; Pavia; Milan, Italy</i>)	4259

<i>RANTES</i> Promoter Genotype and Gastric Cancer Risk in a Japanese Population. T. TAHARA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, I. HIRATA, T. ARISAWA (<i>Aichi; Ishikawa, Japan</i>).....	4265
The Efficacy of Endoscopic Submucosal Dissection Compared with Modified Endoscopic Aspiration Mucosectomy by Assessing the Short-term Therapeutic Results for Differentiated Mucosal Gastric Cancer. T. KATSUBE, M. MURAYAMA, N. ISOHATA, S. ASAKA, K. YAMAGUCHI, K. KUHARA, S. KONNO, T. SHIMAKAWA, Y. NARITAKA, K. OGAWA (<i>Tokyo, Japan</i>)	4271
A Phase II Study of Cisplatin and Temozolomide in Heavily Pre-treated Patients with Temozolomide-refractory High-grade Malignant Glioma. F. ZUSTOVICH, G. LOMBARDI, A. DELLA PUPPA, A. ROTILIO, R. SCIENZA, D. PASTORELLI (<i>Padova, Italy</i>)	4275
The Follow-up of Patients with Non-muscle-invasive Bladder Cancer by Urine Cytology, Abdominal Ultrasound and Urine CYFRA 21-1: A Pilot Study. B. NISMAN, V. YUTKIN, T. PERETZ, A. SHAPIRO, V. BARAK, D. PODE (<i>Jerusalem, Israel</i>)	4281
Psychosocial Outcomes in Long-term Survivors of High-grade Osteosarcoma: A Japanese Single-center Experience. T. YONEMOTO, K. KAMIBEPPU, T. ISHII, S. IWATA, Y. HAGIWARA, S.-I. TATEZAKI (<i>Chiba; Tokyo, Japan</i>).....	4287
Further Studies on the Frequency of Colorectal Cancer in Crohn's Colitis: An 11-Year Survey in the Northwest Stockholm County. C.A. RUBIO, M. KAPRAALI, R. BEFRITS (<i>Stockholm, Sweden</i>).....	4291
Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study. E.M. KARAPANAGIOTOU, P.G. BOURA, G. PAPAMICHALIS, M. KONSTANTINOU, E. SEPSAS, G. CHAMALAKIS, P. SIMSIRIS, I. GKIOZOS, K.N. SYRIGOS (<i>Athens, Greece</i>)	4297
Prognostic Value of Serum Tumor Antigen CA19-9 After Curative Resection of Colorectal Cancer. I. J. PARK, G.-S. CHOI, S.H. JUN (<i>Daegu, South Korea</i>)	4303
Retrospective Study of Venous Thromboembolic and Intracerebral Hemorrhagic Events in Glioblastoma Patients. E. PAN, J.S. TSAI, S.B. MITCHELL (<i>Tampa; Orlando, FL; Los Angeles, CA, USA</i>)	4309
Errata	4315
* Reviews (pages 3759, 3833, 4107)	

Number 11

Experimental Studies

Preferential Expression of the Secreted and Membrane Forms of Tumor Endothelial Marker 7 Transcripts in Osteosarcoma. C. HALDER, C. OSSENDORF, A. MARAN, M. YASZEMSKI, M.E. BOLANDER, B. FUCHS, G. SARKAR (<i>Rochester, MN, USA; Zurich, Switzerland</i>)	4317
Cytogenetic Effects of Exposure to 2.3 GHz Radiofrequency Radiation on Human Lymphocytes <i>In Vitro</i> . I.-L. HANSTEEN, K.O. CLAUSEN, V. HAUGAN, M. SVENDSEN, M.V. SVENDSEN, J.G. ERIKSEN, R. SKIAKER, E. HAUGER, L. LÅGEIDE, A.I. VISTNES, E.H. KURE (<i>Skien; Kjeller; Bø; Oslo, Norway</i>).....	4323
Establishment and Characterization of a Human Gastrointestinal Stromal Tumour (GIST) Xenograft in Athymic Nude Mice. M.-E. REVHEIM, T. SEIERSTAD, J.-M. BERNER, Ø.S. BRULAND, K. RØE, H.O. OHNSTAD, B. BJERKEHAGEN, T. BACH-GANSMO (<i>Oslo; Drammen; Bergen, Norway</i>)	4331
	5315

Mutation Analysis of Hypoxia-inducible Factors <i>HIF1A</i> and <i>HIF2A</i> in Renal Cell Carcinoma. M.R. MORRIS, D.J. HUGHES, Y.-M. TIAN, C.J. RICKETTS, K.W. LAU, D. GENTLE, S. SHUIB, P. SERRANO-FERNANDEZ, J. LUBINSKI, M.S. WIESENER, C.W. PUGH, F. LATIF, P.J. RATCLIFFE, E.R. MAHER (<i>Birmingham; Oxford, UK; Dublin, Ireland; Szczecin, Poland; Erlangen-Nuremberg, Germany</i>).....	4337
Expression of the CD117, COX-2 and HSP90 Antigens and Cell Proliferation in Fine-needle-aspirated Cells from Metastatic Melanomas. V. SVIATOHA, R. KLEINA, E. TANI, L. SKOOG (<i>Solna, Sweden; Riga, Latvia</i>).....	4345
Retinol-induced Intestinal Tumorigenesis in <i>Min/+</i> Mice and Importance of Vitamin D Status. R.B. HETLAND, J. ALEXANDER, J.P. BERG, C. SVENDSEN, J.E. PAULSEN (<i>Oslo, Norway</i>)	4353
Apoptotic Signalling in HeLa Hep2 Cells Following 5 Gy of Cobalt-60 Gamma Radiation. D. ERIKSSON, P.-O. LÖFROTH, L. JOHANSSON, K. RIKLUND, T. STIGBRAND (<i>Umeå, Sweden</i>).....	4361
Activation of Human Monocyte-derived Dendritic Cells <i>In Vitro</i> by Thymax, a Gross Thymic Extract. M. GHONEUM, Y. SETO, S. AGRAWAL (<i>Los Angeles; Irvine, CA, USA; Tokyo, Japan</i>)	4367
ARRY-520, a Novel KSP Inhibitor with Potent Activity in Hematological and Taxane-resistant Tumor Models. R. WOESSNER, B. TUNQUIST, C. LEMIEUX, E. CHLIPALA, S. JACKINSKY, W. DEWOLF JR., W. VOEGTLI, A. COX, S. RANA, P. LEE, D. WALKER (<i>Boulder, CO, USA</i>)	4373
Aneuploidy Is Associated with TP53 Expression but Not with BRCA1 or TERT Expression in Sporadic Colorectal Cancer. A.R. SCHJØLBERG, O.P. CLAUSEN, E. BURUM-AUENSEN, P.M. DE ANGELIS (<i>Oslo; Loerenskog, Norway</i>)	4381
An Immunocompetent Murine Model of Metastatic Mammary Cancer Accessible to Bioluminescence Imaging. M.-A. SHIBATA, E. SHIBATA, J. MORIMOTO, N.A.S. EID, Y. TANAKA, M. WATANABE, Y. OTSUKI (<i>Osaka, Japan</i>)	4389
Changes in <i>UNC5C</i> Gene Methylation during Human Gastric Carcinogenesis. K. HIBI, M. SAKATA, K. SAKURABA, Y.-H. KITAMURA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	4397
Voluntary Wheel Running in Rats Receiving Doxorubicin: Effects on Running Activity and Cardiac Myosin Heavy Chain. D.S. HYDOCK, K.Y. WONDERS, C.M. SCHNEIDER, R. HAYWARD (<i>Greeley, CO; Dayton, OH, USA</i>).....	4401
Imexon Augments Sensitivity of Human Lymphoma Cells to Ionizing Radiation: <i>In Vitro</i> Experimental Study. H. CHO, M. KOTO, O. RIESTERER, D.P. MOLKENTINE, U. GIRI, L. MILAS, M.D. STORY, C.S. HA, U. RAJU (<i>Pusan, Korea; Sendai, Japan; Zurich, Switzerland; Houston; Dallas; San Antonio, TX, USA</i>)	4409
Differing Expression of Metalloprotease and of Adhesion Molecules in Signet-ring Cell and Intestinal Colorectal Carcinoma. D. CABIBI, A. CALASCIBETTA, F. ARAGONA, A. MARTORANA, M. CAMPIONE, R. SANGUEDOLCE (<i>Palermo, Italy</i>)	4417
p38 Inhibitor Intensified Cell Death in Antimycin A-treated As4.1 Juxtaglomerular Cells <i>via</i> the Enhancement of GSH Depletion. Y.H. HAN, H.J. MOON, B.R. YOU, S.Z. KIM, S.H. KIM, W.H. PARK (<i>JeonJu, Republic of Korea</i>)	4423
Effects of Carbon-ion Radiotherapy combined with a Novel Histone Deacetylase Inhibitor, Cyclic Hydroxamic-acid-containing Peptide 31 in Human Esophageal Squamous Cell Carcinoma. M. KANO, S. YAMADA, I. HOSHINO, K. MURAKAMI, Y. AKUTSU, H. SAKATA, T. NISHIMORI, A. USUI, Y. MIYAZAWA, T. KAMADA, H. TSUJII, H. MATSUBARA (<i>Chiba, Japan</i>).....	4433
<i>PTEN</i> Loss Induces Epithelial–Mesenchymal Transition in Human Colon Cancer Cells. K.A. BOWEN, H.Q. DOAN, B.P. ZHOU, Q. WANG, Y. ZHOU, P.G. RYCHAHOU, B.M. EVERS (<i>Galveston, TX, USA</i>)	4439

Prognostic Impact of Protein Overexpression of the Proto-oncogene <i>PIM-1</i> in Gastric Cancer. U. WARNECKE-EBERZ, E. BOLLSCHWEILER, U. DREBBER, R. METZGER, S.E. BALDUS, A.H. HÖLSCHER, S. MÖNIG (Cologne; Duesseldorf, Germany)	4451
Sanguinarine Sensitizes Human Gastric Adenocarcinoma AGS Cells to TRAIL-mediated Apoptosis via Down-regulation of AKT and Activation of Caspase-3. W.Y. CHOI, C.-Y. JIN, M.H. HAN, G.-Y. KIM, N.D. KIM, W.H. LEE, S.-K. KIM, Y.H. CHOI (Pusan; Busan; Jeju, South Korea)	4457
Multidrug Resistance Modulation and Apoptosis Induction of Cancer Cells by Terpenic Compounds Isolated from <i>Euphorbia</i> Species. N. DUARTE, C. RAMALHETE, A. VARGA, J. MOLNÁR, M.-J.U. FERREIRA (Lisbon, Portugal; Berlin, Germany; Szeged, Hungary)	4467
The Anti-angiogenic Activity of NSITC, a Specific Cathepsin L Inhibitor. A. REBBAA, F. CHU, T. SUDHA, C. GALLATI, U. DIER, E. DYSKIN, M. YALCIN, C. BIANCHINI, O. SHAKER, S.A. MOUSA (Rensselaer, NY; Chicago, IL, USA; Cairo, Egypt)	4473
Numerical Abnormalities of Chromosome 9 and <i>p16^{CDKN2A}</i> Gene Deletion Detected by FISH in Non-small Cell Lung Cancer. A.D. PANANI, K. MALIAGA, A. BABANARAKI, I. BELLENIS (Athens, Greece)	4483
Development and Characterization of HAT-sensitive Ewing Tumour Cells for Immunotherapy. C. PFEIFLE, K. REINHARDT, S. HEINS, S. BURDACH, M.S. STAEGE (Halle; München, Germany)	4489
IL-6 Regulates MMP-10 Expression via JAK2/STAT3 Signaling Pathway in a Human Lung Adenocarcinoma Cell Line. X. ZHANG, P. YIN, D. DI, G. LUO, L. ZHENG, J. WEI, J. ZHANG, Y. SHI, J. ZHANG, N. XU (Changzhou, PRC; Lund, Sweden)	4497
Aloe-emodin Induces Cell Death through S-Phase Arrest and Caspase-dependent Pathways in Human Tongue Squamous Cancer SCC-4 Cells. T.-H. CHIU, W.-W. LAI, T.-C. HSIA, J.-S. YANG, T.-Y. LAI, P.-P. WU, C.-Y. MA, C.-C. YEH, C.-C. HO, H.-F. LU, W.G. WOOD, J.-G. CHUNG (Taichung; Taipei, Taiwan, ROC; Minneapolis, MN, USA)	4503
Establishment of Imageable Model of T-cell Lymphoma Growing in Syngenic Mice. D. VETVICKA, O. HOVORKA, L. KOVAR, B. RIHOVA (Prague, Czech Republic)	4513
Antiproliferative and Pro-apoptotic Effects of <i>Uncaria tomentosa</i> in Human Medullary Thyroid Carcinoma Cells. B. RINNER, Z.X. LI, H. HAAS, V. SIEGL, S. STURM, H. STUPPNER, R. PFRAGNER (Graz; Innsbruck, Austria; Shanghai, PRC)	4519
Role of the Pharmaceutical Excipients in the Tamoxifen Activity on MCF-7 and Vero Cell Cultures. T. ROSSI, V. IANNUCELLI, G. COPPI, E. BRUNI, G. BAGGIO (Modena, Italy)	4529
Significance of Methylation Status and the Expression of <i>RECK</i> mRNA in Lung Tissue of Patients with NSCLC. M. PESTA, V. KULDA, O. TOPOLCAN, J. SAFRANEK, J. VRZALOVA, R. CERNY, L. HOLUBEC (Pilsen, Czech Republic)	4535
Catalase Protects Tumor Cells from Apoptosis Induction by Intercellular ROS Signaling. W. BECHTEL, G. BAUER (Freiburg, Germany)	4541
Modulation of Intercellular ROS Signaling of Human Tumor Cells. W. BECHTEL, G. BAUER (Freiburg, Germany)	4559
Reduction of Oxidative DNA Fragmentation by Ascorbic Acid, Zinc and <i>N</i> -Acetylcysteine in Nasal Mucosa Tissue Cultures. P. BAUMEISTER, T. HUEBNER, M. REITER, S. SCHWENK-ZIEGER, U. HARRÉUS (Munich, Germany)	4571
Influence of Imatinib Mesylate on Radiosensitivity of Astrocytoma Cells. E. RANZA, A. BERTOLOTTI, A. FACOETTI, L. MARIOTTI, F. PASI, A. OTTOLENGHI, R. NANO (Pavia, Italy)	4575

<i>In Vitro</i> Effects of Dichloroacetate and CO ₂ on Hypoxic HeLa Cells. K.M. ANDERSON, J. JAJEH, P. GUINAN, M. RUBENSTEIN (<i>Chicago, IL, USA</i>)	4579
The Cytotoxic Effects of Gemtuzumab Ozogamicin (Mylotarg) in Combination with Conventional Antileukemic Agents by Isobologram Analysis <i>In Vitro</i> . M. TANAKA, Y. KANO, M. AKUTSU, S. TSUNODA, T. IZUMI, Y. YAZAWA, S. MIYAWAKI, H. MANO, Y. FURUKAWA (<i>Tochigi; Gunma, Japan</i>)	4589
Reversal of P-gp-mediated Multidrug Resistance by Bromotetrandrine <i>In Vivo</i> Is Associated with Enhanced Accumulation of Chemotherapeutical Drug in Tumor Tissue. L.-M. CHEN, Y.-J. LIANG, X. ZHANG, X.-D. SU, C.-L. DAI, F.-P. WANG, Y.-Y. YAN, L.-Y. TAO, L.-W. FU (<i>Guangzhou; Chengdu, PRC</i>)	4597
Postoperative Radiotherapy for Localized Prostate Cancer: Clinical Significance of Nadir Prostate-specific Antigen Value within 12 Months. K. OGAWA, K. NAKAMURA, T. SASAKI, H. ONISHI, M. KOIZUMI, M. ARAYA, N. MUKUMOTO, MI. MITSUMORI, T. TESHIMA (<i>Okinawa; Oita; Fukuoka; Yamanashi; Osaka; Kyoto, Japan</i>)	4605
Ibadronate May Prevent Colorectal Carcinogenesis in Mice with Ulcerative Colitis. S. SASSA, H. OKABE, N. NEMOTO, H. KIKUCHI, H. KUDO, S. SAKAMOTO (<i>Tokyo; Chiba, Japan</i>)	4615
Mitogenic Activity of Zeranol in Human Breast Cancer Cells Is Enhanced by Leptin and Suppressed by Gossypol. P. XU, W. YE, R. JEN, S.-H. LIN, C.-T. KUO, Y.C. LIN (<i>Columbus; Cincinnati OH, USA; Jinhua, Zhejiang, PRC</i>)	4621
Cyclopamine and Quercetin Suppress the Growth of Leukemia and Lymphoma Cells. T. KAWAHARA, N. KAWAGUCHI-IHARA, Y. OKUHASHI, M. ITOH, N. NARA, S. TOHDA (<i>Tokyo, Japan</i>)	4629
Ovarian Renin–Angiotensin System-regulating Aminopeptidases Are Involved in Progesterone Overproduction in Rats with Mammary Tumours Induced by N-Methyl Nitrosourea. M. DEL PILAR CARRERA, M.J. RAMÍREZ-EXPÓSITO, M.J. GARCÍA, M.D. MAYAS, J.M. MARTÍNEZ-MARTOS (<i>Jaén; Santafé; Málaga, Spain</i>)	4633
The Akt and ERK Activation by Platinum-based Chemotherapy in Ovarian Cancer is Associated with Favorable Patient Outcome. T. OHTA, M. ISOBE, T. TAKAHASHI, M. SAITOH-SEKIGUCHI, T. MOTOYAMA, H. KURACHI (<i>Yamagata, Japan</i>)	4639
BCL6-translocations Affect the Phenotype of Follicular Lymphomas Only in the Absence of t(14;18) <i>IgH/BCL2</i> . W. GOLLUB, B. STASSEK, T. HUCKHAGEL, H.-W. BERND, M. KROKOWSKI, H. MERZ, A.C. FELLER, C. THORNS (<i>Luebeck, Germany</i>)	4649
The Arylhydrocarbon Receptor Is Only Marginally Involved in the Antileukemic Effects of its Ligand Curcumin. A. GOERGENS, M. FRERICKS, C. ESSER (<i>Düsseldorf, Germany</i>)	4657
<i>Clinical Studies</i>	
Long-term Eradication of Locally Recurrent Invasive Follicular Thyroid Carcinoma after Taxane-based Concomitant Chemoradiotherapy. M. TULLOCH-REID, M.C. SKARULIS, S.I. SHERMAN, N.J. SARLIS, L. SANTARPIA (<i>Bethesda, MD; Houston, TX, USA; Florence, Italy</i>)	4665
Differential Expression of CD3 ζ Message and Protein in Tumor Infiltrating Lymphocytes from Solid Tumor Specimens and Malignant Ascites from Patients with Ovarian Carcinoma. J. PAPPAS, A.D. WOLFSON, W.J. JUNG, E.L. OLESZAK, C.W. HELM, R.S. FREEDMAN, A.Y. TSYGANKOV, C.D. PLATSOUKAS (<i>Philadelphia, PA; Houston, TX, USA</i>)	4673
Altered Glucose Metabolism During Chemoradiation for Head and Neck Cancer. N.P. NGUYEN, P. VOS, V. VINH-HUNG, T.L. BOROK, S. DUTTA, U. KARLSSON, H. LEE, T. MARTINEZ, B.-H. JO, L.M. NGUYEN, N. NGUYEN, S. SALLAH (<i>Tucson, AZ; Greenville, NC; Dallas, TX; Los Angeles, CA; Marshfield, WI; Shreveport, LA; Ann Arbor, MI, USA; Geneva, Switzerland; Athens, Greece</i>)	4683

Preoperative Chemotherapy with S-1 and Cisplatin for Highly Advanced Gastric Cancer. A. NASHIMOTO, H. YABUSAKI, S. NAKAGAWA, Y. TAKII, Y. TSUCHIYA, T. OTSUO (<i>Niigata, Japan</i>).....	4689
Patients with Clinical/Radiological Hyperplasia of Mammary Glands Show Pathological Persistence of Temperature of Skin Points. H. LI, X. SHEN, J. YING, L. ZHAO, M. JIN, S. THU, C. SUN, F. VOORHORST, H. SOILAND, T. LENDE, J.P. BAAK (<i>Shanghai, PRC; Stavanger; Bergen, Norway; Amsterdam, The Netherlands</i>)	4697
Epithelial-Myoepithelial Carcinoma of the Minor Salivary Glands: Immunohistochemical and Morphological Features. F. ANGIERO, D. SOZZI, R. SERAMONDI, M.G. VALENTE (<i>Monza; Milan, Italy</i>)	4703
Frozen Section in Axillary Sentinel Lymph Nodes for Diagnosis of Breast Cancer Micrometastasis. J.-C. TILLE, J.-F. EGGER, M. CONDREA DEVILLAZ, G. VLASTOS, M.-F. PELTE (<i>Geneva, Switzerland</i>)	4711
* Review: Immunological Similarities between Cancer and Chronic Fatigue Syndrome: The Common Link to Fatigue? M. MEEUS, W. MISTIAEN, L. LAMBRECHT, J. NIJS (<i>Antwerp; Brussels, Ghent, Belgium</i>)	4717
Utility of a Simplified Molecular Classification of Tumors for Predicting Survival of Patients with Invasive Ductal Breast Carcinoma. M.M. MUÑOZ-DÍAZ, M.J. FERNANDEZ-ACEÑERO, P. SALVADORES, J. SCHNEIDER (<i>Madrid, Spain</i>)	4727
Adenocarcinoma Corpus Uteri Stage I-II: Results of a Treatment Programme Based upon Cytometry. B. LINDAHL, A. MÅSBÄCK, J. PERSSON, J. RANSTAM, R. WILLÉN (<i>Lund; Uppsala, Sweden</i>)	4731
Optical Biopsy System Distinguishing between Hyperplastic and Adenomatous Polyps in the Colon during Colonoscopy. Z. BENES, Z. ANTOS (<i>Prague, Czech Republic</i>)	4737
Potential Pharmacokinetic Interactions Affecting Antitumor Drug Disposition in Cancer Patients. J. LEMACHATTI, D. LEVÉQUE, L. BERETZ, J.P. BERGERAT (<i>Strasbourg, France</i>)	4741
Superiority of Magnetic Resonance Imaging Over Conventional Radiographs in Multiple Myeloma. M. ENGELHARDT, M. KLEBER, A. FRYDRYCHOWICZ, G. PACHE, A. SCHMITT-GRÄFF, R. WÄSCH, B.G.M. DURIE (<i>Freiburg, Germany; Los Angeles, CA, USA</i>)	4745
Expression of CXCR4 and its Ligand SDF-1 in Intestinal-type Gastric Cancer Is Associated with Lymph Node and Liver Metastasis. S. IWASA, T. YANAGAWA, J. FAN, R. KATOH (<i>Kanagawa; Yamanashi; Tsukuba, Japan</i>)	4751
Gastric Metastases Originating from Breast Cancer: Report of 8 Cases and Review of the Literature. D. PECTASIDES, A. PSYRRI, K. PLIARCHOPOULOU, T. FLOROS, G. PAPAXOINIS, M. SKONDRA, G. PAPATSIBAS, A. MACHERAS, G. ATHANASAS, P. ARAPANTONI-DATIOTI, T. ECONOMOPOULOS (<i>Athens; Piraeus, Greece</i>)	4759
Psychosocial Risk Scale (PRS) for Breast Cancer in Patients with Breast Disease: A Prospective Case-Control Study in Kuopio, Finland. M. ESKELINEN, P. OLLONEN (<i>Kuopio, Finland</i>)	4765
Radioimmunotherapy of Heavily Pre-treated, Non-Hodgkin's Lymphoma Patients: Efficacy and Safety in a Routine Setting. F. CICONE, R. BALDINI, M.C. COX, E. RUSSO, F. TORELLI, A. TOFANI, F. SCOPINARO (<i>Rome, Italy</i>)	4771
Wilms' Tumor 1 (WT1) Peptide Immunotherapy for Gynecological Malignancy. S. OHNO, S. KYO, S. MYOJO, S. DOHI, J. ISHIZAKI, K.-I. MIYAMOTO, S. MORITA, J.-I. SAKAMOTO, T. ENOMOTO, T. KIMURA, Y. OKA, A. TSUBOI, H. SUGIYAMA, M. INOUE (<i>Tokyo; Ishikawa; Kanagawa; Aichi; Osaka, Japan</i>)	4779
	5319

Relevance of Oropharyngeal Cancer Lymph Node Metastases in the Submandibular Triangle and the Posterior Triangle Apex. S. WIEGAND, J. ESTERS, H.-H. MÜLLER, T. JÄCKER, G. PAPASPYROU, M. ROEBLER, J.A. WERNER, A.M. SESTERHENN (<i>Marburg, Germany</i>)	4785
Retrospective Analysis of Concurrent vs. Sequential Administration of Radiotherapy and Hormone Therapy Using Aromatase Inhibitor for Hormone Receptor-positive Postmenopausal Breast Cancer. M. ISHITOBI, Y. KOMOIKE, K. MOTOMURA, H. KOYAMA, K. NISHIYAMA, H. INAJI (<i>Osaka, Japan</i>)	4791
* Review: Tumour Biology: Tumour-associated Inflammation <i>versus</i> Antitumor Immunity. B. MÜLLER-HÜBENTHAL, M. AZEMAR, D. LORENZEN, M. HUBER, M.A FREUDENBERG, C. GALANOS, C. UNGER, B. HILDENBRAND (<i>Freiburg; Duderstadt; Aachen, Germany</i>)	4795
MET Is Highly Expressed in Advanced Stages of Colorectal Cancer and Indicates Worse Prognosis and Mortality. A.T.T. DE OLIVEIRA, D. MATOS, A.F. LOGULLO, S.R.M. DA SILVA, R.A. NETO, A. LONGATTO-FILHO, S.S. SAAD (<i>São Paulo, Brazil; Braga, Portugal</i>)	4807
Serum Homocysteine, Cholesterol, Retinol, α -Tocopherol, Glycosylated Hemoglobin and Inflammatory Response during Therapy with Bevacizumab, Oxaliplatin, 5-Fluorouracil and Leucovorin. B. MELICHAR, H. KALÁBOVÁ, L. KRČMOVÁ, M. KAŠPAROVÁ, E. MALÍŘOVÁ, K. MELICHAROVÁ, M. PECKA, R. HYŠPLER, D. SOLICHOVÁ (<i>Hradec Králové; Olomouc, Czech Republic</i>)	4813
Determinants of Small Bowel Toxicity in Postoperative Pelvic Irradiation for Gynaecological Malignancies. A. HUSCHER, M. BIGNARDI, E. MAGRI, E. VITALI, N. PASINETTI, L. COSTA, P. FRATA, S.M. MAGRINI (<i>Brescia, Italy</i>)	4821
The Diagnostic and Prognostic Value of ProGRP in Lung Cancer. B. NISMAN, H. BIRAN, N. RAMU, N. HECHING, V. BARAK, T. PERETZ (<i>Jerusalem; Tel Hashomer, Israel</i>)	4827
Immunohistochemistry of DNA Mismatch Repair Enzyme MSH2 Is Not Correlated with Prognostic Data from Endometrial Carcinomas. A. SCHRÖER, F. KÖSTER, D. FISCHER, R.M. DUBITSCHER, A. WOLLHERMANN, K. DIEDRICH, M. FRIEDRICH, D. SALEHIN (<i>Lübeck; Homburg/Saar; Krefeld, Germany</i>).....	4833
Circulating Tumor Cells in Solid Tumor in Metastatic and Localized Stages. L.M. MAESTRO, J. SASTRE, S.B. RAFAEL, S.B. VEGANZONES, M. VIDAURRETA, M. MARTÍN, C. OLIVIER, V.B. DE LA ORDEN, J.A. GARCIA-SAENZ, R. ALFONSO, M. ARROYO, E. DIAZ-RUBIO (<i>Madrid, Spain</i>).....	4839
<i>Proceedings of the 12th Annual Meeting of the Society of Biotherapeutic Approaches, 6 December, 2008, Fukuoka, Japan; Edited by M. Torisu, M. Katano</i>	
* Review: Anti-glioma Therapy with Temozolomide and Status of the DNA-Repair Gene <i>MGMT</i> . T. FUKUSHIMA, H. TAKESHIMA, H. KATAOKA (<i>Miyazaki, Japan</i>)	4845
* Review: Mechanism for Maintaining Homeostasis in the Immune System of the Intestine. Y. TANIGUCHI, N. YOSHIOKA, K. NAKATA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (<i>Tokushima; Kagawa; Okayama; Yamaguchi; Chiba, Japan</i>).....	4855
* Review: Intestinal Macrophages Involved in the Homeostasis of the Intestine Have the Potential for Responding to LPS. N. YOSHIOKA, Y. TANIGUCHI, A. YOSHIDA, K. NAKATA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (<i>Tokushima; Kagawa; Okayama; Yamaguchi; Chiba, Japan</i>).....	4861
* Review: Improvement of Allergic Dermatitis via Regulation of the Th1/Th2 Immune System Balance by Macrophages Activated with Lipopolysaccharide Derived from <i>Pantoea agglomerans</i> (IP-PA1). A. YOSHIDA, C. KOHCHI, H. INAGAWA, T. NISHIZAWA, G.-I. SOMA (<i>Tokushima; Kagawa; Chiba; Yamaguchi, Japan</i>)	4867

Comparative Immunological Analysis of Innate Immunity Activation after Oral Administration of Wheat Fermented Extract to Teleost Fish. T. KADOWAKI, Y. YASUI, Y. TAKAHASHI, C. KOHCHI, G.-I. SOMA, H. INAGAWA (<i>Yamaguchi; Tokushima; Kagawa; Chiba, Japan</i>)	4871
* Review: Efficacy of Ligand-based Targeting for the EGF System in Cancer. F. YOTSUMOTO, A. SANUI, T. FUKAMI, K. SHIROTA, S. HORIUCHI, H. TSUJIOKA, T. YOSHIZATO, M. KUROKI, S. MIYAMOTO (<i>Fukuoka, Japan</i>)	4879
Correlation between WT1 Expression and Cell Proliferation in Endometrial Cancer. S. DOHI, S. OHNO, Y. OHNO, G.-I. SOMA, S. KYO, M. INOUE (<i>Ishikawa; Tokyo; Tokushima; Chiba, Japan</i>)	4887
A Study of the Postoperative Course in Cases of GIST of the Stomach. The Efficacy of Imatinib in Cases of Recurrence. D. HIGASHI, Y. WATANABE, K. HIRANO, T. SHIMOMURA, Y. EGAWA, T. TOMIYASU, Y. ISHIBASHI, K. FUTAMI, T. MAEKAWA, A. OTA, K. OSHIGE, A. IWASHITA (<i>Chikushino-shi; Kasuga-shi, Japan</i>)	4893
Role of C-Terminal Region of Yeast ADP/ATP Carrier 2 Protein: Dynamics of Flexible C-Terminal Arm. K. OHKURA, H. HORI, Y. SHINOHARA (<i>Chiba; Tokushima, Japan</i>)	4897
* Reviews (pages 4717, 4795, 4845, 4855, 4861, 4867, 4879)	

Number 12

Experimental Studies

HMG-CoA Reductase Inhibition Causes Increased Necrosis and Apoptosis in an <i>In Vivo</i> Mouse Glioblastoma Multiforme Model. S.R. BABABEYGY, N.V. POLEVAYA, S. YOUSSEF, A. SUN, A. XIONG, T. PRUGPICHAILERS, A. VEERAVAGU, L.C. HOU, L. STEINMAN, V. TSE (<i>Stanford; Redwood City, CA, USA</i>)	4901
Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) Is Pyruvylated during 3-Bromopyruvate Mediated Cancer Cell Death. S. GANAPATHY-KANNIAPPAN, J.-F.H. GESCHWIND, R. KUNJITHAPATHAM, M. BUIJS, J.A. VOSSEN, I. TCHERNYSHYOV, R.N. COLE, L.H. SYED, P.P. RAO, S. OTA, M. VALI (<i>Baltimore, MD, USA</i>)	4909
* Review: L1-CAM as a Target for Treatment of Cancer with Monoclonal Antibodies. U.H. WEIDLE, D. EGGLE, S. KLOSTERMANN (<i>Penzberg, Germany</i>)	4919
Galectin-8 Up-regulation During Hypopharyngeal and Laryngeal Tumor Progression and Comparison with Galectin-1, -3 and -7. S. CLUDTS, C. DECAESTECKER, V. MAHILLON, D. CHEVALIER, H. KALTNER, S. ANDRÉ, M. REMMELINK, X. LEROY, H.-J. GABIUS, S. SAUSSEZ (<i>Mons; Brussels, Belgium; Lille, France; Munich, Germany</i>)	4933
Mistletoe Lectin Binds to Multidrug Resistance-associated Protein MRP5. N. NEHMANN, U.M. SCHADE, U. PFÜLLER, M. SCHACHNER, U. SCHUMACHER (<i>Hamburg, Germany</i>)	4941
Simultaneous Identification and Quantification of Proteins by Differential ¹⁶ O/ ¹⁸ O Labeling and UPLC-MS/MS Applied to Mouse Cerebellar Phosphoproteome Following Irradiation. D. WINTER, J. SEIDLER, S. ZIV-LEHRMAN, Y. SHILOH, W.D. LEHMANN (<i>Heidelberg, Germany; Tel Aviv, Israel</i>)	4949
Retinoid-induced Histone Deacetylation Inhibits Telomerase Activity in Estrogen Receptor-negative Breast Cancer Cells. S.M.O. PHIPPS, W.K. LOVE, T. WHITE, L.G. ANDREWS, T.O. TOLLEFSBOL (<i>Birmingham, AL, USA</i>)	4959

Akt Interaction with PLC γ Regulates the G ₂ /M Transition Triggered by FGF Receptors from MDA-MB-231 Breast Cancer Cells. E. BROWAEYS-POLY, D. PERDEREAU, A. LESCUYER, A.-F. BURNOL, K. CAILLIAU (<i>Villeneuve d'Ascq; Paris, France</i>)	4965
A New Amino Acid Derivative of Ursodeoxycholate, (<i>N</i> -L-Glutamyl)-UDCA (UDCA-Glu), to Selectively Release UDCA in the Colon. S. ASCIUTTI, D. CASTELLANI, E. NARDI, O. MORELLI, M. CLEMENTI, F. CHISTOLINI, G. GENTILI, K.D.R. SETCHELL, N. O'CONNELL, R. PELLICCIARI, C. CLERICI (<i>Perugia, Italy; Cincinnati, OH, USA</i>)	4971
Diarylheptanoids Derived from <i>Alpinia officinarum</i> Induce Apoptosis, S-Phase Arrest and Differentiation in Human Neuroblastoma Cells. K. TABATA, Y. YAMAZAKI, M. OKADA, K. FUKUMURA, A. SHIMADA, Y. SUN, K. YASUKAWA, T. SUZUKI (<i>Chiba; Tokyo, Japan</i>)	4981
Infrequent Amplification of <i>JUN</i> in Hepatocellular Carcinoma. M. ENDO, K. YASUI, T. NAKAJIMA, Y. GEN, K. TSUJI, O. DOHI, K. ZEN, H. MITSUYOSHI, M. MINAMI, Y. ITOH, M. TANIWAKI, S. TANAKA, S. ARII, T. OKANOUE, T. YOSHIKAWA (<i>Kyoto; Tokyo; Suita, Japan</i>)	4989
Image Analysis of Breast Cancer Immunohistochemistry-stained Sections Using ImageJ: An RGB-based Model. T. VREKOUSSIS, V. CHANIOTIS, I. NAVROZOGLOU, V. DOUSIAS, K. PAVLAKIS, E.N. STATHOPOULOS, O. ZORAS (<i>Ioannina; Heraklion; Athens, Greece</i>)	4995
The Expression of the Insulin-like Growth Factor II, JIP-1 and WT1 Genes in Porcine Nephroblastoma. W. ENGSTRÖM, M. GRANERUS (<i>Uppsala, Sweden</i>)	4999
Preoperative Plasma Level of IL-10 but not of Proinflammatory Cytokines Is an Independent Prognostic Factor in Patients with Gastric Cancer. A. SZAFLARSKA, A. SZCZEPANIK, M. SIEDLAR, A. CZUPRYNA, M. SIERŻĘGA, T. POPIELA, M. ZEMBALA (<i>Cracow, Poland</i>)	5005
Elevated Levels of HMGB1 in Cancerous and Inflammatory Effusions. N. WINTER, A. MEYER, A. RICHTER, D. KRISPONEIT, J. BULLERDIEK (<i>Bremen; Hannover, Germany</i>)	5013
Estimation of Relationship Between Structure of Newly Synthesized Dihydroimidazoles Determined by a Semiempirical Molecular-orbital Method and their Cytotoxicity. F. TAKEKAWA, H. SAKAGAMI, M. ISHIHARA (<i>Saitama, Japan</i>)	5019
Tumor-specific Cytotoxicity and Type of Cell Death Induced by Gefitinib in Oral Squamous Cell Carcinoma Cell Lines. Q. CHU, O. AMANO, Y. KANDA, S. KUNII, Q. WANG, H. SAKAGAMI (<i>Saitama, Japan; Xi'an, PRC</i>)	5023
CDX2 Expression in Cutaneous Metastatic Carcinomas and Extramammary Paget's Disease. V. LORA, J. KANITAKIS (<i>Lyon, France</i>)	5033
Curcumin Induces Cell Cycle Arrest and Apoptosis in Human Osteosarcoma (HOS) Cells. D.S. LEE, M.K. LEE, J.H. KIM (<i>Seoul, South Korea</i>)	5039
Zeranol Enhances the Proliferation of Pre-adipocytes in Beef Heifers. W. YE, P. XU, W.R. THRELFALL, R. JEN, H. LI, S.-H. LIN, C.-T. KUO, Y.C. LIN (<i>Columbus, OH, USA; Zhejiang, PRC</i>)	5045
Methylation of the <i>MGMT</i> Gene is Frequently Detected in Advanced Gastric Carcinoma. K. HIBI, M. SAKATA, K. YOKOMIZO, Y.-H. KITAMURA, K. SAKURABA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	5053
PPAR γ /PGC-1 α Pathway in E-Cadherin Expression and Motility of HepG2 Cells. H.-J. LEE, Y. SU, P.-H. YIN, H.-C. LEE, C.-W. CHI (<i>Taipei, Taiwan, PRC</i>)	5057
Antitumor and Antiangiogenic Activity of Cediranib in a Preclinical Model of Renal Cell Carcinoma. M. MEDINGER, N. ESSER, U. ZIRRGIEBEL, A. RYAN, J.M. JÜRGENSMEIER, J. DREVS (<i>Freiburg, Germany; MacClesfield, Cheshire, UK</i>)	5065

Autophagy: Novel Action of Panitumumab in Colon Cancer. E. GIANNOPOULOU, A. ANTONACOPOULOU, P. MATSOUKA, H.P. KALOFONOS (<i>Rio, Patras, Greece</i>).....	5077
Non-apoptotic Cell Death Induced by Nutritional Starvation in J774.1 Mouse Macrophage-like Cell Line. M.M. THET, Y. YOKOTE, Q. CHU, Q.-T. WANG, K. KISHINO, N. TAMURA, J. SHIMADA, O. AMANO, Y. KANDA, S. KUNII, F. TAKEKAWA, H. HATANO, C. SHIMADA, H. HASEGAWA, H. SAKAGAMI (<i>Saitama, Japan; Xi'an, Shaanxi, PRC</i>)	5083
Regulating Immunity and Inhibiting Tumor Growth by the Recombinant Peptide sPD-1-CH50. H. QIU, S. LIU, C. XIE, J. LONG, Z. FENG (<i>Wuhan, PRC</i>)	5089
Lung Tumor Growth is Stimulated in IFN- $\gamma^{-/-}$ Mice and Inhibited in IL-4R $\alpha^{-/-}$ Mice. E.F. REDENTE, L.D. DWYER-NIELD, B.S. BARRETT, D.W.H. RICHES, A.M. MALKINSON (<i>Aurora; Denver, CO, USA</i>)	5095
Chitosan Nanoparticles Inhibit the Growth of Human Hepatocellular Carcinoma Xenografts through an Antiangiogenic Mechanism. Y. XU, Z. WEN, Z. XU (<i>Hangzhou, China</i>)	5103
Perioperative Serum VEGF and Extracellular Domains of EGFR and HER2 in Early Breast Cancer. A. ROCCA, G. CANCELLO, V. BAGNARDI, M.T. SANDRI, R. TORRISI, L. ZORZINO, G. VIALE, E. PIETRI, P. VERONESI, S. DELLAPASQUA, F. FERRUCCI, A. LUINI, H. JOHANSSON, R. GHISINI, A. GOLDBIRSCHE, M. COLLEONI (<i>Milan; Meldola, Italy</i>)	5111
Significant Association of <i>ERCC6</i> Single Nucleotide Polymorphisms with Bladder Cancer Susceptibility in Taiwan. C.-H. CHANG, C.-F. CHIU, H.-C. WANG, H.-C. WU, R.-Y. TSAI, C.-W. TSAI, R.-F. WANG, C.-H. WANG, Y.-A. TSOU, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	5121
Diagnostic and Therapeutic Relevance of NY-ESO-1 Expression in Oral Squamous Cell Carcinoma. J. RIES, N. MOLLAOGLU, E. VAIRAKTARIS, F.W. NEUKAM, E. NKENKE (<i>Erlangen, Germany; Ankara, Turkey; Athens, Greece</i>)	5125
DNA Repair Gene <i>XRCC1</i> Polymorphisms and Outcome of Renal Cell Carcinoma in Caucasian Patients. H.S. BACHMANN, H. RÜBBEN, K.W. SCHMID, W. SIFFERT, K. RIEMANN (<i>Essen, Germany</i>)	5131
<i>Clinical Studies</i>	
Docetaxel, Ifosfamide and Cisplatin (DIP) in Squamous Cell Carcinoma of the Head and Neck. P.M. SPECENIER, J. VAN DEN BRANDE, D. SCHRIJVERS, M.T. HUIZING, S. ALTINTAS, J. DYCK, D. VAN DEN WEYNGAERT, C. VAN LAER, J.B. VERMORKEN (<i>Edegem; Antwerp, Belgium</i>).....	5137
Statins and Breast Cancer in Postmenopausal Women without Hormone Therapy. M. EATON, J. EKLOF, J.R. BEAL, A.E. SAHMOUN (<i>Grand Forks; Fargo, ND, USA</i>).....	5143
Phase I Dose Escalation Study of Gemcitabine plus Irinotecan in Advanced Solid Tumors. E. DUGAN, R. TRUAX, K.L. MEADOWS, G.C. BLOBE, M.A. MORSE, N.H. FERNANDO, J.P. GOCKERMAN, W.P. PETROS, H.I. HURWITZ (<i>Durham, NC; Morgantown, WV; Alpharetta, GA, USA</i>)	5149
* Review: Pathology of Prostate Cancer and Focal Therapy ('Male Lumpectomy'). R. MAZZUCHELLI, M. SCARPELLI, L. CHENG, A. LOPEZ-BELTRAN, A.B. GALOSI, Z. KIRKALI, R. MONTIRONI (<i>Ancona, Italy; Indianapolis, IN, USA; Cordoba, Spain; Izmir, Turkey</i>)	5155
Increased Incidence of Papillary Thyroid Cancer Detection among Thyroidectomies in Greece between 1991 and 2006. J. GRINIATSOS, C. TSIGRIS, M. KANAKIS, G. KALTSAS, O. MICHAIL, N. DIMITRIOU, G. ARGYRAKOPOULOU, I. DELLADETSIMA, V. KYRIAKOU, V. SYRIOU, K. ALEXANDRAKI, E. PIKOULIS, A. GIANNOPOULOS, G. KOURAKLIS, E. DIAMANTI-KANDARAKI, E. FELEKOURAS (<i>Athens, Greece</i>)	5163
	5323

* Review: Chemotherapy for Glioblastoma: Current Treatment and Future Perspectives for Cytotoxic and Targeted Agents. G. MINNITI, R. MUNI, G. LANZETTA, P. MARCHETTI, R. MAURIZI ENRICI (<i>Rome; Pozzilli (IS), Italy</i>).....	5171
Claudin-5 Overexpression Correlates with Aggressive Behavior in Serous Ovarian Adenocarcinoma. M. TURUNEN, A. TALVENSAARI-MATTILA, Y. SOINI, M. SANTALA (<i>Oulu; Kuopio, Finland</i>)	5185
Neoplastic Meningitis from Breast Cancer: Feasibility and Activity of Long-term Intrathecal Liposomal Ara-C Combined with Dose-dense Temozolomide. A-L. HOFFMANN, J-H. BUHK, H. STRIK (<i>Göttingen; Marburg, Germany</i>)	5191
Extraskeletal Osteosarcoma with Partial Spontaneous Regression. T. MATSUO, S. SHIMOSE, T. KUBO, Y. MIKAMI, K. ARIHIRO, Y. YASUNAGA, M. OCHI (<i>Hiroshima, Japan</i>)	5197
* Review: A Novel Strategy by Cryoablation for Advanced Hepatoma. S. OSADA, K. YOSHIDA, S. SAJI (<i>Gifu, Japan</i>)	5203
Biweekly Gemcitabine (GEM) in Combination with Erlotinib (ERL): An Active and Convenient Regimen for Advanced Pancreatic Cancer. A. ARDAVANIS, P. KOUNTOURAKIS, A. KARAGIANNIS, D. DOUFEXIS, A.A. TZOVARAS, G. RIGATOS (<i>Athens, Greece</i>)	5211
Concurrent <i>versus</i> Sequential Chemotherapy and Radiotherapy in Limited Disease Small Cell Lung Cancer: A Retrospective Comparative Study. S.Y. EL SHAROUNI, H.B. KAL, A. BARTEN-VAN RIJBROEK, H. STRUIKMANS, J.J. BATTERMANN, F.M.N.H. SCHRAMEL (<i>Utrecht; Leiden; Nieuwegein, The Netherlands</i>).....	5219
Tyrosine Kinase Inhibitor-induced Macrocytosis. D. SCHALLIER, F. TRULLEMANS, C. FONTAINE, L. DECOSTER, J. DE GREVE (<i>Brussels, Belgium</i>)	5225
Central Adiposity as a Major Risk Factor of Ovarian Cancer. L. DELORT, F. KWIATKOWSKI, N. CHALABI, S. SATHI, Y.-J. BIGNON, D.J. BERNARD-GALLON (<i>Clermont-Ferrand, France</i>)	5229
Phase II Trial of the Association of a Methionine-free Diet with Cysteamine Therapy in Melanoma and Glioma. E. THIVAT, M.-C. FARGES, F. BACIN, M. D'INCAN, M.-A. MOURET-REYNIER, E. CELLARIER, J.-C. MADELMONT, M.-P. VASSON, P. CHOLLET, X. DURANDO (<i>Clermont-Ferrand, France</i>)	5235
Low-dose IL-2 Therapy Reduces HCV RNA and HBV DNA: Case Report. R. TOMOVA, K. ANTONOV, A. IVANOVA, J.J.L. JACOBS, J.W. KOTEN, W. DEN OTTER, Z. KRASSTEV (<i>Sofia, Bulgaria; Amsterdam, The Netherlands</i>).....	5241
Routine Use of Pamidronate in NSCLC Patients with Bone Metastasis: Results from a Retrospective Analysis. G. SPIZZO, A. SEEBER, M. MITTERER (<i>Merano, Italy</i>)	5245
Significant Association of DNA Repair Gene <i>Ku80</i> Genotypes with Breast Cancer Susceptibility in Taiwan. H.-C. WANG, C.-S. LIU, C.-FA. CHIU, S.-Y. CHIANG, C.-H. WANG, R.-F. WANG, C.-C. LIN, R.-Y. TSAI, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>).....	5251
FNA Cytology and Frozen Section Examination in Patients with Follicular Lesions of the Thyroid Gland. F. LUMACHI, S. BORSATO, A. TREGNAGHI, F. MARINO, F. POLISTINA, S.M.M. BASSO, H. KOUSSIS, U. BASSO, A. FASSINA (<i>Padova; Vicenza; Pordenone, Italy</i>)	5255
* Reviews (pages 4919, 5155, 5171, 5203)	

Subject Index

(Figures refer to page numbers)

- 125I, anti-*EGFR* Fab, molecular imaging, 4005
 14-3-3 σ , *p53*, *p21*, cisplatin, resistance, senescence, 2009
 4T1, breast cancer, TGF- β , small molecule TGF β RI/ALK5 kinase inhibitor, SM16, 2099
 A431 and A431/Pt human cervical tumor cell lines, platinum drugs, prolonged drug incubation, cytotoxic effect, 3931
 ABC transporters, P-glycoprotein, semi-automated fluorometric method, efflux, ethidium bromide, mouse lymphoma cells, *mdr1*, *ABCBI*, 2173
ABCBI, ABC transporters, P-glycoprotein, semi-automated fluorometric method, efflux, ethidium bromide, mouse lymphoma cells, *mdr1*, 2173
ABCBI, rhodamine 123, ethidium bromide, multidrug resistance, 3989
 Abdominal ultrasound, bladder cancer, surveillance, urine CYFRA 21-1, urine cytology, 4281
 Aberrant crypt foci, 5-hydroxymethylfurfural, 5-sulfooxymethylfurfural, *Min/+* mice, intestinal carcinogenesis, 1921
 Ablation therapy, cryoablation, helper T-cell, immune reaction, hepatoma, review, 5203
 Absolute hardness, 1,2,3,4-tetrahydroisoquinoline, QSAR, cytotoxicity, semiempirical molecular-orbital method, 2265
 Absolute hardness, 1,2,3,4-tetrahydroisoquinoline, QSAR, cytotoxicity, semiempirical molecular-orbital method, 4077
 Abstracts, gynecologic oncology, NOGGO, 1563
 Access to care, colorectal cancer, pancreatic cancer, stage at diagnosis, rurality, 3427
 ACF, TAC-101, chemoprevention, colon carcinogenesis, 2059
 Activated lymphocytes, 5-fluorouracil, transforming growth factor-beta, TGF- β , prostaglandin E₂, PGE₂, 3925
 Acquired prostate cancer, BPH, continuous and intermittent Finasteride, serum CgA data, Gleason score data, 1797
 Actin, latrunculin A, depolymerization, apoptosis, anti-cancer drug, 2091
 Activation state, macrophages, lung cancer, cytokines, 5095
 Acute graft-versus-host disease, cord blood transplantation, standard-risk disease, 1763
 Acute leukemia, *RUNX1*, fusion gene, translocation, myelodysplastic syndrome, gene transcription, review, 1031
 Acute lymphoblastic leukemia, acute myeloid leukemia, children, adults, drug resistance, individual tumor response testing, 1643
 Acute myelogenous leukemia, pyomyositis, methicillin-resistant *Staphylococcus aureus*, high-dose Ara-C, 3361
 Acute myeloid leukemia, acute lymphoblastic leukemia, children, adults, drug resistance, individual tumor response testing, 1643
 ADCC, trastuzumab, esophageal cancer, perforin, granzyme, 2137
 Adenocarcinoma corpus uteri, cytometry, DNA ploidy, treatment, 4731
 Adenocarcinoma of the colon, collision tumor, tumor stem cell, non-small cell lung cancer, 1495
 Adenocarcinoma, cervical cancer, squamous cell carcinoma, tumor markers, 2577
 Adenocarcinoma, gallbladder, fluorescence *in situ* hybridization, *Myc*, gene amplification, *ERBB2*, *EGFR*, 19
 Adenocarcinoma, gallbladder, invasion pattern, vascular invasion, metastasis, 685
 Adenomas, duodenum, Paneth cells, stem cells, migration, 657
 Adenomatous polyps, colonoscopic polypectomy, optical biopsy system, hyperplastic polyps, 4737
 Adenosine-5'-diphosphate, cordycepin (3'-deoxyadenosine), platelet aggregation, hematogenic metastasis, B16-F1 mouse melanoma cell, 3857
 Adenovirus vector, gene therapy, clinical trial, hormone refractory prostate cancer, 1533
 Adenovirus vector, transduction efficacy, RGD, renal cell carcinoma, 2997
 Adenovirus, p27^{kip1}, Jab1, ubiquitin-proteasome system, cholangiocarcinoma, 2015
 Adhesion molecules, APC, colorectal tumours, dog, 2919
 Adhesion, resveratrol, endothelia, ICAM-1, NF- κ B, 355
 Adiponectin, leptin, colorectal cancer, prognosis, 3321
 Adjuvant chemotherapy, breast cancer, feasibility, adriamycin, epirubicin, paclitaxel, 1515
 Adjuvant chemotherapy, local recurrence, stomach carcinoma, 1853
 Adjuvant chemotherapy, operable non-small cell lung cancer, carboplatin, pemetrexed, 4297
 Adjuvant therapy, DNA cytometry, stage II colorectal cancer, prognosis, 99
 Adjuvant therapy, hepatocellular carcinoma, HCC, PHY906, capecitabine, Phase I/II, 4083
 Adoptive cell transfer, immunotherapy, T-cells, 145
 ADP/ATP carrier, molecular dynamics, yAAC2 function, 4897
 Adriamycin, anthracycline, cardiotoxicity, exercise, 4401
 Adriamycin, breast cancer, adjuvant chemotherapy, feasibility, epirubicin, paclitaxel, 1515
 Adults, acute lymphoblastic leukemia, acute myeloid leukemia, children, drug resistance, individual tumor response testing, 1643
 Advanced breast cancer, docetaxel, gemcitabine, 1841
 Advanced gastric cancer, feasibility study, S-1, weekly docetaxel, concurrent radiotherapy, 3385
 Advanced gastric cancer, lentinan, meta-analysis, clinical trials, 2739
 Advanced gastric cancer, S-1, cisplatin, preoperative chemotherapy, neoadjuvant chemotherapy, 4689

- Advanced gastric cancer, S-1, second-line treatment, taxane derivatives, 2863
- Advanced ovarian cancer, late relapse, pegylated liposomal doxorubicin, carboplatin, platinum-sensitive, 4195
- Advanced solid tumors, gemcitabine, irinotecan, phase I, 5149
- Adverse effects, trastuzumab, migraine, headache, 4223
- AE-37, HER-2, helper effect, AE-47, p776, F7, perforin, E75, cancer vaccines, high-affinity CD8⁺ cells, 2427
- AE-47, HER-2, helper effect, AE-37, p776, F7, perforin, E75, cancer vaccines, high-affinity CD8⁺ cells, 2427
- Aerodigestive tract, external beam, radioiodine, radiosensitizer, radiotherapy, paclitaxel, taxane, carboplatin, 4665
- Aerosols, air pollution, cancer, polycyclic aromatic hydrocarbons, ultraviolet-B, vitamin D, 3537
- AFP, alpha-fetoprotein, sodium iodine symporter, NIS, hepatocellular carcinoma, hepatitis B virus enhancer, EIIAPA, 211
- Age, obesity, vitamin D deficiency, seasonal variation, gender, 3713
- Age, ovarian cancer, tumor pattern, debulking surgery, survival, 2809
- Aggressive lymphoma, zevalin, ibritumomab tiuxetan, radioimmunotherapy, non-Hodgkin's lymphoma, indolent lymphoma, 4771
- AhR, HL-60, curcumin, cell cycle, apoptosis, AML, 4657
- AIF, berberine, apoptosis, caspase, SCC-4 cells, EndoG, 4063
- Air pollution, aerosols, cancer, polycyclic aromatic hydrocarbons, ultraviolet-B, vitamin D, 3537
- Akt activation, cytostatic resistance, paclitaxel, Bad phosphorylation, cytochrome *c* release, caspase-3 activation, apoptosis, 159
- Akt isoforms, prognosis, tissue microarray, NSCLC, 4175
- Akt, apoptosis, boswellic acids, PI3 kinase, colon cancer cells, LY294002, wortmannin, 2987
- Akt, curcumin, colorectal cancer, mTOR, Raptor, Rictor, PHLPP, 3185
- AKt, heparin, apoptosis, oral squamous cell carcinoma, 1079
- Akt, inflammation, toll-like receptors, colon cancer, 2473
- Akt, MDA-MB-231, fibroblast growth factor receptor, Chfr, PLC γ , breast cancer, *Xenopus* oocyte, 4965
- Akt, ovarian cancer, chemotherapy, ERK, prognosis, 4639
- Akt, sanguinarine, TRAIL, apoptosis, caspase-3, 4457
- Albendazole, paclitaxel, ovarian cancer, resistance, tubulin, 3791
- Alendronate, chondrosarcoma, antiproliferative activity, apoptosis, 1879
- Alginate/Chitosan microparticles, Tamoxifen, MCF-7, bioavailability, toxicity, 4529
- Alkaloids, *Uncaria tomentosa*, drug resistance, apoptosis, medullary thyroid carcinoma, 4519
- Alkylating agent, *MGMT*, p53, DNA repair, Sp1 transcription factor, drug resistance, 3741
- Alkylating agents, cancer, glioma, O⁶-methylguanine, O⁶-MG, O⁶-methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, promoter methylation, temozolomide, TMZ, review, 3759
- Alkylator, DNA damage, cell cycle arrest, prodrug, bone-marrow sparing, drug resistance, 3845
- ALL, immunogenicity, asparaginases, antibody, IgG immunoglobulin, 299
- Allergic dermatitis, lipopolysaccharide, macrophage, *Pantoea agglomerans*, innate immunity, hygiene hypothesis, review, 4867
- Allograft rejection, cancer, gene therapy, transcriptional targeting, Q5 promoter, cyclophosphamide, 1015
- All-trans retinoic acid, breast cancer, tyrosine phosphorylation, *c-ERBB2/neu*, proliferation, 2899
- Aloe-emodin, apoptosis, caspase, human tongue cancer SCC-4 cells, 4503
- Alpha-fetoprotein, AFP, sodium iodine symporter, NIS, hepatocellular carcinoma, hepatitis B virus enhancer, EIIAPA, 211
- Alpinia officinarum*, diarylheptanoids, apoptosis, S-phase arrest, differentiation, neuroblastoma cells, 4981
- Alternative lengthening, *hTERT*, prognosis, review, 3833
- Alternative splicing, TEM7, osteosarcoma, PCR, metastasis, 4317
- AMA, apoptosis, As4.1, MAPK, ROS, GSH, 4423
- Ameloblastoma, apoptosis, proliferation, TNF-related apoptosis-inducing ligand, 1137
- 2-Aminotropone, benzo[*b*]cyclohept[*e*][1,4]oxazine, tumor-specificity, apoptosis, 1123
- Amitriptyline, antidepressants, chemotherapy-induced neuropathy, neoplasms, neurotoxicity, prevention, 2601
- AML, AhR, HL-60, curcumin, cell cycle, apoptosis, 4657
- Amphiregulin, cancer, HB-EGF, targeted therapy, review, 4879
- Amphiregulin, HB-EGF, targeted therapy, cancer, review, 823
- Amyloid plaques, prion disease, Congo Red, doxorubicin, 2507
- Anaemia, cancer patients, palliative care, fatigue, 2569
- Anal fistula, Crohn's disease, infliximab, 927
- Analog, 1,25(OH)₂D₃, cancer, microarray, review, 3471
- Analogs, vitamin D, antiproliferative effect, microarray, non-steroidal, 3585
- Anaplastic carcinoma, thyroid cancer, intratumoral molecular homogeneity, 2437
- Av β 3 integrin, osteopontin, malignant pleural mesothelioma, 2205
- Av β 6, integrin, EMT, oral SCC, matrix, epithelial-mesenchymal transition, 125
- Av β 6, integrin, TRA-1-60, stem cell, oral SCC, matrix, 2043
- Androgen deprivation, prostate cancer, radiotherapy, conformal, definitive, 2627

- Androgen receptor, prostate, carcinoma, GnRHR, 681
- Androgen, vitamin D, MART-10, prostate cancer, 3547
- Androgen-independent prostate cancer, α -methylacyl-CoA racemase, siRNA, C4-2, LNCaP, 2497
- Androgen-resistant prostate cancer, chemotherapy, docetaxel, vinorelbine, estramustine, zoledronic acid, 769
- Anemia, breast cancer, side-effects, tumor biology, pre-operative chemotherapy, epirubicin, paclitaxel, 2675
- Anemia, leukocytosis, thrombocytosis, non-small cell lung cancer, preoperative, survival, 2687
- Aneuploidy, colorectal cancer, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Angiogenesis factor, hepatocyte growth factor, vascular endothelial growth factor, tumor markers, 3311
- Angiogenesis, animal model, metastasis, experimental therapy, integrin, 131
- Angiogenesis, biomarkers, cediranib, murine renal cell carcinoma, VEGF, 5065
- Angiogenesis, black tea polyphenols, chemoprevention, hepatocellular carcinoma, histone deacetylation, invasion, 2301
- Angiogenesis, cathepsin L, NSITC, ECM, protease, 4473
- Angiogenesis, chitosan nanoparticles, hepatocellular carcinoma, tumor growth, necrosis, *VEGFR2*, 5103
- Angiogenesis, galectin-1, laryngeal cancer, lymphocyte, lectin, prognosis, stroma, 59
- Angiogenesis, heat-shock protein 90, Hsp90, targeted therapy, gastrointestinal cancer, pancreatic cancer, gastric cancer, review, 2031
- Angiogenesis, HMGB1, ELISA, exudates, transudates, 5013
- Angiogenesis, molecular imaging, prostate cancer, tumor vascular remodelling, vascular stabilization, review, 1823
- Angiogenesis, renal cell carcinoma, Tetrac, Tetrac nanoparticles, anti-cancer, anti-angiogenesis, integrin, 3825
- Angiogenesis, uterine cervical carcinomas, basic FGF, VEGF, COX-2, angiopoietin, *IL-8*, thymidine phosphorylase, HIF-1 α , ETS-1, review, 2665
- Angiogenesis, VEGF, tumor vascularity, anti-angiogenic therapy, vandetanib, ZACTIMATM, ZD6474, 1987
- Angiogenesis, *Viscum album*, European mistletoe, matrigel assay, endothelial cells, apoptosis, cancer therapy, 2945
- Angiopoietin, angiogenesis, uterine cervical carcinomas, basic FGF, VEGF, COX-2, *IL-8*, thymidine phosphorylase, HIF-1 α , ETS-1, review, 2665
- Angiopoietin 2, glioblastoma multiforme, meningioma, astrocytoma, VEGF, 731
- Animal model, angiogenesis, metastasis, experimental therapy, integrin, 131
- ANN, PSA, PCA3, prostate cancer, review, 2589
- Anoikis, breast cancer cell, tumor cell intravasation, transendothelial migration, apoptosis, basement membrane degradation, 2347
- Anoikis, cancer, metastasis, malignant potential, cell-based assay, matrix metalloproteinase, MMP, 2541
- Antagonist, human colon cancer, progesterone receptor, microenvironment, natural killer cells, 1611
- Anthracycline, cyclophosphamide, breast cancer, anti-emesis, 5-HT3 receptor antagonist, repeated treatment, constipation, 1721
- Anthracycline, doxorubicin, epirubicin, PPE, hand-foot syndrome, 2307
- Anthracycline-refractory, Kaposi's sarcoma, paclitaxel, 675
- Anthracyclines, topotecan, endometrial cancer, taxanes, stage IV disease, 1761
- Anthracycline, Adriamycin, cardiotoxicity, exercise, 4401
- Anthraquinone, ROS, ER stress, cell death, 327
- Anti-angiogenesis, renal cell carcinoma, angiogenesis, Tetrac, Tetrac nanoparticles, anti-cancer, integrin, 3825
- Anti-angiogenic therapy, VEGF, tumor vascularity, angiogenesis, vandetanib, ZACTIMATM, ZD6474, 1987
- Antiangiogenic, thrombospondin-1, peptide, antibody, endothelial cell, selectivity, 2243
- Antibody therapy, tumor cells, ovarian cancer, ascites, catumaxomab, 1787
- Antibody, immunogenicity, asparaginases, IgG immunoglobulin, ALL, 299
- Antibody, thrombospondin-1, peptide, endothelial cell, antiangiogenic, selectivity, 2243
- Anticancer activity, bacteriophage T4 preparation, BP T4, melanoma, cancer, B16 melanoma, 2361
- Anticancer activity, brine shrimp larvae, MCF-7 cells, selectivity index, 2993
- Anticancer agents, pharmacokinetic interactions, 4741
- Anticancer cytotoxin, parasporin, preferential activity, *Bacillus thuringiensis*, review, 427
- Anti-cancer drug, latrunculin A, actin, depolymerization, apoptosis, 2091
- Anticancer drugs, FEN1, testis tumors, lung cancer, glioblastoma multiforme, astrocytoma, 2453
- Anticancer, renal cell carcinoma, angiogenesis, Tetrac, Tetrac nanoparticles, anti-angiogenesis, integrin, 3825
- Anticoagulant, cerebral hemorrhage, glioblastoma, pulmonary embolism, venous glioblastoma, venous thromboembolism, 4309
- Antidepressants, amitriptyline, chemotherapy-induced neuropathy, neoplasms, neurotoxicity, prevention, 2601
- Anti-EGFR Fab, molecular imaging, ¹²⁵I, 4005
- Anti-emesis, anthracycline, cyclophosphamide, breast cancer, 5-HT3 receptor antagonist, repeated treatment, constipation, 1721

- Antigen selection, splenic marginal zone lymphoma, mutation pattern, 1811
- Anti-*H. pylori* vaccine, VacA, recombinant VacA, neutralizing antibody, CpG-ODN, mucosal immune response, 2393
- Anti-heat-shock protein 70 antibody, heat-shock protein 70, esophageal cancer, ELISA, immunohistochemistry, humoral immune system, 1595
- Anti-inflammatory effect, diethyl 2-chloroazulene-1,3-dicarboxylate, RAW264.7 cells, macrophage, PGE₂, COX-2, PLA2, 379
- Antimicrotubule agents, β 3-tubulin, regulation, AP-1, 3003
- Antineoplastic drugs, pulmonary toxicity, interstitial lung disease, dyspnea, pneumonitis, lung injury, review, 631
- Antioxidants, chemotherapy, combination, colon cancer, orthotopic model, 2421
- Antioxidants, coenzyme Q10, quercetin, nasal mucosa, Comet assay, mini organ cultures, 33
- Antiprogestins, cancer, pharmacology, growth, progestins, Ishikawa cells, 1047
- Anti-proliferation, methylnaltrexone, 5-fluorouracil, SW-480 colorectal cancer cell, MCF-7 breast cancer cell, non-small cell lung cancer cell, NSCLC, cell growth, cell cycle, 2927
- Antiproliferative activity, alendronate, chondrosarcoma, apoptosis, 1879
- Antiproliferative activity, imexon antioxidant, lymphoma cells, ionizing radiation, radiosensitization, 4409
- Antiproliferative effect, vitamin D, analogs, microarray, non-steroidal, 3585
- Antiproliferative, curcumin, cell cycle arrest, apoptosis, 5039
- Antiproliferative, vitamin D analogs, CD-ring, calcemic, 3579
- Antisense oligonucleotide, migration, extracellular matrix, three-dimensional cell-culture model, Boyden chamber, borrelidin, taxol, 5-hexyl-2'-deoxyuridine, signal pathway inhibitors, 2981
- Antitumor activity, oncolytic virus, prodrug therapy, nitroreductase, HSV, 2159
- Antitumor immunity, tumorigenesis, inflammation, review, 4795
- Antitumor, α -mangostin, panaxanthone, chemoprevention, mammary cancer, 2485
- AP, prostate carcinoma, P1NP, PSA, tumour marker, bone metastases, 671
- AP-1, antimicrotubule agents, β 3-tubulin, regulation, 3003
- AP-1, ATF2, p-ATF2, breast cancer, prognosis, immunohistochemistry, Western blot, ERK-1/2, MMP-9, 183
- AP-1, biphenols, radical-scavenging activity, COX-2, NF-kappaB, DFT/B3LYP, lipopolysaccharide, 2403
- AP-1, SP100030, SP100207, NF-kB, tumour growth, 1315
- Apa1, vitamin D receptor, gene polymorphisms, cancer, Fok1, BSm1, Taq1, Cdx2, poly(A), Bgl1, 3511
- APC gene, colorectal cancer, hereditary cancer, familial adenomatous polyposis, 711
- APC, adhesion molecules, colorectal tumours, dog, 2919
- APE1*, BER, lung cancer, cigarette, polymorphism, RFLP, 2417
- APE1*, bladder cancer, polymorphism, *XRCC1*, *XRCC3*, *XPD*, *XPG*, *hOGG1*, 1389
- APL treatment, arsenic trioxide, mice, trace elements, virus, 83
- Apoptosis, (-)-epigallocatechin gallate, EGCG, human adrenal cancer NCI-H295 cells, caspase, 1435
- Apoptosis, 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone, estrogen positive/negative breast cancer cell lines, cytotoxicity, cell cycle, 191
- Apoptosis, 23-hydroxyursolic acid, pentacyclic triterpenes, growth-inhibition, caspases, 995
- Apoptosis, AhR, HL-60, curcumin, cell cycle, AML, 4657
- Apoptosis, alendronate, chondrosarcoma, antiproliferative activity, 1879
- Apoptosis, aloe-emodin, caspase, human tongue cancer SCC-4 cells, 4503
- Apoptosis, AMA, As4.1, MAPK, ROS, GSH, 4423
- Apoptosis, ameloblastoma, proliferation, TNF-related apoptosis-inducing ligand, 1137
- Apoptosis, arsenic trioxide, Calu-6, MAPK, ROS, GSH, 3837
- Apoptosis, Bax, Bcl-2, bFGF, Endostar, HUVEC, 411
- Apoptosis, Bcl-2, bax, *p53*, endometrium carcinoma, real-time PCR, immunohistochemistry, 3977
- Apoptosis, benzo[b]cyclohept[e][1,4]oxazine, 2-aminotropone, tumor-specificity, 1123
- Apoptosis, berberine, caspase, SCC-4 cells, AIF, EndoG, 4063
- Apoptosis, boswellic acids, PI3 kinase, Akt, colon cancer cells, LY294002, wortmannin, 2987
- Apoptosis, breast cancer cell, tumor cell intravasation, transendothelial migration, anoikis, basement membrane degradation, 2347
- Apoptosis, cancer, endometrium, growth, progesterone, mifepristone, cell cycle, Ishikawa cells, 1053
- Apoptosis, cancer, haperforin, chemotherapy, cell cycle, cytoskeleton, 1963
- Apoptosis, capecitabine, thymidine phosphorylase, dihydropyrimidine dehydrogenase, cell proliferation, 2525
- Apoptosis, capsaicin, calcium, reactive oxygen species, mitochondrial membrane potential, human HepG2 cells, 165
- Apoptosis, cell cycle regulatory proteins, caspase 3, staurosporine, leukemic cells, 2893
- Apoptosis, cell proliferation, CDKs, NF-kB, toad skin extract, curcumin, colon cancer, 395
- Apoptosis, cepharanthine, S-1, oral squamous cell carcinoma, TUNEL, combination therapy, xenografts, nude mice, 1263
- Apoptosis, c-FLIP, cancer cell xenografts, immunohistochemistry, 3883

- Apoptosis, chronic lymphocytic leukemia, ER stress, XBP1 splicing, proteasome, 3797
- Apoptosis, circadian rhythm, clock genes, mouse Period2 gene, tumor suppression, cell cycle arrest, synergic effect, cisplatin, 1201
- Apoptosis, colonic 1,25(OH)₂D₃ concentration, gender-dependent, dietary calcium, vitamin D hydroxylases, 3727
- Apoptosis, curcumin, antiproliferative, cell cycle arrest, 5039
- Apoptosis, cytostatic resistance, paclitaxel, Akt activation, Bad phosphorylation, cytochrome *c* release, caspase-3 activation, 159
- Apoptosis, DCA, hypoxia, proliferation, *HIF1A*, 4579
- Apoptosis, diarylheptanoids, S-phase arrest, differentiation, neuroblastoma cells, *Alpinia officinarum*, 4981
- Apoptosis, Euphorbiaceae, *Euphorbia*, triterpenes, steroids, multidrug resistance, P-glycoprotein, 4467
- Apoptosis, galectins, oligosaccharide ligand, cell aggregation, 403
- Apoptosis, gastric carcinoma, Bcl-2, Ki-67, prognostic factors, 703
- Apoptosis, glioblastoma, HMG-CoA reductase, necrosis, pericytes, simvastatin, 4901
- Apoptosis, grape seed procyanidin, colorectal carcinoma, caspase-3, 283
- Apoptosis, green tea polyphenols, Bcl-2, caspase-3, 1417
- Apoptosis, GSK-3 β , prostate cancer, cell signaling pathway, proliferation, prognosis, 2077
- Apoptosis, heparin, Akt, oral squamous cell carcinoma, 1079
- Apoptosis, HL-60, asparagine synthetase, TPA, differentiation, asparaginase, 1303
- Apoptosis, HOCl signaling pathway, catalase, hydrogen peroxide, hypochlorous acid, hydroxyl radical, 4559
- Apoptosis, IGFBP-3, IGF-1, breast cancer, 3785
- Apoptosis, irinotecan, CPT-11, 5-fluorouracil, sequence-dependency, cell cycle, thymidylate synthase, 2083
- Apoptosis, latrunculin A, actin, depolymerization, anti-cancer drug, 2091
- Apoptosis, macromolecular therapeutics, protein transduction domain, survivin, 1423
- Apoptosis, MMPs, autophagy, MDA-MB-231, MDA-MB-435, 1335
- Apoptosis, naphtho[2,3-*b*]furan-4,9-diones, autophagy, caspase, DNA fragmentation, QSAR, 455
- Apoptosis, paclitaxel, colon cancer, MAPK inhibition, PD98059, 261
- Apoptosis, pancreatic cancer, doxycycline, *p53*, *Fas*, *IL-8*, 3995
- Apoptosis, radiation, caspase-2, caspase-8, caspase-9, 4361
- Apoptosis, receptor for advanced glycation end products, RAGE, hypoxia, 1287
- Apoptosis, recombinant adeno-associated virus, rAAV, hypoxia inducible factor, HIF, small interference RNA, siRNA, nuclear factor-kappaB, NF- κ B, proliferation, 1367
- Apoptosis, rhein, caspase-3, ROS, mitochondria membrane potential, cytochrome *c*, 309
- Apoptosis, ribavirin, gene expression profiling, K562, leukemia, cell differentiation, inositide-5'-monophosphate dehydrogenase, IMPDH, 1971
- Apoptosis, riluzole, ion channel, endoplasmic reticulum stress, prostate cancer, 2195
- Apoptosis, sanguinarine, TRAIL, caspase-3, Akt, 4457
- Apoptosis, sesquiterpene lactone, GSH, ROS, autophagy, 1449
- Apoptosis, TP-110, proteasome inhibitor, multiple myeloma, IAP, 977
- Apoptosis, trifluoromethyl acylolins, cytotoxic activity, autophagy, 175
- Apoptosis, tumor necrosis factor-related apoptosis-inducing ligand, non-small cell lung cancer, primary culture, 2905
- Apoptosis, *Uncaria tomentosa*, alkaloids, drug resistance, medullary thyroid carcinoma, 4519
- Apoptosis, *Viscum album*, European mistletoe, angiogenesis, matrigel assay, endothelial cells, cancer therapy, 2945
- ARE-I, prostate cancer, PSA, polymorphism, 1395
- Aromatase inhibitor, breast cancer, ER α , ER β , SERM, 2167
- Aromatase inhibitor, sequence, radiotherapy, hormone therapy, 4791
- Aromatase, breast cancer, estrogen, postmenopausal, 17 beta HSD type 1, Steroid sulphatase, carcinogenesis, review, 1095
- Array CGH, human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, P-STS primary tumor, L-STS lymph node metastasis, H-STS hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, 1951
- ARRY-520, KSP inhibitor, hematological tumors, taxane resistant, 4373
- Arsenic trioxide, APL treatment, mice, trace elements, virus, 83
- Arsenic trioxide, apoptosis, Calu-6, MAPK, ROS, GSH, 3837
- Arsenic, *ERCCI*, DNA repair, drinking water, NER, skin hyperkeratosis, 3253
- Artemisinin-transferrin conjugate, dihydroartemisinin, rat breast tumor, 3807
- Aryl hydrocarbon receptor, lung cancer, *CYP1B1*, *p53*, epidermal growth factor receptor, 509
- Arylamine metabolism, bladder cancer, detoxification, genetic polymorphism, arylesterase, *PONI*, 4041
- Arylesterase, arylamine metabolism, bladder cancer, detoxification, genetic polymorphism, *PONI*, 4041
- As4.1, AMA, apoptosis, MAPK, ROS, GSH, 4423
- Ascites, ovarian cancer, cytokines, chemokines, cell mediated immunity, 2875

- Ascites, tumor cells, ovarian cancer, antibody therapy, catumaxomab, 1787
- Ascorbate, cancer, vitamin C, ascorbic acid, plasma concentration, intravenous, cytotoxicity, complementary and alternative medicine, review, 809
- Ascorbic acid, cancer, vitamin C, ascorbate, plasma concentration, intravenous, cytotoxicity, complementary and alternative medicine, review, 809
- Ascorbic acid, zinc, *N*-acetylcysteine, oxidative DNA damage, FPG-comet assay, 4571
- Asparaginase, HL-60, asparagine synthetase, TPA, differentiation, apoptosis, 1303
- Asparaginase, immunohistochemistry, RNAi knock-down, cell growth, 951
- Asparaginases, immunogenicity, antibody, IgG immunoglobulin, ALL, 299
- Asparagine synthetase, HL-60, TPA, differentiation, asparaginase, apoptosis, 1303
- Astrocytoma, FEN1, testis tumors, lung cancer, glioblastoma multiforme, anticancer drugs, 2453
- Astrocytoma, glioblastoma multiforme, meningioma, angipoinetin 2, VEGF, 731
- Astrocytoma, imatinib mesylate, PDGF receptor, gamma rays, 4575
- ATF2, p-ATF2, breast cancer, prognosis, immunohistochemistry, Western blot, ERK-1/2, AP-1, MMP-9, 183
- ATG, cytotoxicity, hematological malignancies, 1355
- Atrial natriuretic peptide, prostate cancer, cardiac hormones, long-acting atrial natriuretic peptide, Ras, 1889
- AURKA, aurora kinase A, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- AURKB, aurora kinase B, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Aurora kinase A, AURKA, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Aurora kinase B, AURKB, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Autologous transplantation, Ewing's sarcoma, rhabdomyosarcoma, high-dose chemotherapy, 3281
- Autophagy, MMPs, apoptosis, MDA-MB-231, MDA-MB-435, 1335
- Autophagy, naphtho[2,3-*b*]furan-4,9-diones, apoptosis, caspase, DNA fragmentation, QSAR, 455
- Autophagy, panitumumab, redox status, 5077
- Autophagy, sesquiterpene lactone, GSH, ROS, apoptosis, 1449
- Autophagy, tetrahydroisoquinolines, tumor-specificity, cytotoxicity, 3079
- Autophagy, trifluoromethyl acyloins, cytotoxic activity, apoptosis, 175
- Autoradiography, hepatocarcinoma, mesoblastic nephroma, metastasis, parathyroid lymph node, 2121
- Axillary ultrasonography, breast cancer, sentinel node biopsy, scintimammography, fine-needle aspiration cytology, FNA cytology, 491
- AXOR12, metastatin, DSCR1, gene expression, real-time quantitative RT-PCR, epithelial ovarian cancer, 617
- B16 melanoma, bacteriophage T4 preparation, BP T4, melanoma, cancer, anticancer activity, 2361
- B16-F1 mouse melanoma cell, cordycepin (3'-deoxyadenosine), platelet aggregation, hematogenic metastasis, adenosine-5'-diphosphate, 3857
- Bacillus thuringiensis*, parasporin, anticancer cytotoxin, preferential activity, review, 427
- Bacteria, *Salmonella typhimurium*, tumor-targeting, pancreatic cancer, red fluorescent protein, RFP, green fluorescent protein, GFP, imaging, 1873
- Bacteriophage T4 preparation, BP T4, melanoma, cancer, anticancer activity, B16 melanoma, 2361
- Bad phosphorylation, cytostatic resistance, paclitaxel, Akt activation, cytochrome *c* release, caspase-3 activation, apoptosis, 159
- Bak, *p53*, EPO, EPOR, colorectal cancer, 4151
- Barrett's mucosa, glassy cells, 4145
- Basement membrane degradation, breast cancer cell, tumor cell intravasation, transendothelial migration, apoptosis, anoikis, 2347
- Basic FGF, angiogenesis, uterine cervical carcinomas, VEGF, COX-2, angiopoietin, *IL-8*, thymidine phosphorylase, HIF-1 α , ETS-1, review, 2665
- Bax, apoptosis, Bcl-2, bFGF, Endostar, HUVEC, 411
- Bax, Bcl-2, *p53*, apoptosis, endometrium carcinoma, real-time PCR, immunohistochemistry, 3977
- BBN, sirolimus, urothelial lesions, mice, labelling index, 3221
- BCA225, correlation coefficient, tumor marker, CA15-3, KL-6, 4239
- B-cell receptor, chronic lymphocytic leukaemia, prognostic factors, review, 605
- B-cells, ionizing radiation, SOD mimetic, RM-9 prostate cancer, NK cells, cytokines, immune system, 107

- BCG, bladder cancer, immunotherapy, CpG-oligodeoxy-nucleotides, 2067
- Bcl-2, (-)-gossypol, metastasis, prostate cancer, nm23-H1, Bcl-xL, 2179
- Bcl-2, apoptosis, Bax, bFGF, Endostar, HUVEC, 411
- Bcl-2, bax, *p53*, apoptosis, endometrium carcinoma, real-time PCR, immunohistochemistry, 3977
- BCL2, follicular lymphoma, BCL6, translocation, 4649
- Bcl-2, gastric carcinoma, Ki-67, apoptosis, prognostic factors, 703
- Bcl-2, green tea polyphenols, apoptosis, caspase-3, 1417
- BCL6, follicular lymphoma, BCL2, translocation, 4649
- Bcl-xL, (-)-gossypol, metastasis, prostate cancer, nm23-H1, Bcl-2, 2179
- BCRP/ABCG2, gefitinib, HPLC, *EGFR*, 1059
- Benign metastasizing leiomyoma, intravenous leiomyomatosis, 495
- Benzo[b]cyclohept[e][1,4]oxazine, 2-aminotropone, tumor-specificity, apoptosis, 1123
- BER, *APE1*, lung cancer, cigarette, polymorphism, RFLP, 2417
- Berberine, apoptosis, caspase, SCC-4 cells, AIF, EndoG, 4063
- Beta-1,3-glucan, colorectal cancer, lentinan, peripheral blood monocytes, quality of life, superfine dispersed lentinan, 2611
- 17 Beta HSD type 1, breast cancer, estrogen, postmenopausal, aromatase, Steroid sulphatase, carcinogenesis, review, 1095
- Bevacizumab, capecitabine, irinotecan, colorectal cancer, HT29 xenografts, 91
- Bevacizumab, empyema, gastrointestinal perforation, pancreatic cancer, 1665
- Bevacizumab, homocysteine, metastatic colorectal carcinoma, 4813
- bFGF, apoptosis, Bax, Bcl-2, Endostar, HUVEC, 411
- BFT, CDX2, homeobox genes, gene expression, NSCLC, 1281
- Bgl1, vitamin D receptor, gene polymorphisms, cancer, Fok1, BSm1, Taq1, Apa1, Cdx2, poly(A), 3511
- BIBF 1120, multiple myeloma, VEGF receptor inhibitor, Phase I study, pharmacokinetics, 4233
- Bicalutamide, ghrelin, prostate cancer, leuprorelin, 1345
- Bile acids, colon cancer, UDCA, UDCA-Glu, cancer prevention, 4971
- Bile duct neoplasms, pancreas neoplasms, DNA ploidy, computer-assisted, cytometry, image analysis, differential diagnosis, 1579
- Biliary tract carcinoma, pharmacogenomic, cisplatin, DNA repair proteins, polymorphisms, 1835
- Biliary tract, carcinoma, chemotherapy, surgical resection, 1783
- Bioavailability, etoposide, quercetin, P-gp, CYP3A, pharmacokinetics, rats, 1411
- Bioavailability, Tamoxifen, MCF-7, toxicity, alginate/chitosan microparticles, 4529
- Biochemical failure, surgery, prostate cancer, nPSA12, radiotherapy, prognostic factor, 4605
- Biodistribution, breast cancer, tumor-antigen peptides, radiolabeling, tumor-cell binding, 1399
- Biodistribution, polyethylene glycol, PEGylated liposome, reticuloendothelial system, indium-111, HT-29/*luc*, pharmacokinetics, bioluminescence imaging, 2111
- Biological marker, CEA, TIMP-1, lead-time, immunoassay, postoperative follow-up, 75
- Biological markers, malignant astrocytoma, immunobiology, biological therapy, review, 2461
- Biological markers, neo-adjuvant chemotherapy, locally advanced breast cancer, 1621
- Biological materials, colonic carcinoma, neoplastic glands, 1745
- Biological therapy, malignant astrocytoma, immunobiology, biological markers, review, 2461
- Biologically effective dose, cataract induction, late renal dysfunction, dose-effect relationship, 3305
- Bioluminescence imaging, luciferase, mammary cancer, metastasis, 4389
- Bioluminescence imaging, polyethylene glycol, PEGylated liposome, reticuloendothelial system, indium-111, HT-29/*luc*, pharmacokinetics, biodistribution, 2111
- Bioluminescent imaging, ¹⁸F-fluorodeoxyglucose, luciferase, micropositron-emission tomography, microPET, nuclear factor- κ B, 987
- Biomarker, brushing, hnRNPA2/B1, immunoblotting, lung cancer, 1373
- Biomarkers of resistance, rapamycin, mTOR signaling, mTOR phosphorylation, STAT3 phosphorylation, p70S6 and RS6P, human breast epithelial cells, human breast premalignant and tumor epithelial cells, early events in breast tumorigenesis, 1143
- Biomarkers, angiogenesis, cediranib, murine renal cell carcinoma, VEGF, 5065
- Biomarkers, prostate, cancer, PSA, prognosis, review, 3289
- Biotin, biotinidase, hepatocellular carcinoma, liver cirrhosis, fucoidan, HuH-6 cells, LEW rat, 1211
- Biotinidase, hepatocellular carcinoma, liver cirrhosis, fucoidan, HuH-6 cells, LEW rat, biotin, 1211
- Biphenols, radical-scavenging activity, COX-2, NF-kappaB, AP-1, DFT/B3LYP, lipopolysaccharide, 2403
- Bipolar, radiofrequency induced thermotherapy, liver metastases, 1309
- Bisphosphonate, pamidronate, zoledronic acid, LNCaP, osteoblast, osteoclast, 1089
- Bisphosphonate, ulcerative colitis, carcinogenesis, thymidine kinase mRNA, 4615
- Bisphosphonates, hypercalcemia, malignancy, cancer, PTHrP, RANKL, review, 1551

- Black tea polyphenols, angiogenesis, chemoprevention, hepatocellular carcinoma, histone deacetylation, invasion, 2301
- Bladder cancer, arylamine metabolism, detoxification, genetic polymorphism, arylesterase, *PONI*, 4041
- Bladder cancer, cell regulatory proteins, *p53*, pRb, prognosis, 4201
- Bladder cancer, cyclooxygenase-2, *COX-2*, celecoxib, chemoprevention, 3769
- Bladder cancer, *ERCC6*, polymorphism, carcinogenesis, 5121
- Bladder cancer, immunotherapy, CpG-oligodeoxy-nucleotides, BCG, 2067
- Bladder cancer, Ku80, polymorphism, carcinogenesis, 1275
- Bladder cancer, polymorphism, *XRCC1*, *XRCC3*, *XPD*, *XPG*, *APE1*, *hOGG1*, 1389
- Bladder cancer, surveillance, urine CYFRA 21-1, abdominal ultrasound, urine cytology, 4281
- Bladder cancer, susceptibility, metabolising gene, *CYP1A1*, *CYP1B1*, *COMT*, *GSTP1*, *NAT2*, genetic polymorphism, single nucleotide polymorphism, 1631
- Bladder cancer, *XPD*, single nucleotide polymorphism, DNA repair, 3903
- Bladder cancer, *XRCC4*, single nucleotide polymorphism, DNA repair, 1777
- Bladder urothelial carcinoma, 5-fluorouracil, orotate phosphoribosyl transferase, dihydropyrimidine dehydrogenase, 5-chloro-2,4-dihydropyridine, 1001
- Blood–brain barrier, sonodynamic therapy, photosensitizer, normal rat brain, electron microscopic study, 889
- Body weight gain, breast cancer, Zeranol, pre-adipocytes, doubling time, cyclin D1, *p53*, 5045
- Bone cement, bone tumor, radiofrequency ablation, breast cancer, metastases, 2787
- Bone marrow, stem cells, breast cancer, nude mice, GFP, 443
- Bone metastases, leiomyosarcoma, 18-F-FDG-PET, 469
- Bone metastasis, NSCLC, pamidronate, survival, retrospective analysis, 5245
- Bone metastases, prostate carcinoma, PINP, PSA, AP, tumour marker, 671
- Bone metastasis, bone turnover markers, NSCLC, receptor activator of nuclear factor- κ B ligand, osteoprotegerin, osteopontin, 1651
- Bone morphogenetic protein, giant cell tumor, osteoclast-like giant cell, stromal cell, laser microdissection, 2219
- Bone neoplasms, breast neoplasms, diphosphonates, hyperparathyroidism, secondary, calcium, 2707
- Bone recurrences, Vienna protocol, ¹⁵³Sm-EDTMP, 3393
- Bone tumor, radiofrequency ablation, bone cement, breast cancer, metastases, 2787
- Bone turnover markers, NSCLC, bone metastasis, receptor activator of nuclear factor- κ B ligand, osteoprotegerin, osteopontin, 1651
- Bone-marrow sparing, alkylator, DNA damage, cell cycle arrest, prodrug, drug resistance, 3845
- Borrelidin, migration, extracellular matrix, three-dimensional cell-culture model, Boyden chamber, taxol, 5-hexyl-2'-deoxyuridine, signal pathway inhibitors, antisense oligonucleotide, 2981
- Bortezomib, fibroblast growth factor receptor 3, FGFR3, multiple myeloma, 1
- Bortezomib, gefitinib, epidermal growth factor receptor, tumor necrosis factor α , resistance, 2315
- Bortezomib, neuroblastoma, proteasome inhibitor, metastases, xenograft model, 1219
- Bortezomib, proteasome, renal cancer, *p53*, VHL, 2961
- Boswellic acids, apoptosis, PI3 kinase, Akt, colon cancer cells, LY294002, wortmannin, 2987
- Boyden chamber, migration, extracellular matrix, three-dimensional cell-culture model, borrelidin, taxol, 5-hexyl-2'-deoxyuridine, signal pathway inhibitors, antisense oligonucleotide, 2981
- BP T4, bacteriophage T4 preparation, melanoma, cancer, anticancer activity, B16 melanoma, 2361
- BPH, continuous and intermittent Finasteride, serum CgA data, acquired prostate cancer, Gleason score data, 1797
- BPH, CYP17 gene polymorphism, hormonal genes, prostate cancer, North India, 1659
- Brachytherapy, cervical carcinoma, radiotherapy, chemotherapy, 4205
- Brain lesions, brain metastases, ovarian cancer, central nervous system relapse, review, 2793
- Brain metastases, ovarian cancer, central nervous system relapse, brain lesions, review, 2793
- Brain metastasis, high-dose interleukin-2, metastatic melanoma, retrospective study, 4189
- BRCA-1* mutation, Laryngeal cancer, 2703
- BRCA1, breast cancer 1, colorectal cancer, aneuploidy, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Breast cancer 1, BRCA1, colorectal cancer, aneuploidy, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Breast cancer cell, tumor cell intravasation, transendothelial migration, apoptosis, anoikis, basement membrane degradation, 2347
- Breast cancer chemotherapy, oxaliplatin, capecitabine, 2851
- Breast cancer, 2-methoxyestradiol, estrogen, sulfamate, ovarian cancer, prostate cancer, 3751

- Breast cancer, 4T1, TGF- β , small molecule TGF β RI/ALK5 kinase inhibitor, SM16, 2099
- Breast cancer, adjuvant chemotherapy, feasibility, adriamycin, epirubicin, paclitaxel, 1515
- Breast cancer, all-*trans* retinoic acid, tyrosine phosphorylation, *c-ERBB2/neu*, proliferation, 2899
- Breast cancer, anemia, side-effects, tumor biology, pre-operative chemotherapy, epirubicin, paclitaxel, 2675
- Breast cancer, anthracycline, cyclophosphamide, anti-emesis, 5-HT3 receptor antagonist, repeated treatment, constipation, 1721
- Breast cancer, ATF2, p-ATF2, prognosis, immunohistochemistry, Western blot, ERK-1/2, AP-1, MMP-9, 183
- Breast cancer, bone marrow, stem cells, nude mice, GFP, 443
- Breast cancer, bone tumor, radiofrequency ablation, bone cement, metastases, 2787
- Breast cancer, breast disease, psychosocial risk scale, 4765
- Breast cancer, cancer stem cell, Hedgehog signaling, 2147
- Breast cancer, CD4, CD8, tumor-infiltrating lymphocytes, prognostic factors, 2445
- Breast cancer, CDK10, tamoxifen, DNA methylation, cyclin-dependent kinase, 3939
- Breast cancer, circulating tumor cells, 4185
- Breast cancer, cyclooxygenase-2, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, prostaglandin metabolism, 3619
- Breast cancer, ductal *in situ* carcinoma, lymph node, sentinel node biopsy, 1499
- Breast cancer, *EGFR*, HER2, VEGF, surgery, 5111
- Breast cancer, epigenetics, DNA methylation, chemotherapy, 3207
- Breast cancer, ER α , ER β , SERM, aromatase inhibitor, 2167
- Breast cancer, estrogen receptor-negative, Hedgehog signaling pathway, invasion, 871
- Breast cancer, estrogen, postmenopausal, aromatase, 17 beta HSD type 1, Steroid sulphatase, carcinogenesis, review, 1095
- Breast cancer, *Tip60*, polymorphism, carcinogenesis, 3897
- Breast cancer, gamma probe, lymphoscintigraphy, methylene blue dye, sentinel lymph node, 4119
- Breast cancer, gastric metastasis, immunohistochemistry, palliative surgery, hormone therapy, chemotherapy, 4759
- Breast cancer, HER2/neu ECD, trastuzumab, kinetics, tumor marker, 1703
- Breast cancer, homocysteinemia, colorectal cancer, inflammation, 4131
- Breast cancer, hormone receptors, discordance, Her-2/neu, metastases, 1557
- Breast cancer, *hTERT*, circulating DNA, real-time PCR, tumor marker, 2845
- Breast cancer, IGFBP-3, IGF-1, apoptosis, 3785
- Breast cancer, IGFBP-3, tissue microarray, 1131
- Breast cancer, image analysis, immunohistochemistry, 4995
- Breast cancer, Ku80, polymorphism, carcinogenesis, 5251
- Breast cancer, leptomeningeal disease, neoplastic meningitis, chemotherapy, temozolomide, DepoCyte[®], liposomal Ara-C, 5191
- Breast cancer, MDA-MB-231, fibroblast growth factor receptor, Akt, Chfr, PLC γ , *Xenopus* oocyte, 4965
- Breast cancer, microarray, estrogen response gene, 3971
- Breast cancer, neoadjuvant chemotherapy, paclitaxel, pathological response, trastuzumab, 517
- Breast cancer, persistent disseminated tumor cells, trastuzumab, targeted therapy, HER2 status, 4019
- Breast cancer, postmenopausal women, overweight, obese, Statins, epidemiology, 5143
- Breast cancer, renin-angiotensin system, ovary, steroidogenesis, estradiol, 4633
- Breast cancer, retinoic acid, epigenetic, histone deacetylation, telomerase, *hTERT*, 4959
- Breast cancer, RNF11, Smad4, TGF- β , ubiquitination, signal transduction, 2253
- Breast cancer, sentinel lymph node, frozen sections, micrometastasis, immunohistochemistry, 4711
- Breast cancer, sentinel node biopsy, scintimammography, axillary ultrasonography, fine-needle aspiration cytology, FNA cytology, 491
- Breast cancer, skin recurrence, inflammatory recurrence, radiotherapy, mastectomy, overall survival, recurrence-free survival, 1697
- Breast cancer, thyroid cancer, second cancer, 1607
- Breast cancer, tumor-antigen peptides, radiolabeling, tumor-cell binding, biodistribution, 1399
- Breast cancer, vitamin D analogs, estrogen receptor, BT-474 cells, vitamin D receptor stability, 3555
- Breast cancer, vitamin D, 1 α OHase, 155
- Breast cancer, X-ray mammography, ^{99m}Tc-Sestamibi scintimammography, microcalcifications, negative predictive value, ROC curve analysis, 4251
- Breast cancer, Zeranol, leptin, (-)-gossypol, 4621
- Breast cancer, Zeranol, pre-adipocytes, body weight gain, doubling time, cyclin D1, *p53*, 5045
- Breast carcinoma, recurrence, 10 years, 3445
- Breast disease, breast cancer, psychosocial risk scale, 4765
- Breast neoplasms, bone neoplasms, diphosphonates, hyperparathyroidism, secondary, calcium, 2707
- Breast reconstruction, venous coupler, free flap, 2827
- Breast surgery, multiple fibroadenoma, mammoplasty, 2823
- Breast tissue, vitamin D₃, 24-hydroxylase, splice variants, MCF-7, MCF-10, 3641
- Breast, cancer, ductal, molecular classification, survival, 4727
- Breast, carcinoma, clusterin, relapse-free survival, 3909
- Breast, hyperplasia, dysplasia, infrared temperature, skin, 4697

- Brefeldin A, M6P/IGF-II receptor, M6P/IGF-II receptor modulation, M6P, forskolin, melanoma cells, immunoluminescence, 1383
- Brine shrimp larvae, anticancer activity, MCF-7 cells, selectivity index, 2993
- 3-Bromopyruvate, cancer cell death, GAPDH, glycolysis, Hep3B, HepG2, SK-Hep1, 4909
- Bromotetrandrine, multidrug resistance, xenograft, nude mice, drug accumulation, 4597
- Bronchial epithelial cells, promoter methylation, non-small cell lung cancer, methylation-specific PCR, clonal field expansion, endobronchial brush, 363
- Brushing, biomarker, hnRNP A2/B1, immunoblotting, lung cancer, 1373
- BSm1, vitamin D receptor, gene polymorphisms, cancer, Fok1, Taq1, Apa1, Cdx2, poly(A), Bgl1, 3511
- BT-474 cells, breast cancer, vitamin D analogs, estrogen receptor, vitamin D receptor stability, 3555
- BUB1B, budding uninhibited by benzimidazoles 1, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Budding uninhibited by benzimidazoles 1, BUB1B, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Buthionine-SR-sulfoximine, WiDr colon cancer cells, growth factors, 5-fluorouracil, glutathione modulation, L-2-oxothiazolidine-4-carboxylate, 3957
- C/EBP α , estrogen, hypoxia, T-47D cells, 1227
- C4-2, androgen-independent prostate cancer, α -methylacyl-CoA racemase, siRNA, LNCaP, 2497
- CA-125, ovarian cancer, progression, relapse, survival, 2817
- CA15-3, correlation coefficient, tumor marker, KL-6, BCA225, 4239
- CA19-9, preoperative, recurrence, peritoneal recurrence, 4303
- Cachexia, decreased levels, ghrelin, plasma, 3949
- Cadherin, colorectal cancer, catenin, fibronectin, metalloprotease-1, signet-ring cell, 4417
- Calcemic, vitamin D analogs, CD-ring, antiproliferative, 3579
- Calcitriol, non-steroids, prostate cancer, 3605
- Calcium intake, vitamin D insufficiency, dairy calcium, calcium-sensing receptor, extrarenal 25-hydroxyvitamin D-1 α -hydroxylase, 1,25-dihydroxyvitamin D₃, 25-hydroxyvitamin D-24-hydroxylase, review, 3687
- Calcium, breast neoplasms, bone neoplasms, diphosphonates, hyperparathyroidism, secondary, 2707
- Calcium, capsaicin, reactive oxygen species, mitochondrial membrane potential, apoptosis, human HepG2 cells, 165
- Calcium, extrarenal vitamin D synthesis, 1,25-dihydroxyvitamin D₃, colon tumor prevention, vitamin D hydroxylases, estrogen, epigenetic regulation, review, 3705
- Calcium-sensing receptor, vitamin D insufficiency, calcium intake, dairy calcium, extrarenal 25-hydroxyvitamin D-1 α -hydroxylase, 1,25-dihydroxyvitamin D₃, 25-hydroxyvitamin D-24-hydroxylase, review, 3687
- Calicheamicin, gemtuzumab, isobologram, CD33, leukemia, 4589
- Calu-6, arsenic trioxide, apoptosis, MAPK, ROS, GSH, 3837
- Cancer angiogenesis, cancer etiopathogenesis, pH and cancer, multiple drug resistance, MDR, proton transport in cancer, cancer strategy and treatment, review, 2127
- Cancer behavior, ovarian cancer, claudin-5, 5185
- Cancer biomarkers, SELDI-TOF MS, laser microdissection, ovarian cancer, proteomics, 1039
- Cancer cell death, 3-Bromopyruvate, GAPDH, glycolysis, Hep3B, HepG2, SK-Hep1, 4909
- Cancer cell lines, flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, UV, fluorescence spectroscopy, 2273
- Cancer cell lines, flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, UV, fluorescence spectroscopy, structure-activity relationship, 2285
- Cancer cell xenografts, c-FLIP, apoptosis, immunohistochemistry, 3883
- Cancer etiopathogenesis, pH and cancer, multiple drug resistance, MDR, proton transport in cancer, cancer angiogenesis, cancer strategy and treatment, review, 2127
- Cancer immunotherapy, chemotherapy, radiotherapy, surgery, T-regulatory lymphocyte, 1847
- Cancer metastasis, hormone refractory prostate cancer, cancer treatment, TBS-101, natural botanical components, 3917
- Cancer patients, palliative care, fatigue, anaemia, 2569
- Cancer prevention, bile acids, colon cancer, UDCA, UDCA-Glu, 4971
- Cancer prevention, vitamin D analogs, therapy, 3469
- Cancer prognosis, vitamin D, sun bed, skin cancer, review, 3495
- Cancer stem cell, breast cancer, Hedgehog signaling, 2147
- Cancer stem cells, HER2, helper antigen, Ii-key, T-cell, individualized cancer vaccines, 41
- Cancer strategy and treatment, cancer etiopathogenesis, pH and cancer, multiple drug resistance, MDR, proton transport in cancer, cancer angiogenesis, review, 2127
- Cancer susceptibility, gene polymorphisms, Southern Italian region, tumorigenesis, 1709

- Cancer susceptibility, head and neck cancer, microsomal epoxide hydrolase, glutathione-S-transferase, UDP-glucuronosyltransferase, polymorphisms, smoking, review, 753
- Cancer therapy, nanospheres, PLGA, curcumin, S/O/W emulsion, confocal microscopy, 3867
- Cancer therapy, nanotargeted radiopharmaceuticals, nanocarriers, tumor imaging, review, 4107
- Cancer therapy, *Viscum album*, European mistletoe, angiogenesis, matrigel assay, endothelial cells, apoptosis, 2945
- Cancer treatment, hormone refractory prostate cancer, cancer metastasis, TBS-101, natural botanical components, 3917
- Cancer vaccine, Wilms' tumor 1, WT1, peptide, immunotherapy, 4779
- Cancer vaccines, HER-2, helper effect, AE-37, AE-47, p776, F7, perforin, E75, high-affinity CD8⁺ cells, 2427
- Cancer, 1,25(OH)₂D₃, analog, microarray, review, 3471
- Cancer, aerosols, air pollution, polycyclic aromatic hydrocarbons, ultraviolet-B, vitamin D, 3537
- Cancer, alkylating agents, glioma, O⁶-methylguanine, O⁶-MG, O⁶-methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, promoter methylation, temozolomide, TMZ, review, 3759
- Cancer, bacteriophage T4 preparation, BP T4, melanoma, anticancer activity, B16 melanoma, 2361
- Cancer, curcumin, liposomal, dose finding, pancreatic, 1895
- Cancer, ductal, breast, molecular classification, survival, 4727
- Cancer, endometrium, growth, progesterone, mifepristone, cell cycle, apoptosis, Ishikawa cells, 1053
- Cancer, gene therapy, transcriptional targeting, Q5 promoter, allograft rejection, cyclophosphamide, 1015
- Cancer, haperforin, chemotherapy, apoptosis, cell cycle, cytoskeleton, 1963
- Cancer, HB-EGF, amphiregulin, targeted therapy, review, 4879
- Cancer, HB-EGF, amphiregulin, targeted therapy, review, 823
- Cancer, hypercalcemia, malignancy, PTHrP, RANKL, bisphosphonates, review, 1551
- Cancer, invasion, metastasis, molecular chaperones, heat-shock protein 90, geldanamycin, molecularly targeted therapeutics, review, 797
- Cancer, metastasis, malignant potential, cell-based assay, anoikis, matrix metalloproteinase, MMP, 2541
- Cancer, pharmacology, growth, progestins, antiprogestins, Ishikawa cells, 1047
- Cancer, primary culture, *EGFR*, erlotinib, chemoresponse, chemotherapy sensitivity and resistance assay, CSRA, ChemoFx[®], 1993
- Cancer, prostate, biomarkers, PSA, prognosis, review, 3289
- Cancer, radiotherapy, palliative radiation treatment, travel distance, 2641
- Cancer, Stat, lymphocytes, immunosuppression, 2051
- Cancer, therapy, nephrotoxicity, ROS, mitochondria, 2295
- Cancer, vitamin C, ascorbic acid, ascorbate, plasma concentration, intravenous, cytotoxicity, complementary and alternative medicine, review, 809
- Cancer, vitamin D receptor, gene polymorphisms, Fok1, BSm1, Taq1, Apa1, Cdx2, poly(A), Bgl1, 3511
- Canine cutaneous histiocytoma, E-cadherin, immunohistochemistry, tumour regression, 2713
- Cap43, esophageal cancer, independent prognostic factor, 965
- Capecitabine, bevacizumab, irinotecan, colorectal cancer, HT29 xenografts, 91
- Capecitabine, breast cancer chemotherapy, oxaliplatin, 2851
- Capecitabine, gemcitabine, intra-arterial chemotherapy, phase I study, 1547
- Capecitabine, intensity-modulated radiation therapy, head and neck cancer, 2869
- Capecitabine, Phase I/II, hepatocellular carcinoma, HCC, adjuvant therapy, PHY906, 4083
- Capecitabine, phase II study, oral vinorelbine, oral chemotherapy, metastatic breast cancer, 667
- Capecitabine, thymidine phosphorylase, dihydropyrimidine dehydrogenase, cell proliferation, apoptosis, 2525
- Capsaicin, calcium, reactive oxygen species, mitochondrial membrane potential, apoptosis, human HepG2 cells, 165
- Capsaicin, resveratrol, nitric oxide, p53, HCT116 cells, chemoprevention, 3733
- Carbon ion beam therapy, MET PET, Choroidal melanoma, 1507
- Carbon tetrachloride, host-defensive function, innate, priming, triggering, lipid, 837
- Carbon-ion radiotherapy, histone deacetylase inhibitor, esophageal cancer, squamous cell carcinoma, 4433
- Carboplatin, adjuvant chemotherapy, operable non-small cell lung cancer, pemetrexed, 4297
- Carboplatin, advanced ovarian cancer, late relapse, pegylated liposomal doxorubicin, platinum-sensitive, 4195
- Carboplatin, aerodigestive tract, external beam, radioiodine, radiosensitizer, radiotherapy, paclitaxel, taxane, 4665
- Carboplatin, interleukin-2, melanoma, metastatic, second-line treatment, vinorelbine, 1755
- Carcinoembryonic antigen, selenium, trace elements, gastric cancer, 3465
- Carcinogenesis, breast cancer, estrogen, postmenopausal, aromatase, 17 beta HSD type 1, Steroid sulphatase, review, 1095
- Carcinogenesis, colorectal carcinoma, immunohistochemistry, MET, prognosis, survival, 4807
- Carcinogenesis, *ERCC6*, polymorphism, bladder cancer, 5121
- Carcinogenesis, *Tip60*, polymorphism, breast cancer, 3897
- Carcinogenesis, *Exo1*, polymorphism, lung cancer, 725

- Carcinogenesis, intestine, retinol, vitamin D, *Min/+* mouse, 4353
- Carcinogenesis, Ku80, polymorphism, bladder cancer, 1275
- Carcinogenesis, Ku80, polymorphism, breast cancer, 5251
- Carcinogenesis, Ku80, polymorphism, colorectal cancer, 2239
- Carcinogenesis, ulcerative colitis, bisphosphonate, thymidine kinase mRNA, 4615
- Carcinoid of terminal ileum, human neuroendocrine tumor, NET, continuous cell lines, P-STC primary tumor, L-STC lymph node metastasis, H-STC hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Carcinoma, biliary tract, chemotherapy, surgical resection, 1783
- Carcinoma, breast, clusterin, relapse-free survival, 3909
- Carcinoma, prostate, GnRHR, androgen receptor, 681
- Cardiac hormones, prostate cancer, atrial natriuretic peptide, long-acting atrial natriuretic peptide, Ras, 1889
- Cardiac hormones, prostate cancer, vessel dilator, kaliuretic peptide, Ras, 971
- Cardiopulmonary toxicity, Hodgkin's disease, chemotherapy, radiotherapy, 777
- Cardiotoxicity, Adriamycin, anthracycline, exercise, 4401
- Cardiovascular, sunitinib, renal cell carcinoma, tyrosine kinase inhibitor, 1627
- Carrier, RHCC, cisplatin, nano, 11
- Case-control studies, cohort studies, colon cancer, prostate cancer, ecological studies, randomized controlled trials, review, 3597
- Caspase 3, cell cycle regulatory proteins, apoptosis, staurosporine, leukemic cells, 2893
- Caspase, (-)-epigallocatechin gallate, EGCG, apoptosis, human adrenal cancer NCI-H295 cells, 1435
- Caspase, aloe-emodin, apoptosis, human tongue cancer SCC-4 cells, 4503
- Caspase, berberine, apoptosis, SCC-4 cells, AIF, EndoG, 4063
- Caspase, naphtho[2,3-*b*]furan-4,9-diones, apoptosis, autophagy, DNA fragmentation, QSAR, 455
- Caspase-14, salivary gland cancer, vascularization, gene therapy, 3811
- Caspase-2, radiation, apoptosis, caspase-8, caspase-9, 4361
- Caspase-3 activation, cytostatic resistance, paclitaxel, Akt activation, Bad phosphorylation, cytochrome *c* release, apoptosis, 159
- Caspase-3, grape seed procyanidin, colorectal carcinoma, apoptosis, 283
- Caspase-3, green tea polyphenols, apoptosis, Bcl-2, 1417
- Caspase-3, rhein, apoptosis, ROS, mitochondria membrane potential, cytochrome *c*, 309
- Caspase-3, sanguinarine, TRAIL, apoptosis, Akt, 4457
- Caspase-8, radiation, apoptosis, caspase-2, caspase-9, 4361
- Caspase-9, radiation, apoptosis, caspase-2, caspase-8, 4361
- Caspases, 23-hydroxyursolic acid, pentacyclic triterpenes, growth-inhibition, apoptosis, 995
- Catalase, apoptosis, HOCl signaling pathway, hydrogen peroxide, hypochlorous acid, hydroxyl radical, 4559
- Cataract induction, late renal dysfunction, dose-effect relationship, biologically effective dose, 3305
- Catenin, colorectal cancer, cadherin, fibronectin, metalloprotease-1, signet-ring cell, 4417
- Cathepsin L, NSITC, angiogenesis, ECM, protease, 4473
- Catumaxomab, malignant ascites, ovarian cancer, review, 3353
- Catumaxomab, tumor cells, ovarian cancer, ascites, antibody therapy, 1787
- Cavitation, sonodynamic therapy, normal brain, thermal effect, glioblastoma, 943
- CD10, neurofibroma, malignant peripheral nerve sheath tumors, neurofibromatosis, 3149
- CD117, melanoma, COX-2, HSP90, FNA, 4345
- CD133*, quantitative methylation-specific PCR, colorectal cancer, 2235
- CD14, intestinal macrophage, LPS, homeostasis, IgA, review, 4861
- CD14, intestinal macrophages, endoplasmic reticulum, *Golgi apparatus*, 865
- CD3, CD3 ζ , tumor-infiltrating lymphocytes, TIL, epithelial ovarian carcinoma, EOC, malignant ascites, 4673
- CD33, gemtuzumab, calicheamicin, isobologram, leukemia, 4589
- CD3 ζ , CD3, tumor-infiltrating lymphocytes, TIL, epithelial ovarian carcinoma, EOC, malignant ascites, 4673
- CD4, CD8, tumor-infiltrating lymphocytes, breast cancer, prognostic factors, 2445
- CD8, CD4, tumor-infiltrating lymphocytes, breast cancer, prognostic factors, 2445
- CD83, dendritic cells, Thymax, Th1, interferon-gamma, 4367
- Cdc2, gnidimacrin, PKC β II, G₂-phase arrest, p21(WAF1/Cip1), E₂F-4, 1349
- CDDP, S-1, metastatic gastric cancer, phase I study, combination chemotherapy, 1727
- CDH3*, quantitative methylation-specific PCR, colorectal cancer, 2215
- CDH3*, quantitative methylation-specific PCR, gastric carcinoma, 3945
- Cdk1, spontaneous regression, cell loss, Cdk4, clonogenic assays, "starbursts", 1933
- CDK10, breast cancer, tamoxifen, DNA methylation, cyclin-dependent kinase, 3939
- Cdk4, spontaneous regression, cell loss, Cdk1, clonogenic assays, "starbursts", 1933

- CDKN2A* gene, chagas disease, megaesophagus, gene mutation, single nucleotide polymorphism, SNP, *FHIT* gene, *TP53* gene, DNA sequencing, 1243
- CDKs, apoptosis, cell proliferation, NF- κ B, toad skin extract, curcumin, colon cancer, 395
- CD-ring, vitamin D analogs, antiproliferative, calcemic, 3579
- CDX2, BFT, homeobox genes, gene expression, NSCLC, 1281
- CDX2, cutaneous metastases, extramammary Paget's disease, skin, immunohistochemistry, 5033
- Cdx2, vitamin D receptor, gene polymorphisms, cancer, Fok1, BSm1, Taq1, Apa1, poly(A), Bgl1, 3511
- CEA, colorectal cancer, macrophage, intracellular, flow cytometrical, tumor marker, 3245
- CEA, lung cancer, diagnosis, prognosis, ProGRP, NSE, CYFRA 21-1, 4827
- CEA, TIMP-1, lead-time, immunoassay, biological marker, postoperative follow-up, 75
- CEACAM-1, cell adhesion, lymphnode, hematogenous, metastasis, prognostic significance, non-small cell lung cancer, 249
- Cediranib, angiogenesis, biomarkers, murine renal cell carcinoma, VEGF, 5065
- Celecoxib, COX-2 inhibitors, prostate cancer, randomized controlled trial, 1483
- Celecoxib, cyclooxygenase-2, COX-2, bladder cancer, chemoprevention, 3769
- Cell adhesion, CEACAM-1, lymphnode, hematogenous, metastasis, prognostic significance, non-small cell lung cancer, 249
- Cell aggregation, galectins, oligosaccharide ligand, apoptosis, 403
- Cell cycle arrest, alkylator, DNA damage, prodrug, bone-marrow sparing, drug resistance, 3845
- Cell cycle arrest, circadian rhythm, clock genes, mouse *Period2* gene, tumor suppression, apoptosis, synergic effect, cisplatin, 1201
- Cell cycle arrest, curcumin, antiproliferative, apoptosis, 5039
- Cell cycle regulators, malignant peripheral nerve sheath tumor, MPNST, recurrence, metastasis, molecular characterization, Nm-23H1, 1255
- Cell cycle regulatory proteins, apoptosis, caspase 3, staurosporine, leukemic cells, 2893
- Cell cycle, 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone, estrogen positive/negative breast cancer cell lines, cytotoxicity, apoptosis, 191
- Cell cycle, AhR, HL-60, curcumin, apoptosis, AML, 4657
- Cell cycle, cancer, endometrium, growth, progesterone, mifepristone, apoptosis, Ishikawa cells, 1053
- Cell cycle, cancer, haperforin, chemotherapy, apoptosis, cytoskeleton, 1963
- Cell cycle, irinotecan, CPT-11, 5-fluorouracil, sequence-dependency, thymidylate synthase, apoptosis, 2083
- Cell cycle, methylalntrexone, 5-fluorouracil, SW-480 colorectal cancer cell, MCF-7 breast cancer cell, non-small cell lung cancer cell, NSCLC, anti-proliferation, cell growth, 2927
- Cell death, gefitinib, cytotoxicity, hormesis, oral squamous cell carcinoma, 5023
- Cell death, J774.1, nutritional starvation, serine, glutamine, non-apoptosis, 5083
- Cell death, RAW264.7, nutritional starvation, serine, glutamine, glucose, 343
- Cell death, ROS, ER stress, anthraquinone, 327
- Cell death, tumour cell, nutritional deprivation, energy deprivation, cell survival, digital holographic microscopy, dynamic phase difference, 2339
- Cell differentiation, ribavirin, gene expression profiling, K562, leukemia, apoptosis, inositide-5'-monophosphate dehydrogenase, IMPDH, 1971
- Cell fusion, Ewing tumours, HAT selection, gene expression, immunotherapy, 4489
- Cell growth, immunohistochemistry, RNAi knock-down, asparaginase, 951
- Cell growth, methylalntrexone, 5-fluorouracil, SW-480 colorectal cancer cell, MCF-7 breast cancer cell, non-small cell lung cancer cell, NSCLC, anti-proliferation, cell cycle, 2927
- Cell loss, spontaneous regression, Cdk1, Cdk4, clonogenic assays, "starbursts", 1933
- Cell mediated immunity, ovarian cancer, ascites, cytokines, chemokines, 2875
- Cell proliferation, apoptosis, CDKs, NF- κ B, toad skin extract, curcumin, colon cancer, 395
- Cell proliferation, capecitabine, thymidine phosphorylase, dihydropyrimidine dehydrogenase, apoptosis, 2525
- Cell proliferation, connexin, gap junction protein, head-and-neck cancer, 1981
- Cell proliferation, WT1, immunohistochemistry, endometrial cancer, clinicopathological factors, PCNA, 4887
- Cell regulatory proteins, bladder cancer, *p53*, pRb, prognosis, 4201
- Cell signaling pathway, GSK-3 β , prostate cancer, apoptosis, proliferation, prognosis, 2077
- Cell signaling, tissue transglutaminase, chemoresistance, metastasis, focal adhesion kinase, NF- κ B, integrin, review, 1909
- Cell survival, tumour cell, nutritional deprivation, energy deprivation, cell death, digital holographic microscopy, dynamic phase difference, 2339
- Cell-based assay, cancer, metastasis, malignant potential, anoikis, matrix metalloproteinase, MMP, 2541
- Central adiposity, ovarian cancer, risk factors, 5229
- Central nervous system relapse, brain metastases, ovarian cancer, brain lesions, review, 2793

- Central nervous system, ultrasound, echo-contrast agent, microbubbles, malignant glioma, 235
- CENU, methionine-free diet, melanoma, glioma, nitrosourea, 5235
- Cepharanthine, S-1, oral squamous cell carcinoma, apoptosis, TUNEL, combination therapy, xenografts, nude mice, 1263
- C-ERBB2/neu*, all-*trans* retinoic acid, breast cancer, tyrosine phosphorylation, proliferation, 2899
- Cerebellum, phosphoproteome, UPLC, IMAC, oxygen-18, 4949
- Cerebral hemorrhage, anticoagulant, glioblastoma, pulmonary embolism, venous glioblastoma, venous thromboembolism, 4309
- Cervical cancer, squamous cell carcinoma, adenocarcinoma, tumor markers, 2577
- Cervical carcinoma, radiotherapy, chemotherapy, brachytherapy, 4205
- Cervical carcinoma, soluble VEGF members, soluble VEGF receptors, disease progression, tumor markers, vascular endothelial growth factor, 641
- Cervical cytology, uterine cervical neoplasm, TIP47, tumor marker, neoplasm metastasis, 717
- C-FLIP, cancer cell xenografts, apoptosis, immunohistochemistry, 3883
- Chagas disease, megaesophagus, gene mutation, single nucleotide polymorphism, SNP, *FHIT* gene, *TP53* gene, *CDKN2A* gene, DNA sequencing, 1243
- ChemoFx[®], primary culture, cancer, *EGFR*, erlotinib, chemoresponse, chemotherapy sensitivity and resistance assay, CSRA, 1993
- Chemokines, ovarian cancer, ascites, cytokines, cell mediated immunity, 2875
- Chemoprevention, angiogenesis, black tea polyphenols, hepatocellular carcinoma, histone deacetylation, invasion, 2301
- Chemoprevention, capsaicin, resveratrol, nitric oxide, *p53*, HCT116 cells, 3733
- Chemoprevention, cyclooxygenase-2, COX-2, celecoxib, bladder cancer, 3769
- Chemoprevention, TAC-101, colon carcinogenesis, ACF, 2059
- Chemoprevention, α -mangostin, panaxanthone, antitumor, mammary cancer, 2485
- Chemoradiotherapy, laryngeal carcinoma, radiotherapy, larynx preservation, 661
- Chemoresistance, microarray, esophageal cancer, 1163
- Chemoresistance, pancreatic cancer, nafamostat mesilate, gemcitabine, 3173
- Chemoresistance, tissue transglutaminase, cell signaling, metastasis, focal adhesion kinase, NF- κ B, integrin, review, 1909
- Chemoresponse, primary culture, cancer, *EGFR*, erlotinib, chemotherapy sensitivity and resistance assay, CSRA, ChemoFx[®], 1993
- Chemotherapy sensitivity and resistance assay, CSRA, primary culture, cancer, *EGFR*, erlotinib, chemoresponse, ChemoFx[®], 1993
- Chemotherapy, antioxidants, combination, colon cancer, orthotopic model, 2421
- Chemotherapy, breast cancer, gastric metastasis, immunohistochemistry, palliative surgery, hormone therapy, 4759
- Chemotherapy, breast cancer, leptomeningeal disease, neoplastic meningitis, temozolomide, DepoCyte[®], liposomal Ara-C, 5191
- Chemotherapy, cancer immunotherapy, radiotherapy, surgery, T-regulatory lymphocyte, 1847
- Chemotherapy, cancer, haperforin, apoptosis, cell cycle, cytoskeleton, 1963
- Chemotherapy, carcinoma, biliary tract, surgical resection, 1783
- Chemotherapy, cardiopulmonary toxicity, Hodgkin's disease, radiotherapy, 777
- Chemotherapy, cervical carcinoma, radiotherapy, brachytherapy, 4205
- Chemotherapy, colorectal adenocarcinoma, response, molecular changes, tumorigenesis, 3115
- Chemotherapy, colorectal cancer, microsatellite instability, predictive factor, survival, 1615
- Chemotherapy, docetaxel, S-1, gastric cancer, 2775
- Chemotherapy, docetaxel, vinorelbine, estramustine, zoledronic acid, androgen-resistant prostate cancer, 769
- Chemotherapy, *DYRK2*, *p53*, lung cancer, predictive marker, 2753
- Chemotherapy, epigenetics, breast cancer, DNA methylation, 3207
- Chemotherapy, epoetin- α , hemoglobin, quality of life, solid tumors, 693
- Chemotherapy, esophageal cancer, radiotherapy, gastrolymphatic fistula, 525
- Chemotherapy, glioblastoma, radiotherapy, temozolomide, targeted therapy, review, 5171
- Chemotherapy, head and neck cancer, radiation therapy, docetaxel, *ERCC1*, 529
- Chemotherapy, high-grade glioma, temozolomide, tumor necrosis factor-alpha, 911
- Chemotherapy, hyperglycemia, radiation, head and neck cancer, 4683
- Chemotherapy, mesothelioma, nude mice, glycolysis, energetic metabolism, 1443
- Chemotherapy, neuroblastoma, epidermal growth factor receptor, gefitinib, retinoic acid, 1327
- Chemotherapy, osteosarcoma, marriage, fertility, surgery, 763
- Chemotherapy, ovarian cancer, Akt, ERK, prognosis, 4639
- Chemotherapy, pilomyxoid astrocytoma, pilocytic astrocytoma, leptomeningeal dissemination, 919

- Chemotherapy, plasma, VEGF, non-small cell lung cancer, paclitaxel, 2635
- Chemotherapy, recurrent ovarian cancer, treatment-free interval, hormonal therapy, 2831
- Chemotherapy, small cell carcinoma, treatment, outcome, radiation therapy, 3411
- Chemotherapy, temozolomide, cisplatin, malignant, gliomas, 4275
- Chemotherapy-induced neuropathy, amitriptyline, antidepressants, neoplasms, neurotoxicity, prevention, 2601
- Chernobyl accident, thyroidectomy, papillary thyroid cancer, papillary microcarcinomas, 5163
- Chfr, MDA-MB-231, fibroblast growth factor receptor, Akt, PLC γ , breast cancer, *Xenopus* oocyte, 4965
- Children, acute lymphoblastic leukemia, acute myeloid leukemia, adults, drug resistance, individual tumor response testing, 1643
- Chitosan nanoparticles, hepatocellular carcinoma, tumor growth, necrosis, angiogenesis, *VEGFR2*, 5103
- 5-Chloro-2,4-dihydroxypyridine, dihydropyrimidine dehydrogenase, 5-fluorouracil, bladder urothelial carcinoma, orotate phosphoribosyl transferase, 1001
- Cholangiocarcinogenesis, cholangiocarcinoma, gene, molecular, mechanism, Klatskin tumor, review, 1151
- Cholangiocarcinoma, cholangiocarcinogenesis, gene, molecular, mechanism, Klatskin tumor, review, 1151
- Cholangiocarcinoma, p27^{kip1}, Jab1, ubiquitin-proteasome system, adenovirus, 2015
- Cholangiocarcinoma, ZD1839, p27^{kip1}, Jab1, radiation, 1169
- Chondroid differentiation, FISH, GIST, gastrointestinal bleeding, 2761
- Chondrosarcoma, alendronate, antiproliferative activity, apoptosis, 1879
- Chordoma, mTOR, PI3K, PI-103, 1867
- Choroidal melanoma, MET PET, Carbon ion beam therapy, 1507
- Chromosomal aberrations, radio frequency, microwave radiation, pulsed-wave, continuous-wave, promotion, 2885
- Chromosomal aberrations, radio frequency, pulsed waves, continuous waves, promotion, 4323
- Chromosome 9 numerical abnormalities, lung cancer, non-small cell lung cancer, genetic changes, p16^{CDKN2A} gene deletion, FISH technique, 4483
- Chromosome instability, *Rb*, *Trp53*, skin cancer, inflammation, NF κ B, mitotic checkpoint, 3035
- Chronic disease, ICC, hepatitis C, 3239
- Chronic lymphocytic leukaemia, prognostic factors, B-cell receptor, review, 605
- Chronic lymphocytic leukemia, ER stress, XBP1 splicing, apoptosis, proteasome, 3797
- Cigarette, *APE1*, BER, lung cancer, polymorphism, RFLP, 2417
- Circadian rhythm, clock genes, mouse *Period2* gene, tumor suppression, apoptosis, cell cycle arrest, synergic effect, cisplatin, 1201
- Circulating DNA, *hTERT*, breast cancer, real-time PCR, tumor marker, 2845
- Circulating tumor cells, breast cancer, 4185
- Circulating tumor cells, solid tumor, metastatic, localized, stages, 4839
- Cisplatin sensitivity, *EGFR*, HNSCC, proliferation, 1181
- Cisplatin, 14-3-3 σ , p53, p21, resistance, senescence, 2009
- Cisplatin, biliary tract carcinoma, pharmacogenomic, DNA repair proteins, polymorphisms, 1835
- Cisplatin, circadian rhythm, clock genes, mouse *Period2* gene, tumor suppression, apoptosis, cell cycle arrest, synergic effect, 1201
- Cisplatin, clinical trial, docetaxel, ovarian cancer, progression-free survival, 561
- Cisplatin, docetaxel, ifosfamide, head and neck cancer, 5137
- Cisplatin, gastric cancer, neoadjuvant chemotherapy, docetaxel, 5-fluorouracil, DFP, 4211
- Cisplatin, mesothelioma, glycolysis, energetic metabolism, MSTO-211H, 1249
- Cisplatin, methionine, CNS tumours, cytotoxicity, methotrexate, temozolomide, 3103
- Cisplatin, ovarian cancer, salvage treatment, ifosfamide, gemcitabine, 2681
- Cisplatin, RHCC, nano, carrier, 11
- Cisplatin, S-1, advanced gastric cancer, preoperative chemotherapy, neoadjuvant chemotherapy, 4689
- Cisplatin, temozolomide, chemotherapy, malignant, gliomas, 4275
- Cisplatin, vinorelbine orale, pharmacokinetics, phase I, drug-drug interaction, 553
- Claudin, colorectal cancer, clinicopathological factor, marker, 851
- Claudin-5, ovarian cancer, cancer behavior, 5185
- Clear cell adenocarcinoma, ovarian cancer, endometriosis, parietal metastasis, 1591
- Clinical stage, hepatocellular carcinoma, fibrinogen gamma, fibrinogen, tumor thrombosis, 2531
- Clinical trial, cisplatin, docetaxel, ovarian cancer, progression-free survival, 561
- Clinical trial, gene therapy, hormone refractory prostate cancer, adenovirus vector, 1533
- Clinical trials, lentinan, meta-analysis, advanced gastric cancer, 2739
- Clinicopathological factor, colorectal cancer, claudin, marker, 851
- Clinicopathological factors, WT1, immunohistochemistry, endometrial cancer, PCNA, cell proliferation, 4887
- Clinicopathological factors, WT1, immunohistochemistry, endometrial cancer, prognosis, 1691

- Clinico-pathological features, colorectal cancer, perforation, Hartmann's procedure, 1681
- Clinicopathological features, nuclear morphometry, survival, Libyan female breast cancer, 1771
- Clock genes, circadian rhythm, mouse Period2 gene, tumor suppression, apoptosis, cell cycle arrest, synergic effect, cisplatin, 1201
- Clonal field expansion, promoter methylation, non-small cell lung cancer, methylation-specific PCR, bronchial epithelial cells, endobronchial brush, 363
- Clonal tetraploidy, human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, P-ST5 primary tumor, L-ST5 lymph node metastasis, H-ST5 hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, array CGH, 1951
- Clonogenic assays, spontaneous regression, cell loss, Cdk1, Cdk4, "starbursts", 1933
- Clusterin, breast, carcinoma, relapse-free survival, 3909
- CNS tumours, methionine, cytotoxicity, methotrexate, cisplatin, temozolomide, 3103
- Coenzyme Q10, antioxidants, quercetin, nasal mucosa, Comet assay, mini organ cultures, 33
- Cofactor, endometrial hyperplasia, endometrial carcinoma, NCoR, progesterone, 1023
- Cohort studies, case-control studies, colon cancer, prostate cancer, ecological studies, randomized controlled trials, review, 3597
- 3-D Collagen, osteoprotegerin, MG-63 osteoblasts, PC-3 cells, 4013
- Collision tumor, tumor stem cell, non-small cell lung cancer, adenocarcinoma of the colon, 1495
- Colon cancer cells, apoptosis, boswellic acids, PI3 kinase, Akt, LY294002, wortmannin, 2987
- Colon cancer, antioxidants, chemotherapy, combination, orthotopic model, 2421
- Colon cancer, apoptosis, cell proliferation, CDKs, NF- κ B, toad skin extract, curcumin, 395
- Colon cancer, bile acids, UDCA, UDCA-Glu, cancer prevention, 4971
- Colon cancer, case-control studies, cohort studies, prostate cancer, ecological studies, randomized controlled trials, review, 3597
- Colon cancer, gastric cancer, ErbB, neuroglycan-C, proliferation, 229
- Colon cancer, inflammation, toll-like receptors, Akt, 2473
- Colon cancer, *p53*, *EGFR*, colorectal cancer, 785
- Colon cancer, paclitaxel, apoptosis, MAPK inhibition, PD98059, 261
- Colon cancer, protein arginine methyltransferase, PRMT1, prognosis, 1361
- Colon cancer, rectal cancer, grading, estrogen, vitamin D, 3721
- Colon carcinogenesis, inflammatory bowel disease, Crohn's disease, epidemiology, ulcerative colitis, colorectal cancer, molecular biology, review, 2727
- Colon carcinogenesis, TAC-101, chemoprevention, ACF, 2059
- Colon tumor prevention, extrarenal vitamin D synthesis, 1,25dihydroxyvitamin D₃, vitamin D hydroxylases, calcium, estrogen, epigenetic regulation, review, 3705
- Colon, *EGFR*, *ERBB2*, *ERBB3*, *ERBB4*, 1489
- Colonic 1,25(OH)₂D₃ concentration, gender-dependent, dietary calcium, apoptosis, vitamin D hydroxylases, 3727
- Colonic carcinoma, neoplastic glands, biological materials, 1745
- Colonoscopic polypectomy, optical biopsy system, hyperplastic polyps, adenomatous polyps, 4737
- Colonoscopy, polyps, size assessment, 1539
- Colorectal adenocarcinoma, chemotherapy, response, molecular changes, tumorigenesis, 3115
- Colorectal cancer, 5-fluorouracil, 5-FU, oxaliplatin, sulindac sulfide, synergism, 435
- Colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Colorectal cancer, beta-1,3-glucan, lentinan, peripheral blood monocytes, quality of life, superfine dispersed lentinan, 2611
- Colorectal cancer, cadherin, catenin, fibronectin, metalloprotease-1, signet-ring cell, 4417
- Colorectal cancer, capecitabine, bevacizumab, irinotecan, HT29 xenografts, 91
- Colorectal cancer, *CD133*, quantitative methylation-specific PCR, 2235
- Colorectal cancer, *CDH3*, quantitative methylation-specific PCR, 2215
- Colorectal cancer, claudin, clinicopathological factor, marker, 851
- Colorectal cancer, clinico-pathological features, perforation, Hartmann's procedure, 1681
- Colorectal cancer, Crohn's colitis, Sweden, epidemiology, 4291
- Colorectal cancer, curcumin, mTOR, Raptor, Rictor, Akt, PHLPP, 3185
- Colorectal cancer, G protein, GNB4, haplotype, SNP, 1271
- Colorectal cancer, hereditary cancer, familial adenomatous polyposis, APC gene, 711
- Colorectal cancer, homocysteinemia, breast cancer, inflammation, 4131
- Colorectal cancer, inflammatory bowel disease, Crohn's disease, epidemiology, ulcerative colitis, colon carcinogenesis, molecular biology, review, 2727

- Colorectal cancer, *K-ras*, panitumumab, 3369
- Colorectal cancer, Ku80, polymorphism, carcinogenesis, 2239
- Colorectal cancer, leptin, adiponectin, prognosis, 3321
- Colorectal cancer, liver metastases, elderly, resection, 583
- Colorectal cancer, liver metastasis, hepatic arterial infusion, hai, systemic chemotherapy, prognostic factors, 4139
- Colorectal cancer, macrophage, intracellular, flow cytometrical, tumor marker, CEA, 3245
- Colorectal cancer, microsatellite instability, predictive factor, chemotherapy, survival, 1615
- Colorectal cancer, *p16*, quantitative methylation-specific PCR, 275
- Colorectal cancer, *p53*, Bak, EPO, EPOR, 4151
- Colorectal cancer, *p53*, *EGFR*, colon cancer, 785
- Colorectal cancer, pancreatic cancer, stage at diagnosis, rurality, access to care, 3427
- Colorectal cancer, spontaneous regression, metastatic, 465
- Colorectal cancer, stereotactic radiosurgery, liver metastases, unresectable metastases, CyberKnife[®], solid tumours, 3381
- Colorectal cancer, *Tip60*, quantitative real-time PCR, 3953
- Colorectal cancer, *UNC5C*, quantitative methylation-specific PCR, 271
- Colorectal cancer, uroguanylin, *E. coli* heat-stable enterotoxin, guanylyl cyclase C, single photon-emitting computed tomography, SPECT, *in vivo* imaging, 3777
- Colorectal carcinoma, CRC, matrix metalloproteinase, MMP, tissue inhibitor of matrix metalloproteinase, TIMP, microarray analysis, 67
- Colorectal carcinoma, grape seed procyanidin, apoptosis, caspase-3, 283
- Colorectal carcinoma, immunohistochemistry, MET, prognosis, survival, carcinogenesis, 4807
- Colorectal carcinoma, PTP4A3, 3913
- Colorectal carcinoma, *Vimentin*, quantitative methylation-specific PCR, 279
- Colorectal tumours, adhesion molecules, APC, dog, 2919
- Combination chemotherapy, S-1, CDDP, metastatic gastric cancer, phase I study, 1727
- Combination targeted therapy, xenograft, IGF-IR, *EGFR*, VEGF, 1999
- Combination therapy, cepharanthine, S-1, oral squamous cell carcinoma, apoptosis, TUNEL, xenografts, nude mice, 1263
- Combination, antioxidants, chemotherapy, colon cancer, orthotopic model, 2421
- Comet assay, antioxidants, coenzyme Q10, quercetin, nasal mucosa, mini organ cultures, 33
- Comparative immunology, oral administration, IP-PA1, LPS, M1 macrophage, 4871
- Complementary and alternative medicine, cancer, vitamin C, ascorbic acid, ascorbate, plasma concentration, intravenous, cytotoxicity, review, 809
- Complete pelvic lymphadenectomy, endometrial cancer, favorable histological characteristics, pelvic nodal involvement, 2781
- Computer-assisted, bile duct neoplasms, pancreas neoplasms, DNA ploidy, cytometry, image analysis, differential diagnosis, 1579
- COMT*, bladder cancer, susceptibility, metabolising gene, *CYP1A1*, *CYP1B1*, *GSTP1*, *NAT2*, genetic polymorphism, single nucleotide polymorphism, 1631
- COMT*, methylation, *Helicobacter pylori*, gastric mucosa, polymorphism, 2857
- Concomitant elastofibroma, subscapular, olecranon, 503
- Concomitant radio-chemotherapy, glioblastoma, pseudoprogression, radiological assessment, 2607
- Concordance, immunohistochemistry, tissue microarray, discordance, validity, multivariable analysis, 201
- Concurrent chemoradiotherapy, SCLC limited disease, sequential chemoradiotherapy, prophylactic cranial radiotherapy, median survival time, overall survival, 5219
- Concurrent radiotherapy, feasibility study, S-1, weekly docetaxel, advanced gastric cancer, 3385
- Confocal microscopy, nanospheres, PLGA, curcumin, S/O/W emulsion, cancer therapy, 3867
- Conformal, prostate cancer, radiotherapy, definitive, androgen deprivation, 2627
- Congo Red, prion disease, amyloid plaques, doxorubicin, 2507
- Connexin, gap junction protein, head-and-neck cancer, cell proliferation, 1981
- Constipation, anthracycline, cyclophosphamide, breast cancer, anti-emesis, 5-HT3 receptor antagonist, repeated treatment, 1721
- Continuous and intermittent Finasteride, BPH, serum CgA data, acquired prostate cancer, Gleason score data, 1797
- Continuous cell lines, human neuroendocrine tumor, NET, carcinoid of terminal ileum, P-ST5 primary tumor, L-ST5 lymph node metastasis, H-ST5 hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Continuous waves, chromosomal aberrations, radio frequency, pulsed waves, promotion, 4323
- Continuous-wave, chromosomal aberrations, radio frequency, microwave radiation, pulsed-wave, promotion, 2885
- Control theory, enzyme kinetics, prostate cancer, pancreas, vitamin D, review, 3675
- Conventional radiological survey, multiple myeloma, RSS, MRI, 4745
- Cord blood transplantation, acute graft-versus-host disease, standard-risk disease, 1763
- Cordycepin (3'-deoxyadenosine), platelet aggregation, hematogenic metastasis, B16-F1 mouse melanoma cell, adenosine-5'-diphosphate, 3857

- Correlation coefficient, tumor marker, CA15-3, KL-6, BCA225, 4239
- Correlation, P-gp, MRP, expression, leukemia, 1073
- COV 434, vitamin D₃, 1 α -hydroxylase, splice variants, ovarian cancer, HGL5, GLZ, 3627
- COV 434, vitamin D₃, 24-hydroxylase, splice variants, ovarian cancer, HGL5, GLZ, 3635
- COX-2 inhibitors, celecoxib, prostate cancer, randomized controlled trial, 1483
- COX-2, angiogenesis, uterine cervical carcinomas, basic FGF, VEGF, angiopoietin, *IL-8*, thymidine phosphorylase, HIF-1 α , ETS-1, review, 2665
- COX-2, biphenols, radical-scavenging activity, NF-kappaB, AP-1, DFT/B3LYP, lipopolysaccharide, 2403
- COX-2, cyclooxygenase-2, celecoxib, bladder cancer, chemoprevention, 3769
- COX-2, diethyl 2-chloroazulene-1,3-dicarboxylate, RAW264.7 cells, macrophage, PGE₂, PLA2, anti-inflammatory effect, 379
- COX2, leiomyosarcoma, immunohistochemistry, tumor necrosis, 2913
- COX-2, melanoma, CD117, HSP90, FNA, 4345
- COX-2, NSAIDs, DPD, HCA-7, HT-29, 3095
- CpG, plasmacytoid dendritic cell, HNSCC, migration, IFN- α , 3019
- CpG-ODN, VacA, recombinant VacA, neutralizing antibody, anti-*H. pylori* vaccine, mucosal immune response, 2393
- CpG-oligodeoxy-nucleotides, bladder cancer, immunotherapy, BCG, 2067
- CPT-11, irinotecan, 5-fluorouracil, sequence-dependency, cell cycle, thymidylate synthase, apoptosis, 2083
- CRC, colorectal carcinoma, matrix metalloproteinase, MMP, tissue inhibitor of matrix metalloproteinase, TIMP, microarray analysis, 67
- Crohn's colitis, colorectal cancer, Sweden, epidemiology, 4291
- Crohn's disease, inflammatory bowel disease, epidemiology, ulcerative colitis, colorectal cancer, colon carcinogenesis, molecular biology, review, 2727
- Crohn's disease, infliximab, anal fistula, 927
- Cryoablation, helper T-cell, immune reaction, hepatoma, ablation therapy, review, 5203
- CSF-1R, soft tissue tumors, M-CSF, tumor markers, grade, 3861
- CSRA, chemotherapy sensitivity and resistance assay, primary culture, cancer, *EGFR*, erlotinib, chemoresponse, ChemoFx[®], 1993
- CT scan, [18F]-FDG, PET-CT, metastatic colorectal cancer, therapeutic assessment, 2563
- Curcumin, AhR, HL-60, cell cycle, apoptosis, AML, 4657
- Curcumin, antiproliferative, cell cycle arrest, apoptosis, 5039
- Curcumin, apoptosis, cell proliferation, CDKs, NF- κ B, toad skin extract, colon cancer, 395
- Curcumin, colorectal cancer, mTOR, Raptor, Rictor, Akt, PHLPP, 3185
- Curcumin, liposomal, dose finding, pancreatic, cancer, 1895
- Curcumin, nanospheres, PLGA, S/O/W emulsion, confocal microscopy, cancer therapy, 3867
- Cutaneous metastases, CDX2, extramammary Paget's disease, skin, immunohistochemistry, 5033
- CWR22Rv1 cells, prostate cancer, resveratrol, NQO2, 3011
- CXCR4, SDF-1, gastric cancer, metastasis, 4751
- CyberKnife[®], stereotactic radiosurgery, liver metastases, unresectable metastases, colorectal cancer, solid tumours, 3381
- Cyclin D1, breast cancer, Zeranol, pre-adipocytes, body weight gain, doubling time, *p53*, 5045
- Cyclin-dependent kinase, breast cancer, CDK10, tamoxifen, DNA methylation, 3939
- Cyclooxygenase-2, breast cancer, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, prostaglandin metabolism, 3619
- Cyclooxygenase-2, COX-2, celecoxib, bladder cancer, chemoprevention, 3769
- Cyclooxygenase-2, granulosa cells, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, prostaglandin metabolism, 3611
- Cyclopamine, hedgehog, Wnt, quercetin, leukemia, lymphoma, 4629
- Cyclophosphamide, anthracycline, breast cancer, anti-emesis, 5-HT3 receptor antagonist, repeated treatment, constipation, 1721
- Cyclophosphamide, cancer, gene therapy, transcriptional targeting, Q5 promoter, allograft rejection, 1015
- CYFRA 21-1, lung cancer, diagnosis, prognosis, ProGRP, NSE, CEA, 4827
- CYP17 gene polymorphism, hormonal genes, BPH, prostate cancer, North India, 1659
- CYP1A1*, bladder cancer, susceptibility, metabolising gene, *CYP1B1*, *COMT*, *GSTP1*, *NAT2*, genetic polymorphism, single nucleotide polymorphism, 1631
- CYP1B1*, bladder cancer, susceptibility, metabolising gene, *CYP1A1*, *COMT*, *GSTP1*, *NAT2*, genetic polymorphism, single nucleotide polymorphism, 1631
- CYP1B1*, lung cancer, aryl hydrocarbon receptor, *p53*, epidermal growth factor receptor, 509
- CYP3A, etoposide, quercetin, P-gp, pharmacokinetics, bioavailability, rats, 1411
- CYP3A4, cytochrome P450, drug metabolism, dynamic structure, ligand binding, 935
- CYP4A, renal adenocarcinoma, 20-hydroxyeicosatetraenoic acid, eicosanoids, xenograft model, 3819
- Cytarabine, drug resistance, P-glycoprotein, daunorubicin, HL-60 cells, glutathione-S-transferase π , 4071

- Cytochrome *c* release, cytostatic resistance, paclitaxel, Akt activation, Bad phosphorylation, caspase-3 activation, apoptosis, 159
- Cytochrome *c*, rhein, apoptosis, caspase-3, ROS, mitochondria membrane potential, 309
- Cytochrome P450, CYP3A4, drug metabolism, dynamic structure, ligand binding, 935
- Cytogenetic analyses, human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, P-ST5 primary tumor, L-ST5 lymph node metastasis, H-ST5 hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, clonal tetraploidy, array CGH, 1951
- Cytokeratin, oral squamous cell carcinoma, disseminated tumor cells, peripheral blood, SYBR green real-time quantitative reverse transcriptase-polymerase chain reaction, 291
- Cytokine plasma levels, gastric cancer, prognosis, 5005
- Cytokines, ionizing radiation, SOD mimetic, RM-9 prostate cancer, NK cells, B-cells, immune system, 107
- Cytokines, macrophages, lung cancer, activation state, 5095
- Cytokines, ovarian cancer, ascites, chemokines, cell mediated immunity, 2875
- Cytometry, adenocarcinoma corpus uteri, DNA ploidy, treatment, 4731
- Cytometry, bile duct neoplasms, pancreas neoplasms, DNA ploidy, computer-assisted, image analysis, differential diagnosis, 1579
- Cytoplasmic, high-grade astrocytoma, nuclear, p27, prognosis, subcellular localization, 597
- Cytoreduction, lymphadenectomy, lymph node metastasis, ovarian cancer, review, 2837
- Cytoskeleton, cancer, haperforin, chemotherapy, apoptosis, cell cycle, 1963
- Cytostatic resistance, paclitaxel, Akt activation, Bad phosphorylation, cytochrome *c* release, caspase-3 activation, apoptosis, 159
- Cytotoxic activity, trifluoromethyl acyloins, apoptosis, autophagy, 175
- Cytotoxic effect, A431 and A431/Pt human cervical tumor cell lines, platinum drugs, prolonged drug incubation, 3931
- Cytotoxic, onconase, double-stranded RNA, ribonuclease, RNAi, 1067
- Cytotoxicity, 1,2,3,4-tetrahydroisoquinoline, QSAR, semiempirical molecular-orbital method, absolute hardness, 2265
- Cytotoxicity, 1,2,3,4-tetrahydroisoquinoline, QSAR, semiempirical molecular-orbital method, absolute hardness, 4077
- Cytotoxicity, 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone, estrogen positive/negative breast cancer cell lines, cell cycle, apoptosis, 191
- Cytotoxicity, ATG, hematological malignancies, 1355
- Cytotoxicity, cancer, vitamin C, ascorbic acid, ascorbate, plasma concentration, intravenous, complementary and alternative medicine, review, 809
- Cytotoxicity, dihydroimidazoles, QSAR, semiempirical molecular-orbital method, 5019
- Cytotoxicity, gefitinib, hormesis, cell death, oral squamous cell carcinoma, 5023
- Cytotoxicity, methionine, CNS tumours, methotrexate, cisplatin, temozolomide, 3103
- Cytotoxicity, tetrahydroisoquinolines, tumor-specificity, autophagy, 3079
- Cytotoxicity, tetrandrine, neuroblastoma, radiosensitization, 3163
- Dairy calcium, vitamin D insufficiency, calcium intake, calcium-sensing receptor, extrarenal 25-hydroxyvitamin D-1 α -hydroxylase, 1,25-dihydroxyvitamin D₃, 25-hydroxyvitamin D-24-hydroxylase, review, 3687
- Daunorubicin, drug resistance, P-glycoprotein, cytarabine, HL-60 cells, glutathione-S-transferase π , 4071
- DC vaccine, metastatic melanoma, MAGE1 HLA-A24 restricted peptide, T-cell receptor (TCR) beta cDNA cloning, electroporation, 647
- DCA, hypoxia, proliferation, *HIF1A*, apoptosis, 4579
- Debulking surgery, ovarian cancer, age, tumor pattern, survival, 2809
- Decreased levels, ghrelin, plasma, cachexia, 3949
- Definitive, prostate cancer, radiotherapy, conformal, androgen deprivation, 2627
- Delta-like, notch, leukemia, Jagged, 3967
- Demethylation, Wnt pathway, Wnt inhibitory factor-1, promoter hypermethylation, epigallocatechin-3-gallate, EGCG, 2025
- Dendritic cells, pancreatic cancer, immunotherapy, vaccination, 831
- Dendritic cells, Thymax, Th1, interferon-gamma, CD83, 4367
- DepoCyte[®], breast cancer, leptomenigeal disease, neoplastic meningitis, chemotherapy, temozolomide, liposomal Ara-C, 5191
- Depolymerization, latrunculin A, actin, apoptosis, anti-cancer drug, 2091
- Detoxification, arylamine metabolism, bladder cancer, genetic polymorphism, arylesterase, *PONI*, 4041
- DFP, gastric cancer, neoadjuvant chemotherapy, docetaxel, 5-fluorouracil, cisplatin, 4211
- DFT/B3LYP, biphenols, radical-scavenging activity, COX-2, NF-kappaB, AP-1, lipopolysaccharide, 2403
- Diagnosis, lung cancer, prognosis, ProGRP, NSE, CYFRA 21-1, CEA, 4827
- Diagnosis, oral cancer, NY-ESO-1, gene expression, RT-PCR, therapy, 5125
- Diarylheptanoids, apoptosis, S-phase arrest, differentiation, neuroblastoma cells, *Alpinia officinarum*, 4981

- 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone, estrogen positive/negative breast cancer cell lines, cytotoxicity, cell cycle, apoptosis, 191
- 1,3-Diepi-ED-71, ED-71, 1 α ,25-dihydroxyvitamin D₃, 1 α ,25-dihydroxy-2 β -(3-hydroxypropoxy)vitamin D₃, 1-*epi*-ED-71, 3-*epi*-ED-71, 3571
- Dietary calcium, colonic 1,25(OH)₂D₃ concentration, gender-dependent, apoptosis, vitamin D hydroxylases, 3727
- Diethyl 2-chloroazulene-1,3-dicarboxylate, RAW264.7 cells, macrophage, PGE₂, COX-2, PLA2, anti-inflammatory effect, 379
- Differential diagnosis, bile duct neoplasms, pancreas neoplasms, DNA ploidy, computer-assisted, cytometry, image analysis, 1579
- Differentiation, diarylheptanoids, apoptosis, S-phase arrest, neuroblastoma cells, *Alpinia officinarum*, 4981
- Differentiation, HL-60, asparagine synthetase, TPA, asparaginase, apoptosis, 1303
- Digital holographic microscopy, tumour cell, nutritional deprivation, energy deprivation, cell survival, cell death, dynamic phase difference, 2339
- Dihydroartemisinin, artemisinin-transferrin conjugate, rat breast tumor, 3807
- Dihydroimidazoles, QSAR, cytotoxicity, semiempirical molecular-orbital method, 5019
- Dihydropyrimidine dehydrogenase, 5-fluorouracil, bladder urothelial carcinoma, orotate phosphoribosyl transferase, 5-chloro-2,4-dihydropyridine, 1001
- Dihydropyrimidine dehydrogenase, capecitabine, thymidine phosphorylase, cell proliferation, apoptosis, 2525
- Dihydrotestosterone, prostate cancer, glutamatergic system, 371
- 1 α ,25-Dihydroxy-2 β -(3-hydroxypropoxy)vitamin D₃, 1 α ,25-dihydroxyvitamin D₃, ED-71, 1-*epi*-ED-71, 3-*epi*-ED-71, 1,3-*diepi*-ED-71, 3571
- 1,25-Dihydroxyvitamin D, 25-hydroxyvitamin D, 1, survival, vitamin D supplementation, review, 3699
- 1,25Dihydroxyvitamin D₃, extrarenal vitamin D synthesis, 1, colon tumor prevention, vitamin D hydroxylases, calcium, estrogen, epigenetic regulation, review, 3705
- 1,25-Dihydroxyvitamin D₃, vitamin D insufficiency, calcium intake, dairy calcium, calcium-sensing receptor, extrarenal 25-hydroxyvitamin D-1 α -hydroxylase, 25-hydroxyvitamin D-24-hydroxylase, review, 3687
- 1 α ,25-Dihydroxyvitamin D₃, 1 α ,25-dihydroxy-2 β -(3-hydroxypropoxy)vitamin D₃, ED-71, 1-*epi*-ED-71, 3-*epi*-ED-71, 1,3-*diepi*-ED-71, 3571
- Diphosphonates, breast neoplasms, bone neoplasms, hyperparathyroidism, secondary, calcium, 2707
- Discordance, hormone receptors, Her-2/neu, breast cancer, metastases, 1557
- Discordance, immunohistochemistry, tissue microarray, concordance, validity, multivariable analysis, 201
- Disease progression, soluble VEGF members, soluble VEGF receptors, cervical carcinoma, tumor markers, vascular endothelial growth factor, 641
- Disseminated tumor cells, oral squamous cell carcinoma, cytokeratin, peripheral blood, SYBR green real-time quantitative reverse transcriptase-polymerase chain reaction, 291
- Distant metastases, node-negative breast cancer, urokinase-type plasminogen activator, plasminogen activator inhibitor type I, prognostic factor, local recurrence, 1475
- DNA binding, flavonoids, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, 2273
- DNA binding, flavonoids, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, structure-activity relationship, 2285
- DNA cytometry, stage II colorectal cancer, prognosis, adjuvant therapy, 99
- DNA damage, alkylator, cell cycle arrest, prodrug, bone-marrow sparing, drug resistance, 3845
- DNA double-strand breaks, survivin, DNA repair, radioresistance, squamous cell carcinoma, 223
- DNA fragmentation, naphtho[2,3-*b*]furan-4,9-diones, apoptosis, autophagy, caspase, QSAR, 455
- DNA methylation, breast cancer, CDK10, tamoxifen, cyclin-dependent kinase, 3939
- DNA methylation, epigenetics, breast cancer, chemotherapy, 3207
- DNA methylation, ovarian cancer, estrogen receptor, epigenetic, histone deacetylation, 139
- DNA mismatch repair, endometrial cancer, MSH2, immunohistochemistry, 4833
- DNA ploidy, adenocarcinoma corpus uteri, cytometry, treatment, 4731
- DNA ploidy, bile duct neoplasms, pancreas neoplasms, computer-assisted, cytometry, image analysis, differential diagnosis, 1579
- DNA repair proteins, biliary tract carcinoma, pharmacogenomic, cisplatin, polymorphisms, 1835
- DNA repair, arsenic, *ERCC1*, drinking water, NER, skin hyperkeratosis, 3253
- DNA repair, genetic polymorphism, haplotype, renal cell cancer, outcome, *XRCC1*, 5131
- DNA repair, *MGMT*, *p53*, Sp1 transcription factor, drug resistance, alkylating agent, 3741
- DNA repair, radiation, hyperthermia, 1319
- DNA repair, survivin, DNA double-strand breaks, radioresistance, squamous cell carcinoma, 223
- DNA repair, *XPD*, single nucleotide polymorphism, bladder cancer, 3903
- DNA repair, *XRCC4*, single nucleotide polymorphism, bladder cancer, 1777

- DNA sequencing, chagas disease, megaesophagus, gene mutation, single nucleotide polymorphism, SNP, *FHIT* gene, *TP53* gene, *CDKN2A* gene, 1243
- Docetaxel, chemotherapy, vinorelbine, estramustine, zoledronic acid, androgen-resistant prostate cancer, 769
- Docetaxel, cisplatin, clinical trial, ovarian cancer, progression-free survival, 561
- Docetaxel, epithelial ovarian cancer, treatment resistant, phase I/II study, gemcitabine, 1521
- Docetaxel, first-line chemotherapy, gemcitabine, mesothelioma, 3441
- Docetaxel, gastric cancer, neoadjuvant chemotherapy, 5-fluorouracil, cisplatin, DFP, 4211
- Docetaxel, gastric cancer, xenograft model, PSK, 843
- Docetaxel, gemcitabine, advanced breast cancer, 1841
- Docetaxel, head and neck cancer, chemotherapy, radiation therapy, *ERCC1*, 529
- Docetaxel, ifosfamide, cisplatin, head and neck cancer, 5137
- Docetaxel, S-1, gastric cancer, chemotherapy, 2775
- Dog, adhesion molecules, APC, colorectal tumours, 2919
- Dog, telomerase, *TERT*, mammary tissue, immunohistochemistry, RT-PCR, 319
- Domain, programmed death-1, fibronectin, tumor immune therapy, 5089
- Dose finding, curcumin, liposomal, pancreatic, cancer, 1895
- Dose-effect relationship, cataract induction, late renal dysfunction, biologically effective dose, 3305
- Double-stranded RNA, onconase, cytotoxic, ribonuclease, RNAi, 1067
- Doubling time, breast cancer, Zeranol, pre-adipocytes, body weight gain, cyclin D1, *p53*, 5045
- Doxorubicin, anthracycline, epirubicin, PPE, hand-foot syndrome, 2307
- Doxorubicin, formamidinodoxorubicins, resistant cells, uptake, topoisomerase II, 1429
- Doxorubicin, prion disease, amyloid plaques, Congo Red, 2507
- Doxycycline, pancreatic cancer, apoptosis, *p53*, *Fas*, *IL-8*, 3995
- DPC4, pancreatic cancer, *K-ras*, *p53*, *p16*, prognostic markers, 1803
- DPD, NSAIDs, COX-2, HCA-7, HT-29, 3095
- 15dPGJ₂, PPAR γ , IL-6, Stat3, PC-3 cells, prostate cancer, 2331
- Drinking water, arsenic, *ERCC1*, DNA repair, NER, skin hyperkeratosis, 3253
- Drug accumulation, multidrug resistance, xenograft, nude mice, bromotetrandrine, 4597
- Drug metabolism, cytochrome P450, CYP3A4, dynamic structure, ligand binding, 935
- Drug resistance, acute lymphoblastic leukemia, acute myeloid leukemia, children, adults, individual tumor response testing, 1643
- Drug resistance, alkylator, DNA damage, cell cycle arrest, prodrug, bone-marrow sparing, 3845
- Drug resistance, *MGMT*, *p53*, DNA repair, Sp1 transcription factor, alkylating agent, 3741
- Drug resistance, P-glycoprotein, daunorubicin, cytarabine, HL-60 cells, glutathione-S-transferase π , 4071
- Drug resistance, *Uncaria tomentosa*, alkaloids, apoptosis, medullary thyroid carcinoma, 4519
- Drug-drug interaction, vinorelbine orale, cisplatin, pharmacokinetics, phase I, 553
- DSCR1, metastin, AXOR12, gene expression, real-time quantitative RT-PCR, epithelial ovarian cancer, 617
- Ductal *in situ* carcinoma, breast cancer, lymph node, sentinel node biopsy, 1499
- Ductal, cancer, breast, molecular classification, survival, 4727
- Duodenum, adenomas, Paneth cells, stem cells, migration, 657
- Dynamic phase difference, tumour cell, nutritional deprivation, energy deprivation, cell survival, cell death, digital holographic microscopy, 2339
- Dynamic structure, cytochrome P450, CYP3A4, drug metabolism, ligand binding, 935
- DYRK2*, *p53*, lung cancer, predictive marker, chemotherapy, 2753
- Dysplasia, breast, hyperplasia, infrared temperature, skin, 4697
- Dysplasia, epithelium, lectin, malignancy, preneoplasia, galectin-8, 4933
- Dyspnea, pulmonary toxicity, interstitial lung disease, pneumonitis, antineoplastic drugs, lung injury, review, 631
- E. coli* heat-stable enterotoxin, uroguanylin, guanylyl cyclase C, single photon-emitting computed tomography, SPECT, colorectal cancer, *in vivo* imaging, 3777
- E₂F-4, gnidimacrin, PKC β II, G₂-phase arrest, p21(WAF1/Cip1), *cdc2*, 1349
- E75, HER-2, helper effect, AE-37, AE-47, p776, F7, perforin, cancer vaccines, high-affinity CD8⁺ cells, 2427
- Early events in breast tumorigenesis, rapamycin, mTOR signaling, mTOR phosphorylation, STAT3 phosphorylation, biomarkers of resistance, p70S6 and RS6P, human breast epithelial cells, human breast premalignant and tumor epithelial cells, 1143
- Early gastric cancer, endoscopic submucosal dissection, endoscopic aspiration mucosectomy, 4271
- E-cadherin, canine cutaneous histiocytoma, immunohistochemistry, tumour regression, 2713
- Echo-contrast agent, ultrasound, microbubbles, malignant glioma, central nervous system, 235
- ECM, cathepsin L, NSITC, angiogenesis, protease, 4473
- Ecological studies, case-control studies, cohort studies, colon cancer, prostate cancer, randomized controlled trials, review, 3597

- ED-71, 1 α ,25-dihydroxyvitamin D₃, 1 α ,25-dihydroxy-2 β -(3-hydroxypropoxy)vitamin D₃, 1-*epi*-ED-71, 3-*epi*-ED-71, 1,3-di*epi*-ED-71, 3571
- ¹⁵³Sm-EDTMP, bone recurrences, Vienna protocol, 3393
- Efflux, ABC transporters, P-glycoprotein, semi-automated fluorometric method, ethidium bromide, mouse lymphoma cells, *mdr1*, *ABCB1*, 2173
- EGCG, (–)-epigallocatechin gallate, apoptosis, human adrenal cancer NCI-H295 cells, caspase, 1435
- EGCG, genistein, quercetin, phytochemical synergy, prostate cancer cells, 4025
- EGCG, Wnt pathway, Wnt inhibitory factor-1, promoter hypermethylation, demethylation, epigallocatechin-3-gallate, 2025
- EGFP, imageable model, EL-4 T-cell lymphoma, whole body imaging, 4513
- EGFR* mutations, predictive factors, gefitinib, erlotinib, *K-ras* mutations, smoking habits, lung cancer, 2691
- EGFR*, BCRP/ABCG2, gefitinib, HPLC, 1059
- EGFR*, cisplatin sensitivity, HNSCC, proliferation, 1181
- EGFR*, combination targeted therapy, xenograft, IGF-IR, VEGF, 1999
- EGFR*, EGR1, microarray, mutation, 1111
- EGFR*, *ERBB2*, *ERBB3*, *ERBB4*, colon, 1489
- EGFR*, gallbladder, adenocarcinoma, fluorescence *in situ* hybridization, *Myc*, gene amplification, *ERBB2*, 19
- EGFR*, HER2, VEGF, breast cancer, surgery, 5111
- EGFR*, lung cancer, nm23, verapamil, 27
- EGFR*, NSCLC, gefitinib, erlotinib, *KRAS*, mutation, 2767
- EGFR*, *p53*, colorectal cancer, colon cancer, 785
- EGFR*, primary culture, cancer, erlotinib, chemoresistance, chemotherapy sensitivity and resistance assay, CSRA, ChemoFx[®], 1993
- EGFR*-TKI, non-small cell lung cancer, gefitinib, paclitaxel, resistant, 2747
- EGR1, *EGFR*, microarray, mutation, 1111
- Eicosanoids, renal adenocarcinoma, CYP4A, 20-hydroxyeicosatetraenoic acid, xenograft model, 3819
- EIIAPA, hepatitis B virus enhancer, sodium iodine symporter, NIS, hepatocellular carcinoma, alpha-fetoprotein, AFP, 211
- EL-4 T-cell lymphoma, imageable model, EGFP, whole body imaging, 4513
- Elderly, liver metastases, colorectal cancer, resection, 583
- Electron microscopic study, sonodynamic therapy, photosensitizer, normal rat brain, blood–brain barrier, 889
- Electron microscopy, gastric carcinoma, endothelium, pericyte, peg-socket junctions, 449
- Electroporation, DC vaccine, metastatic melanoma, MAGE1 HLA-A24 restricted peptide, T-cell receptor (TCR) beta cDNA cloning, 647
- ELISA, anti-heat-shock protein 70 antibody, heat-shock protein 70, esophageal cancer, immunohistochemistry, humoral immune system, 1595
- ELISA, HMGB1, angiogenesis, exudates, transudates, 5013
- Empirical chemotherapy, non-small cell lung cancer, *in vitro* assay-guided chemotherapy, 4243
- Empyema, bevacizumab, gastrointestinal perforation, pancreatic cancer, 1665
- EMT, integrin, α v β 6, oral SCC, matrix, epithelial–mesenchymal transition, 125
- EMT, *PTEN*, TNF- α , migration, invasion, 4439
- Endobronchial brush, promoter methylation, non-small cell lung cancer, methylation-specific PCR, bronchial epithelial cells, clonal field expansion, 363
- EndoG, berberine, apoptosis, caspase, SCC-4 cells, AIF, 4063
- Endometrial cancer, DNA mismatch repair, MSH2, immunohistochemistry, 4833
- Endometrial cancer, favorable histological characteristics, complete pelvic lymphadenectomy, pelvic nodal involvement, 2781
- Endometrial cancer, matriptase, prognostic significance, 1685
- Endometrial cancer, recurrence, haematogenous failure, myometrial invasion, lymph-vascular space involvement, 1715
- Endometrial cancer, risk groups, treatment, survival, 1585
- Endometrial cancer, topotecan, anthracyclines, taxanes, stage IV disease, 1761
- Endometrial cancer, WT1, immunohistochemistry, clinicopathological factors, PCNA, cell proliferation, 4887
- Endometrial cancer, WT1, immunohistochemistry, clinicopathological factors, prognosis, 1691
- Endometrial carcinoma, endometrial hyperplasia, cofactor, NCoR, progesterone, 1023
- Endometrial hyperplasia, endometrial carcinoma, cofactor, NCoR, progesterone, 1023
- Endometrial stromal sarcoma conservative management pregnancy, 4147
- Endometriosis, ovarian cancer, parietal metastasis, clear cell adenocarcinoma, 1591
- Endometrium carcinoma, Bcl-2, bax, *p53*, apoptosis, real-time PCR, immunohistochemistry, 3977
- Endometrium, cancer, growth, progesterone, mifepristone, cell cycle, apoptosis, Ishikawa cells, 1053
- Endoplasmic reticulum stress, riluzole, ion channel, apoptosis, prostate cancer, 2195
- Endoplasmic reticulum, intestinal macrophages, CD14, *Golgi apparatus*, 865
- Endoscopic aspiration mucosectomy, endoscopic submucosal dissection, early gastric cancer, 4271
- Endoscopic submucosal dissection, endoscopic aspiration mucosectomy, early gastric cancer, 4271

- Endostar, apoptosis, Bax, Bcl-2, bFGF, HUVEC, 411
- Endothelia, resveratrol, adhesion, ICAM-1, NF- κ B, 355
- Endothelial cell, thrombospondin-1, peptide, antibody, antiangiogenic, selectivity, 2243
- Endothelial cells, pleiotrophin, heparin affin regulatory peptide, serum response element, glioma, 349
- Endothelial cells, *Viscum album*, European mistletoe, angiogenesis, matrigel assay, apoptosis, cancer therapy, 2945
- Endothelium, gastric carcinoma, pericyte, peg-socket junctions, electron microscopy, 449
- Energetic metabolism, mesothelioma, glycolysis, cisplatin, MSTO-211H, 1249
- Energetic metabolism, mesothelioma, nude mice, glycolysis, chemotherapy, 1443
- Energy deprivation, tumour cell, nutritional deprivation, cell survival, cell death, digital holographic microscopy, dynamic phase difference, 2339
- Enzyme kinetics, prostate cancer, pancreas, vitamin D, control theory, review, 3675
- EOC, CD3, CD3 ζ , tumor-infiltrating lymphocytes, TIL, epithelial ovarian carcinoma, malignant ascites, 4673
- EpCAM, neoplasms, lung, 1817
- Epidemiology, breast cancer, postmenopausal women, overweight, obese, Statins, 5143
- Epidemiology, colorectal cancer, Crohn's colitis, Sweden, 4291
- Epidemiology, inflammatory bowel disease, Crohn's disease, ulcerative colitis, colorectal cancer, colon carcinogenesis, molecular biology, review, 2727
- Epidermal growth factor receptor, gefitinib, bortezomib, tumor necrosis factor α , resistance, 2315
- Epidermal growth factor receptor, gefitinib, lumbo-peritoneal shunt, meningeal carcinomatosis, lung cancer, T790M, 2759
- Epidermal growth factor receptor, lung cancer, aryl hydrocarbon receptor, *CYP1B1*, *p53*, 509
- Epidermal growth factor receptor, MPC polymer, paclitaxel, targeted therapy, 1009
- Epidermal growth factor receptor, neuroblastoma, gefitinib, chemotherapy, retinoic acid, 1327
- 1-Epi-ED-71, 1 α ,25-dihydroxyvitamin D₃, 1 α ,25-dihydroxy-2 β -(3-hydroxypropoxy)vitamin D₃, ED-71, 3-*epi*-ED-71, 1,3-*diepi*-ED-71, 3571
- 3-Epi-ED-71, 1 α ,25-dihydroxyvitamin D₃, 1 α ,25-dihydroxy-2 β -(3-hydroxypropoxy)vitamin D₃, ED-71, 1-*epi*-ED-71, 1,3-*diepi*-ED-71, 3571
- (-)-Epigallocatechin gallate, EGCG, apoptosis, human adrenal cancer NCI-H295 cells, caspase, 1435
- Epigallocatechin-3-gallate, Wnt pathway, Wnt inhibitory factor-1, promoter hypermethylation, demethylation, EGCG, 2025
- Epigenetic regulation, extrarenal vitamin D synthesis, 1,25dihydroxyvitamin D₃, colon tumor prevention, vitamin D hydroxylases, calcium, estrogen, review, 3705
- Epigenetic, breast cancer, retinoic acid, histone deacetylation, telomerase, *hTERT*, 4959
- Epigenetic, ovarian cancer, estrogen receptor, DNA methylation, histone deacetylation, 139
- Epigenetics, breast cancer, DNA methylation, chemotherapy, 3207
- 14-Epi-MART-10, synthesis, 19-norvitamin D₃, Julia coupling, PZ-HPV-7 cells, HL-60 cells, 3563
- Epirubicin, anthracycline, doxorubicin, PPE, hand-foot syndrome, 2307
- Epirubicin, breast cancer, adjuvant chemotherapy, feasibility, adriamycin, paclitaxel, 1515
- Epirubicin, breast cancer, anemia, side-effects, tumor biology, pre-operative chemotherapy, paclitaxel, 2675
- Epithelial ovarian cancer, metastin, AXOR12, DSCR1, gene expression, real-time quantitative RT-PCR, 617
- Epithelial ovarian cancer, retrospective, registry, prognostic factors, 745
- Epithelial ovarian cancer, treatment resistant, phase I/II study, gemcitabine, docetaxel, 1521
- Epithelial ovarian carcinoma, CD3, CD3 ζ , tumor-infiltrating lymphocytes, TIL, EOC, malignant ascites, 4673
- Epithelial-mesenchymal transition, integrin, α v β 6, EMT, oral SCC, matrix, 125
- Epithelial-mesenchymal transition, Twist, Snail, Sip1, non-small cell lung cancer, 4099
- Epithelial-myoeithelial carcinoma, minor salivary glands, histological variants, immunohistochemistry, 4703
- Epithelium, dysplasia, lectin, malignancy, preneoplasia, galectin-8, 4933
- EPO, *p53*, Bak, EPOR, colorectal cancer, 4151
- Epoetin- α , chemotherapy, hemoglobin, quality of life, solid tumors, 693
- EPOR, *p53*, Bak, EPO, colorectal cancer, 4151
- ER stress, chronic lymphocytic leukemia, XBP1 splicing, apoptosis, proteasome, 3797
- ER stress, ROS, cell death, anthraquinone, 327
- ERas, oncogene, gastric carcinoma, prognosis, 2189
- ErbB, gastric cancer, colon cancer, neuroglycan-C, proliferation, 229
- ERBB2*, *EGFR*, *ERBB3*, *ERBB4*, colon, 1489
- ERBB2*, gallbladder, adenocarcinoma, fluorescence *in situ* hybridization, *Myc*, gene amplification, *EGFR*, 19
- ERBB3*, *EGFR*, *ERBB2*, *ERBB4*, colon, 1489
- ERBB4*, *EGFR*, *ERBB2*, *ERBB3*, colon, 1489
- ERCC1*, arsenic, DNA repair, drinking water, NER, skin hyperkeratosis, 3253
- ERCC1*, head and neck cancer, chemotherapy, radiation therapy, docetaxel, 529
- ERCC6*, polymorphism, bladder cancer, carcinogenesis, 5121
- ERK, ovarian cancer, chemotherapy, Akt, prognosis, 4639
- ERK, Rho, ROCK, GBM, migration, proliferation, 119

- ERK-1/2, ATF2, p-ATF2, breast cancer, prognosis, immunohistochemistry, Western blot, AP-1, MMP-9, 183
- Erlotinib, NSCLC, gefitinib, *EGFR*, *KRAS*, mutation, 2767
- Erlotinib, pancreatic cancer, gemcitabine, overall survival, toxicity, 5211
- Erlotinib, predictive factors, gefitinib, *EGFR* mutations, *K-ras* mutations, smoking habits, lung cancer, 2691
- Erlotinib, primary culture, cancer, *EGFR*, chemoresponse, chemotherapy sensitivity and resistance assay, CSRA, ChemoFx[®], 1993
- ER α , breast cancer, ER β , SERM, aromatase inhibitor, 2167
- ER β , breast cancer, ER α , SERM, aromatase inhibitor, 2167
- Esophageal adenocarcinoma, L1 cell adhesion molecule, tumor marker, therapy target, 1195
- Esophageal cancer, anti-heat-shock protein 70 antibody, heat-shock protein 70, ELISA, immunohistochemistry, humoral immune system, 1595
- Esophageal cancer, Cap43, independent prognostic factor, 965
- Esophageal cancer, carbon-ion radiotherapy, histone deacetylase inhibitor, squamous cell carcinoma, 4433
- Esophageal cancer, chemoresistance, microarray, 1163
- Esophageal cancer, preoperative chemoradiotherapy, mortality, morbidity, prognosis, 2555
- Esophageal cancer, radiotherapy, chemotherapy, gastrolymphatic fistula, 525
- Esophageal cancer, surgery, minimally invasive, outcome, survival, 2719
- Esophageal cancer, trastuzumab, ADCC, perforin, granzyme, 2137
- Esophageal carcinosarcoma, immunohistochemistry, survival analysis, 3375
- Esophagus, Oct3/4, Sox2, immunohistochemistry, RT-PCR, Western blotting, 1233
- Estradiol, breast cancer, renin-angiotensin system, ovary, steroidogenesis, 4633
- Estradiol, FSH, LH, ovarian cancer, prolactin, 1575
- Estramustine, chemotherapy, docetaxel, vinorelbine, zoledronic acid, androgen-resistant prostate cancer, 769
- Estrogen positive/negative breast cancer cell lines, 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone, cytotoxicity, cell cycle, apoptosis, 191
- Estrogen receptor, breast cancer, vitamin D analogs, BT-474 cells, vitamin D receptor stability, 3555
- Estrogen receptor, ovarian cancer, epigenetic, DNA methylation, histone deacetylation, 139
- Estrogen receptor-negative, breast cancer, Hedgehog signaling pathway, invasion, 871
- Estrogen response gene, microarray, breast cancer, 3971
- Estrogen, 2-methoxyestradiol, sulfamate, ovarian cancer, prostate cancer, breast cancer, 3751
- Estrogen, breast cancer, postmenopausal, aromatase, 17 beta HSD type 1, Steroid sulphatase, carcinogenesis, review, 1095
- Estrogen, colon cancer, rectal cancer, grading, vitamin D, 3721
- Estrogen, extrarenal vitamin D synthesis, 1,25dihydroxyvitamin D₃, colon tumor prevention, vitamin D hydroxylases, calcium, epigenetic regulation, review, 3705
- Estrogen, hypoxia, C/EBP α , T-47D cells, 1227
- Ethidium bromide, ABC transporters, P-glycoprotein, semi-automated fluorometric method, efflux, mouse lymphoma cells, *mdr1*, *ABCB1*, 2173
- Ethidium bromide, *ABCB1*, rhodamine 123, multidrug resistance, 3989
- Etoposide, quercetin, P-gp, CYP3A, pharmacokinetics, bioavailability, rats, 1411
- ETS-1, angiogenesis, uterine cervical carcinomas, basic FGF, VEGF, COX-2, angiopoietin, *IL-8*, thymidine phosphorylase, HIF-1 α , review, 2665
- Euphorbia*, Euphorbiaceae, triterpenes, steroids, multidrug resistance, P-glycoprotein, apoptosis, 4467
- Euphorbiaceae, *Euphorbia*, triterpenes, steroids, multidrug resistance, P-glycoprotein, apoptosis, 4467
- European mistletoe, *Viscum album*, angiogenesis, matrigel assay, endothelial cells, apoptosis, cancer therapy, 2945
- Ewing tumour, irradiation, kidney transplantation, organ dose, 3397
- Ewing tumours, EWSR1-FLI1, ribozymes, 1901
- Ewing tumours, HAT selection, gene expression, immunotherapy, cell fusion, 4489
- Ewing's sarcoma, rhabdomyosarcoma, high-dose chemotherapy, autologous transplantation, 3281
- EWSR1-FLI1, Ewing tumours, ribozymes, 1901
- Exercise, Adriamycin, anthracycline, cardiotoxicity, 4401
- Exercise, fatigue, RNase L, nitric oxide, protein kinase R, nuclear factor kappa beta, NF- κ B, intracellular immune dysfunction, natural killer cell, oxidative stress, review, 4717
- Tip60*, polymorphism, breast cancer, carcinogenesis, 3897
- Exo1*, polymorphism, lung cancer, carcinogenesis, 725
- Experimental model, pseudomyxoma peritonei, peritoneal carcinomatosis, intraperitoneal chemotherapy, 4051
- Experimental therapy, angiogenesis, animal model, metastasis, integrin, 131
- Expression, correlation, P-gp, MRP, leukemia, 1073
- External beam, aerodigestive tract, radioiodine, radiosensitizer, radiotherapy, paclitaxel, taxane, carboplatin, 4665
- Extracellular matrix, migration, three-dimensional cell-culture model, Boyden chamber, borrelidin, taxol, 5-hexyl-2'-deoxyuridine, signal pathway inhibitors, antisense oligonucleotide, 2981

- Extramammary Paget's disease, CDX2, cutaneous metastases, skin, immunohistochemistry, 5033
- Extrarenal 25-hydroxyvitamin D-1 α -hydroxylase, vitamin D insufficiency, calcium intake, dairy calcium, calcium-sensing receptor, 1,25-dihydroxyvitamin D₃, 25-hydroxyvitamin D-24-hydroxylase, review, 3687
- Extrarenal vitamin D synthesis, 1,25dihydroxyvitamin D₃, colon tumor prevention, vitamin D hydroxylases, calcium, estrogen, epigenetic regulation, review, 3705
- Exudates, HMGB1, angiogenesis, ELISA, transudates, 5013
- F7, HER-2, helper effect, AE-37, AE-47, p776, perforin, E75, cancer vaccines, high-affinity CD8⁺ cells, 2427
- Familial adenomatous polyposis, colorectal cancer, hereditary cancer, APC gene, 711
- Fas*, pancreatic cancer, doxycycline, apoptosis, p53, *IL-8*, 3995
- Fast track*, surgery, perioperative management, review, 2799
- Fatigue, cancer patients, palliative care, anaemia, 2569
- Fatigue, RNase L, nitric oxide, protein kinase R, nuclear factor kappa beta, NF- κ B, intracellular immune dysfunction, natural killer cell, oxidative stress, exercise, review, 4717
- Favorable histological characteristics, endometrial cancer, complete pelvic lymphadenectomy, pelvic nodal involvement, 2781
- [18F]-FDG, PET-CT, CT scan, metastatic colorectal cancer, therapeutic assessment, 2563
- Feasibility study, S-1, weekly docetaxel, concurrent radiotherapy, advanced gastric cancer, 3385
- Feasibility, breast cancer, adjuvant chemotherapy, adriamycin, epirubicin, paclitaxel, 1515
- FEN1, testis tumors, lung cancer, glioblastoma multiforme, astrocytoma, anticancer drugs, 2453
- Fermented flour extract, innate immunity, macrophage, lipopolysaccharide, IP-PA1, homeostasis, review, 859
- Fertility, osteosarcoma, marriage, surgery, chemotherapy, 763
- 18-F-FDG-PET, leiomyosarcoma, bone metastases, 469
- FGFR3, bortezomib, fibroblast growth factor receptor 3, multiple myeloma, 1
- FHIT* gene, chagas disease, megaesophagus, gene mutation, single nucleotide polymorphism, SNP, *TP53* gene, *CDKN2A* gene, DNA sequencing, 1243
- Fibrinogen gamma, hepatocellular carcinoma, fibrinogen, clinical stage, tumor thrombosis, 2531
- Fibrinogen, hepatocellular carcinoma, fibrinogen gamma, clinical stage, tumor thrombosis, 2531
- Fibroblast growth factor receptor 3, bortezomib, FGFR3, multiple myeloma, 1
- Fibroblast growth factor receptor, MDA-MB-231, Akt, Chfr, PLC γ , breast cancer, *Xenopus* oocyte, 4965
- Fibroc collagenous tissue, soft tissue tumor, lymphocyte infiltration, T lymphocyte, 5197
- Fibronectin, colorectal cancer, cadherin, catenin, metalloprotease-1, signet-ring cell, 4417
- Fibronectin, domain, programmed death-1, tumor immune therapy, 5089
- Fine-needle aspiration cytology, breast cancer, sentinel node biopsy, scintimammography, axillary ultrasonography, FNA cytology, 491
- Fine-needle aspiration cytology, thyroid nodule, thyroid cancer, follicular tumors, frozen section, 5255
- First-line chemotherapy, docetaxel, gemcitabine, mesothelioma, 3441
- Fish oil, vitamin D, 1 α ,25(OH)2D₃, proliferation, ω -3 PUFAs, HepG2, hepatoma, 3591
- FISH technique, lung cancer, non-small cell lung cancer, genetic changes, chromosome 9 numerical abnormalities, p16^{CDKN2A} gene deletion, 4483
- FISH, chondroid differentiation, GIST, gastrointestinal bleeding, 2761
- Flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, 2273
- Flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, structure-activity relationship, 2285
- Flow cytometrical, colorectal cancer, macrophage, intracellular, tumor marker, CEA, 3245
- ¹⁸F-Fluorodeoxyglucose, bioluminescent imaging, luciferase, micropositron-emission tomography, microPET, nuclear factor- κ B, 987
- Fluorescence *in situ* hybridization, gallbladder, adenocarcinoma, *Myc*, gene amplification, *ERBB2*, *EGFR*, 19
- Fluorescence spectroscopy, flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, UV, 2273
- Fluorescence spectroscopy, flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, UV, structure-activity relationship, 2285
- 5-Fluorouracil, 5-FU, oxaliplatin, sulindac sulfide, colorectal cancer, synergism, 435
- 5-Fluorouracil, activated lymphocytes, transforming growth factor-beta, TGF- β , prostaglandin E₂, PGE₂, 3925
- 5-Fluorouracil, bladder urothelial carcinoma, orotate phosphoribosyl transferase, dihydropyrimidine dehydrogenase, 5-chloro-2,4-dihydropyridine, 1001
- 5-Fluorouracil, gastric cancer, neoadjuvant chemotherapy, docetaxel, cisplatin, DFP, 4211
- 5-Fluorouracil, irinotecan, CPT-11, sequence-dependency, cell cycle, thymidylate synthase, apoptosis, 2083
- 5-Fluorouracil, methylnaltrexone, SW-480 colorectal cancer cell, MCF-7 breast cancer cell, non-small cell lung cancer cell, NSCLC, anti-proliferation, cell growth, cell cycle, 2927

- 5-Fluorouracil, WiDr colon cancer cells, growth factors, glutathione modulation, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 3957
- 5-FU, 5-fluorouracil, oxaliplatin, sulindac sulfide, colorectal cancer, synergism, 435
- FNA cytology, breast cancer, sentinel node biopsy, scintimammography, axillary ultrasonography, fine-needle aspiration cytology, 491
- FNA, melanoma, CD117, COX-2, HSP90, 4345
- Focal adhesion kinase, tissue transglutaminase, cell signaling, chemoresistance, metastasis, NF- κ B, integrin, review, 1909
- Focal therapy, prostate cancer, male lumpectomy, review, 5155
- FokI, vitamin D receptor, gene polymorphisms, cancer, BSm1, TaqI, Apa1, Cdx2, poly(A), Bgl1, 3511
- Follicular lymphoma, BCL2, BCL6, translocation, 4649
- Follicular tumors, thyroid nodule, thyroid cancer, fine-needle aspiration cytology, frozen section, 5255
- Formamidineoxorubicins, doxorubicin, resistant cells, uptake, topoisomerase II, 1429
- Forskolin, M6P/IGF-II receptor, M6P/IGF-II receptor modulation, M6P, brefeldin A, melanoma cells, immunoluminescence, 1383
- FoxP3, regulatory T-cell, gastrointestinal cancer, 1527
- Foxp3, splenectomy, liver metastasis, regulatory T-cell, NK cell, 385
- FPG-comet assay, ascorbic acid, zinc, N-acetylcysteine, oxidative DNA damage, 4571
- Free flap, venous coupler, breast reconstruction, 2827
- Frozen section, thyroid nodule, thyroid cancer, follicular tumors, fine-needle aspiration cytology, 5255
- Frozen sections, sentinel lymph node, breast cancer, micrometastasis, immunohistochemistry, 4711
- Frozen, osteosarcoma, talus, liquid nitrogen, reconstruction, 4093
- FSH, estradiol, LH, ovarian cancer, prolactin, 1575
- Fucoidan, biotinidase, hepatocellular carcinoma, liver cirrhosis, HuH-6 cells, LEW rat, biotin, 1211
- Fusion gene, *RUNX1*, translocation, acute leukemia, myelodysplastic syndrome, gene transcription, review, 1031
- G protein, GNB4, haplotype, SNP, colorectal cancer, 1271
- G₂-phase arrest, gnidimacrin, PKC β II, p21(WAF1/Cip1), cdc2, E2F-4, 1349
- α 1,3 Galactosyltransferase, polyethylene glycol, hematological malignancy, leukemia, immunotherapy, 2327
- Galectin-1, angiogenesis, laryngeal cancer, lymphocyte, lectin, prognosis, stroma, 59
- Galectin-8, dysplasia, epithelium, lectin, malignancy, preneoplasia, 4933
- Galectins, oligosaccharide ligand, apoptosis, cell aggregation, 403
- Gallbladder, adenocarcinoma, fluorescence *in situ* hybridization, *Myc*, gene amplification, *ERBB2*, *EGFR*, 19
- Gallbladder, adenocarcinoma, invasion pattern, vascular invasion, metastasis, 685
- Gamma probe, breast cancer, lymphoscintigraphy, methylene blue dye, sentinel lymph node, 4119
- Gamma rays, imatinib mesylate, PDGF receptor, astrocytoma, 4575
- Gap junction protein, connexin, head-and-neck cancer, cell proliferation, 1981
- GAPDH, 3-Bromopyruvate, cancer cell death, glycolysis, Hep3B, HepG2, SK-Hep1, 4909
- Gas chromatography mass spectrometry, lung cancer, volatile organic compounds, VOCs, thermodesorption, 419
- Gastric cancer, colon cancer, ErbB, neuroglycan-C, proliferation, 229
- Gastric cancer, CXCR4, SDF-1, metastasis, 4751
- Gastric cancer, cytokine plasma levels, prognosis, 5005
- Gastric cancer, docetaxel, S-1, chemotherapy, 2775
- Gastric cancer, heat-shock protein 90, Hsp90, targeted therapy, angiogenesis, gastrointestinal cancer, pancreatic cancer, review, 2031
- Gastric cancer, L1, metastasis, prognostic factor, 4033
- Gastric cancer, *mdr1*, methylation, 337
- Gastric cancer, *MGMT*, quantitative methylation-specific PCR, 5053
- Gastric cancer, *MYC* gene, *MYC* protein, *MYC* insertion, hybridization *in situ* fluorescence, 2479
- Gastric cancer, neoadjuvant chemotherapy, docetaxel, 5-fluorouracil, cisplatin, DFP, 4211
- Gastric cancer, oncogene, immunohistochemistry, prognosis, 4451
- Gastric cancer, RANTES promoter, *H. pylori*, polymorphism, 4265
- Gastric cancer, *RUNX3*, methylation, 2619
- Gastric cancer, selenium, trace elements, carcinoembryonic antigen, 3465
- Gastric cancer, *UNC5C*, quantitative methylation-specific PCR, 4397
- Gastric cancer, xenograft model, docetaxel, PSK, 843
- Gastric carcinoma, Bcl-2, Ki-67, apoptosis, prognostic factors, 703
- Gastric carcinoma, *CDH3*, quantitative methylation-specific PCR, 3945
- Gastric carcinoma, endothelium, pericyte, peg-socket junctions, electron microscopy, 449
- Gastric carcinoma, ERas, oncogene, prognosis, 2189
- Gastric carcinoma, *HACE1*, quantitative methylation-specific PCR, 2231
- Gastric carcinoma, *Vimentin*, quantitative methylation-specific PCR, 2227
- Gastric metastasis, breast cancer, immunohistochemistry, palliative surgery, hormone therapy, chemotherapy, 4759
- Gastric mucosa, methylation, *Helicobacter pylori*, *COMT*, polymorphism, 2857

- Gastrointestinal bleeding, chondroid differentiation, FISH, GIST, 2761
- Gastrointestinal cancer, heat-shock protein 90, Hsp90, targeted therapy, angiogenesis, pancreatic cancer, gastric cancer, review, 2031
- Gastrointestinal cancer, regulatory T-cell, FoxP3, 1527
- Gastrointestinal perforation, bevacizumab, empyema, pancreatic cancer, 1665
- Gastro-lymphatic fistula, esophageal cancer, radiotherapy, chemotherapy, 525
- GBM, Rho, ROCK, ERK, migration, proliferation, 119
- Gefitinib, BCRP/ABCG2, HPLC, *EGFR*, 1059
- Gefitinib, bortezomib, epidermal growth factor receptor, tumor necrosis factor α , resistance, 2315
- Gefitinib, cytotoxicity, hormesis, cell death, oral squamous cell carcinoma, 5023
- Gefitinib, lumbo-peritoneal shunt, meningeal carcinomatosis, lung cancer, epidermal growth factor receptor, T790M, 2759
- Gefitinib, neuroblastoma, epidermal growth factor receptor, chemotherapy, retinoic acid, 1327
- Gefitinib, non-small cell lung cancer, paclitaxel, *EGFR*-TKI, resistant, 2747
- Gefitinib, non-small cell lung cancer, treatment failure, post initial gefitinib therapy, 4217
- Gefitinib, NSCLC, erlotinib, *EGFR*, *KRAS*, mutation, 2767
- Gefitinib, predictive factors, erlotinib, *EGFR* mutations, *K-ras* mutations, smoking habits, lung cancer, 2691
- Geldanamycin, cancer, invasion, metastasis, molecular chaperones, heat-shock protein 90, molecularly targeted therapeutics, review, 797
- Gemcitabine, capecitabine, intra-arterial chemotherapy, phase I study, 1547
- Gemcitabine, docetaxel, advanced breast cancer, 1841
- Gemcitabine, docetaxel, first-line chemotherapy, mesothelioma, 3441
- Gemcitabine, epithelial ovarian cancer, treatment resistant, phase I/II study, docetaxel, 1521
- Gemcitabine, irinotecan, phase I, advanced solid tumors, 5149
- Gemcitabine, ovarian cancer, salvage treatment, cisplatin, ifosfamide, 2681
- Gemcitabine, pancreatic cancer, chemoresistance, nafamostat mesilate, 3173
- Gemcitabine, pancreatic cancer, erlotinib, overall survival, toxicity, 5211
- Gemtuzumab, calicheamicin, isobologram, CD33, leukemia, 4589
- Gender difference, *MGMT*, *p53* mutation, and NSCLC, 2535
- Gender, obesity, vitamin D deficiency, seasonal variation, age, 3713
- Gender-dependent, colonic 1,25(OH)₂D₃ concentration, dietary calcium, apoptosis, vitamin D hydroxylases, 3727
- Gene amplification, gallbladder, adenocarcinoma, fluorescence *in situ* hybridization, *Myc*, *ERBB2*, *EGFR*, 19
- Gene amplification, hepatocellular carcinoma, *JUN*, 4989
- Gene expression profiling, ribavirin, K562, leukemia, apoptosis, cell differentiation, inositide-5'-monophosphate dehydrogenase, IMPDH, 1971
- Gene expression, BFT, CDX2, homeobox genes, NSCLC, 1281
- Gene expression, Ewing tumours, HAT selection, immunotherapy, cell fusion, 4489
- Gene expression, metastin, AXOR12, DSCR1, real-time quantitative RT-PCR, epithelial ovarian cancer, 617
- Gene expression, oral cancer, NY-ESO-1, RT-PCR, diagnosis, therapy, 5125
- Gene mutation, chagas disease, megaesophagus, single nucleotide polymorphism, SNP, *FHIT* gene, *TP53* gene, *CDKN2A* gene, DNA sequencing, 1243
- Gene polymorphisms, cancer susceptibility, Southern Italian region, tumorigenesis, 1709
- Gene polymorphisms, vitamin D receptor, cancer, Fok1, BSm1, Taq1, Apa1, Cdx2, poly(A), Bgl1, 3511
- Gene regulation, vitamin D, vitamin D receptor, vitamin D response elements, *in silico* screening, nuclear receptor, review, 3485
- Gene therapy, cancer, transcriptional targeting, Q5 promoter, allograft rejection, cyclophosphamide, 1015
- Gene therapy, caspase-14, salivary gland cancer, vascularization, 3811
- Gene therapy, clinical trial, hormone refractory prostate cancer, adenovirus vector, 1533
- Gene transcription, *RUNX1*, fusion gene, translocation, acute leukemia, myelodysplastic syndrome, review, 1031
- Gene, cholangiocarcinoma, cholangiocarcinogenesis, molecular, mechanism, Klatskin tumor, review, 1151
- Genetic association study, tumor necrosis factor alpha, tumor necrosis factor beta, oral cancer, oncogenesis, polymorphism, 2379
- Genetic changes, lung cancer, non-small cell lung cancer, chromosome 9 numerical abnormalities, p16^{CDKN2A} gene deletion, FISH technique, 4483
- Genetic polymorphism, arylamine metabolism, bladder cancer, detoxification, arylesterase, *PONI*, 4041
- Genetic polymorphism, bladder cancer, susceptibility, metabolising gene, *CYP1A1*, *CYP1B1*, *COMT*, *GSTP1*, *NAT2*, single nucleotide polymorphism, 1631
- Genetic polymorphism, DNA repair, haplotype, renal cell cancer, outcome, *XRCC1*, 5131
- Genetics, renal cell carcinoma, hypoxia-inducible factors, VHL, 4337
- Genistein, EGCG, quercetin, phytochemical synergy, prostate cancer cells, 4025
- Germ cell tumors, immunohistochemical markers, prognostic markers, *p53*, MIB-1, survival, 737

- GFP, bone marrow, stem cells, breast cancer, nude mice, 443
 GFP, green fluorescent protein, *Salmonella typhimurium*, bacteria, tumor-targeting, pancreatic cancer, red fluorescent protein, RFP, imaging, 1873
 Ghrelin, decreased levels, plasma, cachexia, 3949
 Ghrelin, prostate cancer, bicalutamide, leuprorelin, 1345
 Giant basal cell carcinoma, tumor, reconstruction, 2655
 Giant cell tumor, osteoclast-like giant cell, stromal cell, bone morphogenetic protein, laser microdissection, 2219
 Gingival papillae, *p53*, *p63*, *p16*, oral cavity, 3983
 GIST, chondroid differentiation, FISH, gastrointestinal bleeding, 2761
 GIST, imatinib, postoperative course, 4893
 GIST, mouse model, xenograft, targeting, 4331
 Glassy cells, Barrett's mucosa, 4145
 Gleason score data, BPH, continuous and intermittent Finasteride, serum CgA data, acquired prostate cancer, 1797
 Glioblastoma multiforme, FEN1, testis tumors, lung cancer, astrocytoma, anticancer drugs, 2453
 Glioblastoma multiforme, meningioma, astrocytoma, angipoinetin 2, VEGF, 731
 Glioblastoma, anticoagulant, cerebral hemorrhage, pulmonary embolism, venous glioblastoma, venous thromboembolism, 4309
 Glioblastoma, apoptosis, HMG-CoA reductase, necrosis, pericytes, simvastatin, 4901
 Glioblastoma, pseudoprogression, concomitant radio-chemotherapy, radiological assessment, 2607
 Glioblastoma, radiotherapy, chemotherapy, temozolomide, targeted therapy, review, 5171
 Glioblastoma, sonodynamic therapy, normal brain, cavitation, thermal effect, 943
 Glioblastoma, temozolomide, O⁶-methylguanine-DNA methyltransferase, *MGMT*, review, 4845
 Glioma, alkylating agents, cancer, O⁶-methylguanine, O⁶-MG, O⁶-methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, promoter methylation, temozolomide, TMZ, review, 3759
 Glioma, methionine-free diet, CENU, melanoma, nitrosourea, 5235
 Glioma, pleiotrophin, heparin affin regulatory peptide, serum response element, endothelial cells, 349
 Glioma, ultrasound, Photofrin, LRP/ α 2MR, U251MG, U105MG, 897
 Gliomas, temozolomide, cisplatin, chemotherapy, malignant, 4275
 Glucose, RAW264.7, nutritional starvation, serine, glutamine, cell death, 343
 Glutamatergic system, prostate cancer, dihydrotestosterone, 371
 Glutamine, J774.1, nutritional starvation, serine, cell death, non-apoptosis, 5083
 Glutamine, RAW264.7, nutritional starvation, serine, glucose, cell death, 343
 Glutathione modulation, WiDr colon cancer cells, growth factors, 5-fluorouracil, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 3957
 Glutathione-S-transferase π , drug resistance, P-glycoprotein, daunorubicin, cytarabine, HL-60 cells, 4071
 Glutathione-S-transferase, head and neck cancer, microsomal epoxide hydrolase, UDP-glucuronosyltransferase, polymorphisms, cancer susceptibility, smoking, review, 753
 Glycolysis, 3-Bromopyruvate, cancer cell death, GAPDH, Hep3B, HepG2, SK-Hep1, 4909
 Glycolysis, mesothelioma, energetic metabolism, cisplatin, MSTO-211H, 1249
 Glycolysis, mesothelioma, nude mice, energetic metabolism, chemotherapy, 1443
 Glycomimetics, mistletoe lectin, MRP5, phage display mapping, 4941
 GLZ, vitamin D₃, 1 α -hydroxylase, splice variants, ovarian cancer, COV 434, HGL5, 3627
 GLZ, vitamin D₃, 24-hydroxylase, splice variants, ovarian cancer, COV 434, HGL5, 3635
 GNB4, G protein, haplotype, SNP, colorectal cancer, 1271
 Gnidimacrin, PKC β II, G₂-phase arrest, p21(WAF1/Cip1), *cdc2*, E2F-4, 1349
 GnRHR, prostate, carcinoma, androgen receptor, 681
Golgi apparatus, intestinal macrophages, CD14, endoplasmic reticulum, 865
 (-)-Gossypol, metastasis, prostate cancer, nm23-H1, Bcl-2, Bcl-xL, 2179
 (-)-Gossypol, Zeranol, leptin, breast cancer, 4621
 Grade, soft tissue tumors, M-CSF, CSF-1R, tumor markers, 3861
 Grading, colon cancer, rectal cancer, estrogen, vitamin D, 3721
 Granulosa cells, cyclooxygenase-2, 15-hydroxy-prostaglandin dehydrogenase, vitamin D receptor, prostaglandin metabolism, 3611
 Granzyme, trastuzumab, esophageal cancer, ADCC, perforin, 2137
 Grape seed procyanidin, colorectal carcinoma, apoptosis, caspase-3, 283
 Green fluorescent protein, GFP, *Salmonella typhimurium*, bacteria, tumor-targeting, pancreatic cancer, red fluorescent protein, RFP, imaging, 1873
 Green tea polyphenols, apoptosis, Bcl-2, caspase-3, 1417
 Growth factors, WiDr colon cancer cells, 5-fluorouracil, glutathione modulation, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 3957
 Growth, cancer, endometrium, progesterone, mifepristone, cell cycle, apoptosis, Ishikawa cells, 1053
 Growth, cancer, pharmacology, progestins, antiprogestins, Ishikawa cells, 1047

- Growth-inhibition, 23-hydroxyursolic acid, pentacyclic triterpenes, apoptosis, caspases, 995
- GSH, AMA, apoptosis, As4.1, MAPK, ROS, 4423
- GSH, arsenic trioxide, apoptosis, Calu-6, MAPK, ROS, 3837
- GSH, sesquiterpene lactone, ROS, autophagy, apoptosis, 1449
- GSK-3 β , prostate cancer, cell signaling pathway, apoptosis, proliferation, prognosis, 2077
- GSTP1*, bladder cancer, susceptibility, metabolising gene, *CYP1A1*, *CYP1B1*, *COMT*, *NAT2*, genetic polymorphism, single nucleotide polymorphism, 1631
- Guanylyl cyclase C, uroguanylin, *E. coli* heat-stable enterotoxin, single photon-emitting computed tomography, SPECT, colorectal cancer, *in vivo* imaging, 3777
- Gynecologic oncology, abstracts, NOGGO, 1563
- H. pylori*, gastric cancer, RANTES promoter, polymorphism, 4265
- HACE1*, quantitative methylation-specific PCR, gastric carcinoma, 2231
- Haematogenous failure, recurrence, myometrial invasion, lymph-vascular space involvement, endometrial cancer, 1715
- Hai, hepatic arterial infusion, colorectal cancer, liver metastasis, systemic chemotherapy, prognostic factors, 4139
- Hamster, pancreatic duct adenocarcinoma, *LKB1*, mutation, nitrosamine, 4047
- Hand-foot syndrome, anthracycline, doxorubicin, epirubicin, PPE, 2307
- Haperforin, cancer, chemotherapy, apoptosis, cell cycle, cytoskeleton, 1963
- Haplotype, DNA repair, genetic polymorphism, renal cell cancer, outcome, *XRCC1*, 5131
- Haplotype, G protein, GNB4, SNP, colorectal cancer, 1271
- HART, planned neck dissection, pharyngeal cancer, head and neck cancer, primary radio-chemotherapy, lymph node status, 2645
- Hartmann's procedure, clinico-pathological features, colorectal cancer, perforation, 1681
- HAT selection, Ewing tumours, gene expression, immunotherapy, cell fusion, 4489
- HB-EGF, amphiregulin, targeted therapy, cancer, review, 823
- HB-EGF, cancer, amphiregulin, targeted therapy, review, 4879
- HBV DNA, interleukin-2, HCV RNA, 5241
- HCA-7, NSAIDs, COX-2, DPD, HT-29, 3095
- HCC, hepatocellular carcinoma, adjuvant therapy, PHY906, capecitabine, Phase I/II, 4083
- HCT116 cells, capsaicin, resveratrol, nitric oxide, *p53*, chemoprevention, 3733
- HCV RNA, interleukin-2, HBV DNA, 5241
- Head and neck cancer, capecitabine, intensity-modulated radiation therapy, 2869
- Head and neck cancer, chemotherapy, radiation therapy, docetaxel, *ERCC1*, 529
- Head and neck cancer, docetaxel, ifosfamide, cisplatin, 5137
- Head and neck cancer, hyperglycemia, chemotherapy, radiation, 4683
- Head and neck cancer, lymphatics, lymph node metastasis, prognosis, 1675
- Head and neck cancer, microsomal epoxide hydrolase, glutathione-S-transferase, UDP-glucuronosyltransferase, polymorphisms, cancer susceptibility, smoking, review, 753
- Head and neck cancer, neoadjuvant chemotherapy, limited surgery, prognosis, radical surgery, 255
- Head and neck cancer, planned neck dissection, pharyngeal cancer, primary radio-chemotherapy, HART, lymph node status, 2645
- Head and neck cancer, *XRCC1* 194, *XRCC1* 399 polymorphism, survival, 4169
- Head and neck squamous cell carcinoma, oral cavity, oropharynx, prognosis, oncomarker, oxidative stress, malondialdehyde, 4227
- Headache, trastuzumab, adverse effects, migraine, 4223
- Head-and-neck cancer, connexin, gap junction protein, cell proliferation, 1981
- Heat-shock protein 70, anti-heat-shock protein 70 antibody, esophageal cancer, ELISA, immunohistochemistry, humoral immune system, 1595
- Heat-shock protein 90, cancer, invasion, metastasis, molecular chaperones, geldanamycin, molecularly targeted therapeutics, review, 797
- Heat-shock protein 90, Hsp90, targeted therapy, angiogenesis, gastrointestinal cancer, pancreatic cancer, gastric cancer, review, 2031
- Hedgehog signaling pathway, breast cancer, estrogen receptor-negative, invasion, 871
- Hedgehog signaling, breast cancer, cancer stem cell, 2147
- Hedgehog, Wnt, cyclopamine, quercetin, leukemia, lymphoma, 4629
- Helicobacter pylori*, methylation, gastric mucosa, *COMT*, polymorphism, 2857
- Helicobacter pylori*, pre-malignant condition, HSP70-2, polymorphism, 3453
- Helicobacter pylori*, VEGF, polymorphism, intestinal metaplasia, 485
- Helper antigen, HER2, Ii-key, T-cell, cancer stem cells, individualized cancer vaccines, 41
- Helper effect, HER-2, AE-37, AE-47, p776, F7, perforin, E75, cancer vaccines, high-affinity CD8⁺ cells, 2427
- Helper T-cell, cryoablation, immune reaction, hepatoma, ablation therapy, review, 5203
- Hematogenic metastasis, cordycepin (3'-deoxyadenosine), platelet aggregation, B16-F1 mouse melanoma cell, adenosine-5'-diphosphate, 3857

- Hematogenous, CEACAM-1, cell adhesion, lymphnode, metastasis, prognostic significance, non-small cell lung cancer, 249
- Hematological adverse event, tyrosine kinase inhibitors, 5225
- Hematological malignancies, ATG, cytotoxicity, 1355
- Hematological malignancy, polyethylene glycol, α 1,3 galactosyltransferase, leukemia, immunotherapy, 2327
- Hematological tumors, ARRY-520, KSP inhibitor, taxane resistant, 4373
- Hemoglobin, chemotherapy, epoetin- α , quality of life, solid tumors, 693
- Hep3B, 3-Bromopyruvate, cancer cell death, GAPDH, glycolysis, HepG2, SK-Hep1, 4909
- Heparin affin regulatory peptide, pleiotrophin, serum response element, endothelial cells, glioma, 349
- Heparin, apoptosis, Akt, oral squamous cell carcinoma, 1079
- Hepatic arterial infusion, hai, colorectal cancer, liver metastasis, systemic chemotherapy, prognostic factors, 4139
- Hepatitis B virus enhancer, EIIAPA, sodium iodine symporter, NIS, hepatocellular carcinoma, alpha-fetoprotein, AFP, 211
- Hepatitis C, ICC, chronic disease, 3239
- Hepatocarcinoma, mesoblastic nephroma, metastasis, parathymic lymph node, autoradiography, 2121
- Hepatocellular carcinoma, angiogenesis, black tea polyphenols, chemoprevention, histone deacetylation, invasion, 2301
- Hepatocellular carcinoma, biotinidase, liver cirrhosis, fucoidan, HuH-6 cells, LEW rat, biotin, 1211
- Hepatocellular carcinoma, chitosan nanoparticles, tumor growth, necrosis, angiogenesis, *VEGFR2*, 5103
- Hepatocellular carcinoma, fibrinogen gamma, fibrinogen, clinical stage, tumor thrombosis, 2531
- Hepatocellular carcinoma, gene amplification, *JUN*, 4989
- Hepatocellular carcinoma, HCC, adjuvant therapy, PHY906, capecitabine, Phase I/II, 4083
- Hepatocellular carcinoma, HSP70, HLA class I, 539
- Hepatocellular carcinoma, siRNA, migration, metastasis, peroxisome proliferator-activated receptor gamma, 5057
- Hepatocellular carcinoma, sodium iodine symporter, NIS, hepatitis B virus enhancer, EIIAPA, alpha-fetoprotein, AFP, 211
- Hepatocyte growth factor, angiogenesis factor, vascular endothelial growth factor, tumor markers, 3311
- Hepatoma, cryoablation, helper T-cell, immune reaction, ablation therapy, review, 5203
- Hepatoma, vitamin D, $1\alpha,25(\text{OH})_2\text{D}_3$, proliferation, fish oil, ω -3 PUFAs, HepG2, 3591
- HepG2, 3-Bromopyruvate, cancer cell death, GAPDH, glycolysis, Hep3B, SK-Hep1, 4909
- HepG2, vitamin D, $1\alpha,25(\text{OH})_2\text{D}_3$, proliferation, fish oil, ω -3 PUFAs, hepatoma, 3591
- HER2 status, breast cancer, persistent disseminated tumor cells, trastuzumab, targeted therapy, 4019
- HER2, *EGFR*, VEGF, breast cancer, surgery, 5111
- HER2, helper antigen, Ii-key, T-cell, cancer stem cells, individualized cancer vaccines, 41
- HER-2, helper effect, AE-37, AE-47, p776, F7, perforin, E75, cancer vaccines, high-affinity CD8⁺ cells, 2427
- HER2/neu ECD, breast cancer, trastuzumab, kinetics, tumor marker, 1703
- Her-2/neu, hormone receptors, discordance, breast cancer, metastases, 1557
- Hereditary cancer, colorectal cancer, familial adenomatous polyposis, APC gene, 711
- 5-Hexyl-2'-deoxyuridine, migration, extracellular matrix, three-dimensional cell-culture model, Boyden chamber, borrelidin, taxol, signal pathway inhibitors, antisense oligonucleotide, 2981
- HGL5, vitamin D₃, 1α -hydroxylase, splice variants, ovarian cancer, COV 434, GLZ, 3627
- HGL5, vitamin D₃, 24-hydroxylase, splice variants, ovarian cancer, COV 434, GLZ, 3635
- HIF, hypoxia inducible factor, recombinant adeno-associated virus, rAAV, small interference RNA, siRNA, nuclear factor-kappaB, NF- κ B, proliferation, apoptosis, 1367
- HIF1A*, DCA, hypoxia, proliferation, apoptosis, 4579
- HIF-1 α , angiogenesis, uterine cervical carcinomas, basic FGF, VEGF, COX-2, angiopoietin, *IL-8*, thymidine phosphorylase, ETS-1, review, 2665
- HIFU, infiltration, macrophages, lymphocytes, immunological effect, 3877
- High-affinity CD8⁺ cells, HER-2, helper effect, AE-37, AE-47, p776, F7, perforin, E75, cancer vaccines, 2427
- High-dose Ara-C, pyomyositis, methicillin-resistant *Staphylococcus aureus*, acute myelogenous leukemia, 3361
- High-dose chemotherapy, Ewing's sarcoma, rhabdomyosarcoma, autologous transplantation, 3281
- High-dose interleukin-2, metastatic melanoma, brain metastasis, retrospective study, 4189
- High-grade astrocytoma, cytoplasmic, nuclear, p27, prognosis, subcellular localization, 597
- High-grade glioma, chemotherapy, temozolomide, tumor necrosis factor-alpha, 911
- Histological variants, epithelial-myoepithelial carcinoma, minor salivary glands, immunohistochemistry, 4703
- Histone deacetylase inhibitor, carbon-ion radiotherapy, esophageal cancer, squamous cell carcinoma, 4433
- Histone deacetylation, angiogenesis, black tea polyphenols, chemoprevention, hepatocellular carcinoma, invasion, 2301
- Histone deacetylation, breast cancer, retinoic acid, epigenetic, telomerase, *hTERT*, 4959
- Histone deacetylation, ovarian cancer, estrogen receptor, epigenetic, DNA methylation, 139

- HL-60 cells, drug resistance, P-glycoprotein, daunorubicin, cytarabine, glutathione-S-transferase π , 4071
- HL-60 cells, synthesis, 14-*epi*-MART-10, 19-norvitamin D₃, Julia coupling, PZ-HPV-7 cells, 3563
- HL-60, AhR, curcumin, cell cycle, apoptosis, AML, 4657
- HL-60, asparagine synthetase, TPA, differentiation, asparaginase, apoptosis, 1303
- HLA class I, hepatocellular carcinoma, HSP70, 539
- HMGA2-LPP*, lipoma, *LPP-HMGA2*, RT-PCR, 2357
- HMGB1, angiogenesis, ELISA, exudates, transudates, 5013
- HMG-CoA reductase, apoptosis, glioblastoma, necrosis, pericytes, simvastatin, 4901
- HnRNPA2/B1, biomarker, brushing, immunoblotting, lung cancer, 1373
- HNSCC, cisplatin sensitivity, *EGFR*, proliferation, 1181
- HNSCC, oropharynx, oropharyngeal cancer, neck dissection, treatment, 4785
- HNSCC, plasmacytoid dendritic cell, CpG, migration, IFN- α , 3019
- HOCl signaling pathway, apoptosis, catalase, hydrogen peroxide, hypochlorous acid, hydroxyl radical, 4559
- HOCl signaling pathway, hydrogen peroxide, hypochlorous acid, hydroxyl radical, 4541
- Hodgkin's disease, cardiopulmonary toxicity, chemotherapy, radiotherapy, 777
- HOGG1, bladder cancer, polymorphism, *XRCC1*, *XRCC3*, *XPD*, *XPG*, *APE1*, 1389
- Homeobox genes, BFT, CDX2, gene expression, NSCLC, 1281
- Homeostasis, immune system, intestine, TLR4, lipopolysaccharide, IP-PA1, review, 4855
- Homeostasis, innate immunity, macrophage, lipopolysaccharide, IP-PA1, fermented flour extract, review, 859
- Homeostasis, intestinal macrophage, LPS, CD14, IgA, review, 4861
- Homocysteine, bevacizumab, metastatic colorectal carcinoma, 4813
- Homocysteinemia, colorectal cancer, breast cancer, inflammation, 4131
- Hormesis, gefitinib, cytotoxicity, cell death, oral squamous cell carcinoma, 5023
- Hormonal genes, CYP17 gene polymorphism, BPH, prostate cancer, North India, 1659
- Hormonal therapy, recurrent ovarian cancer, chemotherapy, treatment-free interval, 2831
- Hormone receptors, discordance, Her-2/neu, breast cancer, metastases, 1557
- Hormone refractory prostate cancer, cancer metastasis, cancer treatment, TBS-101, natural botanical components, 3917
- Hormone refractory prostate cancer, gene therapy, clinical trial, adenovirus vector, 1533
- Hormone therapy, breast cancer, gastric metastasis, immunohistochemistry, palliative surgery, chemotherapy, 4759
- Hormone therapy, sequence, radiotherapy, aromatase inhibitor, 4791
- Host-defensive function, carbon tetrachloride, innate, priming, triggering, lipid, 837
- HPLC, BCRP/ABCG2, gefitinib, *EGFR*, 1059
- HSP70, hepatocellular carcinoma, HLA class I, 539
- HSP70-2, pre-malignant condition, polymorphism, *Helicobacter pylori*, 3453
- Hsp90, heat-shock protein 90, targeted therapy, angiogenesis, gastrointestinal cancer, pancreatic cancer, gastric cancer, review, 2031
- HSP90, melanoma, CD117, COX-2, FNA, 4345
- HSRT, hypofractionated stereotactic radiotherapy, radioresistant brain metastasis, melanoma, radiosurgery, RS, radiotherapy, 4259
- H-ST5 hepatic metastasis, human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, P-ST5 primary tumor, L-ST5 lymph node metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- HSV, oncolytic virus, prodrug therapy, nitroreductase, antitumor activity, 2159
- HT29 xenografts, capecitabine, bevacizumab, irinotecan, colorectal cancer, 91
- HT-29, NSAIDs, COX-2, DPD, HCA-7, 3095
- HT-29/*luc*, polyethylene glycol, PEGylated liposome, reticuloendothelial system, indium-111, pharmacokinetics, biodistribution, bioluminescence imaging, 2111
- 5-HT3 receptor antagonist, anthracycline, cyclophosphamide, breast cancer, anti-emesis, repeated treatment, constipation, 1721
- HTERT* mRNA, lung cancer, telomerase, RT-PCR, TRAP, survival, 1157
- HTERT*, alternative lengthening, prognosis, review, 3833
- HTERT*, breast cancer, retinoic acid, epigenetic, histone deacetylation, telomerase, 4959
- HTERT*, circulating DNA, breast cancer, real-time PCR, tumor marker, 2845
- HuH-6 cells, biotinidase, hepatocellular carcinoma, liver cirrhosis, fucoidan, LEW rat, biotin, 1211
- Human adrenal cancer NCI-H295 cells, (-)-epigallocatechin gallate, EGCG, apoptosis, caspase, 1435
- Human breast epithelial cells, rapamycin, mTOR signaling, mTOR phosphorylation, STAT3 phosphorylation, biomarkers of resistance, p70S6 and RS6P, human breast premalignant and tumor epithelial cells, early events in breast tumorigenesis, 1143

- Human breast premalignant and tumor epithelial cells, rapamycin, mTOR signaling, mTOR phosphorylation, STAT3 phosphorylation, biomarkers of resistance, p70S6 and RS6P, human breast epithelial cells, early events in breast tumorigenesis, 1143
- Human colon cancer, progesterone receptor, antagonist, microenvironment, natural killer cells, 1611
- Human FOXP3, regulatory T-cells, VEGF, IL-10, TGF- β , immunotherapy, tumor immunity, survival, 881
- Human HepG2 cells, capsaicin, calcium, reactive oxygen species, mitochondrial membrane potential, apoptosis, 165
- Human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, P-ST5 primary tumor, L-ST5 lymph node metastasis, H-ST5 hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Human papillomavirus, oropharyngeal squamous cell carcinoma, vascular endothelial growth factor, hypoxia-inducible factor-1 α , 1467
- Human tongue cancer SCC-4 cells, aloe-emodin, apoptosis, caspase, 4503
- Humoral immune system, anti-heat-shock protein 70 antibody, heat-shock protein 70, esophageal cancer, ELISA, immunohistochemistry, 1595
- HUVEC, apoptosis, Bax, Bcl-2, bFGF, Endostar, 411
- Hybridization *in situ* fluorescence, gastric cancer, *MYC* gene, *MYC* protein, *MYC* insertion, 2479
- Hydrogen peroxide, apoptosis, HOCl signaling pathway, catalase, hypochlorous acid, hydroxyl radical, 4559
- Hydrogen peroxide, HOCl signaling pathway, hypochlorous acid, hydroxyl radical, 4541
- 20-Hydroxyeicosatetraenoic acid, renal adenocarcinoma, CYP4A, eicosanoids, xenograft model, 3819
- Hydroxyl radical, apoptosis, HOCl signaling pathway, catalase, hydrogen peroxide, hypochlorous acid, 4559
- Hydroxyl radical, HOCl signaling pathway, hydrogen peroxide, hypochlorous acid, 4541
- 1 α -Hydroxylase, vitamin D₃, splice variants, ovarian cancer, COV 434, HGL5, GLZ, 3627
- 24-Hydroxylase, vitamin D₃, splice variants, MCF-7, MCF-10, breast tissue, 3641
- 24-hydroxylase, vitamin D₃, splice variants, ovarian cancer, COV 434, HGL5, GLZ, 3635
- 5-Hydroxymethylfurfural, 5-sulfooxymethylfurfural, *Min/+* mice, aberrant crypt foci, intestinal carcinogenesis, 1921
- 15-Hydroxyprostaglandin dehydrogenase, breast cancer, cyclooxygenase-2, vitamin D receptor, prostaglandin metabolism, 3619
- 15-Hydroxy-prostaglandin dehydrogenase, granulosa cells, cyclooxygenase-2, vitamin D receptor, prostaglandin metabolism, 3611
- 23-Hydroxyursolic acid, pentacyclic triterpenes, growth-inhibition, apoptosis, caspases, 995
- 25-hydroxyvitamin D levels, vitamin D, vitamin D receptor, malignant melanoma, 3669
- 25-Hydroxyvitamin D, 1,25-dihydroxyvitamin D, survival, vitamin D supplementation, review, 3699
- 25-Hydroxyvitamin D-1 α -hydroxylase, splicing variants, keratinocyte, 3659
- 25-Hydroxyvitamin D-24-hydroxylase, vitamin D insufficiency, calcium intake, dairy calcium, calcium-sensing receptor, extrarenal 25-hydroxyvitamin D-1 α -hydroxylase, 1,25-dihydroxyvitamin D₃, review, 3687
- Hygiene hypothesis, lipopolysaccharide, macrophage, *Pantoea agglomerans*, innate immunity, allergic dermatitis, review, 4867
- Hypercalcemia, malignancy, cancer, PTHrP, RANKL, bisphosphonates, review, 1551
- Hyperglycemia, chemotherapy, radiation, head and neck cancer, 4683
- Hyperparathyroidism, breast neoplasms, bone neoplasms, diphosphonates, secondary, calcium, 2707
- Hyperplasia, breast, dysplasia, infrared temperature, skin, 4697
- Hyperplastic polyps, colonoscopic polypectomy, optical biopsy system, adenomatous polyps, 4737
- Hyperthermia, radiation, DNA repair, 1319
- Hypochlorous acid, apoptosis, HOCl signaling pathway, catalase, hydrogen peroxide, hydroxyl radical, 4559
- Hypochlorous acid, HOCl signaling pathway, hydrogen peroxide, hydroxyl radical, 4541
- Hypofractionated stereotactic radiotherapy, HSRT, radioresistant brain metastasis, melanoma, radiosurgery, RS, radiotherapy, 4259
- Hypoxia inducible factor, HIF, recombinant adeno-associated virus, rAAV, small interference RNA, siRNA, nuclear factor-kappaB, NF- κ B, proliferation, apoptosis, 1367
- Hypoxia, DCA, proliferation, *HIF1A*, apoptosis, 4579
- Hypoxia, estrogen, C/EBP α , T-47D cells, 1227
- Hypoxia, receptor for advanced glycation end products, RAGE, apoptosis, 1287
- Hypoxia-inducible factor-1 α , oropharyngeal squamous cell carcinoma, human papillomavirus, vascular endothelial growth factor, 1467
- Hypoxia-inducible factors, renal cell carcinoma, VHL, genetics, 4337
- IAP, TP-110, proteasome inhibitor, apoptosis, multiple myeloma, 977
- Ibritumomab tiuxetan, zevalin, radioimmunotherapy, non-Hodgkin's lymphoma, indolent lymphoma, aggressive lymphoma, 4771
- ICAM-1, resveratrol, endothelia, adhesion, NF- κ B, 355
- ICC, hepatitis C, chronic disease, 3239
- IDEA, non-Hodgkin's lymphoma, NHL, salvage, 1749
- IFN- α , plasmacytoid dendritic cell, HNSCC, CpG, migration, 3019

- Ifosfamide, docetaxel, cisplatin, head and neck cancer, 5137
 Ifosfamide, ovarian cancer, salvage treatment, cisplatin, gemcitabine, 2681
 IgA, intestinal macrophage, LPS, homeostasis, CD14, review, 4861
 IGF II, JIP-1, Wilms tumours, 2467
 IGF-1, IGFBP-3, breast cancer, apoptosis, 3785
 IGFBP-3, breast cancer, tissue microarray, 1131
 IGFBP-3, IGF-1, breast cancer, apoptosis, 3785
 IGFBP-3, osteosarcoma, normal bone, 2579
 IGF-I receptor, phosphorylated *MYC-N*, mTOR, neuroblastoma, rapamycin, temsirolimus, 1943
 IGF-II, JIP-1, WT1, Wilms tumour, 4999
 IGF-IR, combination targeted therapy, xenograft, *EGFR*, VEGF, 1999
 IgG immunoglobulin, immunogenicity, asparaginases, antibody, ALL, 299
 Ii-key, HER2, helper antigen, T-cell, cancer stem cells, individualized cancer vaccines, 41
 IL-10, regulatory T-cells, human FOXP3, VEGF, TGF- β , immunotherapy, tumor immunity, survival, 881
 IL-6, melanoma, redness, *IL-8*, 1793
 IL-6, MMP-10, JAK2/STAT3, lung cancer, 4497
 IL-6, PPAR γ , 15dPGJ₂, Stat3, PC-3 cells, prostate cancer, 2331
IL-8, angiogenesis, uterine cervical carcinomas, basic FGF, VEGF, COX-2, angiopoietin, thymidine phosphorylase, HIF-1 α , ETS-1, review, 2665
IL-8, melanoma, redness, *IL-6*, 1793
IL-8, pancreatic cancer, doxycycline, apoptosis, *p53*, *Fas*, 3995
 IMAC, phosphoproteome, UPLC, cerebellum, oxygen-18, 4949
 Image analysis, bile duct neoplasms, pancreas neoplasms, DNA ploidy, computer-assisted, cytometry, differential diagnosis, 1579
 Image analysis, immunohistochemistry, breast cancer, 4995
 Imageable model, EL-4 T-cell lymphoma, EGFP, whole body imaging, 4513
 Imaging, *Salmonella typhimurium*, bacteria, tumor-targeting, pancreatic cancer, red fluorescent protein, RFP, green fluorescent protein, GFP, 1873
 Imatinib mesylate, PDGF receptor, gamma rays, astrocytoma, 4575
 Imatinib, GIST, postoperative course, 4893
 Imexon antioxidant, antiproliferative activity, lymphoma cells, ionizing radiation, radiosensitization, 4409
 Immune reaction, cryoablation, helper T-cell, hepatoma, ablation therapy, review, 5203
 Immune system, intestine, TLR4, lipopolysaccharide, IP-PA1, homeostasis, review, 4855
 Immune system, ionizing radiation, SOD mimetic, RM-9 prostate cancer, NK cells, B-cells, cytokines, 107
 Immune system, ionizing radiation, SOD mimetic, RM-9 prostate cancer, NK cells, B-cells, cytokines, 107
 Immunoassay, CEA, TIMP-1, lead-time, biological marker, postoperative follow-up, 75
 Immunobiology, malignant astrocytoma, biological therapy, biological markers, review, 2461
 Immunoblotting, biomarker, brushing, hnRNPA2/B1, lung cancer, 1373
 Immunoblotting, MAPK, oral cancer, squamous sell carcinoma, phospho-ERK, 303
 Immunogenicity, asparaginases, antibody, IgG immunoglobulin, ALL, 299
 Immunohistochemical markers, germ cell tumors, prognostic markers, *p53*, MIB-1, survival, 737
 Immunohistochemistry, anti-heat-shock protein 70 antibody, heat-shock protein 70, esophageal cancer, ELISA, humoral immune system, 1595
 Immunohistochemistry, ATF2, p-ATF2, breast cancer, prognosis, Western blot, ERK-1/2, AP-1, MMP-9, 183
 Immunohistochemistry, Bcl-2, bax, *p53*, apoptosis, endometrium carcinoma, real-time PCR, 3977
 Immunohistochemistry, breast cancer, gastric metastasis, palliative surgery, hormone therapy, chemotherapy, 4759
 Immuno-histochemistry, canine cutaneous histiocytoma, E-cadherin, tumour regression, 2713
 Immunohistochemistry, CDX2, cutaneous metastases, extramammary Paget's disease, skin, 5033
 Immuno-histochemistry, c-FLIP, cancer cell xenografts, apoptosis, 3883
 Immunohistochemistry, colorectal carcinoma, MET, prognosis, survival, carcinogenesis, 4807
 Immunohistochemistry, COX2, leiomyosarcoma, tumor necrosis, 2913
 Immunohistochemistry, endometrial cancer, DNA mismatch repair, MSH2, 4833
 Immunohistochemistry, epithelial-myoepithelial carcinoma, minor salivary glands, histological variants, 4703
 Immunohistochemistry, esophageal carcinosarcoma, survival analysis, 3375
 Immunohistochemistry, esophagus, Oct3/4, Sox2, RT-PCR, Western blotting, 1233
 Immunohistochemistry, image analysis, breast cancer, 4995
 Immunohistochemistry, oncogene, prognosis, gastric cancer, 4451
 Immunohistochemistry, oral cancer, metallothionein, *p53* protein, prognosis, 1189
 Immunohistochemistry, RNAi knock-down, asparaginase, cell growth, 951
 Immunohistochemistry, S100A4, prognosis, lung cancer, tissue microarray, 2547
 Immunohistochemistry, S100A9, S100A8, thyroid carcinoma, undifferentiated carcinoma, 4157

- Immunohistochemistry, sentinel lymph node, breast cancer, frozen sections, micrometastasis, 4711
- Immunohistochemistry, survivin, urothelial carcinoma, recurrence, 4163
- Immunohistochemistry, telomerase, *TERT*, mammary tissue, dog, RT-PCR, 319
- Immunohistochemistry, tissue microarray, concordance, discordance, validity, multivariable analysis, 201
- Immunohistochemistry, WT1, endometrial cancer, clinicopathological factors, PCNA, cell proliferation, 4887
- Immunohistochemistry, WT1, endometrial cancer, clinicopathological factors, prognosis, 1691
- Immunological effect, HIFU, infiltration, macrophages, lymphocytes, 3877
- Immunoluminescence, M6P/IGF-II receptor, M6P/IGF-II receptor modulation, M6P, brefeldin A, forskolin, melanoma cells, 1383
- Immunosuppression, cancer, Stat, lymphocytes, 2051
- Immunotherapy, adoptive cell transfer, T-cells, 145
- Immunotherapy, bladder cancer, CpG-oligodeoxynucleotides, BCG, 2067
- Immunotherapy, Ewing tumours, HAT selection, gene expression, cell fusion, 4489
- Immunotherapy, hematological malignancy, polyethylene glycol, α 1,3 galactosyltransferase, leukemia, 2327
- Immunotherapy, pancreatic cancer, dendritic cells, vaccination, 831
- Immunotherapy, regulatory T-cells, human FOXP3, VEGF, IL-10, TGF- β , tumor immunity, survival, 881
- Immunotherapy, solid tumors, partial response, stable disease, 567
- Immunotherapy, Wilms' tumor 1, WT1, cancer vaccine, peptide, 4779
- IMPDH, inositide-5'-monophosphate dehydrogenase, ribavirin, gene expression profiling, K562, leukemia, apoptosis, cell differentiation, 1971
- In silico screening, vitamin D, vitamin D receptor, vitamin D response elements, gene regulation, nuclear receptor, review, 3485
- In vitro* assay-guided chemotherapy, non-small cell lung cancer, empirical chemotherapy, 4243
- In vivo* imaging, uroguanylin, *E. coli* heat-stable enterotoxin, guanylyl cyclase C, single photon-emitting computed tomography, SPECT, colorectal cancer, 3777
- Independent prognostic factor, Cap43, esophageal cancer, 965
- Indium-111, polyethylene glycol, PEGylated liposome, reticuloendothelial system, HT-29/*luc*, pharmacokinetics, biodistribution, bioluminescence imaging, 2111
- Individual tumor response testing, acute lymphoblastic leukemia, acute myeloid leukemia, children, adults, drug resistance, 1643
- Individualized cancer vaccines, HER2, helper antigen, Ii-key, T-cell, cancer stem cells, 41
- Indolent lymphoma, zevalin, ibritumomab tiuxetan, radioimmunotherapy, non-Hodgkin's lymphoma, aggressive lymphoma, 4771
- Infiltration, HIFU, macrophages, lymphocytes, immunological effect, 3877
- Inflammation, homocysteinemia, colorectal cancer, breast cancer, 4131
- Inflammation, *Rb*, *Trp53*, chromosome instability, skin cancer, NF κ B, mitotic checkpoint, 3035
- Inflammation, toll-like receptors, Akt, colon cancer, 2473
- Inflammation, tumorigenesis, antitumor immunity, review, 4795
- Inflammatory bowel disease, Crohn's disease, epidemiology, ulcerative colitis, colorectal cancer, colon carcinogenesis, molecular biology, review, 2727
- Inflammatory recurrence, breast cancer, skin recurrence, radiotherapy, mastectomy, overall survival, recurrence-free survival, 1697
- Infliximab, Crohn's disease, anal fistula, 927
- Infrared temperature, breast, hyperplasia, dysplasia, skin, 4697
- Innate immunity, lipopolysaccharide, macrophage, *Pantoea agglomerans*, allergic dermatitis, hygiene hypothesis, review, 4867
- Innate immunity, macrophage, lipopolysaccharide, IP-PA1, fermented flour extract, homeostasis, review, 859
- Innate immunity, prophylaxis, macrophage network, TLR4, review, 817
- Innate, host-defensive function, carbon tetrachloride, priming, triggering, lipid, 837
- Inositide-5'-monophosphate dehydrogenase, IMPDH, ribavirin, gene expression profiling, K562, leukemia, apoptosis, cell differentiation, 1971
- Integrin, angiogenesis, animal model, metastasis, experimental therapy, 131
- Integrin, renal cell carcinoma, angiogenesis, Tetrac, Tetrac nanoparticles, anti-cancer, anti-angiogenesis, 3825
- Integrin, tissue transglutaminase, cell signaling, chemoresistance, metastasis, focal adhesion kinase, NF- κ B, review, 1909
- Integrin, α v β 6, EMT, oral SCC, matrix, epithelial-mesenchymal transition, 125
- Integrin, α v β 6, TRA-1-60, stem cell, oral SCC, matrix, 2043
- Intensity-modulated radiation therapy, capecitabine, head and neck cancer, 2869
- Interferon-gamma, dendritic cells, Thymax, Th1, CD83, 4367
- Interleukin-2, carboplatin, melanoma, metastatic, second-line treatment, vinorelbine, 1755
- Interleukin-2, HCV RNA, HBV DNA, 5241
- Interleukin-6, liver surgery, portal vein embolization, portal vein ligation, liver regeneration, porcine model, 2371
- Internal cancer, sun, skin cancer, vitamin D, vitamin D and cancer, review, 3501

- Interstitial lung disease, pulmonary toxicity, dyspnea, pneumonitis, antineoplastic drugs, lung injury, review, 631
- Interstitial lung disease, survival, non-small cell lung cancer, 2671
- Intestinal carcinogenesis, 5-hydroxymethylfurfural, 5-sulfooxymethylfurfural, *Min/+* mice, aberrant crypt foci, 1921
- Intestinal macrophage, LPS, homeostasis, CD14, IgA, review, 4861
- Intestinal macrophages, CD14, endoplasmic reticulum, *Golgi apparatus*, 865
- Intestinal metaplasia, VEGF, *Helicobacter pylori*, polymorphism, 485
- Intestine, carcinogenesis, retinol, vitamin D, *Min/+* mouse, 4353
- Intestine, immune system, TLR4, lipopolysaccharide, IP-PA1, homeostasis, review, 4855
- Intra-arterial chemotherapy, gemcitabine, capecitabine, phase I study, 1547
- Intracellular immune dysfunction, fatigue, RNase L, nitric oxide, protein kinase R, nuclear factor kappa beta, NF- κ B, natural killer cell, oxidative stress, exercise, review, 4717
- Intracellular, colorectal cancer, macrophage, flow cytometrical, tumor marker, CEA, 3245
- Intraperitoneal chemotherapy, ovarian cancer, platinum, taxane, review, 2803
- Intraperitoneal chemotherapy, pseudomyxoma peritonei, experimental model, peritoneal carcinomatosis, 4051
- Intratumoral molecular homogeneity, anaplastic carcinoma, thyroid cancer, 2437
- Intravenous leiomyomatosis, benign metastasizing leiomyoma, 495
- Intravenous, cancer, vitamin C, ascorbic acid, ascorbate, plasma concentration, cytotoxicity, complementary and alternative medicine, review, 809
- Invasion pattern, gallbladder, adenocarcinoma, vascular invasion, metastasis, 685
- Invasion, angiogenesis, black tea polyphenols, chemoprevention, hepatocellular carcinoma, histone deacetylation, 2301
- Invasion, breast cancer, estrogen receptor-negative, Hedgehog signaling pathway, 871
- Invasion, cancer, metastasis, molecular chaperones, heat-shock protein 90, geldanamycin, molecularly targeted therapeutics, review, 797
- Invasion, EMT, *PTEN*, TNF- α , migration, 4439
- Ion channel, riluzole, apoptosis, endoplasmic reticulum stress, prostate cancer, 2195
- Ionizing radiation, imexon antioxidant, antiproliferative activity, lymphoma cells, radiosensitization, 4409
- Ionizing radiation, SOD mimetic, RM-9 prostate cancer, NK cells, B-cells, cytokines, immune system, 107
- IP-PA1, immune system, intestine, TLR4, lipopolysaccharide, homeostasis, review, 4855
- IP-PA1, innate immunity, macrophage, lipopolysaccharide, fermented flour extract, homeostasis, review, 859
- IP-PA1, oral administration, LPS, M1 macrophage, comparative immunology, 4871
- Irinotecan, capecitabine, bevacizumab, colorectal cancer, HT29 xenografts, 91
- Irinotecan, CPT-11, 5-fluorouracil, sequence-dependency, cell cycle, thymidylate synthase, apoptosis, 2083
- Irinotecan, gemcitabine, phase I, advanced solid tumors, 5149
- Irradiated bone graft, periacetabular bone tumor, vascularized bone graft, microsurgery, 1669
- Irradiation, Ewing tumour, kidney transplantation, organ dose, 3397
- Ishikawa cells, cancer, endometrium, growth, progesterone, mifepristone, cell cycle, apoptosis, 1053
- Ishikawa cells, cancer, pharmacology, growth, progestins, antiprogestins, 1047
- Isobologram, gemtuzumab, calicheamicin, CD33, leukemia, 4589
- Isoforms, L1-CAM, tumorigenesis, signaling, monoclonal antibodies, review, 4919
- J774.1, nutritional starvation, serine, glutamine, cell death, non-apoptosis, 5083
- Jab1, p27^{kip1}, ubiquitin-proteasome system, cholangiocarcinoma, adenovirus, 2015
- Jab1, ZD1839, p27^{kip1}, radiation, cholangiocarcinoma, 1169
- Jagged, notch, leukemia, Delta-like, 3967
- JAK2/STAT3, MMP-10, IL-6, lung cancer, 4497
- JIP-1, IGF II, Wilms tumours, 2467
- JIP-1, IGF-II, WT1, Wilms tumour, 4999
- Jugular vein thrombosis, renal cell carcinoma, metastasis, thyroid, thyroidectomy, neoplastic thrombus, 473
- Julia coupling, synthesis, 14-*epi*-MART-10, 19-norvitamin D₃, PZ-HPV-7 cells, HL-60 cells, 3563
- JUN*, gene amplification, hepatocellular carcinoma, 4989
- K562, ribavirin, gene expression profiling, leukemia, apoptosis, cell differentiation, inositide-5'-monophosphate dehydrogenase, IMPDH, 1971
- Kaliuretic peptide, prostate cancer, cardiac hormones, vessel dilator, Ras, 971
- Kaposi's sarcoma, paclitaxel, anthracycline-refractory, 675
- Keratinocyte, splicing variants, 25-hydroxyvitamin D-1 α -hydroxylase, 3659
- Ki-67 antigen, melatonin, melatonin receptors, MT1, MT2, malignant melanoma, 3887
- Ki-67, gastric carcinoma, Bcl-2, apoptosis, prognostic factors, 703
- Ki-67, Ki-S11, laryngeal cancer, squamous cell carcinoma, 1459
- Kidney transplantation, Ewing tumour, irradiation, organ dose, 3397

- Kinetics, breast cancer, HER2/neu ECD, trastuzumab, tumor marker, 1703
- Ki-S11, Ki-67, laryngeal cancer, squamous cell carcinoma, 1459
- KL-6, correlation coefficient, tumor marker, CA15-3, BCA225, 4239
- Klatskin tumor, cholangiocarcinoma, cholangiocarcinogenesis, gene, molecular, mechanism, review, 1151
- K-ras* mutations, predictive factors, gefitinib, erlotinib, *EGFR* mutations, smoking habits, lung cancer, 2691
- K-ras*, colorectal cancer, panitumumab, 3369
- KRAS*, NSCLC, gefitinib, erlotinib, *EGFR*, mutation, 2767
- K-ras*, pancreatic cancer, *p53*, *p16*, *DPC4*, prognostic markers, 1803
- KSP inhibitor, ARRY-520, hematological tumors, taxane resistant, 4373
- Ku80, polymorphism, bladder cancer, carcinogenesis, 1275
- Ku80, polymorphism, breast cancer, carcinogenesis, 5251
- Ku80, polymorphism, colorectal cancer, carcinogenesis, 2239
- L1 cell adhesion molecule, esophageal adenocarcinoma, tumor marker, therapy target, 1195
- L1, metastasis, gastric cancer, prognostic factor, 4033
- L1-CAM, tumorigenesis, isoforms, signaling, monoclonal antibodies, review, 4919
- L-2-Oxothiazolidine-4-carboxylate, WiDr colon cancer cells, growth factors, 5-fluorouracil, glutathione modulation, buthionine-SR-sulfoximine, 3957
- Labelling index, sirolimus, urothelial lesions, mice, BBN, 3221
- Laminin, metallothionein, proliferation, lymph nodes metastases, oral cancer, 589
- Laparoscopy, prostate cancer, radical prostatectomy, robotics, 1637
- Laryngeal cancer, angiogenesis, galectin-1, lymphocyte, lectin, prognosis, stroma, 59
- Laryngeal cancer, *BRCA-1* mutation, 2703
- Laryngeal cancer, Ki-67, Ki-S11, squamous cell carcinoma, 1459
- Laryngeal carcinoma, radiotherapy, chemoradiotherapy, larynx preservation, 661
- Larynx preservation, laryngeal carcinoma, radiotherapy, chemoradiotherapy, 661
- Laser microdissection, giant cell tumor, osteoclast-like giant cell, stromal cell, bone morphogenetic protein, 2219
- Laser microdissection, SELDI-TOF MS, ovarian cancer, cancer biomarkers, proteomics, 1039
- Late relapse, advanced ovarian cancer, pegylated liposomal doxorubicin, carboplatin, platinum-sensitive, 4195
- Late renal dysfunction, cataract induction, dose-effect relationship, biologically effective dose, 3305
- Late toxicity, prostate cancer, radiotherapy, rectal toxicity, 1831
- Latrunculin A, actin, depolymerization, apoptosis, anti-cancer drug, 2091
- Lead-time, CEA, TIMP-1, immunoassay, biological marker, postoperative follow-up, 75
- Lectin, angiogenesis, galectin-1, laryngeal cancer, lymphocyte, prognosis, stroma, 59
- Lectin, dysplasia, epithelium, malignancy, preneoplasia, galectin-8, 4933
- Leiomyosarcoma, 18-F-FDG-PET, bone metastases, 469
- Leiomyosarcoma, COX2, immunohistochemistry, tumor necrosis, 2913
- Lentinan, beta-1,3-glucan, colorectal cancer, peripheral blood monocytes, quality of life, superfine dispersed lentinan, 2611
- Lentinan, meta-analysis, advanced gastric cancer, clinical trials, 2739
- Leptin, adiponectin, colorectal cancer, prognosis, 3321
- Leptin, Zeranol, (-)-gossypol, breast cancer, 4621
- Leptomeningeal disease, breast cancer, neoplastic meningitis, chemotherapy, temozolomide, DepoCyte[®], liposomal Ara-C, 5191
- Leptomeningeal dissemination, pilomyxoid astrocytoma, pilocytic astrocytoma, chemotherapy, 919
- Leukemia, correlation, P-gp, MRP, expression, 1073
- Leukemia, gemtuzumab, calicheamicin, isobologram, CD33, 4589
- Leukemia, hedgehog, Wnt, cyclopamine, quercetin, lymphoma, 4629
- Leukemia, hematological malignancy, polyethylene glycol, α 1,3 galactosyltransferase, immunotherapy, 2327
- Leukemia, notch, Jagged, Delta-like, 3967
- Leukemia, ribavirin, gene expression profiling, K562, apoptosis, cell differentiation, inositide-5'-monophosphate dehydrogenase, IMPDH, 1971
- Leukemic cells, cell cycle regulatory proteins, apoptosis, caspase 3, staurosporine, 2893
- Leukocytosis, anemia, thrombocytosis, non-small cell lung cancer, preoperative, survival, 2687
- Leuprorelin, ghrelin, prostate cancer, bicalutamide, 1345
- LEW rat, biotinidase, hepatocellular carcinoma, liver cirrhosis, fucoidan, HuH-6 cells, biotin, 1211
- LH, estradiol, FSH, ovarian cancer, prolactin, 1575
- Libyan female breast cancer, nuclear morphometry, survival, clinicopathological features, 1771
- Ligand binding, cytochrome P450, CYP3A4, drug metabolism, dynamic structure, 935
- Limited surgery, head and neck cancer, neoadjuvant chemotherapy, prognosis, radical surgery, 255
- Lipid, host-defensive function, carbon tetrachloride, innate, priming, triggering, 837
- Lipoma, *HMG2-LPP*, *LPP-HMG2*, RT-PCR, 2357
- Lipopolysaccharide, biphenols, radical-scavenging activity, COX-2, NF-kappaB, AP-1, DFT/B3LYP, 2403

- Lipopolysaccharide, immune system, intestine, TLR4, IP-PA1, homeostasis, review, 4855
- Lipopolysaccharide, innate immunity, macrophage, IP-PA1, fermented flour extract, homeostasis, review, 859
- Lipopolysaccharide, macrophage, *Pantoea agglomerans*, innate immunity, allergic dermatitis, hygiene hypothesis, review, 4867
- Liposarcoma, spermatic cord, 677
- Liposomal Ara-C, breast cancer, leptomeningeal disease, neoplastic meningitis, chemotherapy, temozolomide, DepoCyte[®], 5191
- Liposomal, curcumin, dose finding, pancreatic, cancer, 1895
- Liquid nitrogen, osteosarcoma, talus, frozen, reconstruction, 4093
- Liver cirrhosis, biotinidase, hepatocellular carcinoma, fucoidan, HuH-6 cells, LEW rat, biotin, 1211
- Liver metastases, colorectal cancer, elderly, resection, 583
- Liver metastases, radiofrequency induced thermotherapy, bipolar, 1309
- Liver metastases, stereotactic radiosurgery, unresectable metastases, colorectal cancer, CyberKnife[®], solid tumours, 3381
- Liver metastasis, colorectal cancer, hepatic arterial infusion, hai, systemic chemotherapy, prognostic factors, 4139
- Liver metastasis, splenectomy, regulatory T-cell, Foxp3, NK cell, 385
- Liver regeneration, interleukin-6, liver surgery, portal vein embolization, portal vein ligation, porcine model, 2371
- Liver surgery, interleukin-6, portal vein embolization, portal vein ligation, liver regeneration, porcine model, 2371
- LKB1*, pancreatic duct adenocarcinoma, mutation, hamster, nitrosamine, 4047
- L-MYC*, polymorphism, oral squamous cell carcinoma, 2519
- LNCaP, androgen-independent prostate cancer, α -methylacyl-CoA racemase, siRNA, C4-2, 2497
- LNCaP, bisphosphonate, pamidronate, zoledronic acid, osteoblast, osteoclast, 1089
- Local recurrence, adjuvant chemotherapy, stomach carcinoma, 1853
- Local recurrence, node-negative breast cancer, urokinase-type plasminogen activator, plasminogen activator inhibitor type I, prognostic factor, distant metastases, 1475
- Localized, circulating tumor cells, solid tumor, metastatic, stages, 4839
- Locally advanced breast cancer, neo-adjuvant chemotherapy, biological markers, 1621
- Lomefloxacin, sonodynamic, polyethylene glycol, sarcoma180, 243
- Long-acting atrial natriuretic peptide, prostate cancer, cardiac hormones, atrial natriuretic peptide, Ras, 1889
- Low dose chemotherapy, S-1, recurrent head and neck cancer, outpatient chemotherapy, tumor dormancy, 577
- LPP-HMGA2*, *HMGA2-LPP*, lipoma, RT-PCR, 2357
- LPS, intestinal macrophage, homeostasis, CD14, IgA, review, 4861
- LPS, oral administration, IP-PA1, M1 macrophage, comparative immunology, 4871
- LRP/ α 2MR, ultrasound, Photofrin, glioma, U251MG, U105MG, 897
- L-ST5 lymph node metastasis, human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, P-ST5 primary tumor, H-ST5 hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Luciferase, bioluminescence imaging, mammary cancer, metastasis, 4389
- Luciferase, bioluminescent imaging, ¹⁸F-fluorodeoxyglucose, micropositron-emission tomography, microPET, nuclear factor- κ B, 987
- Lumbo-peritoneal shunt, gefitinib, meningeal carcinomatosis, lung cancer, epidermal growth factor receptor, T790M, 2759
- Lung cancer, *APE1*, BER, cigarette, polymorphism, RFLP, 2417
- Lung cancer, aryl hydrocarbon receptor, *CYP1B1*, *p53*, epidermal growth factor receptor, 509
- Lung cancer, biomarker, brushing, hnRNPA2/B1, immunoblotting, 1373
- Lung cancer, diagnosis, prognosis, ProGRP, NSE, CYFRA 21-1, CEA, 4827
- Lung cancer, *DYRK2*, *p53*, predictive marker, chemotherapy, 2753
- Lung cancer, *EGFR*, nm23, verapamil, 27
- Lung cancer, *Exo1*, polymorphism, carcinogenesis, 725
- Lung cancer, FEN1, testis tumors, glioblastoma multiforme, astrocytoma, anticancer drugs, 2453
- Lung cancer, gefitinib, lumbo-peritoneal shunt, meningeal carcinomatosis, epidermal growth factor receptor, T790M, 2759
- Lung cancer, macrophages, cytokines, activation state, 5095
- Lung cancer, MMP-10, IL-6, JAK2/STAT3, 4497
- Lung cancer, non-small cell lung cancer, genetic changes, chromosome 9 numerical abnormalities, p16^{CDKN2A} gene deletion, FISH technique, 4483
- Lung cancer, predictive factors, gefitinib, erlotinib, *EGFR* mutations, *K-ras* mutations, smoking habits, 2691
- Lung cancer, S100A4, prognosis, tissue microarray, immunohistochemistry, 2547
- Lung cancer, telomerase, *hTERT* mRNA, RT-PCR, TRAP, survival, 1157
- Lung cancer, volatile organic compounds, VOCs, gas chromatography mass spectrometry, thermodesorption, 419
- Lung injury, pulmonary toxicity, interstitial lung disease, dyspnea, pneumonitis, antineoplastic drugs, review, 631
- Lung, neoplasms, EpCAM, 1817

- LY294002, apoptosis, boswellic acids, PI3 kinase, Akt, colon cancer cells, wortmannin, 2987
- Lymph node metastasis, head and neck cancer, lymphatics, prognosis, 1675
- Lymph node metastasis, lymphadenectomy, cytoreduction, ovarian cancer, review, 2837
- Lymph node metastasis, proximal gastric cancer, splenectomy, splenic hilus, 3347
- Lymph node metastasis, vulvar cancer, prognosis, survival, staging, SCC-Ag, 545
- Lymph node status, planned neck dissection, pharyngeal cancer, head and neck cancer, primary radio-chemotherapy, HART, 2645
- Lymph node, breast cancer, ductal *in situ* carcinoma, sentinel node biopsy, 1499
- Lymph nodes metastases, metallothionein, laminin, proliferation, oral cancer, 589
- Lymphadenectomy, cytoreduction, lymph node metastasis, ovarian cancer, review, 2837
- Lymphatics, head and neck cancer, lymph node metastasis, prognosis, 1675
- Lymphnode, CEACAM-1, cell adhesion, hematogenous, metastasis, prognostic significance, non-small cell lung cancer, 249
- Lymphocyte infiltration, soft tissue tumor, fibrocollagenous tissue, T lymphocyte, 5197
- Lymphocyte, angiogenesis, galectin-1, laryngeal cancer, lectin, prognosis, stroma, 59
- Lymphocytes, cancer, Stat, immunosuppression, 2051
- Lymphocytes, HIFU, infiltration, macrophages, immunological effect, 3877
- Lymphoma cells, imexon antioxidant, antiproliferative activity, ionizing radiation, radiosensitization, 4409
- Lymphoma, hedgehog, Wnt, cyclopamine, quercetin, leukemia, 4629
- Lymphoscintigraphy, breast cancer, gamma probe, methylene blue dye, sentinel lymph node, 4119
- Lymph-vascular space involvement, recurrence, haematogenous failure, myometrial invasion, endometrial cancer, 1715
- M1 macrophage, oral administration, IP-PA1, LPS, comparative immunology, 4871
- M6P, M6P/IGF-II receptor, M6P/IGF-II receptor modulation, brefeldin A, forskolin, melanoma cells, immunoluminescence, 1383
- M6P/IGF-II receptor modulation, M6P/IGF-II receptor, M6P, brefeldin A, forskolin, melanoma cells, immunoluminescence, 1383
- M6P/IGF-II receptor, M6P/IGF-II receptor modulation, M6P, brefeldin A, forskolin, melanoma cells, immunoluminescence, 1383
- Macromolecular therapeutics, apoptosis, protein transduction domain, survivin, 1423
- Macrophage network, innate immunity, prophylaxis, TLR4, review, 817
- Macrophage, colorectal cancer, intracellular, flow cytometrical, tumor marker, CEA, 3245
- Macrophage, diethyl 2-chloroazulene-1,3-dicarboxylate, RAW264.7 cells, PGE₂, COX-2, PLA2, anti-inflammatory effect, 379
- Macrophage, innate immunity, lipopolysaccharide, IP-PA1, fermented flour extract, homeostasis, review, 859
- Macrophage, lipopolysaccharide, *Pantoea agglomerans*, innate immunity, allergic dermatitis, hygiene hypothesis, review, 4867
- Macrophage, phagocytosis, *tuberculosis*, TLR2, phagosome maturation, survival strategy, short review, 907
- Macrophages, HIFU, infiltration, lymphocytes, immunological effect, 3877
- Macrophages, lung cancer, cytokines, activation state, 5095
- MAD2 mitotic arrest deficient-like 1, MAD2L1, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, 4381
- MAD2L1, MAD2 mitotic arrest deficient-like 1, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, 4381
- MAGE1 HLA-A24 restricted peptide, DC vaccine, metastatic melanoma, T-cell receptor (TCR) beta cDNA cloning, electroporation, 647
- Male lumpectomy, prostate cancer, focal therapy, review, 5155
- Malignancy, dysplasia, epithelium, lectin, preneoplasia, galectin-8, 4933
- Malignancy, hypercalcemia, cancer, PTHrP, RANKL, bisphosphonates, review, 1551
- Malignant ascites, CD3, CD3 ζ , tumor-infiltrating lymphocytes, TIL, epithelial ovarian carcinoma, EOC, 4673
- Malignant ascites, ovarian cancer, catumaxomab, review, 3353
- Malignant astrocytoma, immunobiology, biological therapy, biological markers, review, 2461
- Malignant glioma, ultrasound, echo-contrast agent, microbubbles, central nervous system, 235
- Malignant melanoma, melatonin, melatonin receptors, MT1, MT2, Ki-67 antigen, 3887
- Malignant melanoma, nuclear receptors, peroxisome proliferator-activated receptors, PPAR, vitamin D receptor, VDR, 3647
- Malignant melanoma, phosphodiesterase, phosphodiesterase 1, 1119

- Malignant melanoma, vitamin D, vitamin D receptor, 25-hydroxyvitamin D levels, 3669
- Malignant myoepithelioma, maxillary sinus, proton beam therapy, radiation therapy, 497
- Malignant peripheral nerve sheath tumor, MPNST, recurrence, metastasis, molecular characterization, cell cycle regulators, Nm-23H1, 1255
- Malignant peripheral nerve sheath tumors, neurofibroma, CD10, neurofibromatosis, 3149
- Malignant pleural mesothelioma, osteopontin, $\alpha\beta3$ integrin, 2205
- Malignant portal vein stenosis, metallic stent, pancreatic cancer, 3329
- Malignant potential, cancer, metastasis, cell-based assay, anoikis, matrix metalloproteinase, MMP, 2541
- Malignant, temozolomide, cisplatin, chemotherapy, gliomas, 4275
- Malondialdehyde, head and neck squamous cell carcinoma, oral cavity, oropharynx, prognosis, oncomarker, oxidative stress, 4227
- Mammary cancer, luciferase, bioluminescence imaging, metastasis, 4389
- Mammary cancer, α -mangostin, panaxanthone, antitumor, chemoprevention, 2485
- Mammary tissue, telomerase, *TERT*, dog, immunohistochemistry, RT-PCR, 319
- Mammoplasty, multiple fibroadenoma, breast surgery, 2823
- α -Mangostin, panaxanthone, antitumor, chemoprevention, mammary cancer, 2485
- MAPK inhibition, paclitaxel, apoptosis, colon cancer, PD98059, 261
- MAPK, AMA, apoptosis, As4.1, ROS, GSH, 4423
- MAPK, arsenic trioxide, apoptosis, Calu-6, ROS, GSH, 3837
- MAPK, oral cancer, squamous cell carcinoma, immunoblotting, phospho-ERK, 303
- Marker, colorectal cancer, claudin, clinicopathological factor, 851
- Marriage, osteosarcoma, fertility, surgery, chemotherapy, 763
- MART-10, vitamin D, androgen, prostate cancer, 3547
- Mastectomy, breast cancer, skin recurrence, inflammatory recurrence, radiotherapy, overall survival, recurrence-free survival, 1697
- Matrigel assay, *Viscum album*, European mistletoe, angiogenesis, endothelial cells, apoptosis, cancer therapy, 2945
- Matriptase, endometrial cancer, prognostic significance, 1685
- Matrix metalloproteinase, MMP, cancer, metastasis, malignant potential, cell-based assay, anoikis, 2541
- Matrix metalloproteinase, MMP, tissue inhibitor of matrix metalloproteinase, TIMP, colorectal carcinoma, CRC, microarray analysis, 67
- Matrix, integrin, $\alpha\beta6$, EMT, oral SCC, epithelial-mesenchymal transition, 125
- Matrix, integrin, $\alpha\beta6$, TRA-1-60, stem cell, oral SCC, 2043
- Maxillary sinus, malignant myoepithelioma, proton beam therapy, radiation therapy, 497
- MCF-10, vitamin D₃, 24-hydroxylase, splice variants, MCF-7, breast tissue, 3641
- MCF-7 breast cancer cell, methylglutathione, 5-fluorouracil, SW-480 colorectal cancer cell, non-small cell lung cancer cell, NSCLC, anti-proliferation, cell growth, cell cycle, 2927
- MCF-7 cells, anticancer activity, brine shrimp larvae, selectivity index, 2993
- MCF-7, Tamoxifen, bioavailability, toxicity, alginate/chitosan microparticles, 4529
- MCF-7, vitamin D₃, 24-hydroxylase, splice variants, MCF-10, breast tissue, 3641
- M-CSF, soft tissue tumors, CSF-1R, tumor markers, grade, 3861
- MDA-MB-231, fibroblast growth factor receptor, Akt, Chfr, PLC γ , breast cancer, *Xenopus* oocyte, 4965
- MDA-MB-231, MMPs, apoptosis, autophagy, MDA-MB-435, 1335
- MDA-MB-435, MMPs, apoptosis, autophagy, MDA-MB-231, 1335
- MDR, multiple drug resistance, cancer etiopathogenesis, pH and cancer, proton transport in cancer, cancer angiogenesis, cancer strategy and treatment, review, 2127
- mdr1*, ABC transporters, P-glycoprotein, semi-automated fluorometric method, efflux, ethidium bromide, mouse lymphoma cells, *ABCBI*, 2173
- mdr1*, methylation, gastric cancer, 337
- Mechanism, cholangiocarcinoma, cholangiocarcinogenesis, gene, molecular, Klatskin tumor, review, 1151
- Median survival time, SCLC limited disease, sequential chemoradiotherapy, concurrent chemoradiotherapy, prophylactic cranial radiotherapy, overall survival, 5219
- Medullary thyroid carcinoma, *Uncaria tomentosa*, alkaloids, drug resistance, apoptosis, 4519
- Megaesophagus, chagas disease, gene mutation, single nucleotide polymorphism, SNP, *FHIT* gene, *TP53* gene, *CDKN2A* gene, DNA sequencing, 1243
- Melanoma cells, M6P/IGF-II receptor, M6P/IGF-II receptor modulation, M6P, brefeldin A, forskolin, immunoluminescence, 1383
- Melanoma, bacteriophage T4 preparation, BP T4, cancer, anticancer activity, B16 melanoma, 2361
- Melanoma, carboplatin, interleukin-2, metastatic, second-line treatment, vinorelbine, 1755
- Melanoma, CD117, COX-2, HSP90, FNA, 4345
- Melanoma, methionine-free diet, CENU, glioma, nitrosourea, 5235
- Melanoma, radioresistant brain metastasis, hypofractionated stereotactic radiotherapy, HSRT, radiosurgery, RS, radiotherapy, 4259
- Melanoma, redness, IL-6, *IL-8*, 1793

- Melatonin receptors, melatonin, MT1, MT2, Ki-67 antigen, malignant melanoma, 3887
- Melatonin, melatonin receptors, MT1, MT2, Ki-67 antigen, malignant melanoma, 3887
- MEN1, multiple endocrine neoplasia type 1, transfection, regulated genes, 1859
- Meningeal carcinomatosis, gefitinib, lumbo-peritoneal shunt, lung cancer, epidermal growth factor receptor, T790M, 2759
- Meningioma, glioblastoma multiforme, astrocytoma, angipoietin 2, VEGF, 731
- Mesoblastic nephroma, hepatocarcinoma, metastasis, parathymic lymph node, autoradiography, 2121
- Mesothelioma, docetaxel, first-line chemotherapy, gemcitabine, 3441
- Mesothelioma, glycolysis, energetic metabolism, cisplatin, MSTO-211H, 1249
- Mesothelioma, nude mice, glycolysis, energetic metabolism, chemotherapy, 1443
- MET PET, Choroidal melanoma, Carbon ion beam therapy, 1507
- MET, colorectal carcinoma, immunohistochemistry, prognosis, survival, carcinogenesis, 4807
- Meta-analysis, lentinan, advanced gastric cancer, clinical trials, 2739
- Metabolising gene, bladder cancer, susceptibility, *CYP1A1*, *CYP1B1*, *COMT*, *GSTP1*, *NAT2*, genetic polymorphism, single nucleotide polymorphism, 1631
- Metallic stent, malignant portal vein stenosis, pancreatic cancer, 3329
- Metalloprotease-1, colorectal cancer, cadherin, catenin, fibronectin, signet-ring cell, 4417
- Metallothionein, laminin, proliferation, lymph nodes metastases, oral cancer, 589
- Metallothionein, oral cancer, *p53* protein, prognosis, immunohistochemistry, 1189
- Metastases, bone tumor, radiofrequency ablation, bone cement, breast cancer, 2787
- Metastases, hormone receptors, discordance, Her-2/neu, breast cancer, 1557
- Metastases, neuroblastoma, proteasome inhibitor, bortezomib, xenograft model, 1219
- Metastasis, (-)-gossypol, prostate cancer, nm23-H1, Bcl-2, Bcl-xL, 2179
- Metastasis, angiogenesis, animal model, experimental therapy, integrin, 131
- Metastasis, cancer, invasion, molecular chaperones, heat-shock protein 90, geldanamycin, molecularly targeted therapeutics, review, 797
- Metastasis, cancer, malignant potential, cell-based assay, anoikis, matrix metalloproteinase, MMP, 2541
- Metastasis, CEACAM-1, cell adhesion, lymphnode, hematogenous, prognostic significance, non-small cell lung cancer, 249
- Metastasis, CXCR4, SDF-1, gastric cancer, 4751
- Metastasis, gallbladder, adenocarcinoma, invasion pattern, vascular invasion, 685
- Metastasis, hepatocarcinoma, mesoblastic nephroma, parathymic lymph node, autoradiography, 2121
- Metastasis, L1, gastric cancer, prognostic factor, 4033
- Metastasis, luciferase, bioluminescence imaging, mammary cancer, 4389
- Metastasis, malignant peripheral nerve sheath tumor, MPNST, recurrence, molecular characterization, cell cycle regulators, Nm-23H1, 1255
- Metastasis, renal cell carcinoma, thyroid, thyroidectomy, neoplastic thrombus, jugular vein thrombosis, 473
- Metastasis, siRNA, migration, hepatocellular carcinoma, peroxisome proliferator-activated receptor gamma, 5057
- Metastasis, TEM7, alternative splicing, osteosarcoma, PCR, 4317
- Metastasis, tissue transglutaminase, cell signaling, chemoresistance, focal adhesion kinase, NF- κ B, integrin, review, 1909
- Metastatic breast cancer, phase II study, oral vinorelbine, capecitabine, oral chemotherapy, 667
- Metastatic breast cancer, weekly paclitaxel, phase II study, 625
- Metastatic colorectal cancer, [18F]-FDG, PET-CT, CT scan, therapeutic assessment, 2563
- Metastatic colorectal carcinoma, bevacizumab, homocysteine, 4813
- Metastatic gastric cancer, S-1, CDDP, phase I study, combination chemotherapy, 1727
- Metastatic melanoma, DC vaccine, MAGE1 HLA-A24 restricted peptide, T-cell receptor (TCR) beta cDNA cloning, electroporation, 647
- Metastatic melanoma, high-dose interleukin-2, brain metastasis, retrospective study, 4189
- Metastatic, carboplatin, interleukin-2, melanoma, second-line treatment, vinorelbine, 1755
- Metastatic, circulating tumor cells, solid tumor, localized, stages, 4839
- Metastatic, spontaneous regression, colorectal cancer, 465
- Metastin, AXOR12, DSCR1, gene expression, real-time quantitative RT-PCR, epithelial ovarian cancer, 617
- Methicillin-resistant *Staphylococcus aureus*, pyomyositis, acute myelogenous leukemia, high-dose Ara-C, 3361
- Methionine, CNS tumours, cytotoxicity, methotrexate, cisplatin, temozolomide, 3103
- Methionine-free diet, CENU, melanoma, glioma, nitrosourea, 5235
- Methotrexate, methionine, CNS tumours, cytotoxicity, cisplatin, temozolomide, 3103
- 2-Methoxyestradiol, estrogen, sulfamate, ovarian cancer, prostate cancer, breast cancer, 3751
- α -Methylacyl-CoA racemase, androgen-independent prostate cancer, siRNA, C4-2, LNCaP, 2497

- Methylation, gastric cancer, *RUNX3*, 2619
- Methylation, *Helicobacter pylori*, gastric mucosa, *COMT*, polymorphism, 2857
- Methylation, *mdr1*, gastric cancer, 337
- Methylation-specific PCR, promoter methylation, non-small cell lung cancer, bronchial epithelial cells, clonal field expansion, endobronchial brush, 363
- Methylene blue dye, breast cancer, gamma probe, lymphoscintigraphy, sentinel lymph node, 4119
- Methylene blue, sonodynamic antitumor effect, Sarcoma180, 2411
- O⁶-Methylguanine, O⁶-MG, alkylating agents, cancer, glioma, O⁶-methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, promoter methylation, temozolomide, TMZ, review, 3759
- O⁶-Methylguanine-DNA methyltransferase, *MGMT*, temozolomide, glioblastoma, review, 4845
- O⁶-Methylguanine-DNA-methyltransferase, *MGMT*, alkylating agents, cancer, glioma, O⁶-methylguanine, O⁶-MG, polymorphism, promoter methylation, temozolomide, TMZ, review, 3759
- O⁶-MG, O⁶-methylguanine, alkylating agents, cancer, glioma, O⁶-methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, promoter methylation, temozolomide, TMZ, review, 3759
- Methylnaltrexone, 5-fluorouracil, SW-480 colorectal cancer cell, MCF-7 breast cancer cell, non-small cell lung cancer cell, NSCLC, anti-proliferation, cell growth, cell cycle, 2927
- MG-63 osteoblasts, osteoprotegerin, 3-D collagen, PC-3 cells, 4013
- MGMT*, gender difference, *p53* mutation, and NSCLC, 2535
- MGMT*, O⁶-methylguanine-DNA methyltransferase, temozolomide, glioblastoma, review, 4845
- MGMT*, O⁶-methylguanine-DNA-methyltransferase, alkylating agents, cancer, glioma, O⁶-methylguanine, O⁶-MG, polymorphism, promoter methylation, temozolomide, TMZ, review, 3759
- MGMT*, *p53*, DNA repair, Sp1 transcription factor, drug resistance, alkylating agent, 3741
- MGMT*, quantitative methylation-specific PCR, gastric cancer, 5053
- MIB-1, germ cell tumors, immunohistochemical markers, prognostic markers, *p53*, survival, 737
- Mice, APL treatment, arsenic trioxide, trace elements, virus, 83
- Mice, sirolimus, urothelial lesions, BBN, labelling index, 3221
- Microarray analysis, matrix metalloproteinase, MMP, tissue inhibitor of matrix metalloproteinase, TIMP, colorectal carcinoma, CRC, 67
- Microarray, 1,25(OH)₂D₃, analog, cancer, review, 3471
- Microarray, chemoresistance, esophageal cancer, 1163
- Microarray, *EGFR*, *EGR1*, mutation, 1111
- Microarray, estrogen response gene, breast cancer, 3971
- Microarray, vitamin D, analogs, antiproliferative effect, non-steroidal, 3585
- Microbubbles, ultrasound, echo-contrast agent, malignant glioma, central nervous system, 235
- Microcalcifications, breast cancer, X-ray mammography, ^{99m}Tc-Sestamibi scintimammography, negative predictive value, ROC curve analysis, 4251
- Microenvironment, human colon cancer, progesterone receptor, antagonist, natural killer cells, 1611
- Micrometastasis, sentinel lymph node, breast cancer, frozen sections, immunohistochemistry, 4711
- microPET, micropositron-emission tomography, bioluminescent imaging, ¹⁸F-fluorodeoxyglucose, luciferase, nuclear factor-κB, 987
- Micropositron-emission tomography, microPET, bioluminescent imaging, ¹⁸F-fluorodeoxyglucose, luciferase, nuclear factor-κB, 987
- Microsatellite instability, colorectal cancer, predictive factor, chemotherapy, survival, 1615
- Microsomal epoxide hydrolase, head and neck cancer, glutathione-S-transferase, UDP-glucuronosyltransferase, polymorphisms, cancer susceptibility, smoking, review, 753
- Microsurgery, periacetabular bone tumor, irradiated bone graft, vascularized bone graft, 1669
- Microwave radiation, chromosomal aberrations, radio frequency, pulsed-wave, continuous-wave, promotion, 2885
- Mifepristone, cancer, endometrium, growth, progesterone, cell cycle, apoptosis, Ishikawa cells, 1053
- Mifepristone, progesterone receptor antagonist, murine leukemia, 2977
- Migraine, trastuzumab, adverse effects, headache, 4223
- Migration, duodenum, adenomas, Paneth cells, stem cells, 657
- Migration, EMT, *PTEN*, TNF-α, invasion, 4439
- Migration, extracellular matrix, three-dimensional cell-culture model, Boyden chamber, borrelidin, taxol, 5-hexyl-2'-deoxyuridine, signal pathway inhibitors, antisense oligonucleotide, 2981
- Migration, plasmacytoid dendritic cell, HNSCC, CpG, IFN-α, 3019
- Migration, Rho, ROCK, ERK, GBM, proliferation, 119
- Migration, siRNA, metastasis, hepatocellular carcinoma, peroxisome proliferator-activated receptor gamma, 5057
- Min/+* mice, 5-hydroxymethylfurfural, 5-sulfooxymethylfurfural, aberrant crypt foci, intestinal carcinogenesis, 1921
- Min/+* mouse, carcinogenesis, intestine, retinol, vitamin D, 4353
- Mini organ cultures, antioxidants, coenzyme Q10, quercetin, nasal mucosa, Comet assay, 33
- Minimally invasive, esophageal cancer, surgery, outcome, survival, 2719

- Minor salivary glands, epithelial-myoepithelial carcinoma, histological variants, immunohistochemistry, 4703
- Mistletoe lectin, glycomimetics, MRP5, phage display mapping, 4941
- Mitochondria membrane potential, rhein, apoptosis, caspase-3, ROS, cytochrome *c*, 309
- Mitochondria, cancer, therapy, nephrotoxicity, ROS, 2295
- Mitochondrial membrane potential, capsaicin, calcium, reactive oxygen species, apoptosis, human HepG2 cells, 165
- Mitotic checkpoint, *Rb*, *Trp53*, chromosome instability, skin cancer, inflammation, NF κ B, 3035
- Mitotic spindle proteins, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, telomerase reverse transcriptase, *TERT*, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- MMP, matrix metalloproteinase, cancer, metastasis, malignant potential, cell-based assay, anoikis, 2541
- MMP, matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, TIMP, colorectal carcinoma, CRC, microarray analysis, 67
- MMP-10, IL-6, JAK2/STAT3, lung cancer, 4497
- MMP-9, ATF2, p-ATF2, breast cancer, prognosis, immunohistochemistry, Western blot, ERK-1/2, AP-1, 183
- MMPs, apoptosis, autophagy, MDA-MB-231, MDA-MB-435, 1335
- MMPs, non-small cell lung cancer, mRNA, tissue samples, TIMPs, RT-PCR, 2513
- Molecular biology, inflammatory bowel disease, Crohn's disease, epidemiology, ulcerative colitis, colorectal cancer, colon carcinogenesis, review, 2727
- Molecular changes, colorectal adenocarcinoma, chemotherapy, response, tumorigenesis, 3115
- Molecular chaperones, cancer, invasion, metastasis, heat-shock protein 90, geldanamycin, molecularly targeted therapeutics, review, 797
- Molecular characterization, malignant peripheral nerve sheath tumor, MPNST, recurrence, metastasis, cell cycle regulators, Nm-23H1, 1255
- Molecular classification, cancer, ductal, breast, survival, 4727
- Molecular dynamics, ADP/ATP carrier, *yAAC2* function, 4897
- Molecular imaging, angiogenesis, prostate cancer, tumor vascular remodelling, vascular stabilization, review, 1823
- Molecular imaging, anti-*EGFR* Fab, ¹²⁵I, 4005
- Molecular, cholangiocarcinoma, cholangiocarcinogenesis, gene, mechanism, Klatskin tumor, review, 1151
- Molecularly targeted therapeutics, cancer, invasion, metastasis, molecular chaperones, heat-shock protein 90, geldanamycin, review, 797
- Monoclonal antibodies, L1-CAM, tumorigenesis, isoforms, signaling, review, 4919
- Morbidity, esophageal cancer, preoperative chemoradiotherapy, mortality, prognosis, 2555
- Mortality, esophageal cancer, preoperative chemoradiotherapy, morbidity, prognosis, 2555
- Mouse lymphoma cells, ABC transporters, P-glycoprotein, semi-automated fluorometric method, efflux, ethidium bromide, *mdr1*, *ABCBI*, 2173
- Mouse model, GIST, xenograft, targeting, 4331
- Mouse models, human neuroendocrine tumor, NET, carcinoma of terminal ileum, continuous cell lines, P-STC primary tumor, L-STC lymph node metastasis, H-STC hepatic metastasis, neuroendocrine characteristics, tumorigenicity, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Mouse Period2 gene, circadian rhythm, clock genes, tumor suppression, apoptosis, cell cycle arrest, synergic effect, cisplatin, 1201
- MPC polymer, paclitaxel, epidermal growth factor receptor, targeted therapy, 1009
- MPNST, malignant peripheral nerve sheath tumor, recurrence, metastasis, molecular characterization, cell cycle regulators, Nm-23H1, 1255
- MRI, multiple myeloma, conventional radiological survey, RSS, 4745
- MRNA, non-small cell lung cancer, RECK, tissue samples, RT-PCR, promoter methylation, 4535
- MRNA, non-small cell lung cancer, tissue samples, MMPs, TIMPs, RT-PCR, 2513
- MRP, correlation, P-gp, expression, leukemia, 1073
- MRP5, glycomimetics, mistletoe lectin, phage display mapping, 4941
- MSH2, endometrial cancer, DNA mismatch repair, immunohistochemistry, 4833
- MSTO-211H, mesothelioma, glycolysis, energetic metabolism, cisplatin, 1249
- MT1, melatonin, melatonin receptors, MT2, Ki-67 antigen, malignant melanoma, 3887
- MT2, melatonin, melatonin receptors, MT1, Ki-67 antigen, malignant melanoma, 3887
- MTOR phosphorylation, rapamycin, mTOR signaling, STAT3 phosphorylation, biomarkers of resistance, p70S6 and RS6P, human breast epithelial cells, human breast premalignant and tumor epithelial cells, early events in breast tumorigenesis, 1143
- MTOR signaling, rapamycin, mTOR phosphorylation, STAT3 phosphorylation, biomarkers of resistance, p70S6 and RS6P, human breast epithelial cells, human breast premalignant and tumor epithelial cells, early events in breast tumorigenesis, 1143
- MTOR, chordoma, PI3K, PI-103, 1867
- MTOR, curcumin, colorectal cancer, Raptor, Rictor, Akt, PHLPP, 3185
- MTOR, IGF-I receptor, phosphorylated *MYC-N*, neuroblastoma, rapamycin, temsirolimus, 1943

- Mucosal immune response, VacA, recombinant VacA, neutralizing antibody, anti-*H. pylori* vaccine, CpG-ODN, 2393
- Multidrug resistance, *ABCB1*, rhodamine 123, ethidium bromide, 3989
- Multidrug resistance, Euphorbiaceae, *Euphorbia*, triterpenes, steroids, P-glycoprotein, apoptosis, 4467
- Multidrug resistance, xenograft, nude mice, drug accumulation, bromotetrandrine, 4597
- Multiple drug resistance, MDR, cancer etiopathogenesis, pH and cancer, proton transport in cancer, cancer angiogenesis, cancer strategy and treatment, review, 2127
- Multiple endocrine neoplasia type 1, MEN1, transfection, regulated genes, 1859
- Multiple fibroadenoma, breast surgery, mastoplasty, 2823
- Multiple myeloma, BIBF 1120, VEGF receptor inhibitor, Phase I study, pharmacokinetics, 4233
- Multiple myeloma, bortezomib, fibroblast growth factor receptor 3, FGFR3, 1
- Multiple myeloma, conventional radiological survey, RSS, MRI, 4745
- Multiple myeloma, TP-110, proteasome inhibitor, apoptosis, IAP, 977
- Multiplex, ovarian cancer, tumour markers, panel, 573
- Multivariable analysis, immunohistochemistry, tissue microarray, concordance, discordance, validity, 201
- Murine leukemia, progesterone receptor antagonist, mifepristone, 2977
- Murine renal cell carcinoma, angiogenesis, biomarkers, cediranib, VEGF, 5065
- Mutation pattern, splenic marginal zone lymphoma, antigen selection, 1811
- Mutation, *EGFR*, EGR1, microarray, 1111
- Mutation, NSCLC, gefitinib, erlotinib, *EGFR*, *KRAS*, 2767
- Mutation, pancreatic duct adenocarcinoma, *LKB1*, hamster, nitrosamine, 4047
- Mutations, PDGFR, thymoma, thymic carcinoma, 4057
- MYC* gene, gastric cancer, *MYC* protein, *MYC* insertion, hybridization *in situ* fluorescence, 2479
- MYC* insertion, gastric cancer, *MYC* gene, *MYC* protein, hybridization *in situ* fluorescence, 2479
- MYC* protein, gastric cancer, *MYC* gene, *MYC* insertion, hybridization *in situ* fluorescence, 2479
- Myc*, gallbladder, adenocarcinoma, fluorescence *in situ* hybridization, gene amplification, *ERBB2*, *EGFR*, 19
- Myelodysplastic syndrome, *RUNX1*, fusion gene, translocation, acute leukemia, gene transcription, review, 1031
- Myometrial invasion, recurrence, haematogenous failure, lymph-vascular space involvement, endometrial cancer, 1715
- N-Acetylcysteine, ascorbic acid, zinc, oxidative DNA damage, FPG-comet assay, 4571
- Nafamostat mesilate, pancreatic cancer, chemoresistance, gemcitabine, 3173
- Nano, RHCC, cisplatin, carrier, 11
- Nanocarriers, cancer therapy, nanotargeted radiopharmaceuticals, tumor imaging, review, 4107
- Nanospheres, PLGA, curcumin, S/O/W emulsion, confocal microscopy, cancer therapy, 3867
- Nanotargeted radiopharmaceuticals, cancer therapy, nanocarriers, tumor imaging, review, 4107
- Naphtho[2,3-*b*]furan-4,9-diones, apoptosis, autophagy, caspase, DNA fragmentation, QSAR, 455
- Nasal mucosa, antioxidants, coenzyme Q10, quercetin, Comet assay, mini organ cultures, 33
- NAT2*, bladder cancer, susceptibility, metabolising gene, *CYP1A1*, *CYP1B1*, *COMT*, *GSTP1*, genetic polymorphism, single nucleotide polymorphism, 1631
- Natural botanical components, hormone refractory prostate cancer, cancer metastasis, cancer treatment, TBS-101, 3917
- Natural killer cell, fatigue, RNase L, nitric oxide, protein kinase R, nuclear factor kappa beta, NF- κ B, intracellular immune dysfunction, oxidative stress, exercise, review, 4717
- Natural killer cells, human colon cancer, progesterone receptor, antagonist, microenvironment, 1611
- NCoR, endometrial hyperplasia, endometrial carcinoma, cofactor, progesterone, 1023
- Neck dissection, oropharynx, oropharyngeal cancer, HNSCC, treatment, 4785
- Necrosis, apoptosis, glioblastoma, HMG-CoA reductase, pericytes, simvastatin, 4901
- Necrosis, chitosan nanoparticles, hepatocellular carcinoma, tumor growth, angiogenesis, *VEGFR2*, 5103
- Nedaplatin, weekly paclitaxel, non-small cell lung cancer, phase II study, 1733
- Negative predictive value, breast cancer, X-ray mammography, ^{99m}Tc-Sestamibi scintimammography, microcalcifications, ROC curve analysis, 4251
- Neoadjuvant chemotherapy, breast cancer, paclitaxel, pathological response, trastuzumab, 517
- Neoadjuvant chemotherapy, gastric cancer, docetaxel, 5-fluorouracil, cisplatin, DFP, 4211
- Neoadjuvant chemotherapy, head and neck cancer, limited surgery, prognosis, radical surgery, 255
- Neo-adjuvant chemotherapy, locally advanced breast cancer, biological markers, 1621
- Neoadjuvant chemotherapy, S-1, cisplatin, advanced gastric cancer, preoperative chemotherapy, 4689
- Neoplasm metastasis, uterine cervical neoplasm, TIP47, tumor marker, cervical cytology, 717
- Neoplasms, amitriptyline, antidepressants, chemotherapy-induced neuropathy, neurotoxicity, prevention, 2601
- Neoplasms, lung, EpCAM, 1817
- Neoplastic glands, colonic carcinoma, biological materials, 1745

- Neoplastic meningitis, breast cancer, leptomeningeal disease, chemotherapy, temozolomide, DepoCyte[®], liposomal Ara-C, 5191
- Neoplastic thrombus, renal cell carcinoma, metastasis, thyroid, thyroidectomy, jugular vein thrombosis, 473
- Nephrotoxicity, cancer, therapy, ROS, mitochondria, 2295
- NER, arsenic, *ERCC1*, DNA repair, drinking water, skin hyperkeratosis, 3253
- NET, human neuroendocrine tumor, carcinoid of terminal ileum, continuous cell lines, P-ST5 primary tumor, L-ST5 lymph node metastasis, H-ST5 hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Neuroblastoma cells, diarylheptanoids, apoptosis, S-phase arrest, differentiation, *Alpinia officinarum*, 4981
- Neuroblastoma, cytotoxicity, tetrandrine, radiosensitization, 3163
- Neuroblastoma, epidermal growth factor receptor, gefitinib, chemotherapy, retinoic acid, 1327
- Neuroblastoma, IGF-I receptor, phosphorylated *MYC-N*, mTOR, rapamycin, temsirolimus, 1943
- Neuroblastoma, proteasome inhibitor, bortezomib, metastases, xenograft model, 1219
- Neuroendocrine characteristics, human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, P-ST5 primary tumor, L-ST5 lymph node metastasis, H-ST5 hepatic metastasis, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Neuroendocrine tumors, octreotide, 4127
- Neurofibroma, malignant peripheral nerve sheath tumors, CD10, neurofibromatosis, 3149
- Neurofibromatosis, neurofibroma, malignant peripheral nerve sheath tumors, CD10, 3149
- Neuroglycan-C, gastric cancer, colon cancer, ErbB, proliferation, 229
- Neurotoxicity, amitriptyline, antidepressants, chemotherapy-induced neuropathy, neoplasms, prevention, 2601
- Neutralizing antibody, VacA, recombinant VacA, anti-*H. pylori* vaccine, CpG-ODN, mucosal immune response, 2393
- NF-kappaB, biphenols, radical-scavenging activity, COX-2, AP-1, DFT/B3LYP, lipopolysaccharide, 2403
- NF-kB, apoptosis, cell proliferation, CDKs, toad skin extract, curcumin, colon cancer, 395
- NF-kB, fatigue, RNase L, nitric oxide, protein kinase R, nuclear factor kappa beta, intracellular immune dysfunction, natural killer cell, oxidative stress, exercise, review, 4717
- NF-kB, nuclear factor-kappaB, recombinant adeno-associated virus, rAAV, hypoxia inducible factor, HIF, small interference RNA, siRNA, proliferation, apoptosis, 1367
- NFKB, *Rb*, *Trp53*, chromosome instability, skin cancer, inflammation, mitotic checkpoint, 3035
- NF-kB, resveratrol, endothelia, adhesion, ICAM-1, 355
- NF-kB, SP100030, SP100207, AP-1, tumour growth, 1315
- NF-kB, tissue transglutaminase, cell signaling, chemoresistance, metastasis, focal adhesion kinase, integrin, review, 1909
- NHL, non-Hodgkin's lymphoma, IDEA, salvage, 1749
- NIS, sodium iodine symporter, hepatocellular carcinoma, hepatitis B virus enhancer, EIIAPA, alpha-fetoprotein, AFP, 211
- Nitric oxide, capsaicin, resveratrol, *p53*, HCT116 cells, chemoprevention, 3733
- Nitric oxide, fatigue, RNase L, protein kinase R, nuclear factor kappa beta, NF-kB, intracellular immune dysfunction, natural killer cell, oxidative stress, exercise, review, 4717
- Nitroreductase, oncolytic virus, prodrug therapy, HSV, antitumor activity, 2159
- Nitrosamine, pancreatic duct adenocarcinoma, *LKB1*, mutation, hamster, 4047
- Nitrosourea, methionine-free diet, CENU, melanoma, glioma, 5235
- NK cell, splenectomy, liver metastasis, regulatory T-cell, Foxp3, 385
- NK cells, ionizing radiation, SOD mimetic, RM-9 prostate cancer, B-cells, cytokines, immune system, 107
- NK-1 receptor, oral cancer, substance P, proliferation, 2323
- Nm23, lung cancer, *EGFR*, verapamil, 27
- Nm23-H1, (-)-gossypol, metastasis, prostate cancer, Bcl-2, Bcl-xL, 2179
- Nm-23H1, malignant peripheral nerve sheath tumor, MPNST, recurrence, metastasis, molecular characterization, cell cycle regulators, 1255
- Node-negative breast cancer, urokinase-type plasminogen activator, plasminogen activator inhibitor type I, prognostic factor, distant metastases, local recurrence, 1475
- NOGGO, gynecologic oncology, abstracts, 1563
- Non-apoptosis, J774.1, nutritional starvation, serine, glutamine, cell death, 5083
- Non-Hodgkin's lymphoma, NHL, IDEA, salvage, 1749
- Non-Hodgkin's lymphoma, zevalin, ibritumomab tiuxetan, radioimmunotherapy, indolent lymphoma, aggressive lymphoma, 4771
- Non-small cell lung cancer cell, methylalantrexone, 5-fluorouracil, SW-480 colorectal cancer cell, MCF-7 breast cancer cell, NSCLC, anti-proliferation, cell growth, cell cycle, 2927
- Non-small cell lung cancer, apoptosis, tumor necrosis factor-related apoptosis-inducing ligand, primary culture, 2905
- Non-small cell lung cancer, CEACAM-1, cell adhesion, lymphnode, hematogenous, metastasis, prognostic significance, 249

- Non-small cell lung cancer, collision tumor, tumor stem cell, adenocarcinoma of the colon, 1495
- Non-small cell lung cancer, epithelial-mesenchymal transition, Twist, Snail, Sip1, 4099
- Non-small cell lung cancer, gefitinib, paclitaxel, *EGFR*-TKI, resistant, 2747
- Non-small cell lung cancer, gefitinib, treatment failure, post initial gefitinib therapy, 4217
- Non-small cell lung cancer, *in vitro* assay-guided chemotherapy, empirical chemotherapy, 4243
- Non-small cell lung cancer, interstitial lung disease, survival, 2671
- Non-small cell lung cancer, leukocytosis, anemia, thrombocytosis, preoperative, survival, 2687
- Non-small cell lung cancer, lung cancer, genetic changes, chromosome 9 numerical abnormalities, p16^{CDKN2A} gene deletion, FISH technique, 4483
- Non-small cell lung cancer, mRNA, tissue samples, MMPs, TIMPs, RT-PCR, 2513
- Non-small cell lung cancer, nedaplatin, weekly paclitaxel, phase II study, 1733
- Non-small cell lung cancer, plasma, VEGF, chemotherapy, paclitaxel, 2635
- Non-small cell lung cancer, promoter methylation, methylation-specific PCR, bronchial epithelial cells, clonal field expansion, endobronchial brush, 363
- Non-small cell lung cancer, RECK, tissue samples, mRNA, RT-PCR, promoter methylation, 4535
- Non-steroidal, vitamin D, analogs, antiproliferative effect, microarray, 3585
- Non-steroids, calcitriol, prostate cancer, 3605
- Normal bone, IGFBP-3, osteosarcoma, 2579
- Normal brain, sonodynamic therapy, cavitation, thermal effect, glioblastoma, 943
- Normal rat brain, sonodynamic therapy, photosensitizer, blood-brain barrier, electron microscopic study, 889
- North India, CYP17 gene polymorphism, hormonal genes, BPH, prostate cancer, 1659
- 19-Norvitamin D₃, synthesis, 14-*epi*-MART-10, Julia coupling, PZ-HPV-7 cells, HL-60 cells, 3563
- Notch, leukemia, Jagged, Delta-like, 3967
- NPSA12, surgery, prostate cancer, radiotherapy, biochemical failure, prognostic factor, 4605
- NQO2, prostate cancer, CWR22Rv1 cells, resveratrol, 3011
- NSAIDs, COX-2, DPD, HCA-7, HT-29, 3095
- NSCLC, Akt isoforms, prognosis, tissue microarray, 4175
- NSCLC, BFT, CDX2, homeobox genes, gene expression, 1281
- NSCLC, bone metastasis, pamidronate, survival, retrospective analysis, 5245
- NSCLC, bone turnover markers, bone metastasis, receptor activator of nuclear factor- κ B ligand, osteoprotegerin, osteopontin, 1651
- NSCLC, gefitinib, erlotinib, *EGFR*, *KRAS*, mutation, 2767
- NSCLC, gender difference, MGMT, p53 mutation, 2535
- NSCLC, methylalantrexone, 5-fluorouracil, SW-480 colorectal cancer cell, MCF-7 breast cancer cell, non-small cell lung cancer cell, anti-proliferation, cell growth, cell cycle, 2927
- NSE, lung cancer, diagnosis, prognosis, ProGRP, CYFRA 21-1, CEA, 4827
- NSITC, cathepsin L, angiogenesis, ECM, protease, 4473
- Nuclear factor kappa beta, fatigue, RNase L, nitric oxide, protein kinase R, NF- κ B, intracellular immune dysfunction, natural killer cell, oxidative stress, exercise, review, 4717
- Nuclear factor-kappaB, NF- κ B, recombinant adeno-associated virus, rAAV, hypoxia inducible factor, HIF, small interference RNA, siRNA, proliferation, apoptosis, 1367
- Nuclear factor- κ B, bioluminescent imaging, ¹⁸F-fluorodeoxyglucose, luciferase, micropositron-emission tomography, microPET, 987
- Nuclear morphometry, survival, clinicopathological features, Libyan female breast cancer, 1771
- Nuclear receptor, vitamin D, vitamin D receptor, vitamin D response elements, *in silico* screening, gene regulation, review, 3485
- Nuclear receptors, malignant melanoma, peroxisome proliferator-activated receptors, PPAR, vitamin D receptor, VDR, 3647
- Nuclear, cytoplasmic, high-grade astrocytoma, p27, prognosis, subcellular localization, 597
- Nude mice, bone marrow, stem cells, breast cancer, GFP, 443
- Nude mice, cepharanthine, S-1, oral squamous cell carcinoma, apoptosis, TUNEL, combination therapy, xenografts, 1263
- Nude mice, mesothelioma, glycolysis, energetic metabolism, chemotherapy, 1443
- Nude mice, multidrug resistance, xenograft, drug accumulation, bromotetrandrine, 4597
- Nutritional deprivation, tumour cell, energy deprivation, cell survival, cell death, digital holographic microscopy, dynamic phase difference, 2339
- Nutritional starvation, J774.1, serine, glutamine, cell death, non-apoptosis, 5083
- Nutritional starvation, RAW264.7, serine, glutamine, glucose, cell death, 343
- NY-ESO-1, oral cancer, gene expression, RT-PCR, diagnosis, therapy, 5125
- Obese, breast cancer, postmenopausal women, overweight, Statins, epidemiology, 5143
- Obesity, vitamin D deficiency, seasonal variation, age, gender, 3713
- Oct3/4, esophagus, Sox2, immunohistochemistry, RT-PCR, Western blotting, 1233
- Octreotide, neuroendocrine tumors, 4127
- 1,25(OH)₂D₃, analog, cancer, microarray, review, 3471

- 1 α ,25(OH)2D3, hepatoma, vitamin D, proliferation, fish oil, ω -3 PUFAs, HepG2, 3591
- 1 α OHase, vitamin D, breast cancer, 155
- Olecranon, concomitant elastofibroma, subscapular, 503
- Oligosaccharide ligand, galectins, apoptosis, cell aggregation, 403
- Oncogene, ERas, gastric carcinoma, prognosis, 2189
- Oncogene, immunohistochemistry, prognosis, gastric cancer, 4451
- Oncogenesis, tumor necrosis factor alpha, tumor necrosis factor beta, oral cancer, polymorphism, genetic association study, 2379
- Oncolytic virus, prodrug therapy, nitroreductase, HSV, antitumor activity, 2159
- Oncomarker, head and neck squamous cell carcinoma, oral cavity, oropharynx, prognosis, oxidative stress, malondialdehyde, 4227
- Onconase, double-stranded RNA, cytotoxic, ribonuclease, RNAi, 1067
- Operable non-small cell lung cancer, adjuvant chemotherapy, carboplatin, pemetrexed, 4297
- Optical biopsy system, colonoscopic polypectomy, hyperplastic polyps, adenomatous polyps, 4737
- Oral administration, IP-PA1, LPS, M1 macrophage, comparative immunology, 4871
- Oral cancer, MAPK, squamous cell carcinoma, immunoblotting, phospho-ERK, 303
- Oral cancer, metallothionein, laminin, proliferation, lymph nodes metastases, 589
- Oral cancer, metallothionein, p53 protein, prognosis, immunohistochemistry, 1189
- Oral cancer, NY-ESO-1, gene expression, RT-PCR, diagnosis, therapy, 5125
- Oral cancer, substance P, NK-1 receptor, proliferation, 2323
- Oral cancer, tumor necrosis factor alpha, tumor necrosis factor beta, oncogenesis, polymorphism, genetic association study, 2379
- Oral cavity, gingival papillae, p53, p63, p16, 3983
- Oral cavity, head and neck squamous cell carcinoma, oropharynx, prognosis, oncomarker, oxidative stress, malondialdehyde, 4227
- Oral chemotherapy, phase II study, oral vinorelbine, capecitabine, metastatic breast cancer, 667
- Oral SCC, integrin, $\alpha\beta$ 6, EMT, matrix, epithelial-mesenchymal transition, 125
- Oral SCC, integrin, $\alpha\beta$ 6, TRA-1-60, stem cell, matrix, 2043
- Oral squamous cell carcinoma, cepharanthine, S-1, apoptosis, TUNEL, combination therapy, xenografts, nude mice, 1263
- Oral squamous cell carcinoma, cytokeratin, disseminated tumor cells, peripheral blood, SYBR green real-time quantitative reverse transcriptase-polymerase chain reaction, 291
- Oral squamous cell carcinoma, gefitinib, cytotoxicity, hormesis, cell death, 5023
- Oral squamous cell carcinoma, heparin, apoptosis, AKt, 1079
- Oral squamous cell carcinoma, L-MYC, polymorphism, 2519
- Oral vinorelbine, phase II study, capecitabine, oral chemotherapy, metastatic breast cancer, 667
- Organ dose, Ewing tumour, irradiation, kidney transplantation, 3397
- Organ transplantation, sirolimus, rapamycin, squamous cell carcinoma, vascularization, 1927
- Oropharyngeal cancer, oropharynx, HNSCC, neck dissection, treatment, 4785
- Oropharyngeal squamous cell carcinoma, human papillomavirus, vascular endothelial growth factor, hypoxia-inducible factor-1 α , 1467
- Oropharynx, head and neck squamous cell carcinoma, oral cavity, prognosis, oncomarker, oxidative stress, malondialdehyde, 4227
- Oropharynx, oropharyngeal cancer, HNSCC, neck dissection, treatment, 4785
- Orotate phosphoribosyl transferase, 5-fluorouracil, bladder urothelial carcinoma, dihydropyrimidine dehydrogenase, 5-chloro-2,4-dihydropyridine, 1001
- Orthotopic model, antioxidants, chemotherapy, combination, colon cancer, 2421
- Osteoblast, bisphosphonate, pamidronate, zoledronic acid, LNCaP, osteoclast, 1089
- Osteoclast, bisphosphonate, pamidronate, zoledronic acid, LNCaP, osteoblast, 1089
- Osteoclast-like giant cell, giant cell tumor, stromal cell, bone morphogenetic protein, laser microdissection, 2219
- Osteopontin, bone turnover markers, NSCLC, bone metastasis, receptor activator of nuclear factor- κ B ligand, osteoprotegerin, 1651
- Osteopontin, malignant pleural mesothelioma, $\alpha\beta$ 3 integrin, 2205
- Osteoprotegerin, 3-D collagen, MG-63 osteoblasts, PC-3 cells, 4013
- Osteoprotegerin, bone turnover markers, NSCLC, bone metastasis, receptor activator of nuclear factor- κ B ligand, osteopontin, 1651
- Osteosarcoma, IGFBP-3, normal bone, 2579
- Osteosarcoma, marriage, fertility, surgery, chemotherapy, 763
- Osteosarcoma, post-traumatic growth, post-traumatic stress symptom, psychosocial outcome, 4287
- Osteosarcoma, talus, frozen, liquid nitrogen, reconstruction, 4093
- Osteosarcoma, TEM7, alternative splicing, PCR, metastasis, 4317
- Outcome, DNA repair, genetic polymorphism, haplotype, renal cell cancer, XRCC1, 5131
- Outcome, esophageal cancer, surgery, minimally invasive, survival, 2719
- Outcome, small cell carcinoma, treatment, chemotherapy, radiation therapy, 3411

- Outpatient chemotherapy, S-1, recurrent head and neck cancer, low dose chemotherapy, tumor dormancy, 577
- Ovarian cancer, 2-methoxyestradiol, estrogen, sulfamate, prostate cancer, breast cancer, 3751
- Ovarian cancer, age, tumor pattern, debulking surgery, survival, 2809
- Ovarian cancer, albendazole, paclitaxel, resistance, tubulin, 3791
- Ovarian cancer, ascites, cytokines, chemokines, cell mediated immunity, 2875
- Ovarian cancer, brain metastases, central nervous system relapse, brain lesions, review, 2793
- Ovarian cancer, chemotherapy, Akt, ERK, prognosis, 4639
- Ovarian cancer, cisplatin, clinical trial, docetaxel, progression-free survival, 561
- Ovarian cancer, claudin-5, cancer behavior, 5185
- Ovarian cancer, endometriosis, parietal metastasis, clear cell adenocarcinoma, 1591
- Ovarian cancer, estradiol, FSH, LH, prolactin, 1575
- Ovarian cancer, estrogen receptor, epigenetic, DNA methylation, histone deacetylation, 139
- Ovarian cancer, intraperitoneal chemotherapy, platinum, taxane, review, 2803
- Ovarian cancer, lymphadenectomy, cytoreduction, lymph node metastasis, review, 2837
- Ovarian cancer, malignant ascites, catumaxomab, review, 3353
- Ovarian cancer, multiplex, tumour markers, panel, 573
- Ovarian cancer, progression, relapse, CA-125, survival, 2817
- Ovarian cancer, risk factors, central adiposity, 5229
- Ovarian cancer, salvage treatment, cisplatin, ifosfamide, gemcitabine, 2681
- Ovarian cancer, SELDI-TOF MS, laser microdissection, cancer biomarkers, proteomics, 1039
- Ovarian cancer, tumor cells, ascites, antibody therapy, catumaxomab, 1787
- Ovarian cancer, vitamin D₃, 1 α -hydroxylase, splice variants, COV 434, HGL5, GLZ, 3627
- Ovarian cancer, vitamin D₃, 24-hydroxylase, splice variants, COV 434, HGL5, GLZ, 3635
- Ovary, breast cancer, renin-angiotensin system, steroidogenesis, estradiol, 4633
- Overall survival, breast cancer, skin recurrence, inflammatory recurrence, radiotherapy, mastectomy, recurrence-free survival, 1697
- Overall survival, pancreatic cancer, erlotinib, gemcitabine, toxicity, 5211
- Overall survival, SCLC limited disease, sequential chemoradiotherapy, concurrent chemoradiotherapy, prophylactic cranial radiotherapy, median survival time, 5219
- Overweight, breast cancer, postmenopausal women, obese, Statins, epidemiology, 5143
- Oxaliplatin, 5-fluorouracil, 5-FU, sulindac sulfide, colorectal cancer, synergism, 435
- Oxaliplatin, breast cancer chemotherapy, capecitabine, 2851
- Oxidative DNA damage, ascorbic acid, zinc, *N*-acetylcysteine, FPG-comet assay, 4571
- Oxidative stress, fatigue, RNase L, nitric oxide, protein kinase R, nuclear factor kappa beta, NF- κ B, intracellular immune dysfunction, natural killer cell, exercise, review, 4717
- Oxidative stress, head and neck squamous cell carcinoma, oral cavity, oropharynx, prognosis, oncomarker, malondialdehyde, 4227
- Oxygen-18, phosphoproteome, UPLC, IMAC, cerebellum, 4949
- p16*, gingival papillae, *p53*, *p63*, oral cavity, 3983
- p16*, pancreatic cancer, *K-ras*, *p53*, DPC4, prognostic markers, 1803
- p16*, quantitative methylation-specific PCR, colorectal cancer, 275
- p16^{CDKN2A}* gene deletion, lung cancer, non-small cell lung cancer, genetic changes, chromosome 9 numerical abnormalities, FISH technique, 4483
- PINP, prostate carcinoma, PSA, AP, tumour marker, bone metastases, 671
- p21*(WAF1/Cip1), gnidimacrin, PKC β II, G₂-phase arrest, *cdc2*, E2F-4, 1349
- p21*, 14-3-3 σ , *p53*, cisplatin, resistance, senescence, 2009
- p27*, cytoplasmic, high-grade astrocytoma, nuclear, prognosis, subcellular localization, 597
- p27^{kip1}*, Jab1, ubiquitin-proteasome system, cholangiocarcinoma, adenovirus, 2015
- p27^{kip1}*, ZD1839, Jab1, radiation, cholangiocarcinoma, 1169
- p53* mutation, gender difference, *MGMT*, and NSCLC, 2535
- p53* protein, oral cancer, metallothionein, prognosis, immunohistochemistry, 1189
- p53*, 14-3-3 σ , *p21*, cisplatin, resistance, senescence, 2009
- p53*, Bak, EPO, EPOR, colorectal cancer, 4151
- p53*, Bcl-2, bax, apoptosis, endometrium carcinoma, real-time PCR, immunohistochemistry, 3977
- p53*, bladder cancer, cell regulatory proteins, pRb, prognosis, 4201
- p53*, bortezomib, proteasome, renal cancer, VHL, 2961
- p53*, breast cancer, Zeranol, pre-adipocytes, body weight gain, doubling time, cyclin D1, 5045
- p53*, capsaicin, resveratrol, nitric oxide, HCT116 cells, chemoprevention, 3733
- p53*, *DYRK2*, lung cancer, predictive marker, chemotherapy, 2753
- p53*, *EGFR*, colorectal cancer, colon cancer, 785
- p53*, germ cell tumors, immunohistochemical markers, prognostic markers, MIB-1, survival, 737
- p53*, gingival papillae, *p63*, *p16*, oral cavity, 3983
- p53*, lung cancer, aryl hydrocarbon receptor, *CYP1B1*, epidermal growth factor receptor, 509

- p53*, *MGMT*, DNA repair, Sp1 transcription factor, drug resistance, alkylating agent, 3741
- p53*, pancreatic cancer, doxycycline, apoptosis, *Fas*, *IL-8*, 3995
- p53*, pancreatic cancer, *K-ras*, *p16*, DPC4, prognostic markers, 1803
- p63, gingival papillae, *p53*, *p16*, oral cavity, 3983
- P70S6 and RS6P, rapamycin, mTOR signaling, mTOR phosphorylation, STAT3 phosphorylation, biomarkers of resistance, human breast epithelial cells, human breast premalignant and tumor epithelial cells, early events in breast tumorigenesis, 1143
- p776, HER-2, helper effect, AE-37, AE-47, F7, perforin, E75, cancer vaccines, high-affinity CD8⁺ cells, 2427
- Paclitaxel, aerodigestive tract, external beam, radioiodine, radiosensitizer, radiotherapy, taxane, carboplatin, 4665
- Paclitaxel, albendazole, ovarian cancer, resistance, tubulin, 3791
- Paclitaxel, apoptosis, colon cancer, MAPK inhibition, PD98059, 261
- Paclitaxel, breast cancer, adjuvant chemotherapy, feasibility, adriamycin, epirubicin, 1515
- Paclitaxel, breast cancer, anemia, side-effects, tumor biology, pre-operative chemotherapy, epirubicin, 2675
- Paclitaxel, breast cancer, neoadjuvant chemotherapy, pathological response, trastuzumab, 517
- Paclitaxel, cytostatic resistance, Akt activation, Bad phosphorylation, cytochrome *c* release, caspase-3 activation, apoptosis, 159
- Paclitaxel, Kaposi's sarcoma, anthracycline-refractory, 675
- Paclitaxel, MPC polymer, epidermal growth factor receptor, targeted therapy, 1009
- Paclitaxel, non-small cell lung cancer, gefitinib, *EGFR*-TKI, resistant, 2747
- Paclitaxel, plasma, VEGF, non-small cell lung cancer, chemotherapy, 2635
- Palliative care, cancer patients, fatigue, anaemia, 2569
- Palliative radiation treatment, radiotherapy, cancer, travel distance, 2641
- Palliative surgery, breast cancer, gastric metastasis, immunohistochemistry, hormone therapy, chemotherapy, 4759
- Pamidronate, bisphosphonate, zoledronic acid, LNCaP, osteoblast, osteoclast, 1089
- Pamidronate, NSCLC, bone metastasis, survival, retrospective analysis, 5245
- Panaxanthone, α -mangostin, antitumor, chemoprevention, mammary cancer, 2485
- Pancreas neoplasms, bile duct neoplasms, DNA ploidy, computer-assisted, cytometry, image analysis, differential diagnosis, 1579
- Pancreas, enzyme kinetics, prostate cancer, vitamin D, control theory, review, 3675
- Pancreatic cancer, bevacizumab, empyema, gastrointestinal perforation, 1665
- Pancreatic cancer, chemoresistance, nafamostat mesilate, gemcitabine, 3173
- Pancreatic cancer, colorectal cancer, stage at diagnosis, rurality, access to care, 3427
- Pancreatic cancer, doxycycline, apoptosis, *p53*, *Fas*, *IL-8*, 3995
- Pancreatic cancer, erlotinib, gemcitabine, overall survival, toxicity, 5211
- Pancreatic cancer, heat-shock protein 90, Hsp90, targeted therapy, angiogenesis, gastrointestinal cancer, gastric cancer, review, 2031
- Pancreatic cancer, immunotherapy, dendritic cells, vaccination, 831
- Pancreatic cancer, *K-ras*, *p53*, *p16*, DPC4, prognostic markers, 1803
- Pancreatic cancer, malignant portal vein stenosis, metallic stent, 3329
- Pancreatic cancer, *Salmonella typhimurium*, bacteria, tumor-targeting, red fluorescent protein, RFP, green fluorescent protein, GFP, imaging, 1873
- Pancreatic duct adenocarcinoma, *LKB1*, mutation, hamster, nitrosamine, 4047
- Pancreatic, curcumin, liposomal, dose finding, cancer, 1895
- Panel, ovarian cancer, multiplex, tumour markers, 573
- Paneth cells, duodenum, adenomas, stem cells, migration, 657
- Panitumumab, autophagy, redox status, 5077
- Panitumumab, colorectal cancer, *K-ras*, 3369
- Pantoea agglomerans*, lipopolysaccharide, macrophage, innate immunity, allergic dermatitis, hygiene hypothesis, review, 4867
- Papillary microcarcinomas, thyroidectomy, papillary thyroid cancer, Chernobyl accident, 5163
- Papillary thyroid cancer, thyroidectomy, papillary microcarcinomas, Chernobyl accident, 5163
- Parasporin, anticancer cytotoxin, preferential activity, *Bacillus thuringiensis*, review, 427
- Parathyroid lymph node, hepatocarcinoma, mesoblastic nephroma, metastasis, autoradiography, 2121
- Parietal metastasis, ovarian cancer, endometriosis, clear cell adenocarcinoma, 1591
- Partial response, immunotherapy, solid tumors, stable disease, 567
- P-ATF2, ATF2, breast cancer, prognosis, immunohistochemistry, Western blot, ERK-1/2, AP-1, MMP-9, 183
- Pathological response, breast cancer, neoadjuvant chemotherapy, paclitaxel, trastuzumab, 517
- PC-3 cells, osteoprotegerin, 3-D collagen, MG-63 osteoblasts, 4013
- PC-3 cells, PPAR γ , 15dPGJ₂, IL-6, Stat3, prostate cancer, 2331

- PCA3, PSA, prostate cancer, ANN, review, 2589
 PCNA, WT1, immunohistochemistry, endometrial cancer, clinicopathological factors, cell proliferation, 4887
 PCR, TEM7, alternative splicing, osteosarcoma, metastasis, 4317
 PD98059, paclitaxel, apoptosis, colon cancer, MAPK inhibition, 261
 PDGF receptor, imatinib mesylate, gamma rays, astrocytoma, 4575
 PDGFR, thymoma, thymic carcinoma, mutations, 4057
 Peg-socket junctions, gastric carcinoma, endothelium, pericyte, electron microscopy, 449
 Pegylated liposomal doxorubicin, advanced ovarian cancer, late relapse, carboplatin, platinum-sensitive, 4195
 PEGylated liposome, polyethylene glycol, reticuloendothelial system, indium-111, HT-29/*luc*, pharmacokinetics, biodistribution, bioluminescence imaging, 2111
 Pelvic irradiation, radiotherapy, small bowel toxicity, 4821
 Pelvic nodal involvement, endometrial cancer, favorable histological characteristics, complete pelvic lymphadenectomy, 2781
 Pemetrexed, adjuvant chemotherapy, operable non-small cell lung cancer, carboplatin, 4297
 Pentacyclic triterpenes, 23-hydroxyursolic acid, growth-inhibition, apoptosis, caspases, 995
 Peptide, thrombospondin-1, antibody, endothelial cell, antiangiogenic, selectivity, 2243
 Peptide, Wilms' tumor 1, WT1, cancer vaccine, immunotherapy, 4779
 Perforation, clinico-pathological features, colorectal cancer, Hartmann's procedure, 1681
 Perforin, HER-2, helper effect, AE-37, AE-47, p776, F7, E75, cancer vaccines, high-affinity CD8⁺ cells, 2427
 Perforin, trastuzumab, esophageal cancer, ADCC, granzyme, 2137
 Periacetabular bone tumor, irradiated bone graft, vascularized bone graft, microsurgery, 1669
 Pericyte, gastric carcinoma, endothelium, peg-socket junctions, electron microscopy, 449
 Pericytes, apoptosis, glioblastoma, HMG-CoA reductase, necrosis, simvastatin, 4901
 Perioperative management, fast track, surgery, review, 2799
 Peripheral blood monocytes, beta-1,3-glucan, colorectal cancer, lentinan, quality of life, superfine dispersed lentinan, 2611
 Peripheral blood, oral squamous cell carcinoma, cytokeratin, disseminated tumor cells, SYBR green real-time quantitative reverse transcriptase-polymerase chain reaction, 291
 Peritoneal carcinomatosis, pseudomyxoma peritonei, experimental model, intraperitoneal chemotherapy, 4051
 Peritoneal recurrence, CA19-9, preoperative, recurrence, 4303
 Peroxisome proliferator-activated receptor gamma, siRNA, migration, metastasis, hepatocellular carcinoma, 5057
 Peroxisome proliferator-activated receptors, nuclear receptors, malignant melanoma, PPAR, vitamin D receptor, VDR, 3647
 Persistent disseminated tumor cells, breast cancer, trastuzumab, targeted therapy, HER2 status, 4019
 PET-CT, [18F]-FDG, CT scan, metastatic colorectal cancer, therapeutic assessment, 2563
 PGE₂, 5-fluorouracil, activated lymphocytes, transforming growth factor-beta, TGF-β, prostaglandin E₂, 3925
 PGE₂, diethyl 2-chloroazulene-1,3-dicarboxylate, RAW264.7 cells, macrophage, COX-2, PLA2, anti-inflammatory effect, 379
 P-glycoprotein, ABC transporters, semi-automated fluorometric method, efflux, ethidium bromide, mouse lymphoma cells, *mdr1*, *ABCB1*, 2173
 P-glycoprotein, drug resistance, daunorubicin, cytarabine, HL-60 cells, glutathione-S-transferase π, 4071
 P-glycoprotein, Euphorbiaceae, *Euphorbia*, triterpenes, steroids, multidrug resistance, apoptosis, 4467
 P-gp, correlation, MRP, expression, leukemia, 1073
 P-gp, etoposide, quercetin, CYP3A, pharmacokinetics, bioavailability, rats, 1411
 PH and cancer, cancer etiopathogenesis, multiple drug resistance, MDR, proton transport in cancer, cancer angiogenesis, cancer strategy and treatment, review, 2127
 Phage display mapping, glycomimetics, mistletoe lectin, MRP5, 4941
 Phagocytosis, macrophage, *tuberculosis*, TLR2, phagosome maturation, survival strategy, short review, 907
 Phagosome maturation, macrophage, phagocytosis, *tuberculosis*, TLR2, survival strategy, short review, 907
 Pharmacogenomic, biliary tract carcinoma, cisplatin, DNA repair proteins, polymorphisms, 1835
 Pharmacokinetic interactions, anticancer agents, 4741
 Pharmacokinetics, BIBF 1120, multiple myeloma, VEGF receptor inhibitor, Phase I study, 4233
 Pharmacokinetics, etoposide, quercetin, P-gp, CYP3A, bioavailability, rats, 1411
 Pharmacokinetics, polyethylene glycol, PEGylated liposome, reticuloendothelial system, indium-111, HT-29/*luc*, biodistribution, bioluminescence imaging, 2111
 Pharmacokinetics, vinorelbine orale, cisplatin, phase I, drug-drug interaction, 553
 Pharmacology, cancer, growth, progestins, antiprogestins, Ishikawa cells, 1047
 Pharyngeal cancer, planned neck dissection, head and neck cancer, primary radio-chemotherapy, HART, lymph node status, 2645
 Phase I study, BIBF 1120, multiple myeloma, VEGF receptor inhibitor, pharmacokinetics, 4233
 Phase I study, gemcitabine, capecitabine, intra-arterial chemotherapy, 1547

- Phase I study, S-1, CDDP, metastatic gastric cancer, combination chemotherapy, 1727
- Phase I, gemcitabine, irinotecan, advanced solid tumors, 5149
- Phase I, vinorelbine orale, cisplatin, pharmacokinetics, drug-drug interaction, 553
- Phase I/II study, epithelial ovarian cancer, treatment resistant, gemcitabine, docetaxel, 1521
- Phase I/II, capecitabine, hepatocellular carcinoma, HCC, adjuvant therapy, PHY906, 4083
- Phase II study, metastatic breast cancer, weekly paclitaxel, 625
- Phase II study, nedaplatin, weekly paclitaxel, non-small cell lung cancer, 1733
- Phase II study, oral vinorelbine, capecitabine, oral chemotherapy, metastatic breast cancer, 667
- PHLPP, curcumin, colorectal cancer, mTOR, Raptor, Rictor, Akt, 3185
- Phosphodiesterase 1, phosphodiesterase, malignant melanoma, 1119
- Phosphodiesterase, phosphodiesterase 1, malignant melanoma, 1119
- Phospho-ERK, MAPK, oral cancer, squamous cell carcinoma, immunoblotting, 303
- Phosphoproteome, UPLC, IMAC, cerebellum, oxygen-18, 4949
- Phosphorylated MYC-N, IGF-I receptor, mTOR, neuroblastoma, rapamycin, temsirolimus, 1943
- Photofrin, ultrasound, glioma, LRP/ α 2MR, U251MG, U105MG, 897
- Photosensitizer, sonodynamic therapy, normal rat brain, blood-brain barrier, electron microscopic study, 889
- PHY906, hepatocellular carcinoma, HCC, adjuvant therapy, capecitabine, Phase I/II, 4083
- Phytochemical synergy, EGCG, genistein, quercetin, prostate cancer cells, 4025
- PI-103, chordoma, mTOR, PI3K, 1867
- PI3 kinase, apoptosis, boswellic acids, Akt, colon cancer cells, LY294002, wortmannin, 2987
- PI3K, chordoma, mTOR, PI-103, 1867
- PIK3CA* amplification, prostate cancer, *PTEN* deletion, 1739
- Pilocytic astrocytoma, pilomyxoid astrocytoma, chemotherapy, leptomeningeal dissemination, 919
- Pilomyxoid astrocytoma, pilocytic astrocytoma, chemotherapy, leptomeningeal dissemination, 919
- PKC β II, gnidimacrin, G₂-phase arrest, p21(WAF1/Cip1), cdc2, E2F-4, 1349
- PLA2, diethyl 2-chloroazulene-1,3-dicarboxylate, RAW264.7 cells, macrophage, PGE₂, COX-2, anti-inflammatory effect, 379
- Planned neck dissection, pharyngeal cancer, head and neck cancer, primary radio-chemotherapy, HART, lymph node status, 2645
- Plasma concentration, cancer, vitamin C, ascorbic acid, ascorbate, intravenous, cytotoxicity, complementary and alternative medicine, review, 809
- Plasma, decreased levels, ghrelin, cachexia, 3949
- Plasma, VEGF, non-small cell lung cancer, chemotherapy, paclitaxel, 2635
- Plasmacytoid dendritic cell, HNSCC, CpG, migration, IFN- α , 3019
- Plasminogen activator inhibitor type I, node-negative breast cancer, urokinase-type plasminogen activator, prognostic factor, distant metastases, local recurrence, 1475
- Platelet aggregation, cordycepin (3'-deoxyadenosine), hematogenic metastasis, B16-F1 mouse melanoma cell, adenosine-5'-diphosphate, 3857
- Platinum drugs, A431 and A431/Pt human cervical tumor cell lines, prolonged drug incubation, cytotoxic effect, 3931
- Platinum, ovarian cancer, intraperitoneal chemotherapy, taxane, review, 2803
- Platinum-sensitive, advanced ovarian cancer, late relapse, pegylated liposomal doxorubicin, carboplatin, 4195
- PLC γ , MDA-MB-231, fibroblast growth factor receptor, Akt, Chfr, breast cancer, *Xenopus* oocyte, 4965
- Pleiotrophin, heparin affinity regulatory peptide, serum response element, endothelial cells, glioma, 349
- PLGA, nanospheres, curcumin, S/O/W emulsion, confocal microscopy, cancer therapy, 3867
- PMEDAP, proangiogenic genes, PMEG, T-cell SD-lymphoma, 1295
- PMEG, proangiogenic genes, PMEDAP, T-cell SD-lymphoma, 1295
- Pneumonitis, pulmonary toxicity, interstitial lung disease, dyspnea, antineoplastic drugs, lung injury, review, 631
- Poly(A), vitamin D receptor, gene polymorphisms, cancer, Fok1, BSm1, Taq1, Apa1, Cdx2, Bgl1, 3511
- Polycyclic aromatic hydrocarbons, aerosols, air pollution, cancer, ultraviolet-B, vitamin D, 3537
- Polyethylene glycol, hematological malignancy, α 1,3 galactosyltransferase, leukemia, immunotherapy, 2327
- Polyethylene glycol, PEGylated liposome, reticuloendothelial system, indium-111, HT-29/*luc*, pharmacokinetics, biodistribution, bioluminescence imaging, 2111
- Polyethylene glycol, sonodynamic, lomefloxacin, sarcoma180, 243
- Polymorphism, alkylating agents, cancer, glioma, O⁶-methylguanine, O⁶-MG, O⁶-methylguanine-DNA-methyltransferase, *MGMT*, promoter methylation, temozolomide, TMZ, review, 3759
- Polymorphism, *APE1*, BER, lung cancer, cigarette, RFLP, 2417
- Polymorphism, bladder cancer, *XRCC1*, *XRCC3*, *XPD*, *XPG*, *APE1*, *hOGG1*, 1389
- Polymorphism, *ERCC6*, bladder cancer, carcinogenesis, 5121
- Polymorphism, *Tip60*, breast cancer, carcinogenesis, 3897

- Polymorphism, *Exo1*, lung cancer, carcinogenesis, 725
- Polymorphism, gastric cancer, RANTES promoter, *H. pylori*, 4265
- Polymorphism, Ku80, bladder cancer, carcinogenesis, 1275
- Polymorphism, Ku80, breast cancer, carcinogenesis, 5251
- Polymorphism, Ku80, colorectal cancer, carcinogenesis, 2239
- Polymorphism, *L-MYC*, oral squamous cell carcinoma, 2519
- Polymorphism, methylation, *Helicobacter pylori*, gastric mucosa, *COMT*, 2857
- Polymorphism, pre-malignant condition, HSP70-2, *Helicobacter pylori*, 3453
- Polymorphism, prostate cancer, PSA, ARE-I, 1395
- Polymorphism, tumor necrosis factor alpha, tumor necrosis factor beta, oral cancer, oncogenesis, genetic association study, 2379
- Polymorphism, VEGF, *Helicobacter pylori*, intestinal metaplasia, 485
- Polymorphisms, biliary tract carcinoma, pharmacogenomic, cisplatin, DNA repair proteins, 1835
- Polymorphisms, head and neck cancer, microsomal epoxide hydrolase, glutathione-S-transferase, UDP-glucuronosyltransferase, cancer susceptibility, smoking, review, 753
- Polynucleotides, flavonoids, DNA binding, triplex DNA, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, 2273
- Polynucleotides, flavonoids, DNA binding, triplex DNA, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, structure-activity relationship, 2285
- Polyps, colonoscopy, size assessment, 1539
- PONI*, arylamine metabolism, bladder cancer, detoxification, genetic polymorphism, arylesterase, 4041
- Porcine model, interleukin-6, liver surgery, portal vein embolization, portal vein ligation, liver regeneration, 2371
- Portal vein embolization, interleukin-6, liver surgery, portal vein ligation, liver regeneration, porcine model, 2371
- Portal vein ligation, interleukin-6, liver surgery, portal vein embolization, liver regeneration, porcine model, 2371
- Post initial gefitinib therapy, non-small cell lung cancer, gefitinib, treatment failure, 4217
- Postmenopausal women, breast cancer, overweight, obese, Statins, epidemiology, 5143
- Postmenopausal, breast cancer, estrogen, aromatase, 17 beta HSD type 1, Steroid sulphatase, carcinogenesis, review, 1095
- Postoperative course, GIST, imatinib, 4893
- Postoperative follow-up, CEA, TIMP-1, lead-time, immunoassay, biological marker, 75
- Post-traumatic growth, osteosarcoma, post-traumatic stress symptom, psychosocial outcome, 4287
- Pos-ttraumatic stress symptom, osteosarcoma, post-traumatic growth, psychosocial outcome, 4287
- PPAR, nuclear receptors, malignant melanoma, peroxisome proliferator-activated receptors, vitamin D receptor, VDR, 3647
- PPAR γ , 15dPGJ₂, IL-6, Stat3, PC-3 cells, prostate cancer, 2331
- PPE, anthracycline, doxorubicin, epirubicin, hand-foot syndrome, 2307
- PRb, bladder cancer, cell regulatory proteins, *p53*, prognosis, 4201
- Pre-adipocytes, breast cancer, Zeranol, body weight gain, doubling time, cyclin D1, *p53*, 5045
- Predictive factor, colorectal cancer, microsatellite instability, chemotherapy, survival, 1615
- Predictive factors, gefitinib, erlotinib, *EGFR* mutations, *K-ras* mutations, smoking habits, lung cancer, 2691
- Predictive marker, *DYRK2*, *p53*, lung cancer, chemotherapy, 2753
- Preferential activity, parasporin, anticancer cytotoxin, *Bacillus thuringiensis*, review, 427
- Pre-malignant condition, HSP70-2, polymorphism, *Helicobacter pylori*, 3453
- Preneoplasia, dysplasia, epithelium, lectin, malignancy, galectin-8, 4933
- Preoperative chemoradiotherapy, esophageal cancer, mortality, morbidity, prognosis, 2555
- Pre-operative chemotherapy, breast cancer, anemia, side-effects, tumor biology, epirubicin, paclitaxel, 2675
- Preoperative chemotherapy, S-1, cisplatin, advanced gastric cancer, neoadjuvant chemotherapy, 4689
- Preoperative, CA19-9, recurrence, peritoneal recurrence, 4303
- Preoperative, leukocytosis, anemia, thrombocytosis, non-small cell lung cancer, survival, 2687
- Prevention, amitriptyline, antidepressants, chemotherapy-induced neuropathy, neoplasms, neurotoxicity, 2601
- Primary culture, apoptosis, tumor necrosis factor-related apoptosis-inducing ligand, non-small cell lung cancer, 2905
- Primary culture, cancer, *EGFR*, erlotinib, chemoresponse, chemotherapy sensitivity and resistance assay, CSRA, ChemoFx[®], 1993
- Primary radio-chemotherapy, planned neck dissection, pharyngeal cancer, head and neck cancer, HART, lymph node status, 2645
- Priming, host-defensive function, carbon tetrachloride, innate, triggering, lipid, 837
- Prion disease, amyloid plaques, Congo Red, doxorubicin, 2507
- PRMT1, protein arginine methyltransferase, colon cancer, prognosis, 1361
- Proangiogenic genes, PMEDAP, PMEG, T-cell SD-lymphoma, 1295
- Prodrug therapy, oncolytic virus, nitroreductase, HSV, antitumor activity, 2159

- Prodrug, alkylator, DNA damage, cell cycle arrest, bone-marrow sparing, drug resistance, 3845
- Progesterone receptor antagonist, mifepristone, murine leukemia, 2977
- Progesterone receptor, human colon cancer, antagonist, microenvironment, natural killer cells, 1611
- Progesterone, cancer, endometrium, growth, mifepristone, cell cycle, apoptosis, Ishikawa cells, 1053
- Progesterone, endometrial hyperplasia, endometrial carcinoma, cofactor, NCoR, 1023
- Progestins, cancer, pharmacology, growth, antiprogestins, Ishikawa cells, 1047
- Prognosis, Akt isoforms, tissue microarray, NSCLC, 4175
- Prognosis, angiogenesis, galectin-1, laryngeal cancer, lymphocyte, lectin, stroma, 59
- Prognosis, ATF2, p-ATF2, breast cancer, immunohistochemistry, Western blot, ERK-1/2, AP-1, MMP-9, 183
- Prognosis, bladder cancer, cell regulatory proteins, *p53*, pRb, 4201
- Prognosis, colorectal carcinoma, immunohistochemistry, MET, survival, carcinogenesis, 4807
- Prognosis, cytoplasmic, high-grade astrocytoma, nuclear, p27, subcellular localization, 597
- Prognosis, DNA cytometry, stage II colorectal cancer, adjuvant therapy, 99
- Prognosis, ERas, oncogene, gastric carcinoma, 2189
- Prognosis, esophageal cancer, preoperative chemoradiotherapy, mortality, morbidity, 2555
- Prognosis, gastric cancer, cytokine plasma levels, 5005
- Prognosis, GSK-3 β , prostate cancer, cell signaling pathway, apoptosis, proliferation, 2077
- Prognosis, head and neck cancer, lymphatics, lymph node metastasis, 1675
- Prognosis, head and neck cancer, neoadjuvant chemotherapy, limited surgery, radical surgery, 255
- Prognosis, head and neck squamous cell carcinoma, oral cavity, oropharynx, oncomarker, oxidative stress, malondialdehyde, 4227
- Prognosis, *hTERT*, alternative lengthening, review, 3833
- Prognosis, leptin, adiponectin, colorectal cancer, 3321
- Prognosis, lung cancer, diagnosis, ProGRP, NSE, CYFRA 21-1, CEA, 4827
- Prognosis, oncogene, immunohistochemistry, gastric cancer, 4451
- Prognosis, oral cancer, metallothionein, *p53* protein, immunohistochemistry, 1189
- Prognosis, ovarian cancer, chemotherapy, Akt, ERK, 4639
- Prognosis, prostate, biomarkers, cancer, PSA, review, 3289
- Prognosis, protein arginine methyltransferase, PRMT1, colon cancer, 1361
- Prognosis, S100A4, lung cancer, tissue microarray, immunohistochemistry, 2547
- Prognosis, vulvar cancer, survival, lymph node metastasis, staging, SCC-Ag, 545
- Prognosis, WT1, immunohistochemistry, endometrial cancer, clinicopathological factors, 1691
- Prognostic factor, L1, metastasis, gastric cancer, 4033
- Prognostic factor, node-negative breast cancer, urokinase-type plasminogen activator, plasminogen activator inhibitor type I, distant metastases, local recurrence, 1475
- Prognostic factor, surgery, prostate cancer, nPSA12, radiotherapy, biochemical failure, 4605
- Prognostic factors, CD4, CD8, tumor-infiltrating lymphocytes, breast cancer, 2445
- Prognostic factors, chronic lymphocytic leukaemia, B-cell receptor, review, 605
- Prognostic factors, colorectal cancer, liver metastasis, hepatic arterial infusion, hai, systemic chemotherapy, 4139
- Prognostic factors, epithelial ovarian cancer, retrospective, registry, 745
- Prognostic factors, gastric carcinoma, Bcl-2, Ki-67, apoptosis, 703
- Prognostic factors, small cell neuroendocrine cervical carcinoma, treatment, 477
- Prognostic markers, germ cell tumors, immunohistochemical markers, *p53*, MIB-1, survival, 737
- Prognostic markers, pancreatic cancer, *K-ras*, *p53*, *p16*, DPC4, 1803
- Prognostic significance, CEACAM-1, cell adhesion, lymphnode, hematogenous, metastasis, non-small cell lung cancer, 249
- Prognostic significance, matriptase, endometrial cancer, 1685
- Programmed death-1, domain, fibronectin, tumor immune therapy, 5089
- Progression, ovarian cancer, relapse, CA-125, survival, 2817
- Progression-free survival, cisplatin, clinical trial, docetaxel, ovarian cancer, 561
- ProGRP, lung cancer, diagnosis, prognosis, NSE, CYFRA 21-1, CEA, 4827
- Prolactin, estradiol, FSH, LH, ovarian cancer, 1575
- Proliferation, all-*trans* retinoic acid, breast cancer, tyrosine phosphorylation, *c-ERBB2/neu*, 2899
- Proliferation, ameloblastoma, apoptosis, TNF-related apoptosis-inducing ligand, 1137
- Proliferation, cisplatin sensitivity, *EGFR*, HNSCC, 1181
- Proliferation, DCA, hypoxia, *HIF1A*, apoptosis, 4579
- Proliferation, gastric cancer, colon cancer, ErbB, neuroglycan-C, 229
- Proliferation, GSK-3 β , prostate cancer, cell signaling pathway, apoptosis, prognosis, 2077
- Proliferation, metallothionein, laminin, lymph nodes metastases, oral cancer, 589
- Proliferation, oral cancer, substance P, NK-1 receptor, 2323

- Proliferation, recombinant adeno-associated virus, rAAV, hypoxia inducible factor, HIF, small interference RNA, siRNA, nuclear factor-kappaB, NF- κ B, apoptosis, 1367
- Proliferation, Rho, ROCK, ERK, GBM, migration, 119
- Proliferation, vitamin D, $1\alpha,25(\text{OH})_2\text{D}_3$, fish oil, ω -3 PUFAs, HepG2, hepatoma, 3591
- Prolonged drug incubation, A431 and A431/Pt human cervical tumor cell lines, platinum drugs, cytotoxic effect, 3931
- Promoter hypermethylation, Wnt pathway, Wnt inhibitory factor-1, demethylation, epigallocatechin-3-gallate, EGCG, 2025
- Promoter methylation, alkylating agents, cancer, glioma, O^6 -methylguanine, O^6 -MG, O^6 -methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, temozolomide, TMZ, review, 3759
- Promoter methylation, non-small cell lung cancer, methylation-specific PCR, bronchial epithelial cells, clonal field expansion, endobronchial brush, 363
- Promoter methylation, non-small cell lung cancer, RECK, tissue samples, mRNA, RT-PCR, 4535
- Promotion, chromosomal aberrations, radio frequency, microwave radiation, pulsed-wave, continuous-wave, 2885
- Promotion, chromosomal aberrations, radio frequency, pulsed waves, continuous waves, 4323
- Prophylactic cranial radiotherapy, SCLC limited disease, sequential chemoradiotherapy, concurrent chemoradiotherapy, median survival time, overall survival, 5219
- Prophylaxis, innate immunity, macrophage network, TLR4, review, 817
- Prostaglandin E_2 , 5-fluorouracil, activated lymphocytes, transforming growth factor-beta, TGF- β , PGE $_2$, 3925
- Prostaglandin metabolism, breast cancer, cyclooxygenase-2, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, 3619
- Prostaglandin metabolism, granulosa cells, cyclooxygenase-2, 15-hydroxy-prostaglandin dehydrogenase, vitamin D receptor, 3611
- Prostate cancer cells, EGCG, genistein, quercetin, phytochemical synergy, 4025
- Prostate cancer, (-)-gossypol, metastasis, nm23-H1, Bcl-2, Bcl-xL, 2179
- Prostate cancer, 2-methoxyestradiol, estrogen, sulfamate, ovarian cancer, breast cancer, 3751
- Prostate cancer, angiogenesis, molecular imaging, tumor vascular remodelling, vascular stabilization, review, 1823
- Prostate cancer, calcitriol, non-steroids, 3605
- Prostate cancer, cardiac hormones, atrial natriuretic peptide, long-acting atrial natriuretic peptide, Ras, 1889
- Prostate cancer, cardiac hormones, vessel dilator, kaliuretic peptide, Ras, 971
- Prostate cancer, case-control studies, cohort studies, colon cancer, ecological studies, randomized controlled trials, review, 3597
- Prostate cancer, celecoxib, COX-2 inhibitors, randomized controlled trial, 1483
- Prostate cancer, CWR22Rv1 cells, resveratrol, NQO2, 3011
- Prostate cancer, CYP17 gene polymorphism, hormonal genes, BPH, North India, 1659
- Prostate cancer, enzyme kinetics, pancreas, vitamin D, control theory, review, 3675
- Prostate cancer, focal therapy, male lumpectomy, review, 5155
- Prostate cancer, ghrelin, bicalutamide, leuprorelin, 1345
- Prostate cancer, glutamatergic system, dihydrotestosterone, 371
- Prostate cancer, GSK-3 β , cell signaling pathway, apoptosis, proliferation, prognosis, 2077
- Prostate cancer, laparoscopy, radical prostatectomy, robotics, 1637
- Prostate cancer, *PIK3CA* amplification, *PTEN* deletion, 1739
- Prostate cancer, PPAR γ , 15dPGJ $_2$, IL-6, Stat3, PC-3 cells, 2331
- Prostate cancer, PSA, ARE-I, polymorphism, 1395
- Prostate cancer, PSA, PCA3, ANN, review, 2589
- Prostate cancer, radiotherapy, conformal, definitive, androgen deprivation, 2627
- Prostate cancer, radiotherapy, late toxicity, rectal toxicity, 1831
- Prostate cancer, riluzole, ion channel, apoptosis, endoplasmic reticulum stress, 2195
- Prostate cancer, surgery, nPSA12, radiotherapy, biochemical failure, prognostic factor, 4605
- Prostate cancer, vitamin D, MART-10, androgen, 3547
- Prostate carcinoma, PINP, PSA, AP, tumour marker, bone metastases, 671
- Prostate, biomarkers, cancer, PSA, prognosis, review, 3289
- Prostate, carcinoma, GnRHR, androgen receptor, 681
- Protease, cathepsin L, NSITC, angiogenesis, ECM, 4473
- Proteasome inhibitor, neuroblastoma, bortezomib, metastases, xenograft model, 1219
- Proteasome inhibitor, TP-110, apoptosis, multiple myeloma, IAP, 977
- Proteasome, bortezomib, renal cancer, *p53*, VHL, 2961
- Proteasome, chronic lymphocytic leukemia, ER stress, XBP1 splicing, apoptosis, 3797
- Protein arginine methyltransferase, PRMT1, colon cancer, prognosis, 1361
- Protein kinase R, fatigue, RNase L, nitric oxide, nuclear factor kappa beta, NF- κ B, intracellular immune dysfunction, natural killer cell, oxidative stress, exercise, review, 4717
- Protein transduction domain, apoptosis, macromolecular therapeutics, survivin, 1423

- Proteomics, SELDI-TOF MS, laser microdissection, ovarian cancer, cancer biomarkers, 1039
- Proton beam therapy, malignant myoepithelioma, maxillary sinus, radiation therapy, 497
- Proton transport in cancer, cancer etiopathogenesis, pH and cancer, multiple drug resistance, MDR, cancer angiogenesis, cancer strategy and treatment, review, 2127
- Proximal gastric cancer, splenectomy, lymph node metastasis, splenic hilus, 3347
- PSA, PCA3, prostate cancer, ANN, review, 2589
- PSA, prostate cancer, ARE-I, polymorphism, 1395
- PSA, prostate carcinoma, PINP, AP, tumour marker, bone metastases, 671
- PSA, prostate, biomarkers, cancer, prognosis, review, 3289
- Pseudomyxoma peritonei, experimental model, peritoneal carcinomatosis, intraperitoneal chemotherapy, 4051
- Pseudoprogession, glioblastoma, concomitant radio-chemotherapy, radiological assessment, 2607
- PSK, gastric cancer, xenograft model, docetaxel, 843
- P-ST5 primary tumor, human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, L-ST5 lymph node metastasis, H-ST5 hepatic metastasis, neuroendocrine characteristics, tumorigenicity, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Psychosocial outcome, osteosarcoma, post-traumatic growth, post-traumatic stress symptom, 4287
- Psychosocial risk scale, breast disease, breast cancer, 4765
- PTEN* deletion, prostate cancer, *PIK3CA* amplification, 1739
- PTEN*, EMT, TNF- α , migration, invasion, 4439
- PTHrP, hypercalcemia, malignancy, cancer, RANKL, bisphosphonates, review, 1551
- PTP4A3, colorectal carcinoma, 3913
- Ω -3 PUFAs, vitamin D, $1\alpha,25(\text{OH})_2\text{D}_3$, proliferation, fish oil, HepG2, hepatoma, 3591
- Pulmonary embolism, anticoagulant, cerebral hemorrhage, glioblastoma, venous glioblastoma, venous thromboembolism, 4309
- Pulmonary toxicity, interstitial lung disease, dyspnea, pneumonitis, antineoplastic drugs, lung injury, review, 631
- Pulsed waves, chromosomal aberrations, radio frequency, continuous waves, promotion, 4323
- Pulsed-wave, chromosomal aberrations, radio frequency, microwave radiation, continuous-wave, promotion, 2885
- Pyomyositis, methicillin-resistant *Staphylococcus aureus*, acute myelogenous leukemia, high-dose Ara-C, 3361
- PZ-HPV-7 cells, synthesis, 14-*epi*-MART-10, 19-norvitamin D₃, Julia coupling, HL-60 cells, 3563
- Q5 promoter, cancer, gene therapy, transcriptional targeting, allograft rejection, cyclophosphamide, 1015
- QSAR, 1,2,3,4-tetrahydroisoquinoline, cytotoxicity, semiempirical molecular-orbital method, absolute hardness, 2265
- QSAR, 1,2,3,4-tetrahydroisoquinoline, cytotoxicity, semiempirical molecular-orbital method, absolute hardness, 4077
- QSAR, dihydroimidazoles, cytotoxicity, semiempirical molecular-orbital method, 5019
- QSAR, naphtho[2,3-*b*]furan-4,9-diones, apoptosis, autophagy, caspase, DNA fragmentation, 455
- Quadruplex DNA, flavonoids, DNA binding, polynucleotides, triplex DNA, cancer cell lines, UV, fluorescence spectroscopy, 2273
- Quadruplex DNA, flavonoids, DNA binding, polynucleotides, triplex DNA, cancer cell lines, UV, fluorescence spectroscopy, structure-activity relationship, 2285
- Quality of life, beta-1,3-glucan, colorectal cancer, lentinan, peripheral blood monocytes, superfine dispersed lentinan, 2611
- Quality of life, chemotherapy, epoetin- α , hemoglobin, solid tumors, 693
- Quantitative methylation-specific PCR, *CD133*, colorectal cancer, 2235
- Quantitative methylation-specific PCR, *CDH3*, colorectal cancer, 2215
- Quantitative methylation-specific PCR, *CDH3*, gastric carcinoma, 3945
- Quantitative methylation-specific PCR, *HACE1*, gastric carcinoma, 2231
- Quantitative methylation-specific PCR, *MGMT*, gastric cancer, 5053
- Quantitative methylation-specific PCR, *p16*, colorectal cancer, 275
- Quantitative methylation-specific PCR, *UNC5C*, colorectal cancer, 271
- Quantitative methylation-specific PCR, *UNC5C*, gastric cancer, 4397
- Quantitative methylation-specific PCR, *Vimentin*, colorectal carcinoma, 279
- Quantitative methylation-specific PCR, *Vimentin*, gastric carcinoma, 2227
- Quantitative real-time PCR, *Tip60*, colorectal cancer, 3953
- Quercetin, antioxidants, coenzyme Q10, nasal mucosa, Comet assay, mini organ cultures, 33
- Quercetin, EGCG, genistein, phytochemical synergy, prostate cancer cells, 4025
- Quercetin, etoposide, P-gp, CYP3A, pharmacokinetics, bioavailability, rats, 1411
- Quercetin, hedgehog, Wnt, cyclopamine, leukemia, lymphoma, 4629
- rAAV, recombinant adeno-associated virus, hypoxia inducible factor, HIF, small interference RNA, siRNA, nuclear factor-kappaB, NF- κ B, proliferation, apoptosis, 1367
- Radiation therapy, head and neck cancer, chemotherapy, docetaxel, *ERCC1*, 529

- Radiation therapy, malignant myoepithelioma, maxillary sinus, proton beam therapy, 497
- Radiation therapy, small cell carcinoma, treatment, outcome, chemotherapy, 3411
- Radiation, apoptosis, caspase-2, caspase-8, caspase-9, 4361
- Radiation, hyperglycemia, chemotherapy, head and neck cancer, 4683
- Radiation, hyperthermia, DNA repair, 1319
- Radiation, ZD1839, p27^{kip1}, Jab1, cholangiocarcinoma, 1169
- Radical prostatectomy, laparoscopy, prostate cancer, robotics, 1637
- Radical surgery, head and neck cancer, neoadjuvant chemotherapy, limited surgery, prognosis, 255
- Radical-scavenging activity, biphenols, COX-2, NF-kappaB, AP-1, DFT/B3LYP, lipopolysaccharide, 2403
- Radio frequency, chromosomal aberrations, microwave radiation, pulsed-wave, continuous-wave, promotion, 2885
- Radio frequency, chromosomal aberrations, pulsed waves, continuous waves, promotion, 4323
- Radiofrequency ablation, bone tumor, bone cement, breast cancer, metastases, 2787
- Radiofrequency induced thermotherapy, bipolar, liver metastases, 1309
- Radioimmunotherapy, zevalin, ibritumomab tiuxetan, non-Hodgkin's lymphoma, indolent lymphoma, aggressive lymphoma, 4771
- Radioiodine, aerodigestive tract, external beam, radiosensitizer, radiotherapy, paclitaxel, taxane, carboplatin, 4665
- Radiolabeling, breast cancer, tumor-antigen peptides, tumor-cell binding, biodistribution, 1399
- Radiological assessment, glioblastoma, pseudoprogression, concomitant radio-chemotherapy, 2607
- Radioresistance, survivin, DNA double-strand breaks, DNA repair, squamous cell carcinoma, 223
- Radioresistant brain metastasis, melanoma, hypofractionated stereotactic radiotherapy, HSRT, radiosurgery, RS, radiotherapy, 4259
- Radiosensitization, cytotoxicity, tetrandrine, neuroblastoma, 3163
- Radiosensitization, imexon antioxidant, antiproliferative activity, lymphoma cells, ionizing radiation, 4409
- Radiosensitizer, aerodigestive tract, external beam, radioiodine, radiotherapy, paclitaxel, taxane, carboplatin, 4665
- Radiosurgery, RS, radioresistant brain metastasis, melanoma, hypofractionated stereotactic radiotherapy, HSRT, radiotherapy, 4259
- Radiotherapy, aerodigestive tract, external beam, radioiodine, radiosensitizer, paclitaxel, taxane, carboplatin, 4665
- Radiotherapy, breast cancer, skin recurrence, inflammatory recurrence, mastectomy, overall survival, recurrence-free survival, 1697
- Radiotherapy, cancer immunotherapy, chemotherapy, surgery, T-regulatory lymphocyte, 1847
- Radiotherapy, cardiopulmonary toxicity, Hodgkin's disease, chemotherapy, 777
- Radiotherapy, cervical carcinoma, chemotherapy, brachytherapy, 4205
- Radiotherapy, esophageal cancer, chemotherapy, gastro-lymphatic fistula, 525
- Radiotherapy, glioblastoma, chemotherapy, temozolomide, targeted therapy, review, 5171
- Radiotherapy, laryngeal carcinoma, chemoradiotherapy, larynx preservation, 661
- Radiotherapy, palliative radiation treatment, cancer, travel distance, 2641
- Radiotherapy, prostate cancer, conformal, definitive, androgen deprivation, 2627
- Radiotherapy, prostate cancer, late toxicity, rectal toxicity, 1831
- Radiotherapy, radioresistant brain metastasis, melanoma, hypofractionated stereotactic radiotherapy, HSRT, radiosurgery, RS, 4259
- Radiotherapy, sequence, hormone therapy, aromatase inhibitor, 4791
- Radiotherapy, small bowel toxicity, pelvic irradiation, 4821
- Radiotherapy, surgery, prostate cancer, nPSA12, biochemical failure, prognostic factor, 4605
- RAGE, receptor for advanced glycation end products, hypoxia, apoptosis, 1287
- Randomized controlled trial, celecoxib, COX-2 inhibitors, prostate cancer, 1483
- Randomized controlled trials, case-control studies, cohort studies, colon cancer, prostate cancer, ecological studies, review, 3597
- RANKL, hypercalcemia, malignancy, cancer, PTHrP, bisphosphonates, review, 1551
- RANTES promoter, gastric cancer, *H. pylori*, polymorphism, 4265
- Rapamycin, IGF-I receptor, phosphorylated MYC-N, mTOR, neuroblastoma, temsirolimus, 1943
- Rapamycin, mTOR signaling, mTOR phosphorylation, STAT3 phosphorylation, biomarkers of resistance, p70S6 and RS6P, human breast epithelial cells, human breast premalignant and tumor epithelial cells, early events in breast tumorigenesis, 1143
- Rapamycin, organ transplantation, sirolimus, squamous cell carcinoma, vascularization, 1927
- Raptor, curcumin, colorectal cancer, mTOR, Rictor, Akt, PHLPP, 3185
- Ras, prostate cancer, cardiac hormones, atrial natriuretic peptide, long-acting atrial natriuretic peptide, 1889
- Ras, prostate cancer, cardiac hormones, vessel dilator, kaliuretic peptide, 971

- Rat breast tumor, artemisinin-transferrin conjugate, dihydroartemisinin, 3807
- Rats, etoposide, quercetin, P-gp, CYP3A, pharmacokinetics, bioavailability, 1411
- RAW264.7 cells, diethyl 2-chloroazulene-1,3-dicarboxylate, macrophage, PGE₂, COX-2, PLA2, anti-inflammatory effect, 379
- RAW264.7, nutritional starvation, serine, glutamine, glucose, cell death, 343
- Rb, *Trp53*, chromosome instability, skin cancer, inflammation, NFκB, mitotic checkpoint, 3035
- Reactive oxygen species, capsaicin, calcium, mitochondrial membrane potential, apoptosis, human HepG2 cells, 165
- Real-time PCR, Bcl-2, bax, *p53*, apoptosis, endometrium carcinoma, immunohistochemistry, 3977
- Real-time PCR, *hTERT*, circulating DNA, breast cancer, tumor marker, 2845
- Real-time quantitative RT-PCR, metastin, AXOR12, DSCR1, gene expression, epithelial ovarian cancer, 617
- Receptor activator of nuclear factor-κB ligand, bone turnover markers, NSCLC, bone metastasis, osteoprotegerin, osteopontin, 1651
- Receptor for advanced glycation end products, RAGE, hypoxia, apoptosis, 1287
- RECK, non-small cell lung cancer, tissue samples, mRNA, RT-PCR, promoter methylation, 4535
- Recombinant adeno-associated virus, rAAV, hypoxia inducible factor, HIF, small interference RNA, siRNA, nuclear factor-kappaB, NF-κB, proliferation, apoptosis, 1367
- Recombinant VacA, VacA, neutralizing antibody, anti-*H. pylori* vaccine, CpG-ODN, mucosal immune response, 2393
- Reconstruction, giant basal cell carcinoma, tumor, 2655
- Reconstruction, osteosarcoma, talus, frozen, liquid nitrogen, 4093
- Rectal cancer, colon cancer, grading, estrogen, vitamin D, 3721
- Rectal toxicity, prostate cancer, radiotherapy, late toxicity, 1831
- Recurrence, breast carcinoma, 10 years, 3445
- Recurrence, CA19-9, preoperative, peritoneal recurrence, 4303
- Recurrence, haematogenous failure, myometrial invasion, lymph-vascular space involvement, endometrial cancer, 1715
- Recurrence, malignant peripheral nerve sheath tumor, MPNST, metastasis, molecular characterization, cell cycle regulators, Nm-23H1, 1255
- Recurrence, survivin, urothelial carcinoma, immunohistochemistry, 4163
- Recurrence-free survival, breast cancer, skin recurrence, inflammatory recurrence, radiotherapy, mastectomy, overall survival, 1697
- Recurrent head and neck cancer, S-1, outpatient chemotherapy, low dose chemotherapy, tumor dormancy, 577
- Recurrent ovarian cancer, chemotherapy, treatment-free interval, hormonal therapy, 2831
- Red fluorescent protein, RFP, *Salmonella typhimurium*, bacteria, tumor-targeting, pancreatic cancer, green fluorescent protein, GFP, imaging, 1873
- Redness, melanoma, IL-6, *IL-8*, 1793
- Redox status, panitumumab, autophagy, 5077
- Registry, epithelial ovarian cancer, retrospective, prognostic factors, 745
- Regulated genes, multiple endocrine neoplasia type 1, MEN1, transfection, 1859
- Regulation, antimicrotubule agents, β3-tubulin, AP-1, 3003
- Regulatory T-cell, FoxP3, gastrointestinal cancer, 1527
- Regulatory T-cell, splenectomy, liver metastasis, Foxp3, NK cell, 385
- Regulatory T-cells, human FOXP3, VEGF, IL-10, TGF-β, immunotherapy, tumor immunity, survival, 881
- Relapse, ovarian cancer, progression, CA-125, survival, 2817
- Relapse-free survival, breast, carcinoma, clusterin, 3909
- Renal adenocarcinoma, CYP4A, 20-hydroxyeicosatetraenoic acid, eicosanoids, xenograft model, 3819
- Renal cancer, bortezomib, proteasome, *p53*, VHL, 2961
- Renal cell cancer, DNA repair, genetic polymorphism, haplotype, outcome, *XRCCI*, 5131
- Renal cell carcinoma, adenovirus vector, transduction efficacy, RGD, 2997
- Renal cell carcinoma, angiogenesis, Tetrac, Tetrac nanoparticles, anti-cancer, anti-angiogenesis, integrin, 3825
- Renal cell carcinoma, hypoxia-inducible factors, VHL, genetics, 4337
- Renal cell carcinoma, metastasis, thyroid, thyroidectomy, neoplastic thrombus, jugular vein thrombosis, 473
- Renal cell carcinoma, sunitinib, cardiovascular, tyrosine kinase inhibitor, 1627
- Renin-angiotensin system, breast cancer, ovary, steroidogenesis, estradiol, 4633
- Repeated treatment, anthracycline, cyclophosphamide, breast cancer, anti-emesis, 5-HT₃ receptor antagonist, constipation, 1721
- Resection, liver metastases, colorectal cancer, elderly, 583
- Resistance, 14-3-3σ, *p53*, p21, cisplatin, senescence, 2009
- Resistance, albendazole, paclitaxel, ovarian cancer, tubulin, 3791
- Resistance, gefitinib, bortezomib, epidermal growth factor receptor, tumor necrosis factor α, 2315
- Resistant cells, doxorubicin, formamidine doxorubicins, uptake, topoisomerase II, 1429
- Resistant, non-small cell lung cancer, gefitinib, paclitaxel, *EGFR*-TKI, 2747
- Response, colorectal adenocarcinoma, chemotherapy, molecular changes, tumorigenesis, 3115

- Resveratrol, capsaicin, nitric oxide, *p53*, HCT116 cells, chemoprevention, 3733
- Resveratrol, endothelia, adhesion, ICAM-1, NF- κ B, 355
- Resveratrol, prostate cancer, CWR22Rv1 cells, NQO2, 3011
- Reticuloendothelial system, polyethylene glycol, PEGylated liposome, indium-111, HT-29/*luc*, pharmacokinetics, biodistribution, bioluminescence imaging, 2111
- Retinoic acid, breast cancer, epigenetic, histone deacetylation, telomerase, *hTERT*, 4959
- Retinoic acid, neuroblastoma, epidermal growth factor receptor, gefitinib, chemotherapy, 1327
- Retinol, carcinogenesis, intestine, vitamin D, *Min/+* mouse, 4353
- Retrospective analysis, NSCLC, bone metastasis, pamidronate, survival, 5245
- Retrospective study, high-dose interleukin-2, metastatic melanoma, brain metastasis, 4189
- Retrospective, epithelial ovarian cancer, registry, prognostic factors, 745
- Review, 1,25(OH) $_2$ D $_3$, analog, cancer, microarray, 3471
- Review, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, survival, vitamin D supplementation, 3699
- Review, alkylating agents, cancer, glioma, O 6 -methylguanine, O 6 -MG, O 6 -methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, promoter methylation, temozolomide, TMZ, 3759
- Review, angiogenesis, uterine cervical carcinomas, basic FGF, VEGF, COX-2, angiopoietin, *IL-8*, thymidine phosphorylase, HIF-1 α , ETS-1, 2665
- Review, brain metastases, ovarian cancer, central nervous system relapse, brain lesions, 2793
- Review, cancer therapy, nanotargeted radiopharmaceuticals, nanocarriers, tumor imaging, 4107
- Review, cancer, HB-EGF, amphiregulin, targeted therapy, 4879
- Review, case-control studies, cohort studies, colon cancer, prostate cancer, ecological studies, randomized controlled trials, 3597
- Review, cryoablation, helper T-cell, immune reaction, hepatoma, ablation therapy, 5203
- Review, enzyme kinetics, prostate cancer, pancreas, vitamin D, control theory, 3675
- Review, extrarenal vitamin D synthesis, 1,25dihydroxyvitamin D $_3$, colon tumor prevention, vitamin D hydroxylases, calcium, estrogen, epigenetic regulation, 3705
- Review, fast track, surgery, perioperative management, 2799
- Review, fatigue, RNase L, nitric oxide, protein kinase R, nuclear factor kappa beta, NF- κ B, intracellular immune dysfunction, natural killer cell, oxidative stress, exercise, 4717
- Review, glioblastoma, radiotherapy, chemotherapy, temozolomide, targeted therapy, 5171
- Review, *hTERT*, alternative lengthening, prognosis, 3833
- Review, immune system, intestine, TLR4, lipopolysaccharide, IP-PA1, homeostasis, 4855
- Review, inflammatory bowel disease, Crohn's disease, epidemiology, ulcerative colitis, colorectal cancer, colon carcinogenesis, molecular biology, 2727
- Review, intestinal macrophage, LPS, homeostasis, CD14, IgA, 4861
- Review, L1-CAM, tumorigenesis, isoforms, signaling, monoclonal antibodies, 4919
- Review, lipopolysaccharide, macrophage, *Pantoea agglomerans*, innate immunity, allergic dermatitis, hygiene hypothesis, 4867
- Review, lymphadenectomy, cytoreduction, lymph node metastasis, ovarian cancer, 2837
- Review, malignant ascites, ovarian cancer, catumaxomab, 3353
- Review, malignant astrocytoma, immunobiology, biological therapy, biological markers, 2461
- Review, ovarian cancer, intraperitoneal chemotherapy, platinum, taxane, 2803
- Review, prostate cancer, focal therapy, male lumpectomy, 5155
- Review, prostate, biomarkers, cancer, PSA, prognosis, 3289
- Review, PSA, PCA3, prostate cancer, ANN, 2589
- Review, sun, skin cancer, internal cancer, vitamin D, vitamin D and cancer, 3501
- Review, temozolomide, glioblastoma, O 6 -methylguanine-DNA methyltransferase, *MGMT*, 4845
- Review, tissue transglutaminase, cell signaling, chemoresistance, metastasis, focal adhesion kinase, NF- κ B, integrin, 1909
- Review, tumorigenesis, inflammation, antitumor immunity, 4795
- Review, vitamin D insufficiency, calcium intake, dairy calcium, calcium-sensing receptor, extrarenal 25-hydroxyvitamin D-1 α -hydroxylase, 1,25-dihydroxyvitamin D $_3$, 25-hydroxyvitamin D-24-hydroxylase, 3687
- Review, vitamin D, sun bed, skin cancer, cancer prognosis, 3495
- Review, vitamin D, vitamin D receptor, vitamin D response elements, *in silico* screening, gene regulation, nuclear receptor, 3485
- RFLP, *APE1*, BER, lung cancer, cigarette, polymorphism, 2417
- RFP, red fluorescent protein, *Salmonella typhimurium*, bacteria, tumor-targeting, pancreatic cancer, green fluorescent protein, GFP, imaging, 1873
- RGD, adenovirus vector, transduction efficacy, renal cell carcinoma, 2997
- Rhabdomyosarcoma, Ewing's sarcoma, high-dose chemotherapy, autologous transplantation, 3281
- RHCC, cisplatin, nano, carrier, 11

- Rhein, apoptosis, caspase-3, ROS, mitochondria membrane potential, cytochrome *c*, 309
- Rho, ROCK, ERK, GBM, migration, proliferation, 119
- Rhodamine 123, *ABCB1*, ethidium bromide, multidrug resistance, 3989
- Ribavirin, gene expression profiling, K562, leukemia, apoptosis, cell differentiation, inositide-5'-monophosphate dehydrogenase, IMPDH, 1971
- Ribonuclease, onconase, double-stranded RNA, cytotoxic, RNAi, 1067
- Ribozymes, Ewing tumours, EWSR1-FLI1, 1901
- Rictor, curcumin, colorectal cancer, mTOR, Raptor, Akt, PHLPP, 3185
- Riluzole, ion channel, apoptosis, endoplasmic reticulum stress, prostate cancer, 2195
- Risk factors, ovarian cancer, central adiposity, 5229
- Risk groups, endometrial cancer, treatment, survival, 1585
- RM-9 prostate cancer, ionizing radiation, SOD mimetic, NK cells, B-cells, cytokines, immune system, 107
- RNAi knock-down, immunohistochemistry, asparaginase, cell growth, 951
- RNAi, onconase, double-stranded RNA, cytotoxic, ribonuclease, 1067
- RNase L, fatigue, nitric oxide, protein kinase R, nuclear factor kappa beta, NF- κ B, intracellular immune dysfunction, natural killer cell, oxidative stress, exercise, review, 4717
- RNF11, Smad4, TGF- β , ubiquitination, signal transduction, breast cancer, 2253
- Robotics, laparoscopy, prostate cancer, radical prostatectomy, 1637
- ROC curve analysis, breast cancer, X-ray mammography, ^{99m}Tc-Sestamibi scintimammography, microcalcifications, negative predictive value, 4251
- ROCK, Rho, ERK, GBM, migration, proliferation, 119
- ROS, AMA, apoptosis, As4.1, MAPK, GSH, 4423
- ROS, arsenic trioxide, apoptosis, Calu-6, MAPK, GSH, 3837
- ROS, cancer, therapy, nephrotoxicity, mitochondria, 2295
- ROS, ER stress, cell death, anthraquinone, 327
- ROS, rhein, apoptosis, caspase-3, mitochondria membrane potential, cytochrome *c*, 309
- ROS, sesquiterpene lactone, GSH, autophagy, apoptosis, 1449
- RS, radiosurgery, radioresistant brain metastasis, melanoma, hypofractionated stereotactic radiotherapy, HSRT, radiotherapy, 4259
- RSS, multiple myeloma, conventional radiological survey, MRI, 4745
- RT-PCR, esophagus, Oct3/4, Sox2, immunohistochemistry, Western blotting, 1233
- RT-PCR, *HMGA2-LPP*, lipoma, *LPP-HMGA2*, 2357
- RT-PCR, lung cancer, telomerase, *hTERT* mRNA, TRAP, survival, 1157
- RT-PCR, non-small cell lung cancer, mRNA, tissue samples, MMPs, TIMPs, 2513
- RT-PCR, non-small cell lung cancer, RECK, tissue samples, mRNA, promoter methylation, 4535
- RT-PCR, oral cancer, NY-ESO-1, gene expression, diagnosis, therapy, 5125
- RT-PCR, telomerase, *TERT*, mammary tissue, dog, immunohistochemistry, 319
- RUNX1*, fusion gene, translocation, acute leukemia, myelodysplastic syndrome, gene transcription, review, 1031
- RUNX3*, gastric cancer, methylation, 2619
- Rurality, colorectal cancer, pancreatic cancer, stage at diagnosis, access to care, 3427
- S/O/W emulsion, nanospheres, PLGA, curcumin, confocal microscopy, cancer therapy, 3867
- S-1, advanced gastric cancer, second-line treatment, taxane derivatives, 2863
- S-1, CDDP, metastatic gastric cancer, phase I study, combination chemotherapy, 1727
- S-1, cepharanthine, oral squamous cell carcinoma, apoptosis, TUNEL, combination therapy, xenografts, nude mice, 1263
- S-1, cisplatin, advanced gastric cancer, preoperative chemotherapy, neoadjuvant chemotherapy, 4689
- S-1, docetaxel, gastric cancer, chemotherapy, 2775
- S-1, feasibility study, weekly docetaxel, concurrent radiotherapy, advanced gastric cancer, 3385
- S-1, recurrent head and neck cancer, outpatient chemotherapy, low dose chemotherapy, tumor dormancy, 577
- S100A4, prognosis, lung cancer, tissue microarray, immunohistochemistry, 2547
- S100A8, S100A9, thyroid carcinoma, undifferentiated carcinoma, immunohistochemistry, 4157
- S100A9, S100A8, thyroid carcinoma, undifferentiated carcinoma, immunohistochemistry, 4157
- Salivary gland cancer, caspase-14, vascularization, gene therapy, 3811
- Salmonella typhimurium*, bacteria, tumor-targeting, pancreatic cancer, red fluorescent protein, RFP, green fluorescent protein, GFP, imaging, 1873
- Salvage treatment, ovarian cancer, cisplatin, ifosfamide, gemcitabine, 2681
- Salvage, IDEA, non-Hodgkin's lymphoma, NHL, 1749
- Sanguinarine, TRAIL, apoptosis, caspase-3, Akt, 4457
- Sarcoma180, sonodynamic antitumor effect, methylene blue, 2411
- Sarcoma180, sonodynamic, lomefloxacin, polyethylene glycol, 243
- SCC-4 cells, berberine, apoptosis, caspase, AIF, EndoG, 4063
- SCC-Ag, vulvar cancer, prognosis, survival, lymph node metastasis, staging, 545
- Scintimammography, breast cancer, sentinel node biopsy, axillary ultrasonography, fine-needle aspiration cytology, FNA cytology, 491

- SCLC limited disease, sequential chemoradiotherapy, concurrent chemoradiotherapy, prophylactic cranial radiotherapy, median survival time, overall survival, 5219
- SDF-1, CXCR4, gastric cancer, metastasis, 4751
- Seasonal variation, obesity, vitamin D deficiency, age, gender, 3713
- Second cancer, thyroid cancer, breast cancer, 1607
- Secondary, breast neoplasms, bone neoplasms, diphosphonates, hyperparathyroidism, calcium, 2707
- Second-line treatment, advanced gastric cancer, S-1, taxane derivatives, 2863
- Second-line treatment, carboplatin, interleukin-2, melanoma, metastatic, vinorelbine, 1755
- SELDI-TOF MS, laser microdissection, ovarian cancer, cancer biomarkers, proteomics, 1039
- Selectivity index, anticancer activity, brine shrimp larvae, MCF-7 cells, 2993
- Selectivity, thrombospondin-1, peptide, antibody, endothelial cell, antiangiogenic, 2243
- Selenium, trace elements, gastric cancer, carcinoembryonic antigen, 3465
- Semi-automated fluorometric method, ABC transporters, P-glycoprotein, efflux, ethidium bromide, mouse lymphoma cells, *mdr1*, *ABCBI*, 2173
- Semiempirical molecular-orbital method, 1,2,3,4-tetrahydroisoquinoline, QSAR, cytotoxicity, absolute hardness, 2265
- Semiempirical molecular-orbital method, 1,2,3,4-tetrahydroisoquinoline, QSAR, cytotoxicity, absolute hardness, 4077
- Semiempirical molecular-orbital method, dihydroimidazoles, QSAR, cytotoxicity, 5019
- Senescence, 14-3-3 σ , p53, p21, cisplatin, resistance, 2009
- Sentinel lymph node, breast cancer, frozen sections, micrometastasis, immunohistochemistry, 4711
- Sentinel lymph node, breast cancer, gamma probe, lymphoscintigraphy, methylene blue dye, 4119
- Sentinel node biopsy, breast cancer, ductal *in situ* carcinoma, lymph node, 1499
- Sentinel node biopsy, breast cancer, scintimammography, axillary ultrasonography, fine-needle aspiration cytology, FNA cytology, 491
- Sequence, radiotherapy, hormone therapy, aromatase inhibitor, 4791
- Sequence-dependency, irinotecan, CPT-11, 5-fluorouracil, cell cycle, thymidylate synthase, apoptosis, 2083
- Sequential chemoradiotherapy, SCLC limited disease, concurrent chemoradiotherapy, prophylactic cranial radiotherapy, median survival time, overall survival, 5219
- Serine, J774.1, nutritional starvation, glutamine, cell death, non-apoptosis, 5083
- Serine, RAW264.7, nutritional starvation, glutamine, glucose, cell death, 343
- SERM, breast cancer, ER α , ER β , aromatase inhibitor, 2167
- Serum CgA data, BPH, continuous and intermittent Finasteride, acquired prostate cancer, Gleason score data, 1797
- Serum response element, pleiotrophin, heparin affin regulatory peptide, endothelial cells, glioma, 349
- Sesquiterpene lactone, GSH, ROS, autophagy, apoptosis, 1449
- ^{99m}Tc-Sestamibi scintimammography, breast cancer, X-ray mammography, microcalcifications, negative predictive value, ROC curve analysis, 4251
- Short review, macrophage, phagocytosis, *tuberculosis*, TLR2, phagosome maturation, survival strategy, 907
- Side-effects, breast cancer, anemia, tumor biology, pre-operative chemotherapy, epirubicin, paclitaxel, 2675
- Signal pathway inhibitors, migration, extracellular matrix, three-dimensional cell-culture model, Boyden chamber, borrelidin, taxol, 5-hexyl-2'-deoxyuridine, antisense oligonucleotide, 2981
- Signal transduction, RNF11, Smad4, TGF- β , ubiquitination, breast cancer, 2253
- Signaling, L1-CAM, tumorigenesis, isoforms, monoclonal antibodies, review, 4919
- Signet-ring cell, colorectal cancer, cadherin, catenin, fibronectin, metalloprotease-1, 4417
- Simvastatin, apoptosis, glioblastoma, HMG-CoA reductase, necrosis, pericytes, 4901
- Single nucleotide polymorphism, bladder cancer, susceptibility, metabolising gene, *CYP1A1*, *CYP1B1*, *COMT*, *GSTP1*, *NAT2*, genetic polymorphism, 1631
- Single nucleotide polymorphism, SNP, chagas disease, megaesophagus, gene mutation, *FHIT* gene, *TP53* gene, *CDKN2A* gene, DNA sequencing, 1243
- Single nucleotide polymorphism, *XPD*, bladder cancer, DNA repair, 3903
- Single nucleotide polymorphism, XRCC4, bladder cancer, DNA repair, 1777
- Single photon-emitting computed tomography, SPECT, uroguanylin, *E. coli* heat-stable enterotoxin, guanylyl cyclase C, colorectal cancer, *in vivo* imaging, 3777
- Sip1, epithelial-mesenchymal transition, Twist, Snail, non-small cell lung cancer, 4099
- siRNA, androgen-independent prostate cancer, α -methylacyl-CoA racemase, C4-2, LNCaP, 2497
- SiRNA, migration, metastasis, hepatocellular carcinoma, peroxisome proliferator-activated receptor gamma, 5057
- siRNA, small interference RNA, recombinant adeno-associated virus, rAAV, hypoxia inducible factor, HIF, nuclear factor-kappaB, NF- κ B, proliferation, apoptosis, 1367
- Sirolimus, organ transplantation, rapamycin, squamous cell carcinoma, vascularization, 1927
- Sirolimus, urothelial lesions, mice, BBN, labelling index, 3221

- Size assessment, colonoscopy, polyps, 1539
- SK-Hep1, 3-Bromopyruvate, cancer cell death, GAPDH, glycolysis, Hep3B, HepG2, 4909
- Skin cancer, *Rb*, *Trp53*, chromosome instability, inflammation, NFkB, mitotic checkpoint, 3035
- Skin cancer, sun, internal cancer, vitamin D, vitamin D and cancer, review, 3501
- Skin cancer, vitamin D, sun bed, cancer prognosis, review, 3495
- Skin hyperkeratosis, arsenic, *ERCC1*, DNA repair, drinking water, NER, 3253
- Skin recurrence, breast cancer, inflammatory recurrence, radiotherapy, mastectomy, overall survival, recurrence-free survival, 1697
- Skin, breast, hyperplasia, dysplasia, infrared temperature, 4697
- Skin, CDX2, cutaneous metastases, extramammary Paget's disease, immunohistochemistry, 5033
- SM16, breast cancer, 4T1, TGF- β , small molecule TGF β RI/ALK5 kinase inhibitor, 2099
- Smad4, RNF11, TGF- β , ubiquitination, signal transduction, breast cancer, 2253
- Small bowel toxicity, radiotherapy, pelvic irradiation, 4821
- Small cell carcinoma, treatment, outcome, chemotherapy, radiation therapy, 3411
- Small cell neuroendocrine cervical carcinoma, prognostic factors, treatment, 477
- Small interference RNA, siRNA, recombinant adeno-associated virus, rAAV, hypoxia inducible factor, HIF, nuclear factor-kappaB, NF-kB, proliferation, apoptosis, 1367
- Small molecule TGF β RI/ALK5 kinase inhibitor, breast cancer, 4T1, TGF- β , SM16, 2099
- Smoking habits, predictive factors, gefitinib, erlotinib, *EGFR* mutations, *K-ras* mutations, lung cancer, 2691
- Smoking, head and neck cancer, microsomal epoxide hydrolase, glutathione-S-transferase, UDP-glucuronosyltransferase, polymorphisms, cancer susceptibility, review, 753
- Snail, epithelial-mesenchymal transition, Twist, Sip1, non-small cell lung cancer, 4099
- SNP, G protein, GNB4, haplotype, colorectal cancer, 1271
- SNP, single nucleotide polymorphism, chagas disease, megaesophagus, gene mutation, *FHIT* gene, *TP53* gene, *CDKN2A* gene, DNA sequencing, 1243
- SOD mimetic, ionizing radiation, RM-9 prostate cancer, NK cells, B-cells, cytokines, immune system, 107
- Sodium iodine symporter, NIS, hepatocellular carcinoma, hepatitis B virus enhancer, EIIAPA, alpha-fetoprotein, AFP, 211
- Soft tissue tumor, lymphocyte infiltration, fibrocollagenous tissue, T lymphocyte, 5197
- Soft tissue tumors, M-CSF, CSF-1R, tumor markers, grade, 3861
- Solid tumor, circulating tumor cells, metastatic, localized, stages, 4839
- Solid tumors, chemotherapy, epoetin- α , hemoglobin, quality of life, 693
- Solid tumors, immunotherapy, partial response, stable disease, 567
- Solid tumours, stereotactic radiosurgery, liver metastases, unresectable metastases, colorectal cancer, CyberKnife[®], 3381
- Soluble VEGF members, soluble VEGF receptors, cervical carcinoma, disease progression, tumor markers, vascular endothelial growth factor, 641
- Soluble VEGF receptors, soluble VEGF members, cervical carcinoma, disease progression, tumor markers, vascular endothelial growth factor, 641
- Sonodynamic antitumor effect, methylene blue, Sarcoma180, 2411
- Sonodynamic therapy, normal brain, cavitation, thermal effect, glioblastoma, 943
- Sonodynamic therapy, photosensitizer, normal rat brain, blood-brain barrier, electron microscopic study, 889
- Sonodynamic, lomefloxacin, polyethylene glycol, sarcoma180, 243
- Southern Italian region, gene polymorphisms, cancer susceptibility, tumorigenesis, 1709
- Sox2, esophagus, Oct3/4, immunohistochemistry, RT-PCR, Western blotting, 1233
- Sp1 transcription factor, *MGMT*, *p53*, DNA repair, drug resistance, alkylating agent, 3741
- SP100030, SP100207, AP-1, NF-kB, tumour growth, 1315
- SP100207, SP100030, AP-1, NF-kB, tumour growth, 1315
- SPECT, single photon-emitting computed tomography, uroguanylin, *E. coli* heat-stable enterotoxin, guanylyl cyclase C, colorectal cancer, *in vivo* imaging, 3777
- Spermatic cord, liposarcoma, 677
- S-phase arrest, diarylheptanoids, apoptosis, differentiation, neuroblastoma cells, *Alpinia officinarum*, 4981
- Splenectomy, liver metastasis, regulatory T-cell, Foxp3, NK cell, 385
- Splenectomy, proximal gastric cancer, lymph node metastasis, splenic hilus, 3347
- Splenic hilus, proximal gastric cancer, splenectomy, lymph node metastasis, 3347
- Splenic marginal zone lymphoma, mutation pattern, antigen selection, 1811
- Splice variants, vitamin D₃, 1 α -hydroxylase, ovarian cancer, COV 434, HGL5, GLZ, 3627
- Splice variants, vitamin D₃, 24-hydroxylase, MCF-7, MCF-10, breast tissue, 3641
- Splice variants, vitamin D₃, 24-hydroxylase, ovarian cancer, COV 434, HGL5, GLZ, 3635
- Splicing variants, 25-hydroxyvitamin D-1 α -hydroxylase, keratinocyte, 3659

- Spontaneous regression, cell loss, Cdk1, Cdk4, clonogenic assays, "starbursts", 1933
- Spontaneous regression, colorectal cancer, metastatic, 465
- Squamous cell carcinoma, carbon-ion radiotherapy, histone deacetylase inhibitor, esophageal cancer, 4433
- Squamous cell carcinoma, cervical cancer, adenocarcinoma, tumor markers, 2577
- Squamous cell carcinoma, Ki-67, Ki-S11, laryngeal cancer, 1459
- Squamous cell carcinoma, organ transplantation, sirolimus, rapamycin, vascularization, 1927
- Squamous cell carcinoma, survivin, DNA double-strand breaks, DNA repair, radioresistance, 223
- Squamous cell carcinoma, MAPK, oral cancer, immunoblotting, phospho-ERK, 303
- Stable disease, immunotherapy, solid tumors, partial response, 567
- Stage at diagnosis, colorectal cancer, pancreatic cancer, rurality, access to care, 3427
- Stage II colorectal cancer, DNA cytometry, prognosis, adjuvant therapy, 99
- Stage IV disease, topotecan, endometrial cancer, anthracyclines, taxanes, 1761
- Stages, circulating tumor cells, solid tumor, metastatic, localized, 4839
- Staging, vulvar cancer, prognosis, survival, lymph node metastasis, SCC-Ag, 545
- Standard-risk disease, cord blood transplantation, acute graft-versus-host disease, 1763
- "Starbursts", spontaneous regression, cell loss, Cdk1, Cdk4, clonogenic assays, 1933
- Stat, cancer, lymphocytes, immunosuppression, 2051
- STAT3 phosphorylation, rapamycin, mTOR signaling, mTOR phosphorylation, biomarkers of resistance, p70S6 and RS6P, human breast epithelial cells, human breast premalignant and tumor epithelial cells, early events in breast tumorigenesis, 1143
- Stat3, PPAR γ , 15dPGJ₂, IL-6, PC-3 cells, prostate cancer, 2331
- Statins, breast cancer, postmenopausal women, overweight, obese, epidemiology, 5143
- Staurosporine, cell cycle regulatory proteins, apoptosis, caspase 3, leukemic cells, 2893
- Stem cell, integrin, $\alpha\beta 6$, TRA-1-60, oral SCC, matrix, 2043
- Stem cells, bone marrow, breast cancer, nude mice, GFP, 443
- Stem cells, duodenum, adenomas, Paneth cells, migration, 657
- Stereotactic radiosurgery, liver metastases, unresectable metastases, colorectal cancer, CyberKnife[®], solid tumours, 3381
- Steroid sulphatase, breast cancer, estrogen, postmenopausal, aromatase, 17 beta HSD type 1, carcinogenesis, review, 1095
- Steroidogenesis, breast cancer, renin-angiotensin system, ovary, estradiol, 4633
- Steroids, Euphorbiaceae, *Euphorbia*, triterpenes, multidrug resistance, P-glycoprotein, apoptosis, 4467
- Stomach carcinoma, adjuvant chemotherapy, local recurrence, 1853
- Stroma, angiogenesis, galectin-1, laryngeal cancer, lymphocyte, lectin, prognosis, 59
- Stromal cell, giant cell tumor, osteoclast-like giant cell, bone morphogenetic protein, laser microdissection, 2219
- Structure-activity relationship, flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, 2285
- Subcellular localization, cytoplasmic, high-grade astrocytoma, nuclear, p27, prognosis, 597
- Subscapular, concomitant elastofibroma, olecranon, 503
- Substance P, oral cancer, NK-1 receptor, proliferation, 2323
- Sulfamate, 2-methoxyestradiol, estrogen, ovarian cancer, prostate cancer, breast cancer, 3751
- 5-Sulfooxymethylfurfural, 5-hydroxymethylfurfural, *Min/+* mice, aberrant crypt foci, intestinal carcinogenesis, 1921
- Sulindac sulfide, 5-fluorouracil, 5-FU, oxaliplatin, colorectal cancer, synergism, 435
- Sun bed, vitamin D, skin cancer, cancer prognosis, review, 3495
- Sun, skin cancer, internal cancer, vitamin D, vitamin D and cancer, review, 3501
- Sunitinib, renal cell carcinoma, cardiovascular, tyrosine kinase inhibitor, 1627
- Superfine dispersed lentinan, beta-1,3-glucan, colorectal cancer, lentinan, peripheral blood monocytes, quality of life, 2611
- Surgery, cancer immunotherapy, chemotherapy, radiotherapy, T-regulatory lymphocyte, 1847
- Surgery, *EGFR*, *HER2*, *VEGF*, breast cancer, 5111
- Surgery, fast track, perioperative management, review, 2799
- Surgery, osteosarcoma, marriage, fertility, chemotherapy, 763
- Surgery, prostate cancer, nPSA12, radiotherapy, biochemical failure, prognostic factor, 4605
- Surgey, esophageal cancer, minimally invasive, outcome, survival, 2719
- Surgical resection, carcinoma, biliary tract, chemotherapy, 1783
- Surveillance, bladder cancer, urine CYFRA 21-1, abdominal ultrasound, urine cytology, 4281
- Survival analysis, esophageal carcinosarcoma, immunohistochemistry, 3375
- Survival strategy, macrophage, phagocytosis, *tuberculosis*, TLR2, phagosome maturation, short review, 907
- Survival, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, vitamin D supplementation, review, 3699
- Survival, cancer, ductal, breast, molecular classification, 4727

- Survival, colorectal cancer, microsatellite instability, predictive factor, chemotherapy, 1615
- Survival, colorectal carcinoma, immunohistochemistry, MET, prognosis, carcinogenesis, 4807
- Survival, endometrial cancer, risk groups, treatment, 1585
- Survival, esophageal cancer, surgery, minimally invasive, outcome, 2719
- Survival, germ cell tumors, immunohistochemical markers, prognostic markers, *p53*, MIB-1, 737
- Survival, interstitial lung disease, non-small cell lung cancer, 2671
- Survival, leukocytosis, anemia, thrombocytosis, non-small cell lung cancer, preoperative, 2687
- Survival, lung cancer, telomerase, *hTERT* mRNA, RT-PCR, TRAP, 1157
- Survival, NSCLC, bone metastasis, pamidronate, retrospective analysis, 5245
- Survival, nuclear morphometry, clinicopathological features, Libyan female breast cancer, 1771
- Survival, ovarian cancer, age, tumor pattern, debulking surgery, 2809
- Survival, ovarian cancer, progression, relapse, CA-125, 2817
- Survival, regulatory T-cells, human FOXP3, VEGF, IL-10, TGF- β , immunotherapy, tumor immunity, 881
- Survival, vulvar cancer, prognosis, lymph node metastasis, staging, SCC-Ag, 545
- Survival, *XRCC1* 194, *XRCC1* 399 polymorphism, head and neck cancer, 4169
- Survivin, apoptosis, macromolecular therapeutics, protein transduction domain, 1423
- Survivin, DNA double-strand breaks, DNA repair, radioresistance, squamous cell carcinoma, 223
- Survivin, urothelial carcinoma, recurrence, immunohistochemistry, 4163
- Susceptibility, bladder cancer, metabolising gene, *CYP1A1*, *CYP1B1*, *COMT*, *GSTP1*, *NAT2*, genetic polymorphism, single nucleotide polymorphism, 1631
- SW-480 colorectal cancer cell, methylalantrexone, 5-fluorouracil, MCF-7 breast cancer cell, non-small cell lung cancer cell, NSCLC, anti-proliferation, cell growth, cell cycle, 2927
- Sweden, colorectal cancer, Crohn's colitis, epidemiology, 4291
- SYBR green real-time quantitative reverse transcriptase-polymerase chain reaction, oral squamous cell carcinoma, cytokeratin, disseminated tumor cells, peripheral blood, 291
- Synergic effect, circadian rhythm, clock genes, mouse Period2 gene, tumor suppression, apoptosis, cell cycle arrest, cisplatin, 1201
- Synergism, 5-fluorouracil, 5-FU, oxaliplatin, sulindac sulfide, colorectal cancer, 435
- Synthesis, 14-*epi*-MART-10, 19-norvitamin D₃, Julia coupling, PZ-HPV-7 cells, HL-60 cells, 3563
- Systemic chemotherapy, colorectal cancer, liver metastasis, hepatic arterial infusion, hai, prognostic factors, 4139
- T lymphocyte, soft tissue tumor, lymphocyte infiltration, fibrocollagenous tissue, 5197
- T-47D cells, estrogen, hypoxia, C/EBP α , 1227
- T790M, gefitinib, lumbo-peritoneal shunt, meningeal carcinomatosis, lung cancer, epidermal growth factor receptor, 2759
- TAC-101, chemoprevention, colon carcinogenesis, ACF, 2059
- Talus, osteosarcoma, frozen, liquid nitrogen, reconstruction, 4093
- Tamoxifen, breast cancer, CDK10, DNA methylation, cyclin-dependent kinase, 3939
- Tamoxifen, MCF-7, bioavailability, toxicity, alginate/chitosan microparticles, 4529
- Taq1, vitamin D receptor, gene polymorphisms, cancer, Fok1, BSm1, Apa1, Cdx2, poly(A), Bgl1, 3511
- Targeted therapy, breast cancer, persistent disseminated tumor cells, trastuzumab, HER2 status, 4019
- Targeted therapy, cancer, HB-EGF, amphiregulin, review, 4879
- Targeted therapy, glioblastoma, radiotherapy, chemotherapy, temozolomide, review, 5171
- Targeted therapy, HB-EGF, amphiregulin, cancer, review, 823
- Targeted therapy, heat-shock protein 90, Hsp90, angiogenesis, gastrointestinal cancer, pancreatic cancer, gastric cancer, review, 2031
- Targeted therapy, MPC polymer, paclitaxel, epidermal growth factor receptor, 1009
- Targeting, GIST, mouse model, xenograft, 4331
- Taxane derivatives, advanced gastric cancer, S-1, second-line treatment, 2863
- Taxane resistant, ARRY-520, KSP inhibitor, hematological tumors, 4373
- Taxane, aerodigestive tract, external beam, radioiodine, radiosensitizer, radiotherapy, paclitaxel, carboplatin, 4665
- Taxane, ovarian cancer, intraperitoneal chemotherapy, platinum, review, 2803
- Taxanes, topotecan, endometrial cancer, anthracyclines, stage IV disease, 1761
- Taxol, migration, extracellular matrix, three-dimensional cell-culture model, Boyden chamber, borrelidin, 5-hexyl-2'-deoxyuridine, signal pathway inhibitors, antisense oligonucleotide, 2981
- TBS-101, hormone refractory prostate cancer, cancer metastasis, cancer treatment, natural botanical components, 3917
- T-cell receptor (TCR) beta cDNA cloning, DC vaccine, metastatic melanoma, MAGE1 HLA-A24 restricted peptide, electroporation, 647
- T-cell SD-lymphoma, proangiogenic genes, PMEDAP, PMEG, 1295

- T-cell, HER2, helper antigen, li-key, cancer stem cells, individualized cancer vaccines, 41
- T-cells, adoptive cell transfer, immunotherapy, 145
- Telomerase reverse transcriptase, *TERT*, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Telomerase, breast cancer, retinoic acid, epigenetic, histone deacetylation, *hTERT*, 4959
- Telomerase, lung cancer, *hTERT* mRNA, RT-PCR, TRAP, survival, 1157
- Telomerase, *TERT*, mammary tissue, dog, immunohistochemistry, RT-PCR, 319
- TEM7, alternative splicing, osteosarcoma, PCR, metastasis, 4317
- Temozolomide, breast cancer, leptomeningeal disease, neoplastic meningitis, chemotherapy, DepoCyte[®], liposomal Ara-C, 5191
- Temozolomide, chemotherapy, high-grade glioma, tumor necrosis factor-alpha, 911
- Temozolomide, cisplatin, chemotherapy, malignant, gliomas, 4275
- Temozolomide, glioblastoma, O⁶-methylguanine-DNA methyltransferase, *MGMT*, review, 4845
- Temozolomide, glioblastoma, radiotherapy, chemotherapy, targeted therapy, review, 5171
- Temozolomide, methionine, CNS tumours, cytotoxicity, methotrexate, cisplatin, 3103
- Temozolomide, TMZ, alkylating agents, cancer, glioma, O⁶-methylguanine, O⁶-MG, O⁶-methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, promoter methylation, review, 3759
- Temsirolimus, IGF-I receptor, phosphorylated *MYC*-N, mTOR, neuroblastoma, rapamycin, 1943
- TERT*, telomerase reverse transcriptase, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, tumor protein *p53*, *TP53*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- TERT*, telomerase, mammary tissue, dog, immunohistochemistry, RT-PCR, 319
- Testis tumors, FEN1, lung cancer, glioblastoma multiforme, astrocytoma, anticancer drugs, 2453
- Tetrac nanoparticles, renal cell carcinoma, angiogenesis, Tetrac, anti-cancer, anti-angiogenesis, integrin, 3825
- Tetrac, renal cell carcinoma, angiogenesis, Tetrac nanoparticles, anti-cancer, anti-angiogenesis, integrin, 3825
- 1,2,3,4-Tetrahydroisoquinoline, QSAR, cytotoxicity, semiempirical molecular-orbital method, absolute hardness, 2265
- 1,2,3,4-Tetrahydroisoquinoline, QSAR, cytotoxicity, semiempirical molecular-orbital method, absolute hardness, 4077
- Tetrahydroisoquinolines, tumor-specificity, cytotoxicity, autophagy, 3079
- Tetrandrine, cytotoxicity, neuroblastoma, radiosensitization, 3163
- TGF- β , 5-fluorouracil, activated lymphocytes, transforming growth factor-beta, prostaglandin E₂, PGE₂, 3925
- TGF- β , breast cancer, 4T1, small molecule TGF β RI/ALK5 kinase inhibitor, SM16, 2099
- TGF- β , regulatory T-cells, human FOXP3, VEGF, IL-10, immunotherapy, tumor immunity, survival, 881
- TGF- β , RNF11, Smad4, ubiquitination, signal transduction, breast cancer, 2253
- Th1, dendritic cells, Thymax, interferon-gamma, CD83, 4367
- Therapeutic assessment, [18F]-FDG, PET-CT, CT scan, metastatic colorectal cancer, 2563
- Therapy target, L1 cell adhesion molecule, esophageal adenocarcinoma, tumor marker, 1195
- Therapy, cancer, nephrotoxicity, ROS, mitochondria, 2295
- Therapy, oral cancer, NY-ESO-1, gene expression, RT-PCR, diagnosis, 5125
- Therapy, vitamin D analogs, cancer prevention, 3469
- Thermal effect, sonodynamic therapy, normal brain, cavitation, glioblastoma, 943
- Thermodesorption, lung cancer, volatile organic compounds, VOCs, gas chromatography mass spectrometry, 419
- Three-dimensional cell-culture model, migration, extracellular matrix, Boyden chamber, borrelidin, taxol, 5-hexyl-2'-deoxyuridine, signal pathway inhibitors, antisense oligonucleotide, 2981
- Thrombocytosis, leukocytosis, anemia, non-small cell lung cancer, preoperative, survival, 2687
- Thrombospondin-1, peptide, antibody, endothelial cell, antiangiogenic, selectivity, 2243
- Thymax, dendritic cells, Th1, interferon-gamma, CD83, 4367
- Thymic carcinoma, PDGFR, thymoma, mutations, 4057
- Thymidine kinase mRNA, ulcerative colitis, carcinogenesis, bisphosphonate, 4615
- Thymidine phosphorylase, angiogenesis, uterine cervical carcinomas, basic FGF, VEGF, COX-2, angiopoietin, *IL-8*, HIF-1 α , ETS-1, review, 2665
- Thymidine phosphorylase, capecitabine, dihydropyrimidine dehydrogenase, cell proliferation, apoptosis, 2525
- Thymidylate synthase, irinotecan, CPT-11, 5-fluorouracil, sequence-dependency, cell cycle, apoptosis, 2083
- Thymoma, PDGFR, thymic carcinoma, mutations, 4057
- Thyroid cancer, anaplastic carcinoma, intratumoral molecular homogeneity, 2437
- Thyroid cancer, breast cancer, second cancer, 1607
- Thyroid cancer, thyroid nodule, follicular tumors, fine-needle aspiration cytology, frozen section, 5255

- Thyroid carcinoma, S100A9, S100A8, undifferentiated carcinoma, immunohistochemistry, 4157
- Thyroid nodule, thyroid cancer, follicular tumors, fine-needle aspiration cytology, frozen section, 5255
- Thyroid, renal cell carcinoma, metastasis, thyroidectomy, neoplastic thrombus, jugular vein thrombosis, 473
- Thyroidectomy, papillary thyroid cancer, papillary microcarcinomas, Chernobyl accident, 5163
- Thyroidectomy, renal cell carcinoma, metastasis, thyroid, neoplastic thrombus, jugular vein thrombosis, 473
- TIL, CD3, CD3 ζ , tumor-infiltrating lymphocytes, epithelial ovarian carcinoma, EOC, malignant ascites, 4673
- TIMP, tissue inhibitor of matrix metalloproteinase, matrix metalloproteinase, MMP, colorectal carcinoma, CRC, microarray analysis, 67
- TIMP-1, CEA, lead-time, immunoassay, biological marker, postoperative follow-up, 75
- TIMPs, non-small cell lung cancer, mRNA, tissue samples, MMPs, RT-PCR, 2513
- TIP47, uterine cervical neoplasm, tumor marker, cervical cytology, neoplasm metastasis, 717
- Tip60*, quantitative real-time PCR, colorectal cancer, 3953
- Tissue inhibitor of matrix metalloproteinase, TIMP, matrix metalloproteinase, MMP, colorectal carcinoma, CRC, microarray analysis, 67
- Tissue microarray, Akt isoforms, prognosis, NSCLC, 4175
- Tissue microarray, breast cancer, IGFBP-3, 1131
- Tissue microarray, immunohistochemistry, concordance, discordance, validity, multivariable analysis, 201
- Tissue microarray, S100A4, prognosis, lung cancer, immunohistochemistry, 2547
- Tissue samples, non-small cell lung cancer, mRNA, MMPs, TIMPs, RT-PCR, 2513
- Tissue samples, non-small cell lung cancer, RECK, mRNA, RT-PCR, promoter methylation, 4535
- Tissue transglutaminase, cell signaling, chemoresistance, metastasis, focal adhesion kinase, NF- κ B, integrin, review, 1909
- TLR2, macrophage, phagocytosis, *tuberculosis*, phagosome maturation, survival strategy, short review, 907
- TLR4, immune system, intestine, lipopolysaccharide, IP-PA1, homeostasis, review, 4855
- TLR4, innate immunity, prophylaxis, macrophage network, review, 817
- TMZ, temozolomide, alkylating agents, cancer, glioma, O⁶-methylguanine, O⁶-MG, O⁶-methylguanine-DNA-methyltransferase, *MGMT*, polymorphism, promoter methylation, review, 3759
- TNF-related apoptosis-inducing ligand, ameloblastoma, apoptosis, proliferation, 1137
- TNF- α , EMT, *PTEN*, migration, invasion, 4439
- Toad skin extract, apoptosis, cell proliferation, CDKs, NF- κ B, curcumin, colon cancer, 395
- Toll-like receptors, inflammation, Akt, colon cancer, 2473
- Topoisomerase II, doxorubicin, formamidineoxorubicins, resistant cells, uptake, 1429
- Topotecan, endometrial cancer, anthracyclines, taxanes, stage IV disease, 1761
- Toxicity, pancreatic cancer, erlotinib, gemcitabine, overall survival, 5211
- Toxicity, Tamoxifen, MCF-7, bioavailability, alginate/chitosan microparticles, 4529
- TP-110, proteasome inhibitor, apoptosis, multiple myeloma, IAP, 977
- TP53* gene, chagas disease, megaesophagus, gene mutation, single nucleotide polymorphism, SNP, *FHIT* gene, *CDKN2A* gene, DNA sequencing, 1243
- TP53*, tumor protein *p53*, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- TPA, HL-60, asparagine synthetase, differentiation, asparaginase, apoptosis, 1303
- TRA-1-60, integrin, α v β 6, stem cell, oral SCC, matrix, 2043
- Trace elements, APL treatment, arsenic trioxide, mice, virus, 83
- Trace elements, selenium, gastric cancer, carcinoembryonic antigen, 3465
- TRAIL, sanguinarine, apoptosis, caspase-3, Akt, 4457
- Transcriptional targeting, cancer, gene therapy, Q5 promoter, allograft rejection, cyclophosphamide, 1015
- Transduction efficacy, adenovirus vector, RGD, renal cell carcinoma, 2997
- Transendothelial migration, breast cancer cell, tumor cell intravasation, apoptosis, anoikis, basement membrane degradation, 2347
- Transfection, multiple endocrine neoplasia type 1, MEN1, regulated genes, 1859
- Transforming growth factor-beta, 5-fluorouracil, activated lymphocytes, TGF- β , prostaglandin E₂, PGE₂, 3925
- Translocation, follicular lymphoma, BCL2, BCL6, 4649
- Translocation, *RUNX1*, fusion gene, acute leukemia, myelodysplastic syndrome, gene transcription, review, 1031
- Transudates, HMGB1, angiogenesis, ELISA, exudates, 5013
- TRAP, lung cancer, telomerase, *hTERT* mRNA, RT-PCR, survival, 1157
- Trastuzumab, adverse effects, migraine, headache, 4223
- Trastuzumab, breast cancer, HER2/neu ECD, kinetics, tumor marker, 1703
- Trastuzumab, breast cancer, neoadjuvant chemotherapy, paclitaxel, pathological response, 517
- Trastuzumab, breast cancer, persistent disseminated tumor cells, targeted therapy, HER2 status, 4019

- Trastuzumab, esophageal cancer, ADCC, perforin, granzyme, 2137
- Travel distance, radiotherapy, palliative radiation treatment, cancer, 2641
- Treatment failure, non-small cell lung cancer, gefitinib, post initial gefitinib therapy, 4217
- Treatment resistant, epithelial ovarian cancer, phase I/II study, gemcitabine, docetaxel, 1521
- Treatment, adenocarcinoma corpus uteri, cytometry, DNA ploidy, 4731
- Treatment, endometrial cancer, risk groups, survival, 1585
- Treatment, oropharynx, oropharyngeal cancer, HNSCC, neck dissection, 4785
- Treatment, small cell carcinoma, outcome, chemotherapy, radiation therapy, 3411
- Treatment, small cell neuroendocrine cervical carcinoma, prognostic factors, 477
- Treatment-free interval, recurrent ovarian cancer, chemotherapy, hormonal therapy, 2831
- T-regulatory lymphocyte, cancer immunotherapy, chemotherapy, radiotherapy, surgery, 1847
- Trifluoromethyl acyloins, cytotoxic activity, apoptosis, autophagy, 175
- Triggering, host-defensive function, carbon tetrachloride, innate, priming, lipid, 837
- Triplex DNA, flavonoids, DNA binding, polynucleotides, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, 2273
- Triplex DNA, flavonoids, DNA binding, polynucleotides, quadruplex DNA, cancer cell lines, UV, fluorescence spectroscopy, structure-activity relationship, 2285
- Triterpenes, Euphorbiaceae, *Euphorbia*, steroids, multidrug resistance, P-glycoprotein, apoptosis, 4467
- Trp53, Rb, chromosome instability, skin cancer, inflammation, NFkB, mitotic checkpoint, 3035
- Tuberculosis, macrophage, phagocytosis, TLR2, phagosome maturation, survival strategy, short review, 907
- Tubulin, albendazole, paclitaxel, ovarian cancer, resistance, 3791
- B3-tubulin, antimicrotubule agents, regulation, AP-1, 3003
- Tumor biology, breast cancer, anemia, side-effects, pre-operative chemotherapy, epirubicin, paclitaxel, 2675
- Tumor cell intravasation, breast cancer cell, transendothelial migration, apoptosis, anoikis, basement membrane degradation, 2347
- Tumor cells, ovarian cancer, ascites, antibody therapy, catumaxomab, 1787
- Tumor dormancy, S-1, recurrent head and neck cancer, outpatient chemotherapy, low dose chemotherapy, 577
- Tumor growth, chitosan nanoparticles, hepatocellular carcinoma, necrosis, angiogenesis, *VEGFR2*, 5103
- Tumor imaging, cancer therapy, nanotargeted radiopharmaceuticals, nanocarriers, review, 4107
- Tumor immune therapy, domain, programmed death-1, fibronectin, 5089
- Tumor immunity, regulatory T-cells, human FOXP3, VEGF, IL-10, TGF- β , immunotherapy, survival, 881
- Tumor marker, breast cancer, HER2/neu ECD, trastuzumab, kinetics, 1703
- Tumor marker, colorectal cancer, macrophage, intracellular, flow cytometrical, CEA, 3245
- Tumor marker, correlation coefficient, CA15-3, KL-6, BCA225, 4239
- Tumor marker, *hTERT*, circulating DNA, breast cancer, real-time PCR, 2845
- Tumor marker, L1 cell adhesion molecule, esophageal adenocarcinoma, therapy target, 1195
- Tumor marker, uterine cervical neoplasm, TIP47, cervical cytology, neoplasm metastasis, 717
- Tumor markers, angiogenesis factor, hepatocyte growth factor, vascular endothelial growth factor, 3311
- Tumor markers, cervical cancer, squamous cell carcinoma, adenocarcinoma, 2577
- Tumor markers, soft tissue tumors, M-CSF, CSF-1R, grade, 3861
- Tumor markers, soluble VEGF members, soluble VEGF receptors, cervical carcinoma, disease progression, vascular endothelial growth factor, 641
- Tumor necrosis factor alpha, tumor necrosis factor beta, oral cancer, oncogenesis, polymorphism, genetic association study, 2379
- Tumor necrosis factor beta, tumor necrosis factor alpha, oral cancer, oncogenesis, polymorphism, genetic association study, 2379
- Tumor necrosis factor α , gefitinib, bortezomib, epidermal growth factor receptor, resistance, 2315
- Tumor necrosis factor-alpha, chemotherapy, high-grade glioma, temozolomide, 911
- Tumor necrosis factor-related apoptosis-inducing ligand, apoptosis, non-small cell lung cancer, primary culture, 2905
- Tumor necrosis, COX2, leiomyosarcoma, immunohistochemistry, 2913
- Tumor pattern, ovarian cancer, age, debulking surgery, survival, 2809
- Tumor protein *p53*, *TP53*, colorectal cancer, aneuploidy, breast cancer 1, BRCA1, telomerase reverse transcriptase, *TERT*, mitotic spindle proteins, aurora kinase A, AURKA, aurora kinase B, AURKB, budding uninhibited by benzimidazoles 1, BUB1B, MAD2 mitotic arrest deficient-like 1, MAD2L1, 4381
- Tumor stem cell, collision tumor, non-small cell lung cancer, adenocarcinoma of the colon, 1495
- Tumor suppression, circadian rhythm, clock genes, mouse Period2 gene, apoptosis, cell cycle arrest, synergic effect, cisplatin, 1201

- Tumor thrombosis, hepatocellular carcinoma, fibrinogen gamma, fibrinogen, clinical stage, 2531
- Tumor vascular remodelling, angiogenesis, molecular imaging, prostate cancer, vascular stabilization, review, 1823
- Tumor vascularity, VEGF, angiogenesis, anti-angiogenic therapy, vandetanib, ZACTIMA™, ZD6474, 1987
- Tumor, giant basal cell carcinoma, reconstruction, 2655
- Tumor-antigen peptides, breast cancer, radiolabeling, tumor-cell binding, biodistribution, 1399
- Tumor-cell binding, breast cancer, tumor-antigen peptides, radiolabeling, biodistribution, 1399
- Tumorigenesis, colorectal adenocarcinoma, chemotherapy, response, molecular changes, 3115
- Tumorigenesis, gene polymorphisms, cancer susceptibility, Southern Italian region, 1709
- Tumorigenesis, inflammation, antitumor immunity, review, 4795
- Tumorigenesis, L1-CAM, isoforms, signaling, monoclonal antibodies, review, 4919
- Tumorigenicity, human neuroendocrine tumor, NET, carcinoid of terminal ileum, continuous cell lines, P-ST5 primary tumor, L-ST5 lymph node metastasis, H-ST5 hepatic metastasis, neuroendocrine characteristics, mouse models, cytogenetic analyses, clonal tetraploidy, array CGH, 1951
- Tumor-infiltrating lymphocytes, CD3, CD3 ζ , TIL, epithelial ovarian carcinoma, EOC, malignant ascites, 4673
- Tumor-infiltrating lymphocytes, CD4, CD8, breast cancer, prognostic factors, 2445
- Tumor-specificity, benzo[*b*]cyclohept[*e*][1,4]oxazine, 2-aminotropone, apoptosis, 1123
- Tumor-specificity, tetrahydroisoquinolines, cytotoxicity, autophagy, 3079
- Tumor-targeting, *Salmonella typhimurium*, bacteria, pancreatic cancer, red fluorescent protein, RFP, green fluorescent protein, GFP, imaging, 1873
- Tumour cell, nutritional deprivation, energy deprivation, cell survival, cell death, digital holographic microscopy, dynamic phase difference, 2339
- Tumour growth, SP100030, SP100207, AP-1, NF- κ B, 1315
- Tumour marker, prostate carcinoma, P1NP, PSA, AP, bone metastases, 671
- Tumour markers, ovarian cancer, multiplex, panel, 573
- Tumour regression, canine cutaneous histiocytoma, E-cadherin, immuno-histochemistry, 2713
- TUNEL, cepharanthine, S-1, oral squamous cell carcinoma, apoptosis, combination therapy, xenografts, nude mice, 1263
- Twist, epithelial-mesenchymal transition, Snail, Sip1, non-small cell lung cancer, 4099
- Tyrosine kinase inhibitor, sunitinib, renal cell carcinoma, cardiovascular, 1627
- Tyrosine kinase inhibitors, hematological adverse event, 5225
- Tyrosine phosphorylation, all-*trans* retinoic acid, breast cancer, *c-ERBB2/neu*, proliferation, 2899
- U105MG, ultrasound, Photofrin, glioma, LRP/ α 2MR, U251MG, 897
- U251MG, ultrasound, Photofrin, glioma, LRP/ α 2MR, U105MG, 897
- Ubiquitination, RNF11, Smad4, TGF- β , signal transduction, breast cancer, 2253
- Ubiquitin-proteasome system, p27^{kip1}, Jab1, cholangiocarcinoma, adenovirus, 2015
- UDCA, bile acids, colon cancer, UDCA-Glu, cancer prevention, 4971
- UDCA-Glu, bile acids, colon cancer, UDCA, cancer prevention, 4971
- UDP-glucuronosyltransferase, head and neck cancer, microsomal epoxide hydrolase, glutathione-S-transferase, polymorphisms, cancer susceptibility, smoking, review, 753
- Ulcerative colitis, carcinogenesis, bisphosphonate, thymidine kinase mRNA, 4615
- Ulcerative colitis, inflammatory bowel disease, Crohn's disease, epidemiology, colorectal cancer, colon carcinogenesis, molecular biology, review, 2727
- Ultrasound, echo-contrast agent, microbubbles, malignant glioma, central nervous system, 235
- Ultrasound, Photofrin, glioma, LRP/ α 2MR, U251MG, U105MG, 897
- Ultraviolet-B, aerosols, air pollution, cancer, polycyclic aromatic hydrocarbons, vitamin D, 3537
- UNC5C*, quantitative methylation-specific PCR, colorectal cancer, 271
- UNC5C*, quantitative methylation-specific PCR, gastric cancer, 4397
- Uncaria tomentosa*, alkaloids, drug resistance, apoptosis, medullary thyroid carcinoma, 4519
- Undifferentiated carcinoma, S100A9, S100A8, thyroid carcinoma, immunohistochemistry, 4157
- Unresectable metastases, stereotactic radiosurgery, liver metastases, colorectal cancer, CyberKnife®, solid tumours, 3381
- UPLC, phosphoproteome, IMAC, cerebellum, oxygen-18, 4949
- Uptake, doxorubicin, formamidinodoxorubicins, resistant cells, topoisomerase II, 1429
- Urine CYFRA 21-1, bladder cancer, surveillance, abdominal ultrasound, urine cytology, 4281
- Urine cytology, bladder cancer, surveillance, urine CYFRA 21-1, abdominal ultrasound, 4281
- Uroguanylin, *E. coli* heat-stable enterotoxin, guanylyl cyclase C, single photon-emitting computed tomography, SPECT, colorectal cancer, *in vivo* imaging, 3777

- Urokinase-type plasminogen activator, node-negative breast cancer, plasminogen activator inhibitor type I, prognostic factor, distant metastases, local recurrence, 1475
- Urothelial carcinoma, survivin, recurrence, immunohistochemistry, 4163
- Urothelial lesions, sirolimus, mice, BBN, labelling index, 3221
- Uterine cervical carcinomas, angiogenesis, basic FGF, VEGF, COX-2, angiopoietin, *IL-8*, thymidine phosphorylase, HIF-1 α , ETS-1, review, 2665
- Uterine cervical neoplasm, TIP47, tumor marker, cervical cytology, neoplasm metastasis, 717
- UV, flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, fluorescence spectroscopy, 2273
- UV, flavonoids, DNA binding, polynucleotides, triplex DNA, quadruplex DNA, cancer cell lines, fluorescence spectroscopy, structure-activity relationship, 2285
- VacA, recombinant VacA, neutralizing antibody, anti-*H. pylori* vaccine, CpG-ODN, mucosal immune response, 2393
- Vaccination, pancreatic cancer, immunotherapy, dendritic cells, 831
- Validity, immunohistochemistry, tissue microarray, concordance, discordance, multivariable analysis, 201
- Vandetanib, VEGF, tumor vascularity, angiogenesis, anti-angiogenic therapy, ZACTIMA™, ZD6474, 1987
- Vascular endothelial growth factor, angiogenesis factor, hepatocyte growth factor, tumor markers, 3311
- Vascular endothelial growth factor, oropharyngeal squamous cell carcinoma, human papillomavirus, hypoxia-inducible factor-1 α , 1467
- Vascular endothelial growth factor, soluble VEGF members, soluble VEGF receptors, cervical carcinoma, disease progression, tumor markers, 641
- Vascular invasion, gallbladder, adenocarcinoma, invasion pattern, metastasis, 685
- Vascular stabilization, angiogenesis, molecular imaging, prostate cancer, tumor vascular remodelling, review, 1823
- Vascularization, caspase-14, salivary gland cancer, gene therapy, 3811
- Vascularization, organ transplantation, sirolimus, rapamycin, squamous cell carcinoma, 1927
- Vascularized bone graft, periacetabular bone tumor, irradiated bone graft, microsurgery, 1669
- VDR, nuclear receptors, malignant melanoma, peroxisome proliferator-activated receptors, PPAR, vitamin D receptor, 3647
- VEGF receptor inhibitor, BIBF 1120, multiple myeloma, Phase I study, pharmacokinetics, 4233
- VEGF, angiogenesis, biomarkers, cediranib, murine renal cell carcinoma, 5065
- VEGF, angiogenesis, uterine cervical carcinomas, basic FGF, COX-2, angiopoietin, *IL-8*, thymidine phosphorylase, HIF-1 α , ETS-1, review, 2665
- VEGF, combination targeted therapy, xenograft, IGF-IR, *EGFR*, 1999
- VEGF, *EGFR*, HER2, breast cancer, surgery, 5111
- VEGF, glioblastoma multiforme, meningioma, astrocytoma, angiopoietin 2, 731
- VEGF, *Helicobacter pylori*, polymorphism, intestinal metaplasia, 485
- VEGF, plasma, non-small cell lung cancer, chemotherapy, paclitaxel, 2635
- VEGF, regulatory T-cells, human FOXP3, IL-10, TGF- β , immunotherapy, tumor immunity, survival, 881
- VEGF, tumor vascularity, angiogenesis, anti-angiogenic therapy, vandetanib, ZACTIMA™, ZD6474, 1987
- VEGFR2*, chitosan nanoparticles, hepatocellular carcinoma, tumor growth, necrosis, angiogenesis, 5103
- Venous coupler, free flap, breast reconstruction, 2827
- Venous glioblastoma, anticoagulant, cerebral hemorrhage, glioblastoma, pulmonary embolism, venous thromboembolism, 4309
- Venous thromboembolism, anticoagulant, cerebral hemorrhage, glioblastoma, pulmonary embolism, venous glioblastoma, 4309
- Verapamil, lung cancer, *EGFR*, nm23, 27
- Vessel dilator, prostate cancer, cardiac hormones, kaliuretic peptide, Ras, 971
- VHL, bortezomib, proteasome, renal cancer, *p53*, 2961
- VHL, renal cell carcinoma, hypoxia-inducible factors, genetics, 4337
- Vienna protocol, bone recurrences, ¹⁵³Sm-EDTMP, 3393
- Vimentin*, quantitative methylation-specific PCR, colorectal carcinoma, 279
- Vimentin*, quantitative methylation-specific PCR, gastric carcinoma, 2227
- Vinorelbine orale, cisplatin, pharmacokinetics, phase I, drug-drug interaction, 553
- Vinorelbine, carboplatin, interleukin-2, melanoma, metastatic, second-line treatment, 1755
- Vinorelbine, chemotherapy, docetaxel, estramustine, zoledronic acid, androgen-resistant prostate cancer, 769
- Virus, APL treatment, arsenic trioxide, mice, trace elements, 83
- Viscum album*, European mistletoe, angiogenesis, matrigel assay, endothelial cells, apoptosis, cancer therapy, 2945
- Vitamin C, cancer, ascorbic acid, ascorbate, plasma concentration, intravenous, cytotoxicity, complementary and alternative medicine, review, 809
- Vitamin D analogs, breast cancer, estrogen receptor, BT-474 cells, vitamin D receptor stability, 3555
- Vitamin D analogs, cancer prevention, therapy, 3469
- Vitamin D analogs, CD-ring, antiproliferative, calcemic, 3579

- Vitamin D and cancer, sun, skin cancer, internal cancer, vitamin D, review, 3501
- Vitamin D deficiency, obesity, seasonal variation, age, gender, 3713
- Vitamin D hydroxylases, colonic 1,25(OH)₂D₃ concentration, gender-dependent, dietary calcium, apoptosis, 3727
- Vitamin D hydroxylases, extrarenal vitamin D synthesis, 1,25dihydroxyvitamin D₃, colon tumor prevention, calcium, estrogen, epigenetic regulation, review, 3705
- Vitamin D insufficiency, calcium intake, dairy calcium, calcium-sensing receptor, extrarenal 25-hydroxyvitamin D-1 α -hydroxylase, 1,25-dihydroxyvitamin D₃, 25-hydroxyvitamin D-24-hydroxylase, review, 3687
- Vitamin D receptor stability, breast cancer, vitamin D analogs, estrogen receptor, BT-474 cells, 3555
- Vitamin D receptor, breast cancer, cyclooxygenase-2, 15-hydroxyprostaglandin dehydrogenase, prostaglandin metabolism, 3619
- Vitamin D receptor, gene polymorphisms, cancer, Fok1, BSm1, Taq1, Apa1, Cdx2, poly(A), Bgl1, 3511
- Vitamin D receptor, granulosa cells, cyclooxygenase-2, 15-hydroxy-prostaglandin dehydrogenase, prostaglandin metabolism, 3611
- Vitamin D receptor, nuclear receptors, malignant melanoma, peroxisome proliferator-activated receptors, PPAR, VDR, 3647
- Vitamin D receptor, vitamin D, 25-hydroxyvitamin D levels, malignant melanoma, 3669
- Vitamin D receptor, vitamin D, vitamin D response elements, *in silico* screening, gene regulation, nuclear receptor, review, 3485
- Vitamin D response elements, vitamin D, vitamin D receptor, *in silico* screening, gene regulation, nuclear receptor, review, 3485
- Vitamin D supplementation, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, survival, review, 3699
- Vitamin D, 1 α ,25(OH)₂D₃, proliferation, fish oil, ω -3 PUFAs, HepG2, hepatoma, 3591
- Vitamin D, aerosols, air pollution, cancer, polycyclic aromatic hydrocarbons, ultraviolet-B, 3537
- Vitamin D, analogs, antiproliferative effect, microarray, non-steroidal, 3585
- Vitamin D, breast cancer, 1 α OHase, 155
- Vitamin D, carcinogenesis, intestine, retinol, *Min/+* mouse, 4353
- Vitamin D, colon cancer, rectal cancer, grading, estrogen, 3721
- Vitamin D, enzyme kinetics, prostate cancer, pancreas, control theory, review, 3675
- Vitamin D, MART-10, androgen, prostate cancer, 3547
- Vitamin D, sun bed, skin cancer, cancer prognosis, review, 3495
- Vitamin D, sun, skin cancer, internal cancer, vitamin D and cancer, review, 3501
- Vitamin D, vitamin D receptor, 25-hydroxyvitamin D levels, malignant melanoma, 3669
- Vitamin D, vitamin D receptor, vitamin D response elements, *in silico* screening, gene regulation, nuclear receptor, review, 3485
- Vitamin D₃, 1 α -hydroxylase, splice variants, ovarian cancer, COV 434, HGL5, GLZ, 3627
- Vitamin D₃, 24-hydroxylase, splice variants, MCF-7, MCF-10, breast tissue, 3641
- Vitamin D₃, 24-hydroxylase, splice variants, ovarian cancer, COV 434, HGL5, GLZ, 3635
- VOCs, volatile organic compounds, lung cancer, gas chromatography mass spectrometry, thermodesorption, 419
- Volatile organic compounds, VOCs, lung cancer, gas chromatography mass spectrometry, thermodesorption, 419
- Vulvar cancer, prognosis, survival, lymph node metastasis, staging, SCC-Ag, 545
- Weekly docetaxel, feasibility study, S-1, concurrent radiotherapy, advanced gastric cancer, 3385
- Weekly paclitaxel, metastatic breast cancer, phase II study, 625
- Weekly paclitaxel, nedaplatin, non-small cell lung cancer, phase II study, 1733
- Western blot, ATF2, p-ATF2, breast cancer, prognosis, immuno-histochemistry, ERK-1/2, AP-1, MMP-9, 183
- Western blotting, esophagus, Oct3/4, Sox2, immunohistochemistry, RT-PCR, 1233
- Whole body imaging, imageable model, EL-4 T-cell lymphoma, EGFP, 4513
- WiDr colon cancer cells, growth factors, 5-fluorouracil, glutathione modulation, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 3957
- Wilms tumour, JIP-1, IGF-II, WT1, 4999
- Wilms tumours, IGF II, JIP-1, 2467
- Wilms' tumor 1, WT1, cancer vaccine, peptide, immunotherapy, 4779
- Wnt inhibitory factor-1, Wnt pathway, promoter hypermethylation, demethylation, epigallocatechin-3-gallate, EGCG, 2025
- Wnt pathway, Wnt inhibitory factor-1, promoter hypermethylation, demethylation, epigallocatechin-3-gallate, EGCG, 2025
- Wnt, hedgehog, cyclopamine, quercetin, leukemia, lymphoma, 4629
- Wortmannin, apoptosis, boswellic acids, PI3 kinase, Akt, colon cancer cells, LY294002, 2987
- WT1, immunohistochemistry, endometrial cancer, clinicopathological factors, PCNA, cell proliferation, 4887
- WT1, immunohistochemistry, endometrial cancer, clinicopathological factors, prognosis, 1691
- WT1, JIP-1, IGF-II, Wilms tumour, 4999
- WT1, Wilms' tumor 1, cancer vaccine, peptide, immunotherapy, 4779

- XBP1 splicing, chronic lymphocytic leukemia, ER stress, apoptosis, proteasome, 3797
- Xenograft model, gastric cancer, docetaxel, PSK, 843
- Xenograft model, neuroblastoma, proteasome inhibitor, bortezomib, metastases, 1219
- Xenograft model, renal adenocarcinoma, CYP4A, 20-hydroxyeicosatetraenoic acid, eicosanoids, 3819
- Xenograft, combination targeted therapy, IGF-IR, *EGFR*, VEGF, 1999
- Xenograft, GIST, mouse model, targeting, 4331
- Xenograft, multidrug resistance, nude mice, drug accumulation, bromotetraandrine, 4597
- Xenografts, cepharanthine, S-1, oral squamous cell carcinoma, apoptosis, TUNEL, combination therapy, nude mice, 1263
- Xenopus* oocyte, MDA-MB-231, fibroblast growth factor receptor, Akt, Chfr, PLC γ , breast cancer, 4965
- XPD*, bladder cancer, polymorphism, *XRCC1*, *XRCC3*, *XPG*, *APE1*, *hOGG1*, 1389
- XPD*, single nucleotide polymorphism, bladder cancer, DNA repair, 3903
- XPG*, bladder cancer, polymorphism, *XRCC1*, *XRCC3*, *XPD*, *APE1*, *hOGG1*, 1389
- X-ray mammography, breast cancer, ^{99m}Tc -Sestamibi scintimammography, microcalcifications, negative predictive value, ROC curve analysis, 4251
- XRCC1* 194, *XRCC1* 399 polymorphism, head and neck cancer, survival, 4169
- XRCC1* 399 polymorphism, *XRCC1* 194, head and neck cancer, survival, 4169
- XRCC1*, bladder cancer, polymorphism, *XRCC3*, *XPD*, *XPG*, *APE1*, *hOGG1*, 1389
- XRCC1*, DNA repair, genetic polymorphism, haplotype, renal cell cancer, outcome, 5131
- XRCC3*, bladder cancer, polymorphism, *XRCC1*, *XPD*, *XPG*, *APE1*, *hOGG1*, 1389
- XRCC4*, single nucleotide polymorphism, bladder cancer, DNA repair, 1777
- YAAC2 function, ADP/ATP carrier, molecular dynamics, 4897
- 10 Years, breast carcinoma, recurrence, 3445
- ZACTIMATM, VEGF, tumor vascularity, angiogenesis, anti-angiogenic therapy, vandetanib, ZD6474, 1987
- ZD1839, p27^{kip1}, Jab1, radiation, cholangiocarcinoma, 1169
- ZD6474, VEGF, tumor vascularity, angiogenesis, anti-angiogenic therapy, vandetanib, ZACTIMATM, 1987
- Zeranol, breast cancer, pre-adipocytes, body weight gain, doubling time, cyclin D1, *p53*, 5045
- Zeranol, leptin, (-)-gossypol, breast cancer, 4621
- Zevalin, ibritumomab tiuxetan, radioimmunotherapy, non-Hodgkin's lymphoma, indolent lymphoma, aggressive lymphoma, 4771
- Zinc, ascorbic acid, *N*-acetylcysteine, oxidative DNA damage, FPG-comet assay, 4571
- Zoledronic acid, bisphosphonate, pamidronate, LNCaP, osteoblast, osteoclast, 1089

Authors Index

(Figures refer to page numbers)

- Abarzua F, 1685
 Abbate I, 2845
 Abdalla F, 1771
 Abe H, 919
 Abeyama K, 1287
 Abo H, 661
 Abrahamsson P-A, 3917
 Acharya B, 1533, 2997
 Acht T, 3939
 Adachi M, 1733, 2315
 Adachi S, 1521
 Adamo V, 403
 Adamopoulou M, 3401
 Afonso J, 3221
 Ağaçhan B, 1389, 1395, 2417
 Ager C, 419
 Agnantis N, 3465
 Agrawal S, 4367
 Aguiriano Moser V, 1951
 Aguzzi A, 303
 Ahmad F, 1595
 Ahmed BH, 1151
 Ahn EH, 2899
 Ahn JS, 1817
 Ahn M-J, 1817
 Aieta M, 1709
 Aigner T, 2579
 Ajioka Y, 3375
 Akamatsu K, 2195
 Akao Y, 1449, 2485
 Akine Y, 497
 Akiyama H, 2863
 Akiyama M, 1521
 Akiyama N, 235
 Akiyama Y, 647
 Akiyoshi T, 261
 Akporiaye ET, 2099
 Aksoy P, 2417
 Akther J, 4051
 Akutsu M, 4589
 Akutsu Y, 4433
 Alakus H, 1271
 Alberti S, 951
 Alexander J, 1921, 4353
 Alexandraki K, 5163
 Alexanian A, 3819
 Alfonso R, 4839
 Al-Kadhimi Z, 3281
 Alkotyfan K, 3421
 Allouche S, 1249, 1443
 Alonso-Varona A, 3957
 Alrawi SJ, 1151
 Al-Saad S, 4175
 Al-Shabrawey M, 3811
 Al-Shagahin H, 3421
 Al-Shibli K, 4175
 Altintas S, 5137
 Alves A, 2713
 Amadi N, 2977
 Amann A, 419
 Amano O, 343, 5023, 5083
 Amant F, 1039
 Amaral L, 2173, 3989
 Ambrosino G, 3381
 Amir E, 2707
 Anami K, 2753
 Anant S, 2009
 Anderson KM, 4579
 Ando K, 2315
 Ando S, 2635
 André S, 59, 4933
 Andrews LG, 4959
 Andriamisanratsoa N, 4119
 Andritzky B, 249
 Andrulis IL, 1557
 Angelopoulou K, 319
 Angelopoulou MK, 1811
 Angiero F, 3983, 4703
 Annese P, 4201
 Annovazzi L, 3087
 Antecka E, 3059
 Antonacopoulou A, 5077
 Antonescu C, 1867
 Antonov K, 5241
 Antonsson A, 2893
 Antos Z, 4737
 Aoi T, 2997
 Aoki D, 561
 Aoki H, 3347
 Aoki R, 561
 Aoki T, 1001
 Apostolaki A, 3977
 Apostolaki D, 631
 Aragona F, 4417
 Arai K, 4157
 Arai MA, 3563
 Arai N, 1079
 Araki N, 2357
 Arantes-Rodrigues R, 3221
 Arany I, 2295
 Arao T, 1111
 Arapantoni-Dadioti P, 737, 4759
 Aravantinos G, 693, 737, 745
 Araya M, 4605
 Arbeille B, 2347
 Archondakis A, 4163
 Archontaki M, 2655
 Ardavanis A, 1361, 5211
 Argilés JM, 1315
 Argyrakopoulou G, 5163
 Ariga H, 1831
 Ariga T, 525
 Arihiro K, 5197
 Arii S, 4989
 Ariizumi T, 2219
 Arisawa T, 337, 485, 2857, 3453, 4265
 Ariyama H, 1727
 Armakolas A, 371
 Arnogiannaki N, 2655, 3977
 Arranz JL, 2127
 Arrieta I, 3185
 Arroyo M, 4839
 Arun S, 3811
 Asaga T, 1515
 Asaka S, 4271
 Ascutti S, 4971
 Ashida T, 1023
 Assumção PP, 2479
 Athanasas G, 4759
 Athanassiou E, 529
 Audrain O, 1697
 Augustin S, 1335
 Aukim-Hastie C, 3289
 Aung HH, 2927
 Avgoustidis D, 2379, 3401
 Avramis EV, 299
 Avramis VI, 299
 Awad ZT, 1151
 Ayabe T, 2687
 Ayala GE, 2077
 Ayuk F, 1355
 Azarbayjani F, 3311
 Azemar M, 4795
 Azmi PB, 2253
 Azuma H, 2195, 2497
 Baak JP, 4697
 Baba E, 1727
 Bababeygy SR, 4901
 Babanaraki A, 4483
 Babo I, 2981
 Bach-Gansmo T, 4331
 Bachmann HS, 5131
 Bachmann R, 4019
 Bacin F, 5235
 Badar S, 3791
 Badisa RB, 2993
 Badowska W, 1643
 Baek MK, 355
 Baggio G, 4529
 Bagnardi V, 5111
 Bakare O, 191
 Bako F, 2121
 Bakshandeh-Bath A, 3069
 Balcerska A, 1643
 Baldini R, 4771
 Baldus SE, 1157, 4451
 Baliga R, 2295
 Balint A, 717
 Baltaziak M, 4151
 Baltzer P, 2823
 Balwierz W, 1643
 Bamias A, 529, 745
 Banerjee S, 395
 Banfalvi G, 2121
 Banys M, 4019
 Barak V, 1793, 4281, 4827
 Barrett BS, 5095
 Bar-Sela G, 1853
 Barten-Van Rijbroek A, 5219
 Barth P, 2067, 2645
 Bartl M, 495
 Bartók K, 681
 Basato M, 3931
 Base W, 731
 Basile G, 3157
 Basso SMM, 5255
 Basso U, 1551, 5255
 Bassotti G, 2761
 Batista De Paula AM, 1189
 Batistatou A, 3465
 Battaglia M, 4201
 Battermann JJ, 5219
 Batuello CN, 1319

- Bau D-T, 725, 1275, 1777, 2239, 3897, 3903, 5121, 5251
 Bauer G, 4541, 4559
 Baumeister P, 33, 4571
 Beal JR, 5143
 Bechtel W, 4541, 4559
 Becker S, 3611, 3619, 3627, 3635, 3641, 4019
 Befrits R, 4291
 Beham A, 1951
 Behmel A, 1951
 Bekaert V, 4119
 Bektaş-Kayhan K, 2519
 Belisle A, 1591
 Bellenis I, 4483
 Bellocq J-P, 4119
 Bellotti V, 2507
 Bellyei S, 717
 Belmonte B, 3149
 Belsanova B, 2767
 Bénéchie M, 1963
 Benedicenti S, 3983
 Benericetti E, 2461
 Benes Z, 4737
 Benesova L, 1803, 2767
 Berard M, 1335, 2347
 Berdel WE, 1157, 4233
 Beretz L, 4741
 Berg JP, 4353
 Bergerat JP, 4741
 Berghe WV, 3797
 Berhe S, 191
 Bernard-Gallon DJ, 1631, 5229
 Bernd H-W, 4649
 Berner J-M, 4331
 Bertaccini A, 473, 1345
 Bertolotti A, 4575
 Besselsen DG, 2099
 Besser MJ, 145
 Beullens I, 3585
 Beyene D, 191
 Bhakat KK, 3741
 Bharali DJ, 3825
 Bhat G, 139
 Bianchi C, 2691
 Bianchi F, 4251
 Bianchini C, 4473
 Bianchino G, 1709
 Bickers B, 3289
 Biesterfeld S, 201, 1579
 Bifulco G, 477
 Bignardi M, 4259, 4821
 Bignon J, 1963
 Bignon Y-J, 1631, 5229
 Billberg I, 2641
 Bir AS, 465
 Biran H, 4827
 Bisegna R, 567
 Bisping G, 4233
 Bjerkehagen B, 4331
 Blankenstein MA, 75
 Blobel GC, 5149
 Blohmer J-U, 641
 Bobos M, 529
 Bocangel D, 3741
 Boccardo F, 1621
 Boder J, 1771
 Bodis J, 717
 Bodner-Adler B, 495
 Boehmer D, 2793
 Boelens J, 605, 3797
 Bognar Z, 159
 Boiteux J-P, 1631
 Bojic A, 1627
 Bokemeyer C, 249
 Boland P, 1867
 Bolander ME, 4317
 Bollet MA, 1475
 Bölling T, 3397
 Bollschweiler E, 1157, 4451
 Bonanno E, 1499
 Bonfante V, 777
 Bonner E, 3721
 Bordeleau L, 1557
 Borgonovo K, 2691
 Börngen K, 3053
 Borok TL, 4683
 Boronkai A, 717
 Borošenko V, 711
 Borsato S, 491, 5255
 Bössenroth D, 1309
 Bosviel R, 1631
 Boucher BJ, 3597
 Bouillet P, 2563
 Bouillon R, 3471, 3579, 3585
 Boura PG, 4297
 Bourgeois H, 4195
 Bouvet M, 1873
 Bowen KA, 2473, 4439
 Boyle P, 1739
 Brabender J, 1157, 1281
 Bracke M, 3797
 Brackett D, 3417
 Bradley-Dunlop D, 2099
 Bradshaw T, 2273
 Braidwood L, 2159
 Bramis J, 785
 Bramis K, 785
 Brand F-X, 1703
 Brandi M, 1841
 Brandstetter A, 3939
 Brasse D, 4119
 Bratta M, 567
 Braun S, 2803
 Bravo M, 2323
 Brazowski E, 3925
 Breast Cancer Study Group of the Institut Curie, 1475
 Breinig M, 4057
 Bremke M, 2645
 Bremnes RM, 4175
 Brener S, 2323
 Brennan MF, 1255
 Brenner DM, 1557
 Brenner S, 1793
 Briand M, 1443
 Briasoulis E, 745
 Bristow RE, 2875
 Brivio F, 1847
 Brockmann J, 3397
 Brockmann MA, 3261
 Brollo A, 1137
 Broom RJ, 1557
 Broström O, 1539
 Browaeys-Poly E, 4965
 Brower SL, 1993
 Brown SM, 2159
 Browning P, 1933
 Brozek W, 3721
 Brueckl WM, 67
 Bruha F, 2767
 Bruha J, 2371
 Bruland ØS, 4331
 Brunello A, 1551
 Bruni E, 4529
 Brünner N, 75
 Bruns F, 2627
 Bu G, 897
 Buck AK, 1423
 Bücken B, 3641
 Budach V, 2645, 3411
 Budai B, 3095
 Bufo P, 4201
 Bugat R, 553
 Buhk J-H, 5191
 Buhl R, 201
 Bühling KJ, 1575
 Buhmeida A, 99, 1771
 Buhr H-J, 1309
 Bui F, 491
 Buijs M, 4909
 Buitrago-Pérez A, 3035
 Bukowski RM, 2961
 Bullerdiek J, 5013
 Buonomo O, 1499
 Burbano RR, 2479
 Burdach S, 4489
 Burdach SEG, 1901
 Burk R, 2961
 Burkholder I, 249
 Burmeister CB, 3769
 Burnier MN, Jr, 3059
 Burnol A-F, 4965
 Burum-Auensen E, 4381
 Bush JE, 1993
 Busia A, 777
 Busquets S, 1315
 Bustin SA, 155, 3785
 Busund L-T, 3861, 4175
 Cabibi D, 3149, 4417
 Cadron I, 1039
 Cai G, 4005
 Cailliau K, 4965
 Çakalir C, 4041
 Calascibetta A, 4417
 Calcagno DQ, 2479
 Caldera V, 3087
 Camara O, 2823, 2827, 2837
 Cammann H, 2589
 Campione M, 4417
 Campisi B, 1709
 Cancellato G, 5111
 Candeloro G, 567
 Canobbio L, 1621
 Cantore M, 1547, 1835
 Cao B, 4005
 Capelli E, 2461
 Caradonna G, 3149
 Caramés M, 3957
 Cardoso SV, 1189
 Carlberg C, 3485
 Carluccio R, 473
 Carmona-Saez P, 1971
 Carpenter R, 155, 3785
 Carrieri G, 4201
 Caruso RA, 449
 Carvalho VM, 3065
 Casado A, 4185
 Casamassima F, 3381
 Casova M, 573

- Castellani D, 4971
 Castelo A, 3365
 Castiglione E, 3059
 Cataldegirmen G, 1195
 Cates JMM, 2913
 Cavazzana A, 1715
 Cecchin D, 491
 Ceciliani F, 2507
 Celka M, 2361
 Cellarier E, 5235
 Čepurnienė K, 3125
 Cereda C, 2507
 Cerny R, 4535
 Ceroni M, 2507
 Cervi E, 2761
 Cervi G, 2761
 Chadha MK, 4127
 Chalabi N, 5229
 Chamalakis G, 4297
 Chamoux A, 1631
 Chan JY, 3043
 Chang C-C, 2899
 Chang Chao-Hsiang, 1275,
 1777, 2239, 3459, 3897,
 3903, 5121
 Chang Chih-Hsien, 987, 4107
 Chang C-L, 1275, 1777,
 2239, 3903
 Chang Han, 509
 Chang HJ, 355
 Chang H-L, 3195
 Chang Hyun, 4243
 Chang J, 4243
 Chang T-J, 987
 Chang Y-H, 3139
 Chang Y-J, 987
 Chaniotis V, 4995
 Charalabopoulos A, 3465
 Charalabopoulos K, 3465
 Charalampopoulos A, 3465
 Charpidou AG, 631, 1651
 Charvalos E, 3401
 Chau Z, 119
 Check D, 1611
 Check JH, 1611, 2977
 Chen C, 1367
 Chen C-T, 165
 Chen C-Y, 2535
 Chen FC-K, 1575
 Chen F-D, 211
 Chen G-W, 309, 327
 Chen H-J, 1435
 Chen H-S, 2239, 3897
 Chen Jin-Cherng, 3163
 Chen Jung-Chou, 165
 Chen L-M, 4597
 Chen TC, 3547, 3563, 3591
 Chen Yan, 411
 Chen Yun, 3163
 Cheng A-L, 1665
 Cheng C-L, 1637
 Cheng L, 5155
 Cheng M, 3845
 Cheng Y-C, 4083
 Cheng Y-W, 2535
 Chern J, 2977
 Cheung H-K, 2099
 Chevalier D, 59, 4933
 Chhabra A, 1909
 Chi C-W, 211, 5057
 Chiacchio S, 4251
 Chiang J-H, 4063
 Chiang K-C, 3547, 3591
 Chiang S-Y, 5251
 Chiao PJ, 3173, 3995
 Chiba N, 1009
 Chiba T, 2619
 Chida S, 243, 2411, 3877
 Chida T, 3563
 Chikakiyo M, 385
 Chikazawa N, 843
 Chirumbole M, 3427
 Chishima T, 1515
 Chistolini F, 4971
 Chiu C-F, 725, 1275, 1777,
 3897, 5121
 Chiu C-FA, 5251
 Chiu T-H, 309, 4503
 Chiu Y-J, 1435
 Chlipala E, 4373
 Chlumska A, 2371
 Chmelik R, 2339
 Cho CH, 229
 Cho DH, 3027, 3115
 Cho H, 4409
 Choe Y, 1201
 Choi G-S, 4303
 Choi J-S, 1411
 Choi SH, 4243
 Choi WY, 4457
 Choi YH, 4457
 Chollet P, 5235
 Chopra SS, 2799
 Choschzick M, 545
 Chou C-C, 283
 Chow LWC, 2525
 Chow T-H, 2111
 Chow WA, 3281
 Choy E, 1867
 Christ H, 2655
 Christensen IJ, 75
 Christmann M, 2453
 Christodoulou C, 693
 Christofferson RH, 3311
 Chu E, 4083
 Chu F, 4473
 Chu P, 3239
 Chu Q, 3211, 5023, 5083
 Chu SWL, 3791
 Chua TC, 4051
 Chujo M, 2753
 Chung J-G, 165, 309, 327,
 1435, 3139, 4063, 4503
 Chung Y-C, 283
 Ciatti F, 4131
 Cicarma E, 3495, 3501
 Cicchetti G, 473
 Cicone F, 4771
 Cilotti A, 4251
 Cionini L, 4205
 Cittadini A, 1709
 Clark JS, 2295
 Claudy A, 1927
 Clausen KO, 2885, 4323
 Clausen OP, 4381
 Clementi M, 4971
 Clemons MJ, 1557, 2707
 Clerici C, 4971
 Cludts S, 59, 4933
 Cognetti F, 2607
 Cohen-Sinai T, 145
 Colaço A, 3221
 Cole DEC, 2707
 Cole RN, 4909
 Coley HM, 1483
 Collan Y, 99, 1771
 Colleoni M, 5111
 Colonna M, 1703
 Colucci G, 675, 1841
 Combe M, 4195
 Concin N, 2803
 Condrea Devillaz M, 4711
 Consorzio Interuniversitario
 Nazionale per la Bio-
 Oncologia (CINBO), Italy,
 403
 Contino G, 1499
 Cooperwood JS, 2993
 Copeland RL, Jr, 191
 Coppi G, 4529
 Corato M, 2507
 Corcoran E, 1999
 Cordes C, 1459
 Cordes T, 3611, 3619, 3627,
 3635, 3641
 Cormio L, 4201
 Coronella J, 2243
 Corsetti S, 1841
 Cosio S, 1715, 4205
 Cossu E, 1499
 Costa C, 3035
 Costa L, 4821
 Costantin G, 3381
 Coulter DW, 1943
 Couto I, 2173
 Cova E, 2507
 Coviello M, 2845
 Cox A, 4373
 Cox MC, 4771
 Crapo JD, 107
 Creatsas G, 2781
 Crépin M, 1335, 2347
 Cretin J, 4195
 Cristofani R, 1715
 Croce S, 4119
 Croner RS, 67
 Cross HS, 3685, 3687, 3705,
 3721, 3727
 Crowe JP, 3861
 Csejtej A, 4169
 Cui R, 2205
 Cui ZY, 1817
 Cumashi A, 403
 Czech T, 731
 Czupryna A, 5005
 Czyżewska J, 3049
 D'Alessandro R, 3321
 D'Amico G, 1847
 D'Egidio M, 403
 D'Incan M, 5235
 Da S. Manoel-Caetano F,
 1243
 Da Silva SRM, 4807
 Dąbrowska K, 2361
 Daemen A, 1039
 Dafni U, 693
 Dahlback A, 3495, 3501
 Dai C-L, 4597
 Dai H, 2077
 Daibes-Figueroa S, 3777
 Dalan B, 2417
 Dalhaug A, 2641

- Dalianis T, 11
 Dalpke A, 2067
 Danesi R, 1835
 Dang D, 125, 2043
 Danielczyk K, 3887
 Daniele A, 2845
 Darling-Reed SF, 2993
 Das JR, 191
 Das T, 2421
 Daum S, 3411
 Davis FB, 3825
 Davis GJ, 75
 Davis PJ, 3825
 Day TW, 3883
 De Angelis PM, 4381
 De Arruda Cardoso Smith M, 2479
 De Blasio A, 4169
 De Braekeleer E, 1031
 De Braekeleer M, 1031
 De Carvalho Machado V, 1189
 De Clercq P, 3579, 3585
 De Cremoux P, 1475
 De Greve J, 5225
 De Jong WK, 363
 De La Orden V, 4185, 4839
 De La Torre J-C, 4185
 De Marco L, 3065
 De Moor B, 1039, 3585
 De Oliveira ATT, 4807
 De Rosa N, 477
 De Santis M, 4259
 De Stefano R, 473
 De Vico G, 2919
 Deacu L, 1579
 Decaestecker C, 59, 4933
 Decoster L, 5225
 Decullier E, 1927
 Deen S, 2437
 Deevi DS, 1999
 Degeorges A, 1475
 Deger S, 2589
 Deichmueller CMC, 2627
 Del Freo A, 1547, 1835
 Del Monte G, 1499, 3321, 3369
 Del Monte G, 4131
 Del Pilar Carrera M, 4633
 Del Tacca M, 1835
 Del Vecchio M, 4259
 Delaney T, 1867
 Deliconstantinos G, 2781
 Delignat S, 2945
 Della Puppa A, 4275
 Della Rovere F, 3157
 Della Seta R, 1547
 Delladetsima I, 5163
 Dellapasqua S, 5111
 Delord J-P, 553
 Delort L, 1631, 5229
 Den Otter W, 5241
 Denley RC, 1255
 Denzer N, 3511
 Derka S, 2379
 Derwich K, 1643
 Des Guetz G, 1615
 Dessy E, 3983
 Dewolf W, Jr, 4373
 Di Cesare S, 3059
 Di Cosimo S, 2691
 Di Cristofano C, 1715
 Di D, 4497
 Di Giovanni S, 2607
 Di Lauro L, 1841
 Di Mario F, 3931
 Di Ronza S, 503
 Diamandis EP, 3269
 Diamanti-Kandaraki E, 5163
 Diaz-Montes TP, 2875
 Díaz-Rubio E, 4185, 4839
 Dickinson D, 3811
 Diedrich K, 3469, 3611, 3619, 3627, 3635, 3641, 4833
 Dienemann H, 4057
 Dier U, 4473
 Diéras V, 1475
 Dilana KD, 631, 1651
 Dimakou K, 1373
 Dimas K, 2009
 Dimitriadou E, 1811
 Dimitriou N, 5163
 Dimmler A, 67
 Dimopoulos MA, 745
 Ding H-J, 3459
 Dittmer C, 3619
 Divella R, 2845
 Divona L, 503
 Dix E, 1611
 Dizayi N, 3917
 Doan HQ, 2473, 4439
 Dobashi Y, 19
 Dobnig H, 3699
 Dodbiba E, 503
 Dohi O, 4989
 Dohi S, 1691, 4779, 4887
 Doi H, 2485
 Doi T, 1515
 Doillon C, 4013
 Doki Y, 2547, 4211
 Donaldson JC, 3845
 Donnem T, 4175
 Dorlaque L, 67
 Dorresteijn LDA, 4223
 Dotan Z, 145
 Doufexis D, 5211
 Dousias V, 4995
 Dowaki S, 685
 Dowd MK, 2179
 Dowell BL, 75
 Dranitsaris G, 2707
 Drapeau C, 443
 Drebber U, 4451
 Dreslerova J, 2513
 Drevs J, 5065
 Drouin P, 1591
 Duan R-D, 2987
 Duan Z, 1867
 Duarte N, 3989, 4467
 Dubitscher RM, 4833
 Dudek AZ, 1495, 4189
 Dugan E, 5149
 Dugan U, 91
 Dulaj L, 3233
 Dulebohn R, 3811
 Dumontet C, 3003
 Dunlop T, 3647
 Dunn PD, 2159
 Durak H, 4041
 Durando X, 5235
 Durie BGM, 4745
 Dutta S, 4683
 Duvillard P, 4147
 Dwyer-Nield LD, 5095
 Dyck J, 5137
 Dynlacht JR, 1319
 Dyskin E, 3825, 4473
 Dziegiel P, 589, 3887
 Eaton M, 5143
 Economopoulos T, 737, 745, 769, 4759
 Eden CG, 1483
 Edler L, 249
 Eelen G, 3471, 3579, 3585
 Efferson CL, 41, 2427
 Egawa K, 1015
 Egawa S, 1169, 1201, 2015
 Egawa Y, 927, 4893
 Egbe A, 2823, 2827
 Egger J-F, 4711
 Eggle D, 4919
 Ehrlichová M, 2951
 Eichelbaum EJ, 971, 1889
 Eid NAS, 4389
 Eisenthal A, 3925
 Eklof J, 5143
 El Badaoui A, 2563
 El Khalfaoui K, 2793
 El Sharouni SY, 5219
 Elahi A, 1255
 Ellenhorn J, 1467
 Elluru SR, 2945
 Elzagheid A, 99
 Ember I, 2295, 4169
 Emi Y, 2555
 Endo K, 2357, 2555
 Endo M, 2747, 4989
 Endo N, 2219
 Endo S-I, 1607, 3329
 Engebraaten O, 131
 Engelen K, 3585
 Engelhardt M, 4745
 Engenhart-Cabillic R, 2645
 Engström W, 2467, 4999
 Enomoto T, 3375, 4779
 Enwerem NM, 191
 Erdamar S, 2077
 Ergen A, 1389, 1395, 2417, 2519
 Ergün S, 1823
 Eriksen JG, 2885, 4323
 Eriksson D, 4361
 Eriksson M, 11
 Ernoux P, 59
 Ernst I, 3397
 Esaki T, 1727
 Eskelinen M, 4765
 Esser C, 4657
 Esser N, 5065
 Esteban F, 2323
 Esters J, 4785
 Estlin EJ, 2971, 3103
 Eto K, 1681
 Eulenburg CZ, 545, 2817
 Euvrard S, 1927
 Evangelou A, 3465
 Evans S, 3917
 Evans TR, 2159
 Evers BM, 2473, 3185, 4439
 Evtimova V, 951
 Eytan K, 3925

- Fabi A, 2607
 Fabiano V, 449
 Fabrini MG, 4205
 Facchetti A, 2461, 4259, 4575
 Fakhri MG, 465
 Faldum A, 201
 Fan B-L, 2531
 Fan J, 4751
 Fan M-J, 327
 Fang Y, 1255
 Fann P, 3239
 Fanucchi A, 1715
 Farges M-C, 5235
 Farina G, 2691
 Farkas L, 159
 Farkas R, 717
 Farronato D, 3983
 Farronato G, 3983
 Fassina A, 491, 5255
 Fattoruso SI, 1841
 Faure M, 1927
 Fauvel-Lafève F, 1335, 2347
 Febbraro A, 3381
 Fedele F, 449
 Feher G, 4169
 Fehm T, 4019
 Feldman D, 3605
 Felekouras E, 2681, 5163
 Felipe De La Cruz P L, 3221
 Feller AC, 4649
 Feng Z, 5089
 Ferdous T, 1263
 Férec C, 1031
 Ferlini C, 3003
 Fernandes BF, 3059
 Fernando NH, 5149
 Fernandez-Aceñero MJ, 4727
 Ferrari AB, 2761
 Ferreira De Aguiar MC, 1189
 Ferreira M-JU, 3989, 4467
 Ferretti G, 491
 Ferroni P, 3321, 4131
 Ferrucci F, 5111
 Fersis N, 951
 Fiala O, 2371
 Figgemeier E, 11
 Figueras M, 1315
 Filip S, 667
 Filipiak W, 419
 Filipits M, 3939
 Finek J, 667, 2513
 Finocchiaro G, 449
 Fischer D, 3611, 3619, 3627, 3635, 3641, 4833
 Fischer T, 2675
 Fischgräbe J, 2167
 Fisk B, 2427
 Flanagan JN, 3547
 Flasch A, 3819
 Fleischman E, 2719
 Flis S, 435
 Floros T, 769, 4759
 Flucke U, 469
 Fodstad Ø, 131
 Foggi P, 1841
 Fontaine C, 5225
 Fontana L, 1631
 Foo A, 4083
 Fora AA, 465
 Formica V, 3321, 3369
 Forte LR, 3777
 Forzani B, 119
 Foster PA, 3751
 Fotiou S, 2781
 Fotopoulou C, 2799, 2809
 Fountzilias G, 529, 693, 737, 745
 Fourquet A, 1475
 Fox SB, 1483
 Francescon P, 3381
 Francis Z, 4119
 Frank C, 3299
 Frankel P, 3281
 Frata P, 4821
 Frech S, 1675
 Frederiksen C, 75
 Freedman RS, 4673
 Frericks B, 1309
 Frericks M, 4657
 Frese S, 2905
 Frese-Schaper M, 2905
 Freudenberg MA, 4795
 Friboulet A, 2945
 Fric D, 4195
 Fridman E, 145
 Friedrich M, 3469, 3611, 3619, 3627, 3635, 3641, 4833
 Frisk P, 83
 Frolov A, 2077
 Frydrychowicz A, 4745
 Fu L, 3967
 Fu L-W, 4597
 Fu O-Y, 3131
 Fuchino R, 881
 Fuchs B, 4317
 Fuchs I, 641
 Fuger A, 641
 Fuii S, 2863
 Fuji K, 1533
 Fujibuchi T, 4093
 Fujii H, 2137
 Fujii M, 1981
 Fujii N, 1749
 Fujii S, 583
 Fujimori J, 3833
 Fujimoto J, 2665
 Fujimoto K, 1831
 Fujioka S, 3995
 Fujisawa M, 1533
 Fujisawa S, 2403
 Fujishima H, 1727
 Fujita Hiroshi, 485, 2857, 3453
 Fujita Hiroyuki, 1521
 Fujita T, 1681, 3995
 Fujita Y, 1111
 Fujitani K, 3385
 Fujiwara H, 2091
 Fujiwara M, 4033
 Fujiwara Y, 4211
 Fukahori M, 2863
 Fukai Y, 965, 1595
 Fukami T, 823, 4879
 Fukuchi M, 965, 1595
 Fukumitsu N, 497
 Fukumura K, 4981
 Fukuoka J, 2547
 Fukuoka K, 2205
 Fukushima M, 4157
 Fukushima Takeo, 889, 897, 911, 919, 943
 Fukushima Toshihiro, 3361
 Fukushima Tsuyoshi, 4845
 Fulchignoni-Lataud M-C, 1227
 Fumagalli L, 1847
 Funamizu N, 235
 Furuhashi H, 235
 Furukawa K, 3995
 Furukawa M, 4047
 Furukawa Y, 4589
 Furuse H, 1001
 Furutani M, 4239
 Furutani Y, 4239
 Futami K, 927, 4893
 Gabius H-J, 59, 4933
 Gadducci A, 1715, 4205
 Gagnon GA, 2387
 Gaini RM, 303
 Gairard B, 4119
 Gajda M, 2823, 2827
 Gál B, 4227
 Galanos C, 4795
 Galetta D, 675
 Gall C, 4019
 Gallati C, 4473
 Gallyas F, Jr, 159
 Galosi AB, 5155
 Ganapathi MK, 2961
 Ganapathi R, 2961
 Ganapathy-Kanniappan S, 4909
 Gao H, 41, 2427
 Gao T, 3185
 Gao Y, 411
 Gao Z, 2025
 Garassino MC, 2691
 Garavello W, 303
 García MJ, 4633
 García-Alonso I, 3957
 García-Escudero R, 3035
 García-Sáenz JÁ, 4185, 4839
 Gardovskis A, 711
 Gardovskis J, 711
 Garman-Vik S, 131
 Garrisi VM, 2845
 Gärtner B, 3669
 Gartner W, 731
 Gaschler-Markefski B, 4233
 Gauchez A-S, 1703
 Gawad KA, 1195
 Gebbia V, 1841
 Gee JR, 3769
 Gehrman M, 3939
 Geisel J, 3669
 Gen Y, 4989
 Genazzani AR, 1715
 Genell A, 1585
 Gentili G, 4971
 Gentle D, 4337
 Gentner B, 67
 Geoerger B, 1327
 Gerstenmeyer A, 1327
 Gerunda G, 3381
 Geschwind J-FH, 4909
 Getoff N, 3179
 Gharbi M, 4119
 Gheza F, 2761
 Ghiconti I, 737
 Ghisini R, 5111

- Ghoneum M, 4367
 Giampaolino P, 477
 Giannakopoulos K, 2681
 Giannarelli D, 1841
 Giannopoulos A, 2681, 2851, 5163
 Giannopoulou E, 5077
 Gibbs JF, 4127
 Giblin MF, 3777
 Giercksky KE, 1233
 Giesecking F, 545
 Gil L, 1643
 Gil-Montoya JA, 2323
 Gioia A, 1499
 Giotta F, 1841
 Giovannetti E, 1835
 Giri B, 395
 Giri U, 4409
 Gisterek I, 2445
 Gitstein G, 3925
 Gitto G, 449
 Giuntoli RL, II, 2875
 Gkini E, 3441
 Gkiozos I, 631, 3441, 4297
 Glashörster M, 3397
 Glatt H, 1921
 Gobel G, 4169
 Gocho T, 3173
 Gockerman JP, 5149
 Goergens A, 4657
 Gogas H, 2681, 2851
 Goldhirsch A, 5111
 Gollub W, 4649
 Gomes A, 395
 Gomez RS, 3065
 Gong M, 2025
 González-Moles MA, 2323
 Goodman CB, 2993
 Gordian E, 3207
 Görmüş U, 1389, 1395, 2417
 Górski A, 2361
 Görski B, 2703
 Goto T, 271, 275, 279, 2215, 2227, 2231, 2235, 2357, 3945, 3953, 4397, 5053
 Gotoh A, 1533, 2997
 Götte K, 1675
 Götte M, 2167
 Gottschlich S, 1459
 Gouveris P, 769
 Gown A, 2437
 Gräber S, 3669
 Grabowski DR, 2961
 Granata A, 3157
 Grandin L, 1475
 Granerus M, 2467, 4999
 Grant WB, 3537, 3597, 3687
 Greenberg R, 3925
 Grénman R, 1181
 Grespi S, 4205
 Gridley DS, 107
 Grieco V, 1709
 Grierson I, 1933
 Griffith OL, 2437
 Grimfjärd P, 1859
 Grimminger P, 1281
 Griniatsos J, 5163
 Groen HJM, 363
 Grönberg M, 1859
 Grosso M, 4251
 Grucker D, 4119
 Gu T, 2205
 Guadagni F, 3321, 3369, 4131
 Guan M, 1
 Guerra E, 951
 Gugger M, 2905
 Guglielmi R, 3381
 Guglielmini P, 1621
 Guialis A, 1373
 Guidi M, 1345
 Guimarães AC, 2479
 Guinan P, 4579
 Gulhati P, 3185
 Guo Q, 411
 Gupta L, 1659
 Gusani N, 3427
 Gustavsson J, 1539
 Gut I, 2951
 Guy L, 1631
 Guyonnet J-L, 4119
 Guzińska-Ustymowicz K, 3049, 3913
 Ha CS, 4409
 Haane C, 1219
 Haanpää M, 2601
 Haas H, 4519
 Haas O, 1951
 Haegeman G, 3797
 Hafiz G, 2519
 Hagita N, 4239
 Hagiwara Y, 763, 4287
 Hah J-H, 255
 Hahn EG, 67
 Hahn M, 4019
 Hahn T, 2099
 Haidopoulos D, 3401
 Haim N, 1853
 Halder C, 4317
 Halon A, 2445
 Halpern JL, 2913
 Hama S, 597
 Hamada K, 2997
 Hamada T, 2619
 Hamaguchi Y, 1515
 Han DH, 1417
 Han J-Y, 2393
 Han MH, 4457
 Han YH, 3837, 4423
 Han Z, 2009
 Handel-Fernandez ME, 2051
 Hannemann S, 1355
 Hansteen I-L, 2885, 4323
 Hanyu K, 1681
 Hara H, 3563
 Hara I, 1533
 Hara M, 2687
 Hara Y, 1763, 2301
 Harada K, 1263
 Harada M, 1001, 1727, 1749
 Harada Y, 3563
 Harano M, 3347
 Harbeck N, 2675
 Hardy S, 2159
 Hargitai Z, 2121
 Harguindey S, 2127
 Harisi R, 2981
 Harmon D, 1867
 Harréus U, 33, 4571
 Harrington KJ, 1651
 Hartmann CJ, 3179
 Hasebe M, 1507
 Hasegawa H, 5083
 Hasegawa K, 561
 Hashimoto A, 235
 Hashimoto Ken, 175, 455, 1123, 1303, 3079
 Hashimoto Koji, 1607, 3329
 Hashmi H, 1771
 Hassan S, 11
 Hassid VJ, 1151
 Hata K, 617
 Hata M, 497
 Hatakeyama S, 3571
 Hatano Hajime, 2265, 3079, 4077, 5083
 Hatano Hiroshi, 2219
 Hatziapostolou M, 349
 Haugan V, 2885, 4323
 Hauger E, 2885, 4323
 Havighurst TC, 3769
 Hayakawa K, 1211
 Hayashi H, 1201, 2015
 Hayashi K, 1873, 3563
 Hayashi S, 889, 897
 Hayashi S-I, 3971
 Hayashi T, 1287
 Hayward R, 4401
 Hazama S, 539, 1527, 2611
 He L, 1335
 He W, 1233
 Healey J, 1867
 Heching N, 4827
 Hedborg F, 3311
 Hegele A, 2067
 Heimbrog D, 91
 Heins S, 4489
 Hellberg D, 2577
 Heller G, 3939
 Helm CW, 4673
 Hemmi H, 2009
 Henderson A, 1483
 Hennig G, 3939
 Henriksson R, 1489
 Heo DS, 255
 Herbert LM, 2051
 Hercbergs A, 3825
 Herceg ME, 2913
 Herlem D, 1963
 Hermes P, 3261
 Herrmann J, 2823, 2827
 Herveau S, 3003
 Hesse M, 1901
 Hetland RB, 4353
 Heubner M, 1787, 3449
 Heudes D, 2945
 Heutte N, 1443
 Hexeberg S, 3713
 Hibi K, 271, 275, 279, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Hicklin DJ, 1999
 Hidaka T, 597
 Higashi D, 927, 4893
 Higashi H, 1157
 Higashihara E, 1533
 Higashijima J, 385
 Higashiyama T, 4157
 Higgins B, 91
 Hildenbrand B, 4795
 Hill J, 2961
 Hilska M, 99

- Hiltunen J, 3393
 Hinata N, 1533
 Hirabayashi K, 685
 Hirakawa C, 2541
 Hirakawa E, 617
 Hirakawa H, 2525
 Hirakawa K, 2189
 Hiramatsu Y, 1685
 Hirano K, 927, 4893
 Hirano Y, 1001
 Hirao M, 3385
 Hirata I, 337, 485, 2857, 3453, 4265
 Hirata K, 2059
 Hirohara S, 3173
 Hirokawa M, 4157
 Hirose M, 1073
 Hirose T, 1733, 2315
 Hirose Y, 3361
 Hisamatsu K, 625
 Hisamoto A, 2759
 Hiwatashi K, 1287
 Hizawa N, 2671
 Ho C-C, 327, 4503
 Ho T-Y, 987
 Ho Yaik T, 3751
 Ho Yung-Tsuan, 165, 4063
 Hocsak E, 717
 Hoelscher AH, 1157
 Hoffman RM, 27, 443, 1873, 2421
 Hoffman TJ, 3777
 Hoffmann A-L, 5191
 Hoffmann M, 1459
 Hofmann R, 2067
 Höger H, 1951
 Hohenberger W, 67
 Holick MF, 3547, 3591
 Hölscher AH, 1281, 4451
 Holt GE, 2913
 Holubec L, Jr, 573, 667
 Holubec L, 2371, 2513, 4535
 Holý A, 1295
 Homann N, 3069
 Homma T, 1739
 Hong I-H, 2393
 Hong K-S, 2393
 Hong S, 4243
 Hongo A, 1685
 Honoki K, 4047
 Höög CM, 1539
 Hori H, 935, 4897
 Horiguchi J, 517, 625
 Horiuchi A, 1023
 Horiuchi C, 661
 Horiuchi K, 1879
 Horiuchi S, 4879
 Hörl WH, 731
 Hörmann K, 1675
 Hornemann A, 3611
 Hornicek FJ, 1867, 1879
 Hornyak L, 2121
 Horvath G, 1585
 Hosaka T, 2315
 Hoshiai H, 561, 617
 Hoshina S, 2403
 Hoshino I, 4433
 Hoshino M, 2219
 Hosokawa K, 1521
 Hosoya Y, 3375
 Hotta T, 2219
 Hotta Y, 2219
 Hou LC, 4901
 Hou M-F, 3131
 Houchen CW, 2009
 Hovorka O, 4513
 Howard A, 3427
 Howarth A, 1933
 Hrdý J, 1295
 Hsia T-C, 309, 4063, 4503
 Hsiang C-Y, 987
 Hsieh T-C, 3011, 3459, 4025
 Hsieh Y-J, 211
 Hsu C-P, 283
 Hsu N-Y, 725
 Hsu S, 3811
 Hsu Y-C, 283
 Hsu Y-M, 2239
 Huang C-C, 1131
 Huang J, 851
 Huang J, 851, 1739
 Huang L-J, 1435
 Huang S-C, 3131
 Huang Shawn, 3299
 Huang S-P, 165
 Huang Su, 3883
 Huang W-W, 1435
 Huang Y-W, 2179, 3195
 Huber M, 4795
 Huckhagel T, 4649
 Huebner T, 4571
 Huff F, 3811
 Hughes A, 1
 Hughes DJ, 4337
 Hühn R, 1901
 Huizing MT, 5137
 Hung M-S, 2025
 Hunter W, 299
 Hunyadi J, 2121
 Huo Q, 851
 Hurwitz HI, 5149
 Huscher A, 4821
 Husøy T, 1921
 Huss D, 4119
 Hussain-Hakimjee EA, 3555
 Huzarski T, 2703
 Hwang J-J, 211, 2111
 Hwang O-K, 2393
 Hwu L, 211
 Hydock DS, 4401
 Hyšpler R, 3337, 4813
 Hyun YL, 3027
 Iacobelli S, 403
 Iafrate J, 1867
 Iannuccelli V, 4529
 Ibuki N, 2497
 Icard P, 1249, 1443
 Ichikawa D, 2091
 Ichikawa Y, 1515, 2863
 Ichinose Y, 4217
 Ida H, 2619
 Ideo A, 175
 Idris T, 1761
 Igawa S, 2747
 Iguchi C, 1607, 3329
 Ihara K, 1669
 Ihnen M, 2817
 Iida T, 3995
 Iihara H, 1721
 Iijima H, 843
 Iijima M, 977
 Iino Y, 517
 Iinuma M, 2485
 Iizasa T, 2635
 Iizuka A, 647, 1349
 Ikarashi Y, 1349
 Ikebe M, 843
 Ikeda D, 977
 Ikeda F, 517
 Ikeda K, 1749, 1763
 Ikeda M, 1783
 Ikoma H, 2091
 Ikushiro S, 3563
 Ilbäck N-G, 83
 Iley J, 2273, 2285
 Ilhan A, 731
 Ilkovitch D, 2051
 Im S-A, 255
 Imaizumi T, 685
 Imoto I, 19
 Improta G, 1709
 Inaba M, 1515
 Inadome Y, 497
 Inagawa H, 817, 859, 865, 907, 4855, 4861, 4867, 4871
 Inaji H, 4791
 Inamoto T, 2497
 Ingolic E, 1951
 Inokuchi S, 685
 Inose T, 3375
 Inoue F, 2315
 Inoue H, 4157
 Inoue M, 809, 1691, 4779, 4887
 Inoue Sayaka, 1079
 Inoue Shuichi, 1079
 Inoue T, 911
 Inoue Y, 2059
 Insabato L, 477
 Ioannides CG, 41, 2427
 Ioannides MG, 2427
 Ip S-W, 4063
 Iragavarapu-Charyulu V, 2051
 Irmak S, 1823
 Irmejs A, 711
 Isaksson-Mettävainio M, 1489
 Isbir T, 1389, 1395, 2417, 2519, 4041
 Ishibashi K, 271, 275, 279, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Ishibashi Y, 927, 4893
 Ishida H, 2315
 Ishida T, 2525
 Ishihara K, 1009
 Ishihara Mariko, 2265, 3079, 4077, 5019
 Ishihara Masashi, 1721
 Ishii H, 2403
 Ishii T, 763
 Ishii T, 763, 4287
 Ishikawa A, 2635
 Ishikawa H, 1507, 2671
 Ishikawa T, 1515
 Ishikawa Y, 517
 Ishitobi M, 4791
 Ishiyama S, 2427
 Ishizaki J, 4779
 Ishizawa S, 235

- Ishizuka B, 561
 Ishizuka S, 3563
 Isobe M, 4639
 Isohata N, 4271
 Isonishi S, 561
 Istfan NW, 3591
 Itakura J, 19
 Itakura M, 1607, 2635, 3329
 Itani Y, 1521
 Itashiki Y, 1263
 Ito E, 4239
 Ito F, 1111
 Ito Kensaku, 4099
 Ito Kimihiko, 1521
 Ito Kosei, 2619
 Ito Seiji, 2403
 Ito Shigeru, 4033
 Ito Yasuhiro, 4157
 Ito Yoshiaki, 2619
 Ito Yoshinori, 625
 Ito Yuichi, 4033
 Ito Yuko, 2195
 Itoh M, 4629
 Itoh T, 1449
 Itoh Y, 1721, 4989
 Itzhaki O, 145
 Iurisci I, 403
 Ivanova A, 5241
 Iwanaga R, 1669
 Iwao H, 3361
 Iwasa S, 4751
 Iwasaki H, 851
 Iwashita A, 4893
 Iwata M, 485, 2857, 3453
 Iwata S, 763, 4287
 Iwata T, 385
 Iyer RV, 4127
 Izbicki JR, 1195
 Izumi T, 4589
 Jablon DM, 2025
 Jäcker T, 4785
 Jackinsky S, 4373
 Jackson LA, 2473
 Jacobi U, 2307
 Jacobs JLL, 5241
 Jæger R, 1047
 Jaenicke F, 545, 2817
 Jaffre F, 1697
 Jäger M, 1787, 3433
 Jajeh J, 4579
 Jakobsen A-M, 1585
 Jakobson Å, 3311
 Jakubiszyn J, 2703
 Jammaz IA, 1399
 Janeckova H, 2339
 Jänicke F, 183
 Janinis J, 693
 Janke K, 3397
 Japanese Patterns of Care
 Study Working Subgroup
 of Prostate Cancer, 4605
 Japink D, 3245
 Javle MM, 4127
 Jaworowska E, 2703
 Jelen M, 589
 Jelen-Krzeszewska J, 589
 Jelinek EM, 3433
 Jen R, 4621, 5045
 Jeney A, 2981, 3095
 Jenkins PJ, 155, 3785
 Jeong Jae Heon, 4243
 Jeong Jin Hyun, 1417
 Jeong K-S, 2393
 Jeske S, 3019
 Jhanwar SC, 1255
 Jhanwar-Uniyal M, 119
 Ji A-R, 2393
 Jiang G, 223
 Jiang Z, 4083
 Jin C-Y, 4457
 Jin M, 4697
 Jinno H, 1009
 Jo B-H, 4683
 Jo E, 843
 Jo S, 1467
 Jobo T, 561
 Johansson H, 5111
 Johansson L, 4361
 Johnson K, 2243
 Johnson SM, 3185
 Jonas D, 671
 Jones M, 1933
 Jones SJM, 2437
 Joseph P, 2993
 Joumard L, 1631
 Juell S, 131
 Juhasz A, 1467
 Jun SH, 4303
 Jung K, 2589
 Jung M, 4243
 Jung S, 2817
 Jung WJ, 4673
 Jung YD, 355
 Jürgensmeier JM, 5065
 Juzeniene A, 3495
 Kadofuku T, 2315
 Kadoma Y, 2403
 Kadowaki T, 4871
 Kagawa T, 1783
 Kageyama S-I, 2547
 Kağnici ÖF, 4041
 Kagohashi K, 2671
 Kagota S, 3857
 Kahl P, 4057
 Kaifi JT, 1195
 Kaileh M, 3797
 Kaina B, 2453
 Kaira K, 2747
 Kaizaki R, 2189
 Kajiwara Y, 597
 Kakeji Y, 2555
 Kakinohana Y, 525
 Kal HB, 3305, 5219
 Kalábová H, 3337, 4813
 Kalay E, 1395
 Kalfakakou V, 3465
 Kalkani E, 3401
 Kallay E, 3727
 Kalofonos HP, 745, 693,
 5077
 Kalogera-Fountzila A, 529
 Kalogeras KT, 529
 Kalpadakis C, 1811
 Kalso E, 2601
 Kaltner H, 4933
 Kaltsas G, 5163
 Kamada T, 4433
 Kamano T, 485, 2857, 3453
 Kameda A, 2775
 Kameda C, 843, 871, 2147
 Kamibeppu K, 4287
 Kamidono S, 1533
 Kamiya Y, 485, 2857, 3453
 Kamposioras K, 769
 Kamura T, 561
 Kanaan YM, 191
 Kanakis M, 5163
 Kanamoto T, 3211
 Kanczuga-Koda L, 4151
 Kanda T, 3375
 Kanda Y, 343, 5023, 5083
 Kaneda H, 1111
 Kang SY, 3909
 Kanitakis J, 1927, 5033
 Kaňkova K, 4227
 Kano M, 4433
 Kano Y, 4589
 Kanome T, 2315
 Kao C-H, 3459
 Kapoor N, 3281
 Kapraali M, 4291
 Karadeniz A, 2519
 Karafoka E, 785
 Karageorgopoulou S, 769
 Karagiannis A, 5211
 Karamanos N, 3227
 Karameris A, 4163
 Karapanagiotou EM, 631,
 1651, 4297
 Karatzas T, 2681
 Karayannopoulou G, 529
 Kardamakis D, 703
 Karimata H, 525
 Karina M, 693
 Karlsson M, 1539
 Karlsson U, 3299, 4683
 Karstens JH, 2627
 Kasahara A, 1515
 Kashiwara H, 2759
 Kashima H, 1023
 Kasimir-Bauer S, 1787, 3449
 Kašparová M, 4813
 Kassanos D, 3977
 Kastendieck H, 249
 Kasuya G, 525
 Katano M, 261, 831, 843,
 871, 881, 2147
 Kataoka H, 4845
 Kataoka Y, 2541
 Katayama K, 1059, 1515
 Katayose Y, 1169, 1201,
 2015
 Kates R, 2675
 Katirtzoglou N, 3441
 Kato H, 965, 1595, 3375
 Kato J, 2015
 Kato K, 1727
 Kato N, 2009
 Katoh R, 4751
 Katopodis H, 4013
 Katsimpoula S, 1373
 Katsube K-I, 3967
 Katsube T, 4271
 Katsuoka Y, 2497
 Katz Y, 2977
 Kaul S, 951
 Kaur P, 1659
 Kautiainen H, 2601
 Kautio A-L, 2601
 Kavalari R, 3269
 Kaveri SV, 2945
 Kawabata H, 2357

- Kawaguchi Y, 935, 2137
 Kawaguchi-Ihara N, 4629
 Kawahara K, 2753
 Kawahara T, 4629
 Kawai A, 2219
 Kawakami M, 661
 Kawamura K, 243, 2411
 Kawano D, 4099
 Kawano K, 41
 Kawano Y, 2753
 Kawase M, 175, 2265, 3079, 4077
 Kawashima H, 1089, 2219
 Kazatchkine MD, 2945
 Ke C-C, 211
 Kearney J, 1999
 Keck JG, 3845
 Keedy VL, 2913
 Keilholz U, 3411
 Keisari Y, 145
 Kellaf S, 1335
 Kelley MR, 1319
 Kellokumpu-Lehtinen P, 1755
 Kelson AB, 3845
 Kemona A, 3049, 3913
 Kenessey I, 2981
 Kern MA, 4057
 Kertai P, 2121
 Khalaf S, 155, 3785
 Khayat AS, 2479
 Khoury T, 1151
 Khuong-Huu F, 1963
 Ki M-R, 2393
 Kiagia M, 1651
 Kidani T, 4093
 Kienast J, 4233
 Kiesel L, 2167
 Kigawa G, 271, 275, 279, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Kihara K, 797
 Kihara M, 4157
 Kijima H, 685
 Kik K, 1429
 Kikuchi H, 455, 4615
 Kikuchi M, 517
 Kikuchi S, 2091
 Kim CW, 3027, 3115
 Kim G-Y, 4457
 Kim H, 1201
 Kim Hee Sung, 3909
 Kim Hyo Song, 1817
 Kim JC, 3027, 3115
 Kim JH, 1417, 5039
 Kim J-H, 4243
 Kim KH, 255
 Kim KM, 355
 Kim Kyungjin, 1201
 Kim Kyungmann, 3769
 Kim MB, 3027
 Kim MH, 355
 Kim MY, 3733
 Kim ND, 4457
 Kim SH, 4423
 Kim SK, 4243
 Kim S-K, 4457
 Kim SM, 355
 Kim So Hee, 1143
 Kim Suhn Hee, 3837, 4423
 Kim S-Y, 255
 Kim SY, 3027, 3115
 Kim SZ, 3837, 4423
 Kim TW, 3027, 3115
 Kim Y, 1817
 Kim YS, 3027, 3115
 Kim YT, 4243
 Kimmig R, 1787, 3449
 Kimura H, 2635
 Kimura J, 2863
 Kimura T, 4779
 Kinugasa T, 851
 Kirkali Z, 5155
 Kisakesen HI, 4041
 Kishino K, 343, 5083
 Kiss I, 4169
 Kita D, 1739
 Kitagawa Y, 1009
 Kitamura Y-H, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Kitano H, 2547
 Kito A, 1515
 Kittaka A, 3547, 3563
 Kiura K, 2759
 Kiyama S, 2497
 Kiyohara Y, 647
 Kleber M, 4745
 Klein R, 3511
 Kleina R, 4345
 Kleinhans H, 1195
 Klepzig M, 671
 Klocker H, 1739
 Klostermann S, 4919
 Klouras N, 3227
 Knippen S, 183
 Kobayashi K, 1763, 4157
 Kobayashi M, 1123, 2739
 Kobayashi S, 995
 Kobayashi T, 235
 Kobr J, 2371
 Koch I, 2823, 2827
 Koda M, 4151
 Kodama J, 1685
 Kodani I, 3811
 Kodera Y, 2739, 4033
 Koehler C, 3411
 Koga F, 797
 Koga K, 261, 871, 881
 Kogner P, 3311
 Kohchi C, 817, 859, 865, 907, 4855, 4861, 4867, 4871
 Kohlhof P, 3261
 Koibuchi Y, 517
 Koike M, 1607, 3329, 4033
 Koizumi M, 4605
 Kökény S, 1971
 Kokkalis G, 2655
 Kokuba Y, 2091
 Kolinsky K, 91
 Koltai K, 4169
 Komarnicki M, 1643
 Komatsu F, 911, 919
 Komiyama M, 647
 Komoike Y, 4791
 Komori C, 243, 2411, 3877
 Komori Y, 1721
 Kondi-Pafiti A, 2781
 Kondo Y, 995
 Könemann S, 3397
 Köninger A, 641
 Konishi H, 2091
 Konishi I, 1023
 Konno S, 4271
 Kono K, 2137
 Konstantinou M, 4297
 Köpstein U, 1575
 Korkolis DP, 2655
 Kormunda S, 667
 Kornafel J, 2445
 Kornafel J, 589
 Korytowska A, 2703
 Kosaka T, 2863
 Koskas M, 4147
 Kosmidis PA, 529, 2727
 Köster F, 4833
 Köstner K, 3511
 Kostřica R, 4227
 Kosuge M, 1681
 Koten JW, 5241
 Koto M, 1831, 4409
 Kotsalos A, 3465
 Kotteas E, 3441
 Koumariou A, 769
 Kountourakis P, 5211
 Kouraklis G, 5163
 Kouroumalis E, 1361
 Koussis H, 5255
 Koutras A, 693
 Koutsellini H, 4163
 Koutsilieris M, 371, 2331, 4013
 Kovacs K, 3759
 Kovář J, 2951
 Kovar L, 4513
 Kowalczyk J, 1643
 Koyama H, 4791
 Koyanagi J, 455
 Kozevnikova R, 667
 Kozina G, 3433
 Kraljić I, 1797
 Kralovánszky J, 3095
 Kram A, 2703
 Kramer H, 363
 Krastev Z, 5241
 Krauspe R, 3433
 Krawczuk-Rybak M, 1643
 Krawczyk N, 4019
 Krčmová L, 3337, 4813
 Krenács T, 681
 Kriebitzsch C, 3471
 Kriner M, 641
 Krisponeit D, 5013
 Kriwanek S, 3721
 Kröger N, 1355
 Krohn V, 1181
 Krokowski M, 4649
 Kropff M, 4233
 Ku F-M, 283
 Kubo A, 1507
 Kubo F, 1287
 Kubo M, 871, 2147
 Kubo Tadahiko, 3833, 5197
 Kubo Takahiro, 2357
 Kubo Toshio, 2759
 Kubodera N, 3571
 Kubonishi S, 1763
 Kubota T, 2091
 Küçükhüseyin Ö, 2417
 Kudo H, 4615
 Kudo K, 1111

- Kudo N, 2219
 Kuei A, 3239
 Kuemmel S, 641
 Kuhara K, 4271
 Kulda V, 2513, 4535
 Kulendran M, 1095
 Kumar A, 2933
 Kümme A, 201
 Kumon H, 1685
 Kunii S, 343, 5023, 5083
 Kunisaki C, 583, 2863
 Kunitomo M, 3857
 Kunjithapatham R, 4909
 Kuo C-T, 4621, 5045
 Kuo S-C, 1435, 3139
 Kuo Y-S, 2239, 3897
 Kurachi H, 4639
 Kuratsukuri K, 1089
 Kure EH, 2885, 4323
 Kurihara T, 379, 455, 1123
 Kurishima K, 2671
 Kurisu K, 597
 Kurita N, 385
 Kurita Y, 1001
 Kurokawa Y, 3385
 Kuroki H, 927
 Kuroki Masahide, 823, 851, 4879
 Kuroki Motomu, 851
 Kuroki S, 871, 2147
 Kurosumi M, 3971
 Kurth A, 2787
 Kurzepa A, 2361
 Kurzrock R, 1895
 Kusaba H, 1727
 Kusić Z, 1797
 Kusumoto S, 1733, 2315
 Kutsuna T, 1079
 Kuvshinoff B, 4127
 Kuwada E, 1015
 Kuwano H, 965, 1595, 3375
 Kuwano M, 965
 Kwiatkowski F, 5229
 Kyo S, 1691, 4779, 4887
 Kyriakou V, 5163
 Kyritsi L, 1933
 Kyrtsolis M-C, 1811
 La Torre G, 1709
 La Verde N, 2691
 Laack E, 249
 Laato M, 99
 Laban C, 155, 3785
 Laborde E, 3845
 Lacalamita R, 2845
 Lacko A, 2445
 Lacko M, 753
 Lacoste E, 3807
 Lademann J, 2307
 Laffranchi A, 777
 Lagadas A, 2681
 Lågeide L, 2885, 4323
 Lagodny J, 1327
 Lagunova Z, 3495, 3501, 3713
 Lah TT, 3269
 Lai H, 3807
 Lai J-C, 2535
 Lai K-C, 309, 1435
 Lai T-Y, 4503
 Lai W-W, 327, 4503
 Laing RW, 1483
 Laliscia C, 4205
 Lambrecht L, 4717
 Lamm W, 1627
 Landt S, 641
 Lang SA, 2031
 Lang U, 1761
 Langer F, 2719
 Langley SEM, 1483
 Lansing L, 3825
 Lanzetta G, 5171
 Larsen U, 1355
 Larsson A, 3311
 Larsson R, 11
 Lashkari A, 3281
 Latif F, 4337
 Latinwo LM, 2993
 Lattuada P, 4259
 Latvala A, 2569
 Lau KW, 4337
 Laube F, 1383
 Laudisi A, 3321
 Laurent JF, 1697
 Laureys J, 3579
 Lavau-Denes S, 2563
 Lavoue V, 1697
 Le Brun-Ly V, 2563
 Leal MF, 2479
 Leandros E, 785
 Lee C-H, 211
 Lee DS, 5039
 Lee H, 2535, 4683
 Lee H-C, 5057
 Lee H-J, 5057
 Lee H-S, 1817
 Lee H-Z, 1275
 Lee JJ, 255
 Lee K-T, 995
 Lee MK, 5039
 Lee P, 4373
 Lee SC, 3043
 Lee S-K, 2393
 Lee T-W, 987
 Lee W-C, 2099
 Lee WH, 4457
 Lee W-Y, 3131
 Lee YJ, 4243
 Leers MPG, 3245
 Leese MP, 3751
 Lefresne F, 553
 Legakis I, 3949
 Legrand C, 1335, 2347
 Lehmann K, 1309
 Lehmann WD, 4949
 Lein M, 2589
 Lekka I, 737
 Lemachatti J, 4741
 Lemanski C, 3299
 Lembessis P, 371, 2331
 Lemieux C, 4373
 Leminen A, 2601
 Lenander C, 1745
 Lende T, 4697
 Lenz A, 971, 1889
 Leobon S, 2563
 Leocata P, 1137
 Leonard T, 3427
 Leong L, 3281
 Lerner M, 3417
 Leroy X, 59, 4933
 Lescuyer A, 4965
 Leuschner I, 1459
 Levea C, 465
 Levéque D, 4741
 Leveque J, 1697
 Levin N, 2243
 Levine PA, 2869
 Lewis J, 3811
 Lewis P, 3427
 Li Hen, 4697
 Li Hong, 5045
 Li Huiling, 1999
 Li L, 2243
 Li R, 2077
 Li T-C, 4063
 Li Xinguo, 1411
 Li X-L, 2927
 Li Xueyan, 27
 Li Yufeng, 41, 2427
 Li Yunxian, 4005
 Li ZJ, 229
 Li ZX, 4519
 Liang P-C, 1665
 Liang S-Y, 725, 1275
 Liang Y-J, 4597
 Liao C-L, 4063
 Liao Y-M, 2239
 Liapakis IE, 2655
 Liava A, 703
 Lichtenegger W, 641, 1575, 2793, 2809
 Liebig B, 1901
 Lim D, 1467
 Lin Cheng-Chieh, 725, 1777, 3897, 5251
 Lin Chin-Chung, 309
 Lin J-G, 165, 4063
 Lin J-P, 165
 Lin K-L, 1435
 Lin M-L, 327
 Lin P, 509
 Lin S-H, 4621, 5045
 Lin S-Y, 327
 Lin W-J, 2111
 Lin W-J, 987
 Lin Y-C, 2025
 Lin YC, 2179, 3195, 4621, 5045
 Lin Y-H, 283
 Lin Y-Y, 2111
 Lin Z-Z, 1665
 Lindahl B, 4731
 Lindberg F, 3713
 Linder S, 11
 Lindhofer H, 1787
 Lindström AK, 2577
 Ling FC, 1281
 Ling LE, 2099
 Ling Y, 411
 Lise M, 4139
 Liska V, 2371
 Lissoni P, 1847
 Litwin A, 4127
 Liu C-L, 283
 Liu C-S, 1777, 3903, 5251
 Liu D, 3777
 Liu D-L, 2531
 Liu J-J, 2987
 Liu J-M, 1963
 Liu K-C, 309, 327
 Liu L, 139
 Liu R-S, 211, 2111

- Liu S-H, 4083
Liu Shaoping, 5089
Liu Suling, 3195
Liu W, 1423
Liu X, 1467
Ljuslinder I, 1489
Lo C, 165
Lo Muzio L, 2919
Loddenkemper C, 3411
Loera S, 1467
Löfroth P-O, 4361
Logan P, 3059
Logullo AF, 4807
Lombardi G, 4275
Lombardo J, 4127
Lomholt AF, 75
Long J, 5089
Long MC, 299
Longatto Filho A, 3365, 4807
Löning T, 183
Loo C, 2579
Loo WTY, 2525
Lopes C, 2713, 3221
Lopez DM, 2051
Lopez M, 1841
Lopez-Beltran A, 5155
Lopez-Egido JR, 1859
López-Soriano FJ, 1315
López-Tarruella S, 4185
Lora V, 5033
Lorenzen D, 4795
Lortholary A, 4195
Lorusso V, 1841
Lorz C, 3035
Lourenço L, 3221
Louwagie J, 363
Lövborg H, 11
Love WK, 4959
Lovell DP, 1483
Loyola AM, 1189
Lu C, 1233
Lu C-C, 4063
Lu H, 2347
Lu H-F, 309, 4503
Lu N, 411
Lu Y, 1249
Lubiński Jakub, 2703
Lubiński Jan, 2703, 4337
Ludin A, 3299
Ludovici G, 3369
Ludwig DL, 1999
Luh F, 3239
Luini A, 5111
Lumachi F, 491, 1551, 3381, 5255
Luo G, 4497
Luo-Owen X, 107
Lurje G, 1281
Lust S, 605, 3797
Lv F, 27
Ma C-Y, 4503
Ma H, 443, 2421
Ma W, 3845
Macanas-Pirard P, 1483
Mach CM, 1895
Macheras A, 3465, 4759
Machino M, 2403
Mack MG, 2787
Madelenat P, 4147
Madelmont J-C, 5235
Maeda Y, 1749, 1763
Maegawa M, 1111
Maehara Y, 2555, 4099
Maekawa T, 927, 4893
Maestro De Las Casas ML, 4185
Maestro LM, 4839
Magdelénat H, 1475
Maggioni D, 303
Magistro S, 3983
Magri E, 4821
Magrini SM, 4821
Mahadevan D, 2099
Maher ER, 4337
Mahillon V, 4933
Mahmoudi N, 2563
Mahner S, 545, 2817
Maiolino P, 2919
Majumdar APN, 395
Makinde AY, 107
Makino H, 2863
Makrilia N, 1373, 3441
Makuuchi H, 685
Maliaga K, 4483
Malkinson AM, 5095
Malmer B, 1489
Maloney SC, 3059
Maliřova E, 4813
Mambrini A, 1547, 1835
Mammano E, 4139
Manca G, 4251
Mancosu P, 4259
Mancuso A, 2691
Manda R, 965
Mandato VD, 477
Mandic R, 1181
Manhardt T, 3727
Mankin H, 1867
Manni JJ, 753
Mano H, 4589
Mano T, 1263
Manome Y, 235
Maran A, 4317
Marcelis S, 3579, 3585
Marchal K, 3585
Marchetti P, 5171
Marchiori D, 473, 1345
Margaritis L, 3977
Marian T, 2121
Mariani G, 4251
Marin C, 4119
Marini C, 4251
Marino F, 5255
Mariotti L, 4575
Mariotti S, 4131
Markel G, 145
Markopoulos C, 2851
Markus R, 1771
Marlia E, 473
Marnitz-Schultze S, 3411
Marshall J-C, 3059
Martano A, 503
Martano M, 2919
Martelli L, 3931
Martelli M, 3931
Martelli O, 2691
Marth C, 2803
Martin J, 2563
Martín M, 4185, 4839
Martinez T, 4683
Martínez-Cruz AB, 3035
Martínez-Martos JM, 4633
Martini F, 3321, 4131
Martins A, 2173, 3989
Martins C, 3059
Martins M, 2173, 3989
Martorana A, 4417
Martorana G, 473, 1345
Martschick A, 2307
Maruyama K, 647
Maruyama N, 485, 2857, 3453
Maruyama R, 4217
Marzola MC, 491, 4251
Masaki Y, 3361
Måsbäck A, 4731
Mashiah J, 1793
Mashtare T, 4127
Masojć B, 2703
Masoudi H, 2437
Massaad-Massade L, 1227
Masubuchi Y, 935
Masuda N, 965, 1595
Masuda T, 2555
Matejovic M, 2371
Matera E-L, 3003
Mathelin C, 4119
Mathew L, 1895
Mathieu C, 3579
Mathieu JS, 3547
Mathioudaki K, 1361
Matkowski R, 589, 2445
Matono K, 2083
Matos D, 4807
Matsouka P, 5077
Matsubara H, 4433
Matsuda G, 2863
Matsuda H, 661
Matsuda K, 2611
Matsueda S, 41, 2427
Matsui T, 927, 2091, 2739
Matsui Y, 1349, 2357
Matsukawa H, 3347
Matsumoto C, 1515
Matsumoto K, 1111
Matsumoto M, 3971
Matsumoto S, 919
Matsumura K, 1089
Matsunaga T, 1981
Matsuo K, 583, 1749
Matsuo T, 3833, 5197
Matsuoka K-I, 1749
Matsuoka R, 4239
Matsuura K, 1721
Matsuyama M, 685, 1089
Matsuzaki T, 2189
Matsuzuka F, 4157
Matthews C, 2273
Mattsson L, 1539
Matysiak M, 1643
Matzouridis T, 3949
Maubon A, 2563
Maurizi Enrici R, 5171
Mayas MD, 4633
Mayer F, 4195
Maywald N, 1355
Mazzocchi M, 503
Mazzucchelli R, 5155
McCarthy K, 155, 3785
McEntee E, 2927
McGown A, 2971, 3103
McVittie CJ, 3785

- Meadows KL, 5149
 Medinger M, 5065
 Meeus M, 4717
 Mehta K, 1909
 Mehta RG, 3555
 Meister M, 4057
 Melato M, 1137
 Melbārde-Gorkuša I, 711
 Melichar B, 3337, 4813
 Melicharová K, 3337, 4813
 Mellai M, 3087
 Mendonça B, 3365
 Mentze M, 1575
 Mercado-Pimentel ME, 2099
 Meregalli S, 1847
 Merlini G, 2507
 Merz H, 4649
 Mesbah H, 1697
 Messer R, 3811
 Messina G, 1847
 Metro G, 2607
 Metsios A, 3465
 Metzger R, 1157, 1281, 4451
 Meyer A, 5013
 Mibu R, 261
 Michail O, 5163
 Miekisch W, 419
 Miglietta L, 1621
 Mignot L, 1475
 Mikami Y, 661, 5197
 Miki M, 3361
 Miklaševičs E, 711
 Mikoviny T, 419
 Milas L, 4409
 Milde-Langosch K, 183
 Miller B, 3819
 Miller K, 2589
 Miller N, 1557
 Miller PD, 1483
 Mimura K, 2137
 Min SY, 3909
 Minagawa N, 2059
 Minami K, 2775
 Minami M, 4989
 Minami T, 617
 Minarik M, 1803, 2767
 Minarikova P, 1803
 Mineo TC, 1499
 Ming LH, 1001
 Minik O, 717
 Minniti G, 5171
 Mir LM, 3125
 Mirka H, 2371
 Misailidou D, 529
 Misawa K, 4033
 Misawa T, 3173
 Missailidis S, 2273, 2285
 Mistiaen W, 4717
 Mitchell SB, 4309
 Mitra S, 3741
 Mitsugi K, 1727
 Mitsuhashi J, 1059
 Mitsumori MI, 4605
 Mitsuya M, 1831
 Mitsuyoshi H, 4989
 Mitterer M, 5245
 Miura N, 4099
 Miya A, 4157
 Miyagawa K, 2619
 Miyahara E, 2775
 Miyamoto K-I, 4779
 Miyamoto S, 823, 4879
 Miyamoto T, 1023
 Miyashita A, 2619
 Miyata H, 4211
 Miyata M, 1533
 Miyatani T, 385
 Miyauchi A, 4157
 Miyawaki M, 2753
 Miyawaki S, 4589
 Miyazaki K, 2671
 Miyazaki T, 965, 1595
 Miyazawa Y, 4433
 Miyoshi T, 1163
 Mizuguchi H, 2997
 Mizukami H, 271, 275, 279, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Mizukami Y, 2137
 Mizuki E, 427
 Mizuma M, 1169, 1201, 2015
 Mizutani K, 3109
 Mo J, 3253
 Moan J, 3495, 3501, 3713
 Moats-Staats BM, 1943
 Mocellin S, 4139
 Mochida Y, 965
 Moe BG, 1053
 Moe BT, 1047
 Moerman P, 1039
 Mokbel K, 1095
 Molin Y, 83
 Molina A, 3281
 Molkentine DP, 4409
 Mollaoglu N, 5125
 Molnár J, 2173, 3989, 4467
 Moltz CC, 3299
 Momiyama N, 1515
 Momose I, 977
 Monaco M, 3157
 Mönig S, 4451
 Monmasu H, 837
 Monteil J, 2563
 Montironi R, 3365, 5155
 Moon HJ, 3837, 4423
 Moon HJ, 4423
 Moon YW, 4243
 Moore-Carrasco R, 1315
 Moral M, 3035
 Moreas I, 4163
 Moreira Da Silva V, 3221
 Morelli O, 4971
 Morere J-F, 1615
 Mori M, 4211
 Mori Y, 1263
 Morice P, 4147
 Morii T, 1879
 Morimoto J, 2485, 4389
 Morioka H, 1879
 Morisaki T, 831, 843, 881
 Morise Z, 1783
 Morita H, 1119
 Morita M, 2555
 Morita S, 1515, 4779
 Morita T, 2219
 Moritz P, 1539
 Morodomi Y, 4099
 Moroga T, 2753
 Morresi-Hauf A, 4057
 Morris DL, 3791, 4051
 Morris MR, 4337
 Morse MA, 5149
 Moser C, 2031
 Mosley SA, 1895
 Motohashi N, 455, 1123
 Motoi F, 1169, 1201, 2015
 Motomura K, 4791
 Motoyama T, 4639
 Mouret-Reynier M-A, 5235
 Mousa SA, 3825, 4473
 Mousa SS, 3825
 Mousseau M, 1703
 Mugiya S, 1001
 Mukensnabl P, 2767
 Mukerjee A, 3867
 Mukerji P, 2421
 Mukumoto N, 4605
 Muley T, 4057
 Mulhovo S, 3989
 Müller CSL, 3511
 Müller H-H, 3421, 4785
 Müller J, 11
 Müller V, 183
 Müller-Hübenthal B, 4795
 Müller-Tidow C, 1157
 Mulligan AM, 1557
 Mumford JL, 3253
 Muni R, 5171
 Muñoz M, 2323
 Muñoz-Díaz MM, 4727
 Münzel A-K, 1459
 Munzert G, 4233
 Murakami H, 2747
 Murakami K, 4433
 Murakami Y, 2403
 Murali R, 119
 Muramatsu K, 1669
 Muranyi E, 2121
 Murata T, 1119
 Murayama M, 4271
 Murayama S, 525
 Murthaiyah P, 1495
 Murugan RS, 2301
 Mus R, 469
 Muscat J, 3427
 Mutai H, 1981
 Muto Y, 3445
 Myojo S, 4779
 Myoui A, 2357
 Na YS, 3027
 Nabeshima K, 851, 919
 Nadasi E, 2295
 Nagai S, 261, 843, 881
 Nagakura C, 1873
 Nagamine T, 1211
 Nagano Y, 583, 2863
 Nagaoka H, 517
 Nagaoka R, 517
 Nagasaka M, 485, 2857, 3453
 Nagata H, 2619
 Nagata J, 2059
 Nagata M, 2219
 Nagata N, 2059
 Nagini S, 2301
 Naito T, 2747
 Najim N, 2971, 3103
 Naka N, 2357
 Nakabayashi S, 3547
 Nakagawa S, 2541, 4689
 Nakai H, 617

- Nakajima K, 4211
 Nakajima M, 965, 1595, 3375
 Nakajima T, 2635, 4989
 Nakamura H, 19
 Nakamura Katsumasa, 4605
 Nakamura Kazuki, 3857
 Nakamura Keihiro, 1685
 Nakamura Masafumi, 261, 831, 843, 871, 881, 2147
 Nakamura Masakatsu, 485, 2857, 3453, 4265
 Nakamura R, 2671
 Nakamura Y, 455, 2747
 Nakanishi H, 4033
 Nakano H, 485
 Nakano H, 485, 3453
 Nakano S, 1727
 Nakano T, 2205
 Nakao A, 4033
 Nakase I, 3807
 Nakashima H, 3211
 Nakashima M, 1733
 Nakata K, 865, 4855, 4861
 Nakatani T, 1089
 Nakayama G, 4033
 Nakayama H, 497
 Nakayama Y, 2059
 Nakazawa K, 19
 Nakazawa S, 2611
 Nakazima A, 3361
 Namba N, 1763
 Nannizzi S, 1835
 Nano R, 2461, 4575
 Naoe M, 1533, 2997
 Nap M, 3245
 Nappi C, 477
 Nara N, 4629
 Narazaki K, 1831
 Nardi E, 4971
 Narita T, 1123
 Naritaka Y, 4271
 Narter F, 1395, 1389
 Narui K, 1515
 Nashimoto A, 4689
 Nasioulas G, 2727
 Nasothimiou E, 1651
 Nasu Y, 1685
 Natoli C, 403
 Natsugoe S, 1287
 Nautiyal J, 395
 Navarria P, 4259
 Navrozoglou I, 4995
 Neckers L, 797
 Necozone S, 567
 Nehmann N, 1219, 4941
 Neiss S, 1281
 Nemoto H, 271, 275, 279, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Nemoto N, 4615
 Nesland JM, 1233
 Neto RA, 4807
 Neubauer H, 4019
 Neukam FW, 291, 2379, 3191, 5125
 Neumaier-Probst E, 3261
 Nevozhay D, 2361
 Newman SP, 3751
 Neziri D, 731
 Nguyen LM, 3299, 4683
 Nguyen N, 4683
 Nguyen NP, 3299, 4683
 Nguyen PD, 3299
 Nicolas P, 1615
 Nicolini G, 303
 Nieder C, 2641
 Niederle B, 1951
 Nielse HJ, 75
 Nielsen P, 1867
 Niemeyer CM, 1327
 Nifantiev NE, 403
 Niho T, 661
 Nii K, 927
 Niiya M, 1763
 Nijs J, 4717
 Nikolaidou M-E, 3977
 Nikolaou M, 737
 Nikolova T, 2453
 Ning Z, 3253
 Ninomiya M, 3347
 Ninone SA, 4259
 Nio Y, 1607, 3329
 Nishi T, 3329
 Nishida A, 2759
 Nishida T, 2497, 4211
 Nishie-Kataoka M, 1763
 Nishimaki T, 525
 Nishimori H, 1749, 1763
 Nishimori T, 4433
 Nishimura G, 661
 Nishimura H, 2635
 Nishio K, 1111, 2205
 Nishio M, 2619
 Nishioka M, 385
 Nishishiro M, 379
 Nishiyama K, 4791
 Nishizaki M, 3347
 Nishizawa T, 817, 859, 865, 907, 4855, 4861, 4867
 Nisman B, 4281, 4827
 Nitti D, 4139
 Nittke T, 3705, 3727
 Niwa M, 2541
 Nkenke E, 291, 2379, 3191, 5125
 Noaki L, 1681
 Noda K, 561
 Noguchi K, 1015, 1059
 Noguchi M, 497, 1079
 Nojiri K, 583
 Nomi H, 2497
 Nomoto S, 497
 Nomura M, 995
 Nomura Y, 919
 Nonaka M, 889, 943
 Norris CM, 1987
 Norum J, 2641
 Nosek V, 1803
 Noso Y, 2775
 Noto K, 1079
 Novak RF, 1143
 Novak S, 3939
 Novotny Z, 573
 Nozawa R, 4157
 Nozawa Y, 1449
 Ntinis A, 4163
 Nunnari M, 449
 Nürnberg B, 3669
 O'Malley FP, 1557
 Oba K, 2739
 Obenauf AC, 1951
 Öberg E, 1489
 Obermaier B, 1271
 Obermayer-Pietsch B, 3699
 Ochi M, 3833, 5197
 Ochi N, 2759
 Ochiai K, 561
 Ochiai T, 2091
 Ochsenreither S, 3411
 O'Connell N, 4971
 Oda A, 1169, 1201, 2015
 Odawara H, 517
 Odenthal E, 1327
 Oelke M, 2875
 Offner F, 605, 3797
 Ogata Y, 2083
 Ogawa Kaoru, 1981
 Ogawa Kazuhiko, 525, 4605
 Ogawa Kenji, 4271
 Ogawa Kohichi, 889
 Ogawa Masaichi, 1681
 Ogawa Masayuki, 455
 Ogawa Y, 1831
 Ogbureke KUE, 3811
 Ogliari P, 2507
 Ogose A, 2219
 Ogunkolade W, 155, 3785
 Ogura K, 1733
 Ohara G, 2671
 Ohara K, 497
 Ohara M, 2775
 Ohashi M, 2611
 Ohashi R, 2205
 Ohashi Y, 561
 Ohba M, 427
 Ohgaki H, 1739
 Ohguchi K, 1449
 Ohkura K, 935, 4897
 Ohmori T, 1733, 2315
 Ohmura T, 911
 Ohnishi K, 1089
 Ohnishi T, 1733, 2315
 Ohno S, 809, 1691, 3347, 4239, 4779, 4887
 Ohno Y, 809, 1691, 4887
 Ohnstad HO, 4331
 Ohsaki H, 617
 Ohshita C, 647
 Ohta I, 1515
 Ohta M, 911
 Ohta T, 4639
 Ohtani Y, 685
 Ohtsuka H, 1169, 1201, 2015
 Ohuchi N, 2525
 Oida Y, 685
 Oikawa M, 1169
 Oikonomopoulou K, 3269
 Oizumi H, 343
 Oizumi T, 343
 Ojima I, 2951
 Ojima Y, 3347
 Oka M, 539, 1527, 2611
 Oka Y, 4779
 Okabe H, 4615
 Okabe Y, 1783
 Okada K, 243, 2411, 3877
 Okada K-I, 685
 Okada M, 4981
 Okada S, 2555
 Okamoto K, 2091
 Okanoue T, 4989

- Okarvi SM, 1399
 Okegawa T, 1533
 Okubo M, 485, 2857, 3453
 Okuda K, 1733, 2315
 Okuhashi Y, 4629
 Oláh E, 1971
 Olah JN, 2981
 Olbert PJ, 2067
 Oleszak EL, 4673
 Oliva B, 4185
 Oliveira PA, 3221
 Olivier C, 4839
 Ollonen P, 4765
 Omachi T, 1681
 Omori H, 1607, 3329
 Onishi H, 4605
 Onitsuka K, 2059
 Onitsuka T, 2687
 Ono A, 2747
 Ono HA, 2863
 Ono K, 2525
 Ono M, 965
 Ono Y, 927
 Onogawa T, 1169, 1201, 2015
 Ooi A, 19
 Opolski A, 2361
 Ørbo A, 1047, 1053
 Orellana ME, 3059
 Oremek GM, 671
 Orfanidou D, 1373
 Orfeuvre H, 4195
 Orive G, 2127
 Orlandi M, 1547, 1835
 Orlando FA, 1151
 Orsaria P, 1499
 Osada S, 5203
 Oshige K, 4893
 Oshima T, 2863
 Oshiro S, 911, 919
 Oskay-Oezcelik G, 2793
 Oskay-Özcelik G, 1575, 2307, 2831
 Ossendorf C, 4317
 Oszczapowicz I, 1429
 Ota A, 4893
 Ota M, 583
 Ota S, 4909
 Otová B, 1295
 Otsuji E, 2091, 2619
 Otsuki Y, 2195, 2485, 4389
 Otsuo T, 4689
 Otterbach F, 3449
 Ottolenghi A, 4575
 Ou Y-C, 1637
 Oude Ophuis MB, 753
 Oved K, 145
 Overbey D, 3777
 Oyama T, 517, 3375
 Oyen WJG, 469
 Ozawa H, 1981
 Özbek S, 11
 Ozono S, 1001
 Öztürk O, 4041
 Öztürk T, 4041
 Pácal L, 4227
 Pacetti P, 1547, 1835
 Pache G, 4745
 Packman K, 91
 Pagotto U, 1345
 Paku S, 2981
 Palakurthi S, 2933
 Palanki M, 1315
 Palladoro F, 1345
 Palli D, 1539
 Palmieri F, 1345
 Palmirota R, 3321, 3369, 4131
 Palmqvist R, 1489
 Palomares T, 3957
 Pan E, 4309
 Panani AD, 4483
 Panayiotidis P, 1811
 Pangalis GA, 1811
 Panoskaltzis T, 2781
 Panotopoulou E, 3977
 Panoussopoulos S-G, 785
 Pantazis P, 2009
 Pap É, 3095
 Papachroni KK, 4013
 Papadaki EA, 1811
 Papadimitriou E, 349
 Papadokostopoulou A, 1361
 Papadopoulos O, 2681, 2851
 Papageorgiou E, 371, 2331
 Papailiou JG, 785
 Papaioannou N, 319
 Papakonstantinou K, 2781
 Papakostas P, 529, 693
 Papamichalis G, 4297
 Papaspyrou G, 4785
 Papatsibas G, 769, 4759
 Papavassiliou AG, 4013
 Papaxoinis G, 737, 745, 769, 4759
 Papp J, 1971
 Pappas J, 4673
 Paradiso A, 2845
 Paraiso D, 4195
 Paramio JM, 3035
 Parisi A, 449
 Park CK, 1817
 Park IJ, 4303
 Park J-K, 2393
 Park JS, 355
 Park K, 1817
 Park S-I, 2393
 Park WH, 3837, 4423
 Parodi MA, 1621
 Pasi F, 4575
 Pasinetti N, 4821
 Pasqualetti F, 4205
 Pasquier D, 1703
 Pastorelli D, 4275
 Patel VR, 1637
 Patrino-Georgoula M, 1373
 Patsouris E, 2379, 3191, 4163
 Patzelt A, 2307
 Paulsen JE, 1921, 4353
 Paulsson G, 1585
 Pavārs M, 711
 Pavlakis K, 4995
 Pavlidis N, 745
 Pavlikova I, 667
 Payan R, 1703
 Paz B, 1467
 Pearlstein RD, 107
 Pecka M, 3337, 4813
 Pectasides D, 737, 745, 769, 4759
 Pectasides E, 737, 769
 Pedrini L, 473
 Pellicciari R, 4971
 Pelte M-F, 4711
 Pento JT, 3417
 Peoples GE, 41, 2427
 Perdereau D, 4965
 Perdigão PF, 3065
 Pereira S, 2421
 Peretz T, 4281, 4827
 Perneti R, 1345
 Perret G-Y, 1615
 Perretta T, 1499
 Perrone F, 4205
 Persons KS, 3547, 3591
 Persson J, 4731
 Persson JL, 2893, 3917
 Persson M, 4175
 Peschos D, 3465
 Pesek M, 2513, 2767
 Pessach Y, 1793
 Pesta M, 2513, 4535
 Peterlik M, 3685, 3687, 3705, 3721
 Peters SO, 3069
 Peters WHM, 753
 Petignat P, 1591
 Petrella G, 1499
 Petroni G, 2869
 Petros WP, 5149
 Petru E, 1761, 2803
 Petsas T, 703
 Peyri N, 1335, 2347
 Pezzuolo D, 1547
 Pfeifle C, 4489
 Pfohler C, 3669
 Pfragner R, 1951, 4519
 Pfüller U, 4941
 Phan V, 3281
 Philippé J, 3797
 Philippou A, 4013
 Philips N, 3233
 Phipps SMO, 4959
 Piccoli R, 477
 Piccolo E, 403
 Pieber TR, 3699
 Pienta KJ, 3109
 Pietri E, 5111
 Pietzner K, 2793
 Pikoulis E, 5163
 Pilati P, 4139
 Pilz S, 3699
 Pinault A, 1963
 Pires I, 2713
 Pirie-Shepherd S, 2243
 Pissimissis N, 371
 Pistolese C, 1499
 Pitulis N, 2331
 Pizzi G, 449
 Platini C, 4195
 Platsoucas CD, 4673
 Pliarchopoulou K, 4759
 Poci I, 2121
 Pode D, 4281
 Podmore ID, 2971, 3103
 Pogany G, 2981
 Poimenidi E, 349
 Poleyaya NV, 4901
 Polistina F, 3381, 5255
 Politi E, 4163
 Pollok KE, 3883

- Polyzos A, 1651, 2681, 2851
 Polyzos K, 2681, 2851
 Pontes TB, 2479
 Popiela T, 5005
 Porichi O, 3977
 Porojnicu AC, 3495, 3501, 3713
 Porro G, 1847
 Portarena I, 3321
 Posekany KJ, 2387
 Potter BVL, 3751
 Poulain L, 1249, 1443
 Pouquet M, 2563
 Pourgholami MH, 3791
 Povolato M, 491
 Powell S, 4189
 Poźniak G, 2361
 Pozsgai E, 717
 Prager G, 2719
 Prantner I, 4169
 Prater S, 3811
 Prazakova M, 573
 Prenkert M, 4071
 Pries R, 3019, 3053
 Proschek D, 2787
 Proschek P, 2787
 Prost F, 2945
 Prugpichailers T, 4901
 Pryczynicz A, 3049, 3913
 Psyrrri A, 769, 4759
 Pudelko M, 2445
 Puente J, 4185
 Pugh CW, 4337
 Pujade-Lauraine E, 4195
 Pulcini G, 2761
 Puozzo C, 553
 Purohit A, 3751
 Pyrhönen S, 99
 Qin H, 3811
 Qing C, 3079
 Qin-Tao W, 3079
 Qiu H, 5089
 Quaranta M, 2845
 Queiroga FL, 2713
 Rabczynski J, 2703
 Rabiau N, 1631
 Rabinovich GA, 403
 Raczzyk C, 4127
 Radhi J, 2579
 Radke I, 2167
 Radl AC, 2803
 Radzikowski C, 2361
 Rafael SB, 4839
 Ragazzi E, 3931
 Ragazzon PA, 2273, 2285
 Rai Y, 625
 Raju U, 4409
 Ralli M, 3441
 Ramachandran K, 3207
 Ramalhete C, 3989, 4467
 Ramanathapuram L, 2099
 Ramanujam RJ, 2009
 Ramírez-Expósito MJ, 4633
 Ramon J, 145
 Ramos DM, 125, 2043
 Rampin L, 4251
 Ramqvist T, 11
 Ramu N, 4827
 Rana S, 4373
 Ranstam J, 4731
 Ranza E, 4575
 Rao PH, 1255
 Rao PP, 4909
 Raskin K, 1867
 Ratcliffe PJ, 4337
 Rausch MP, 2099
 Ravanel N, 1703
 Rawnaq T, 1195
 Rea S, 567
 Read P, 2869
 Rebbaa A, 4473
 Recchia F, 567
 Redente EF, 5095
 Reed MJ, 3751
 Reibel J, 2869
 Reich O, 1823
 Reichelt U, 1195
 Reichrath J, 3469, 3511, 3647, 3659, 3669
 Reimer D, 2803
 Reinhardt K, 4489
 Reinthaller A, 2803
 Reiter M, 33, 4571
 R Emmelink M, 4933
 Ren B, 223
 Reshkin SJ, 2127
 Reske SN, 1423
 Ressler S, 2579
 Restucci B, 2919
 Réti A, 3095
 Revheim M-E, 4331
 Rey al F, 1475
 Ri G, 4239
 Rice SD, 1993
 Richardsen E, 3861
 Riches DWH, 5095
 Richter A, 5013
 Richter H, 2307
 Ricketts CJ, 4337
 Riedel F, 1675
 Riegler M, 2719
 Rieker RJ, 4057
 Riemann K, 1271, 5131
 Ries J, 291, 5125
 Riesterer O, 4409
 RIGatos G, 5211
 Rihova B, 4513
 Rikiyama T, 1169, 1201, 2015
 Riklund K, 4361
 Rinner B, 4519
 Riondino S, 3321, 4131
 Rittenhouse H, 2589
 Ritz J-P, 1309
 Rival-Tringali A-L, 1927
 Rizvi A, 107
 Rizzardi C, 1137
 Ro S, 3027
 Roca H, 3109
 Rocca A, 5111
 Rodgarkia-Dara CJ, 1181
 Rodolico V, 3149
 Rodrigues L, 2173
 Rodríguez-Lajusticia L, 4185
 Røe K, 4331
 Roedel F, 67
 Roeßler M, 4785
 Rogers O, 2875
 Roggan A, 1309
 Roh SA, 3027, 3115
 Rokutanda N, 517
 Roma A, 1551
 Roman RJ, 3819
 Roncella M, 4251
 Rose M, 4083
 Roselli M, 1499, 3321, 3369, 4131
 Rosenberg A, 1867
 Rossi A, 2691
 Rossi E, 2761
 Rossi T, 4529
 Rössler J, 1327
 Rotilio A, 4275
 Rotondo F, 3759
 Rouault J-P, 3003
 Roudaut PY, 2563
 Rouquette S, 1697
 Rovelli F, 1847
 Roxas G, 2243
 Rübben H, 5131
 Rubello D, 4251
 Rubenstein M, 4579
 Rubini V, 2845
 Rubio CA, 657, 1539, 1745, 4145, 4291
 Rudas M, 3939
 Rudolph P, 1459
 Ruel C, 1467
 Rufanova VA, 3819
 Ruiz-Ávila I, 2323
 Runnebaum IB, 2823, 2827
 Runyan RB, 2099
 Rupp K, 33
 Russillo M, 2607
 Russo E, 4771
 Ryan A, 1987, 5065
 Rybicki LR, 2961
 Rychahou PG, 4439
 Saad SS, 4807
 Saarto T, 2601
 Sadler S, 125
 Saeki H, 2555
 Safa AR, 3883
 Safranek J, 2513, 4535
 Sagae S, 561
 Sager G, 1047, 1053
 Sahanas S, 1811
 Sahnoun AE, 5143
 Saif MW, 4083
 Saijo N, 2315
 Saito H, 3563
 Saito K, 3375
 Saito M, 271, 275, 279, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Saito T, 597
 Saitoh-Sekiguchi M, 4639
 Saiz C, 3035
 Saji S, 5203
 Sakagami H, 175, 343, 379, 455, 1123, 1303, 2265, 3079, 3211, 4077, 5019, 5023, 5083
 Sakai M, 3375
 Sakai T, 3361
 Sakaki T, 3547, 3563
 Sakakura C, 2091, 2619
 Sakamoto H, 3971
 Sakamoto J, 2739
 Sakamoto J-I, 4779
 Sakamoto K, 539, 1981, 3375

- Sakamoto S, 911, 4615
 Sakamoto T, 2497
 Sakata H, 4433
 Sakata M, 271, 275, 279, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Sakayama K, 4093
 Sakayauchi T, 1831
 Sako T, 2059
 Sakoda M, 1287
 Sakuraba K, 279, 2215, 2231, 2235, 3945, 3953, 4397, 5053
 Sakurai S, 3375
 Salehi F, 3759
 Salehin D, 3611, 3619, 3641, 4833
 Salek C, 1803
 Salhab M, 1095
 Sallah S, 3299, 4683
 Salmenoja H, 2569
 Salminen E, 2569
 Salmon R, 1475
 Šalomskaitė-Davalgienė S, 3125
 Salvador S, 4119
 Salvadores P, 4727
 Salzman P, 4227
 Salzman R, 4227
 Samantas E, 693, 745
 Sambaziotis D, 4163
 Sambucetti L, 3845
 Sanada Y, 271, 275, 279, 2215, 2227, 2231, 2235, 3945, 3953, 4397, 5053
 Sandri MT, 5111
 Sandusky GE, 3883
 Sanguedolce F, 4201, 4417
 Sano A, 3375
 Sano T, 3375
 Sansoucie L, 1611, 2977
 Santala M, 5185
 Santarpia L, 4665
 Santinelli A, 3365
 Santos L, 3221
 Santos M, 3035
 Sanui A, 4879
 Saracino A, 4201
 Sarkar FH, 395
 Sarkar G, 4317
 Sarlis NJ, 4665
 Sasada S, 3347
 Sasaki H, 2091
 Sasaki K, 889
 Sasaki K, 943
 Sasaki T, 1169, 3807, 4605
 Sasano H, 2525, 3971
 Sassa S, 4615
 Sastre J, 4185, 4839
 Sastre-Garau X, 1475
 Satih S, 1631
 Satih S, 5229
 Šatkauskas S, 3125
 Sato A, 517
 Sato C, 1119
 Sato Norihiro, 261, 843, 871, 2147
 Sato Noriyuki, 539
 Sato T, 2863
 Sato Y, 1607, 3329
 Satoh H, 2671
 Satoh K, 3211
 Saussede-Aim J, 3003
 Saussez S, 59, 4933
 Savignoni A, 1475
 Savino E, 2845
 Savonarola A, 3369, 4131
 Savvatis K, 2809
 Sawada D, 3563
 Sawada T, 2189
 Sawaki T, 3361
 Saxena A, 1067
 Saxena SK, 1067
 Sayeeduddin M, 2077
 Sburlati P, 2691
 Scarpelli M, 5155
 Schachner M, 1195, 4941
 Schachter J, 145, 1793
 Schade UM, 4941
 Schadendorf D, 3669
 Schaeffer DJ, 443
 Schaeffer R, 4119
 Schafer G, 1739
 Schaller G, 641
 Schallier D, 5225
 Schauer C, 2803
 Scheithauer BW, 3759
 Schiffer D, 3087
 Schillaci L, 3149
 Schillaci O, 1499
 Schirmacher P, 4057
 Schischmanoff O, 1615
 Schjølberg AR, 4381
 Schlegel KA, 291
 Schmid KW, 1271, 5131
 Schmid P, 641
 Schmid RA, 2905
 Schmidinger M, 1627
 Schmidt LH, 201
 Schmidt SC, 2799
 Schmieder K, 3261
 Schmittel A, 3411
 Schmitt-Gräff A, 4745
 Schmitz KJ, 1271
 Schnabel P, 4057
 Schneider A, 3411
 Schneider CM, 4401
 Schneider J, 4727
 Schneider M, 1137
 Schneider PM, 1157, 1281
 Schoppmann SF, 2719
 Schrader AJ, 2067
 Schrader M, 2589
 Schramel FMNH, 5219
 Schrijvers D, 5137
 Schröder C, 183
 Schröder A, 4833
 Schubert J, 419
 Schuch G, 249
 Schüller A, 2905
 Schult-Kronefeld O, 249
 Schumacher G, 2799, 2809
 Schumacher U, 249, 1219, 4941
 Schurr PG, 1195
 Schwab J, 1867
 Schwartz HS, 2913
 Schwartz L, 1443
 Schwarz J, 545, 2817
 Schwenk-Zieger S, 4571
 Scienza R, 4275
 Scopa CD, 703
 Scopinaro F, 4771
 Scorigliano A, 1361
 Scorsetti M, 4259
 Scuderi N, 503
 Seabra AD, 2479
 Seabra L, 1933
 Sebastian M, 201
 Sebening C, 4057
 Sediva M, 667
 Seeber A, 5245
 Sefrhansova L, 667
 Segawa N, 2497
 Segrelles C, 3035
 Sehouli J, 641, 1575, 2307, 2793, 2799, 2809, 2817, 2831, 2837, 3353
 Seidler J, 4949
 Seidman R, 145
 Seierstad T, 4331
 Seifeddine R, 1227
 Seifert M, 3647, 3659
 Seike J-I, 1163
 Seino Y, 3971
 Seitz M, 1823
 Seiz M, 3261
 Sekine F, 843
 Selvaggi FP, 4201
 Sengupta R, 395
 Sengupta S, 3741
 Sensi L, 473
 Seo N, 1015
 Sepsas E, 4297
 Seramondi R, 3983, 4703
 Serefoglou Z, 2379, 3191
 Sergi C, 2579
 Sergi D, 1841
 Seriu T, 625
 Serly J, 3989
 Serrano-Fernandez P, 2703, 4337
 Sertznig P, 3647
 Serve H, 1157
 Sesterhenn AM, 2645
 Sesterhenn AM, 3421, 4785
 Setchell KDR, 4971
 Seth A, 1659
 Seth AK, 2253
 Seto T, 4217
 Seto Y, 4367
 Seuter S, 3485
 Sgambato A, 1709
 Shah S, 1495
 Shaker O, 4473
 Shao Y-Y, 1665
 Shapiro A, 4281
 Sharma S, 3759
 Sheen-Chen S-M, 1131
 Shen C, 1423
 Shen X, 4697
 Sherman AA, 403
 Sherman SI, 4665
 Shi W, 1987
 Shi Y, 4497
 Shibaguchi H, 851
 Shibao K, 2059
 Shibata E, 2485, 4389

- Shibata K, 1059
 Shibata M-A, 2195, 2485, 4389
 Shibata S, 1467
 Shibata T, 337, 485, 2857, 3453, 4265
 Shibata Y, 1727
 Shiloh Y, 4949
 Shimada A, 4981
 Shimada C, 5083
 Shimada H, 583, 1515
 Shimada J, 175, 5083
 Shimada M, 385
 Shimada T, 1009
 Shimada Y, 3877
 Shimakawa T, 4271
 Shimizu D, 1515
 Shimizu K, 1119, 2205
 Shimizu S, 1515
 Shimizu T, 2687
 Shimoji H, 525
 Shimomura T, 4893
 Shimose S, 3833, 5197
 Shin ES, 3027
 Shinagawa K, 1749, 1763
 Shinden S, 577
 Shingyoji M, 2635
 Shinohara Y, 935, 4897
 Shinozuka K, 3857
 Shinto O, 2189
 Shiotani A, 577
 Shioyama Y, 497
 Shiozaki S, 3347
 Shiozawa T, 1023
 Shirahata A, 271, 275, 279, 2227, 2235, 3953, 4397, 5053
 Shirai T, 1733, 2315
 Shirakawa T, 1533
 Shirane T, 677
 Shiraso S, 2015
 Shirasou S, 1169, 1201
 Shirata NK, 3365
 Shirota K, 4879
 Shirouzu K, 2083
 Shoda M, 843
 Shogen K, 1067
 Shoji F, 4099
 Shrestha P, 597
 Shuib S, 4337
 Shukuya T, 2747
 Siakantaris MP, 1811
 Siedlar M, 5005
 Siegl V, 1951, 4519
 Siemann DW, 1987
 Sierżęga M, 5005
 Siffert W, 1271, 3449, 5131
 Sigal-Zafrani B, 1475
 Siki Y, 2219
 Silva AE, 1243
 Silva F, 2713
 Silveira AFP, 1243
 Silveira-Júnior JB, 1189
 Silvestris N, 675
 Simmons C, 1557, 2707
 Simomura T, 927
 Simon C, 2067
 Simone G, 2845
 Simsiris P, 4297
 Singal R, 3207
 Singer BB, 1823
 Singh NP, 3807
 Singh SK, 1659
 Sini V, 4131
 Sinn AL, 3883
 Sinzinger H, 3393
 Skagias L, 4163
 Skalicky T, 2371
 Skarlos DV, 693, 745
 Skarulis MC, 4665
 Skelton IV WP, 971, 1889
 Skiaker R, 2885, 4323
 Skogseid B, 1859
 Sköldenberg EG, 3311
 Skondra M, 4759
 Skoog L, 4345
 Skornick Y, 3925
 Skyttä T, 1755
 Slater JM, 107
 Šmejkalová B, 2951
 Smetana K, Jr, 59
 Smith HJ, 3299
 Smith JA, 1895
 Smollich M, 2167
 So S, 4083
 Sobol G, 1643
 Sobti RC, 1659
 Sohda M, 965, 1595, 3375
 Sohma Y, 2195
 Sohn JH, 4243
 Soiland H, 4697
 Soini Y, 5185
 Solichová D, 3337, 4813
 Solomayer E-F, 4019
 Soma G-I, 809, 817, 859, 865, 907, 4855, 4861, 4867, 4871, 4887
 Somlo G, 1, 1467, 3281
 Son H, 1201
 Son K, 3995
 Song S, 223
 Sonoyama T, 2091
 Sonta-Jakimczyk D, 1643
 Sooriakumaran P, 1483
 Sørbye SW, 3861
 Sorokin A, 3819
 Sosef MN, 3245
 Sousa-Diniz C, 3221
 Sozzi D, 4703
 Spajčić B, 1797
 Spanjaard RA, 3547
 Spanne O, 2641
 Specenier PM, 5137
 Spengler G, 2173, 3989
 Spila A, 3321, 4131
 Spizzo G, 5245
 Sptawński J, 435
 Sponring A, 419
 Springfield D, 1867
 Spyridonidou S, 3191
 Spytzkowska B, 589
 Sredni ST, 3365
 Srinivas S, 3605
 Stachtea X, 3227
 Staeger MS, 1901, 4489
 Ståhlberg P, 1859
 Stamopoulos P, 785
 Stassek B, 4649
 Staszek U, 2445
 Stathopoulos EN, 4995
 Stathopoulos GP, 3949
 Stathopoulos J, 3949
 Stefaniak J, 1643
 Stefanic M, 4233
 Steffler D, 4169
 Steiner M, 1853
 Steiner P, 1999
 Steinman L, 4901
 Stelzer I, 1951
 Stendahl U, 2577
 Stenling R, 1489
 Stephan C, 2589
 Sterry W, 2307
 Stetefeld J, 11
 Stief CG, 1823
 Stig R, 1539
 Stigbrand T, 4361
 Stoeltzing O, 2031
 Stölting S, 3069
 Stoltz AS, 3069
 Stopfer P, 4233
 Story MD, 4409
 Strid H, 4071
 Strik H, 5191
 Strnad R, 1803
 Strojnik T, 3269
 Struikmans H, 5219
 Struwe H, 1271
 Stuppner H, 4519
 Sturm S, 4519
 Styczynski J, 1643
 Su J-M, 509
 Su T, 4083
 Su X-D, 4597
 Su Y, 5057
 Suda T, 1515
 Sudha T, 4473
 Suga A, 1123
 Suga T, 2611
 Suga Y, 2611
 Sugahara S, 497
 Sugawara Y, 4093
 Sugimoto Y, 1059, 3195
 Sugioka A, 1783
 Sugiura T, 3563
 Sugiyama H, 1691, 1763, 4779
 Sugiyama K, 597
 Sugiyama T, 1733, 2315
 Sulkowska M, 4151
 Sulkowski S, 4151
 Sumegi B, 717
 Sun A, 4901
 Sun C, 4697
 Sun S, 2927
 Sun S-S, 3459
 Sun X, 1739
 Sun Y, 971, 1889, 4981
 Sung JY, 229
 Sung M-W, 255
 Suo Z, 1233
 Surguladze D, 1999
 Susa M, 1879
 Susumu N, 561
 Sutnar A, 2371
 Suzuki A, 1023
 Suzuki F, 1303
 Suzuki H, 831, 843, 881
 Suzuki K, 1507
 Suzuki M, 2611
 Suzuki Nao, 561
 Suzuki Nobutaka, 1691, 809

- Suzuki Norio, 243, 3877
 Suzuki R, 235
 Suzuki S, 19
 Suzuki Takahisa, 2775
 Suzuki Takashi, 2525
 Suzuki Takashi, 4981
 Suzuki Toru, 2997
 Suzuki Toshio, 243, 2411
 Svejda B, 1951
 Svendsen C, 1921, 4353
 Svendsen M, 2885, 4323
 Svendsen MV, 4323
 Sviatoha V, 4345
 Svoboda T, 667
 Świtała-Jeleń K, 2361
 Syed LH, 4909
 Sykora R, 2371
 Syper D, 2361
 Syrigos KN, 631, 1373, 1651, 3441, 4297
 Syriou V, 5163
 Syrjänen K, 2569
 Syrjänen K, 99, 2577
 Syrjänen S, 2577
 Syro LV, 3759
 Szabo A, 159
 Szabó J, 681
 Szaflarska A, 5005
 Szanto A, 159
 Szanyi I, 2295, 4169
 Szczarska-Nowak K, 2361
 Szczepanik A, 5005
 Szelachowska J, 589, 2445
 Szende B, 681
 Szepesváry Z, 681
 Szewczyk K, 2445
 Szigeti A, 159, 717
 Szmigiero L, 1429
 Szynglarewicz B, 2445
 Tabata K, 4981
 Tabata T, 1521
 Tachibana K, 897
 Tagawa T, 1119
 Tagawa Y, 2541
 Taguchi K, 1721
 Taguchi T, 661, 1669
 Tahara T, 337, 485, 2857, 3453, 4265
 Tai S, 647
 Taira Z, 837
 Tajima K, 2205
 Tajima T, 625
 Takada N, 2403
 Takagawa R, 2863
 Takagi K, 3563
 Takahama K, 485, 2857
 Takahara K, 2497
 Takahashi F, 2205
 Takahashi K, 2205
 Takahashi M, 661
 Takahashi T, 995, 2747, 4639, 4871
 Takai Y, 1831
 Takakura N, 3347
 Takamura M, 3329
 Takamura Y, 4157
 Takano A, 455
 Takano K, 919
 Takano M, 3563
 Takashima M, 539
 Takata D, 517
 Takaya M, 995
 Takaya Y, 2541
 Takechi H, 1163
 Takeda H, 3329
 Takeda K, 1831
 Takei H, 3971
 Takekawa F, 3079, 4077, 5019, 5083
 Takenaka A, 1533
 Takenaka K, 1749
 Takenaka T, 4099
 Takeno S, 2753
 Takenouchi K, 3563
 Takeshima H, 4845
 Takeuchi H, 3445
 Takeuchi S, 1521
 Takeuchi Y, 763
 Takeura C, 1783
 Takeyoshi I, 517
 Taki T, 625
 Takigawa N, 2759
 Takiguchi S, 4211
 Takii M, 1263
 Takii Y, 4689
 Takikawa M, 647
 Talieri M, 1361
 Talmage DA, 2899
 Talvensaari-Mattila A, 5185
 Tamaki W, 525
 Tamesa T, 539
 Tamiya A, 2747
 Tamura K, 625, 1507
 Tamura N, 5083
 Tamvakis N, 737
 Tan BK, 3471
 Tan BK-H, 3043
 Tan D, 1151
 Tana R, 1715
 Tanabe M, 1515
 Tanahashi Y, 1783
 Tanaka A, 455
 Tanaka H, 843, 871, 2147
 Tanaka Kaoru, 1111
 Tanaka Kazushi, 1533
 Tanaka Kunichiko, 2541
 Tanaka Kuniya, 583
 Tanaka Makiko, 685
 Tanaka Masao, 831, 871, 881, 2147, 3361
 Tanaka Masaru, 4589
 Tanaka N, 3375
 Tanaka R, 1727
 Tanaka Shinji, 4989
 Tanaka Shoji, 2403
 Tanaka Tomoaki, 1089
 Tanaka Toshihiro, 851
 Tanaka Y, 4389
 Tang L, 443
 Tang N-Y, 165
 Tang PA, 1557
 Tang R-P, 1131
 Tangoku A, 1163
 Tani E, 4345
 Tani Y, 1669
 Tanigawa N, 2485
 Taniguchi Y, 865, 859, 4855, 4861
 Tanimoto M, 1749, 1763, 2759
 Taniwaki M, 4989
 Tanizawa K, 1721
 Tanji N, 4093
 Tao L-Y, 4597
 Tarkowski R, 589
 Tarle M, 1797
 Tarnowska C, 2703
 Tartarini R, 1547, 1835
 Tasaka T, 843
 Tashiro H, 3445
 Tateno T, 1287
 Tatezaki S-I, 4287
 Tatezaki S-I, 763
 Taube C, 201
 Tauchi H, 4093
 Tawfik A, 3811
 Tchernyshyov I, 4909
 Tenta R, 2331, 4013
 Terakubo S, 3211
 Terao S, 1533, 2997
 Terpos E, 1651
 Teshima T, 4605
 Tessari E, 4139
 Tessitore L, 3087
 Tetè S, 3983
 Teti G, 1715
 Tezuka H, 2547
 Thakur H, 1659
 Theodoropoulos GE, 785
 Thet MM, 5083
 Thiel A, 3019
 Thiel E, 3411
 Thill M, 3611, 3619, 3627, 3635, 3641
 Thivat E, 5235
 Thöm I, 249
 Thomas A, 641, 2675
 Thomas C, 1933
 Thomas CY, 2869
 Thomé M, 3627, 3635
 Thorns C, 4649
 Threlfall WR, 5045
 Thu S, 4697
 Tian X, 2009
 Tian Y-M, 4337
 Tibold A, 4169
 Tidefelt U, 4071
 Tien Y-W, 1665
 Tilgen W, 3469, 3511, 3647, 3659, 3669
 Tilki D, 1823
 Tille J-C, 4711
 Timar F, 2981
 Timirci Ö, 1389
 Timotheadou E, 745
 Tina E, 4071
 Tinari N, 403
 Tinazzi A, 2691
 Ting G, 2111, 4107
 Tisi E, 1847
 Tobita K, 685
 Tofani A, 4771
 Toga T, 1607
 Togo S, 583
 Tohda S, 3967, 4629
 Toita T, 525
 Tokuishu K, 2753
 Tokumaru Y, 1981
 Tokunaga E, 2555
 Tokuno K, 539, 1527
 Tokuyue K, 497
 Tolis C, 529

- Tollefsbol TO, 139, 4959
Tolve I, 4201
Tomandl J, 4227
Tomaschitz A, 3699
Tomita K, 1873
Tomita M, 2687
Tomita T, 1981
Tomiyasu T, 927, 4893
Tommasi S, 2845
Tomoda C, 4157
Tomova R, 5241
Tong R, 2927
Tonra JR, 1999
Topolcan O, 573, 2513, 4535
Torelli F, 4771
Torigoe S, 2083
Torigoe T, 539
Torri T, 1547
Torri V, 2691
Torrise R, 5111
Tostes D, 2323
Tot T, 2577
Tóthová E, 4227
Tountas N, 769
Tourkantonis I, 3441
Toyama Y, 1879
Toyoshima T, 291, 3191
Traficante A, 1709
Traino C, 4251
Tredici G, 303
Tregnaghi A, 491, 5255
Trencsenyi G, 2121
Trenkle T, 3019, 3053
Treska V, 2371, 2513
Treves AJ, 145
Triantafillidis JK, 2727
Trikha M, 131
Trimble EL, 2781
Trochon V, 2347
Trofimovičs G, 711
Troppmair J, 419
Truax R, 5149
Trudel LJ, 3733
Trullemans F, 5225
Truskinovsky AM, 1495
Tsai C-W, 725, 1275, 1777, 3897, 3903, 5121
Tsai JS, 4309
Tsai R-Y, 3897, 3903, 5121, 5251
Tsalic M, 1853
Tsamandas AC, 703
Tsavaris N, 2681, 2851
Tse TTM, 229
Tse V, 4901
Tsekeris P, 529
Tseng H-C, 725
Tseng S-H, 3163
Tseng Y-L, 2111
Tserkezoglou A, 3977
Tsiamalos P, 703
Tsiatis AC, 2913
Tsigris C, 2681, 5163
Tsimpoukis S, 631
Tsou Y-A, 3903, 5121
Tsubamoto H, 1521
Tsuboi A, 4779
Tsuchiya H, 1873, 4093, 4689
Tsuda N, 41, 2427
Tsugu H, 911, 919
Tsuji H, 1507
Tsuji KA, 4989
Tsuji H, 1507, 4433
Tsujioka T, 3385
Tsujioka M, 4047
Tsujioka H, 4879
Tsujiuchi T, 4047
Tsukahara T, 4239
Tsukuda M, 661
Tsunami M, 2547
Tsunoda S, 4589
Tsutani Y, 2775
Tsuya A, 2747
Tsvetkov YE, 403
Tsygankov AY, 4673
Tubiana-Mathieu N, 2563
Tuettenberg J, 3261
Tulloch-Reid M, 4665
Tunquist B, 4373
Turna A, 2417
Turunen M, 5185
Tüzüner BM, 4041
Twardowski P, 3281
Tyynelä K, 1755
Tzelepi V, 703
Tzenou T, 1811
Tzovaras AA, 5211
Ubai TA, 2497
Uchikawa J, 1023
Udagawa Y, 561
Ueda K, 1079
Ueda M, 1009
Ueda T, 2357
Ueda Y, 837
Ueki A, 2403
Uemori A, 427
Ueno S, 1287
Ueno Y, 897
Ueyama Y, 1263
Uggla B, 4071
Umeda Y, 4239
Umehara H, 3361
Umemura S, 2759
Umemura S-I, 889, 943
Unger C, 4795
Umno M, 1169, 1201, 2015
Ünür M, 2519
Upadhyay T, 3233
Urasinski T, 1643
Urbánek L, 3337
Urso G, 4259
Ushijima K, 561
Ushiyama T, 1001
Usui A, 4433
Uto M, 1195
Utsunomiya H, 919
Uwagawa T, 3173
Uzzan B, 1615
Vagenas K, 703
Vagstad G, 2641
Vairaktaris E, 291, 2379, 3191, 5125
Vajkoczy P, 3261
Valavanis C, 737
Valdes F, 3281
Valente G, 3087
Valente MG, 4703
Valentiner U, 1219
Vali M, 4909
Vallböhmer D, 1157, 1281
Vamvouka C, 529
Van Bokhoven MMJA, 4223
Van Camp M, 3471
Van De Plas R, 1039
Van Den Brande J, 5137
Van Den Weyngaert D, 5137
Van Der Graaf WT, 469
Van Gele M, 3797
Van Gorp T, 1039
Van Huyen J-PD, 2945
Van Kempen-Harteveld ML, 3305
Van Laarhoven HWM, 469
Van Laer C, 5137
Van Melckebeke H, 3797
Van Rooij FG, 4223
Vanags A, 711
Vandroux JC, 2563
Vanella P, 1621
Vanhoecke B, 605, 3585, 3797
Varga A, 4467
Varga Z, 4169
Varin E, 1249, 1443
Varjas T, 2295
Varsos Z, 3109
Varvaras D, 1499
Vasou O, 4163
Vassal G, 1327
Vassilakopoulos T, 1811
Vassiliadis V, 2655
Vassiliou S, 2379
Vassiliou V, 703
Vasson M-P, 5235
Vaszók T, 1971
Vaziri SAJ, 2961
Veeravagu A, 4901
Veganzones S, 4185, 4839
Veith R, 2707
Venat-Bouvet L, 2563
Venslauskas MS, 3125
Ventura L, 1137
Venuti A, 449
Verbeke S, 2563
Vereide AB, 1047, 1053
Vergote I, 1039
Verlinden L, 3471, 3579, 3585
Verma A, 1909
Vermorken JB, 5137
Veronesi P, 5111
Verpooten GF, 363
Verstappen CCP, 4223
Verstuyf A, 3471, 3579, 3585
Vesely DL, 971, 1889
Vesely P, 2339
Vetvicka D, 4513
Vezyraki P, 3465
Viale G, 5111
Vici P, 1841
Vidaurreta M, 4185, 4839
Vidiri A, 2607
Vieth R, 3675
Vigorè L, 1847
Vigorito S, 4259
Vihinen P, 1755
Vikinge T, 11
Villanacci V, 2761
Villani F, 777
Villani M, 777
Vincent-Salomon A, 1475

- Vinh-Hung V, 4683
 Vinken M, 469
 Vinothini G, 2301
 Viola G, 1841
 Vishwanatha JK, 3867
 Vistnes AI, 2885, 4323
 Vitali E, 4821
 Vitucci C, 1841
 Vitullo G, 1345
 Viveiros M, 2173, 3989
 Viviani S, 777
 Vlastos G, 4711
 Vlemmas I, 319
 Voegtli W, 4373
 Voelker K, 545
 Vogl TJ, 2787
 Vogl UM, 1627
 Volkert WA, 3777
 Volterrani D, 4251
 Von Deimling A, 3261
 Voorhorst F, 4697
 Vora N, 1467
 Vos P, 3299, 4683
 Vossen JA, 4909
 Votavova M, 667
 Votruba I, 1295
 Vrekoussis T, 4995
 Vrzalova J, 573, 2513, 4535
 Vuoristo M-S, 1755
 Vycital O, 2371
 Vylliotis A, 2379, 3191
 Wachowiak J, 1643
 Wada J, 261, 831, 843, 881
 Wada M, 1009
 Wade TJ, 3253
 Waelkens E, 1039
 Wagener C, 249
 Wagner G, 495
 Wagner L, 731
 Wagner T, 3069
 Wahl ML, 2127
 Wakabayashi H, 379, 455, 1123
 Wakabayashi N, 4047
 Walker D, 4373
 Walker F, 4147
 Wallwiener D, 4019
 Wan PJ, 2179
 Wang C-H, 725, 3903, 5121, 5251
 Wang C-K, 509
 Wang C-Z, 2927
 Wang F-H, 211
 Wang F-P, 4597
 Wang H, 1889
 Wang H, 971
 Wang H-C, 725, 1275, 2239, 3897, 5121, 5251
 Wang H-E, 2111, 4107
 Wang John, 1637
 Wang Junsheng, 1233
 Wang L, 851
 Wang L-S, 2179, 3195
 Wang M-F, 2239
 Wang Qi, 1233
 Wang Qingding, 4439
 Wang Qintao, 3211, 5023
 Wang Q-T, 5083
 Wang R-F, 1777, 3897, 3903, 5121, 5251
 Wang R-F, 5251
 Wang Sen, 411
 Wang Shu, 1859
 Wang S-J, 2111
 Wang T, 2025
 Wang Xiaofu, 3185
 Wang Xin, 4005
 Wang Yi, 1859
 Wang Yongbao, 2009
 Wang Zhong, 1233
 Wang Zhuo, 3845
 Ward HWC, 3299
 Wardenius H, 1933
 Warm M, 2675
 Warnecke-Eberz U, 1157, 4451
 Wäsch R, 4745
 Wasowska-Lukawska M, 1429
 Watabe T, 577
 Wataha J, 3811
 Watanabe J, 1009
 Watanabe Makiko, 661
 Watanabe Makoto, 2857
 Watanabe Makoto, 485
 Watanabe Masahito, 4389
 Watanabe Michiaki, 1681
 Watanabe Michiko, 235
 Watanabe S, 2611
 Watanabe Yasuko, 935
 Watanabe Yasuyuki, 4893
 Watanabe Yoh, 561, 617
 Watanabe Yoshihiro, 1119
 Wataya H, 4217
 Watkinson LD, 3777
 Wdzieczak-Bakala J, 1963
 Webb TJ, 2875
 Weber B, 4195
 Weber G, 1971
 Weber KT, 3845
 Wegener G, 2627
 Wei J, 4497
 Weidle UH, 951, 4919
 Wein A, 67
 Weiss K, 3393
 Weissbach L, 1879
 Wen Z, 5103
 Werner JA, 1181, 2645, 3421, 4785
 Westhoff B, 3433
 Wheeler TM, 2077
 White R, 1933
 White T, 4959
 Wieczorek M, 1643
 Wiegand S, 1181, 4785
 Wiesener MS, 4337
 Wietrzyk J, 2361
 Wiewrodt R, 201
 Wikman O, 1539
 Wilczynski SP, 1467
 Wilding GE, 4127
 Wiley JE, 2387
 Wilkie MB, 1943
 Williams C, 1591
 Williams V, 191
 Willich N, 3397
 Willén R, 4731
 Wimberger P, 1787, 3449
 Winiewicz A, 4151
 Winter D, 4949
 Winter N, 5013
 Winter R, 1761
 Wirtz RM, 67
 Wiseman SM, 2437
 Witte L, 1999
 Woelber L, 545, 2817
 Woessner R, 4373
 Wogan GN, 3733
 Wolfson AD, 4673
 Wollenberg B, 3019, 3053
 Woll-Hermann A, 4833
 Wollner M, 1853
 Wolters HH, 3397
 Wonders KY, 4401
 Wong B, 2707
 Woo H-Y, 3909
 Wood WG, 4063, 4503
 Woopen H, 3353
 Wu C-C, 165
 Wu C-N, 2239
 Wu H-C, 1275, 1777, 3459, 3903, 5121
 Wu JM, 4025
 Wu J-Y, 2535
 Wu M, 3811
 Wu P-P, 327, 1435, 4503
 Wu T-C, 2535
 Wu WKK, 229
 Wu X-X, 27
 Wulff S, 3053
 Wülfing P, 2167
 Wyche JH, 2009
 Wysocki M, 1643
 Xi H, 1157
 Xia Y, 3253
 Xie C, 5089
 Xie J-T, 2927
 Ximeris M, 1811
 Xiong A, 4901
 Xiros N, 769
 Xu H, 3845
 Xu L, 223
 Xu N, 4005, 4497
 Xu P, 4621, 5045
 Xu R, 261
 Xu Y, 5103
 Xu Zhidong, 5103
 Xu Zirong, 2025
 Xynopoulos D, 1361
 Yabe H, 1879
 Yabusaki H, 4689
 Yabuuchi S, 1169, 1201, 2015
 Yaegashi N, 3971
 Yagi H, 823
 Yagi M, 2611
 Yalcin M, 3825, 4473
 Yamada H, 3995
 Yamada K, 2009
 Yamada S, 1831, 4433
 Yamagishi S, 583
 Yamaguchi K, 647, 2059, 4271
 Yamaguchi N, 1515
 Yamaguchi Y, 3971
 Yamai H, 1163
 Yamamoto A, 647
 Yamamoto H, 4093
 Yamamoto Katsumi, 455
 Yamamoto Kazuyoshi, 4211
 Yamamoto Kuniharu, 1169, 1201, 2015

- Yamamoto M, 897, 943
Yamamoto Nobuyuki, 2747
Yamamoto Norio, 1873
Yamamoto S, 2753
Yamamoto Tatsuhito, 2611
Yamamoto Toshiyuki, 4239
Yamamura Y, 4033
Yamaoka T, 1733, 2315
Yamasaki Akio, 843, 871, 881
Yamasaki Ayako, 4047
Yamasaki F, 597
Yamasaki H, 3385
Yamasaki M, 4211
Yamashiro H, 1015
Yamashita H, 337, 485, 2857, 3453, 4265
Yamashita S-I, 2753
Yamashita T, 577
Yamashita Y, 851
Yamauchi K, 1873
Yamazaki N, 647
Yamazaki Y, 4981
Yamamoto S, 661
Yan Y-Y, 4597
Yanaga K, 1681, 3173, 3995
Yanagawa T, 4751
Yanagi T, 1507
Yanai F, 919
Yanai K, 261, 881
Yang C, 1867
Yang C-R, 1637
Yang C-S, 2111
Yang J-L, 3861
Yang J-S, 309, 327, 1435, 3139, 4063, 4503
Yang M-D, 309, 2239
Yang S-F, 3131
Yang Y, 411
Yang Z, 443, 2421
Yano T, 4099
Yao H, 3845
Yao P, 4051
Yap OWS, 139
Yapjajakis C, 2379, 3191, 3401
Yashiro M, 2189
Yasuda H, 2547
Yasuda K, 2189
Yasuda T, 3953
Yasui K, 4989
Yasui N, 2357
Yasui Y, 4871
Yasukawa K, 4981
Yasunaga Y, 3833, 5197
Yaszemski M, 4317
Yaylim İ, 2417
Yaylim-Eraltan İ, 2519
Yazawa N, 685
Yazawa Y, 4589
Yazbeck C, 4147
Yazumi S, 2619
Ye F, 223
Ye W, 3195, 4005, 4621, 5045
Yeh C-C, 4503
Yeh K-T, 2535
Yeh S-H, 211
Yekebas EF, 1195
Yellepeddi VK, 2933
Yen Y, 1, 1467, 3239, 4083
Yiakoumis X, 1811
Yiğit N, 1395
Yin P, 4497
Yin P-H, 5057
Ying J, 4697
Yokoe T, 517
Yokomizo K, 5053
Yokote H, 1111
Yokote Y, 343, 5083
Yom CK, 3909
Yoneda K, 677
Yonemoto T, 763, 4287
Yoo S-E, 2393
Yoon S, 1867
Yoon SN, 3115
Yoshida A, 865, 907, 4861, 4867
Yoshida H, 1169, 1201, 2015, 4157
Yoshida J, 4047
Yoshida Kazuhiro, 5203
Yoshida Ken, 3385
Yoshida M, 1349
Yoshida S, 539, 1527
Yoshida T, 1163
Yoshikawa H, 2357
Yoshikawa Kozo, 385
Yoshikawa Kyosan, 1507
Yoshikawa N, 3857
Yoshikawa T, 4989
Yoshimoto M, 1515
Yoshimura R, 1089
Yoshinaga K, 2555
Yoshino I, 4099
Yoshino Shin, 1527
Yoshino Shinichiro, 943
Yoshino S-I, 889
Yoshino T, 677
Yoshioka D, 337, 485, 2857, 3453, 4265
Yoshioka N, 859, 865, 4855, 4861
Yoshizato T, 4879
Yotsumoto F, 823, 4879
You BR, 3837, 4423
You L, 2025
Youssef S, 4901
Yu CS, 3115
Yu C-Y, 987
Yu F-S, 309, 327
Yu L, 229
Yu Z, 1367
Yuan C-S, 2927
Yuasa Y, 1163
Yukata K, 2357
Yutkin V, 4281
Zacherl J, 2719
Zadák Z, 3337
Zajc I, 3269
Zalatnai A, 3095
Zambirinis CP, 785
Zamboglou N, 529
Zamparese R, 4201
Zanardi I, 2951
Zanco P, 3381
Zander A, 1355
Zang X-P, 3417
Zanni E, 473
Zaramboukas T, 529
Zavlaris M, 319
Zavoral M, 1803
Zeillinger R, 1039
Zeimet AG, 2803
Zeitraeger I, 67
Zembala M, 5005
Zen K, 4989
Zerbini MCN, 3365
Zerilli M, 3149
Zeybek Ü, 2417
Zhang A, 4005
Zhang C, 27
Zhang H, 1131
Zhang Jichen, 4497
Zhang Jun, 4497
Zhang K, 1467
Zhang R, 4005
Zhang Xiamei, 2099
Zhang Xiaodong, 1249, 1443
Zhang Xiaoying, 4497
Zhang Xu, 4597
Zhang Y, 1079
Zhang Y-E, 91
Zhao J, 851
Zhao L, 4697
Zhao M, 1873, 2421
Zhao P, 4005
Zhao X, 3547
Zheng L, 4497
Zheng S, 3547
Zhi X, 2025
Zhou B, 1
Zhou BP, 4439
Zhou L, 27
Zhou S, 3845
Zhou S-P, 283
Zhou Yanfei, 191
Zhou Yuning, 4439
Zhu C, 223
Zhu L, 1
Zhu W-L, 2531
Zhu W-X, 2531
Zhu Z, 1999
Zieger S, 33
Ziegler B, 3939
Zielinski CC, 1627
Zilkens C, 3433
Zirrgiebel U, 5065
Ziv-Lehrman S, 4949
Zizi A, 737
Zöchbauer-Müller S, 3939
Zohrabian VM, 119
Zolnierek A, 2445
Zolota V, 703
Zoras O, 4995
Zorzino L, 5111
Zoso A, 2875
Zucchetta P, 491
Zukowski K, 1143
Zupa A, 1709
Zurbuchen U, 1309
Zustovich F, 4275
Zwerschke W, 2579
Zweyer M, 1137

Errata

Volume 28 (2008), No 6B, page 3855:

The name of the sixth author should read:

TAKEHITO SHUKUYA¹

Volume 28 (2008), No 6B, page 3909:

The name of the last author should read:

GUSTAVO DE LA ROZA³

Volume 20 (2000), page 2389:

Please correct the names of the first and third authors, as indicated below:

TATSUHEI KONDO¹, TESURO KUBOTA², HIROSHI TANIMURA², HIROKI YAMAUE³, SEIJI AKIYAMA⁴,
YOSHIHIKO MAEHARA⁵, NOBUHIKO TANIGAWA⁶, MASAKI KITAJIMA², HIROSHI TAKAGI⁴,
and JAPAN RESEARCH SOCIETY FOR APPROPRIATE CANCER CHEMOTHERAPY¹

Volume 29, page 156:

The last sentence of the legend of Figure 1 should read:

*VDR primers and probes (forward-ATCTGCATCGTCTCCCAGAT- and reverse-AGCGGATGTACGTCTGCAGTG-)
and a hydrolysis probe (-TGATTGAGGCCATCCAGGACCGG-)*

Volume 29, page 3185:

The second author's affiliation should read:

PAT GULHATI^{1,4*}

Editorial Staff

Managing Editor and Executive Publisher: J.G. DELINASSIOS, Athens, Greece

Assistant Managing Editor: S. AZOUDIS

Production Editor: E. ILIADIS, Athens, Greece

Editorial Office

International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd.,
Kapandriti, P.O.Box 22, Attiki 19014, Greece
Tel and Fax: +30-22950-53389

Please visit the IAR websites: www.iar-anticancer.org; www.ar.iarjournals.org

e-mails:

Editor: editor@iar-anticancer.org; Journals: journals@iar-anticancer.org; IAR: iar@iar-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published monthly. Each annual volume contains twelve issues and index.

Copyright: Once a manuscript has been published in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

ANTICANCER RESEARCH is available in print (ISSN: 0250-7005) and online (ISSN: 1791-7530) through Stanford University's HighWire Press with access to full text/PDF articles from all previous volumes since January 1st, 2004. For 2009 online/print subscription rates, please visit the IAR websites: www.iar-anticancer.org; www.ar.iarjournals.org

Annual Subscription Rates 2010: Institutional subscription online: Euro 1,650.00. Institutional subscription print: Euro 1,670.00. Institutional subscription online & print: Euro 1,700.00. Personal subscription online: Euro 780.00. Personal subscription print: Euro 800.00. Personal subscription online & print: Euro 830.00. Prices include rapid delivery and insurance. Previous volumes of Anticancer Research (Vol. 1-29, 1981-2009) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Executive Publisher of Anticancer Research, Athens, Greece and should be sent to the Editorial Office.

Correspondence: (subscription orders, reprint orders, change of address, disposition of submitted manuscripts, advertising rates requests, and general editorial matters) should be directed to Dr. J.G. Delinassios, Executive Publisher and Managing Editor, Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including *Current Contents (Life Sciences)*, *Science Citation Index*, *Index Medicus*, *Biological Abstracts*, *PubMed*, *Chemical Abstracts*, *Excerpta Medica*, *University of Sheffield Biomedical Information Service*, *Current Clinical Cancer*, *AIDS Abstracts*, *Elsevier Bibliographic Database*, *EMBASE*, *Compendex*, *GEOBASE*, *EMBiology*, *Elsevier BIOBASE*, *FLUIDEX*, *World Textiles*, *Scopus*, *Progress in Palliative Care*, *Cambridge Scientific Abstracts*, *Cancergram (International Cancer Research Data Bank)*, *MEDLINE*, *Reference Update - RIS Inc.*, *PASCAL-CNRS*, *Inpharma-Reactions (Datastar, BRS)*, *CABS*, *Immunology Abstracts*, *Telegen Abstracts*, *Genetics Abstracts*, *Nutrition Research Newsletter*, *Dairy Science Abstracts*, *Current Titles in Dentistry*, *Inpharma Weekly*, *BioBase*, *MedBase*, *CAB Abstracts/Global Health Databases*, *Investigational Drugs Database*, *VINITI Abstracts Journal*, *Leeds Medical Information*, *PubsHub*, *Sociedad Iberoamericana de Información Científica (SIIC) Databases*.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2009 \$2.00 +0.40.

The Editors and Publishers of the journal ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

Editorial Office

International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd.,
Kapandriti, P.O.Box 22, Attiki 19014, Greece
Tel and Fax: +30-22950-53389

PHOTOCOMPOSITION BY IAR
PRINTED BY ENTYPPO, GREECE
PRINTED ON ACID-FREE PAPER

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Summer AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.